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Abstract 
Tuberculosis (TB) and malaria continue to be major public health concerns, globally claiming 
2-3 million deaths every year. A number of efficacious drugs are available for the treatment 
of TB and malaria, which, through various combination therapies, are fully effective in 
treating these diseases. However, the wide spread resistance in M. tuberculosis (Mtb) and P. 
falciparum, the causative agents of TB and malaria, respectively, has made the existing 
therapies less effective. Thus novel agents able to circumvent drug resistance and other 
challenges associated with existing TB and malaria treatments are urgently needed.  
The development of a new drug is a lengthy and costly process; therefore, approaches that 
can save both time and money need to be emphasised. Drug repositioning is one such 
approach that has been applied in this project. Drug repositioning basically involves a 
situation where a drug active in one disease is derivatised or used as a template for the 
synthesis of derivatives active in another disease. This approach has the potential to 
significantly shorten the drug discovery process.   
This study focused on the repositioning of two drugs, the antibacterial agent fusidic acid and 
the antipsychotic agent metergoline, in TB and/or malaria via medicinal chemistry 
approaches. New semisynthetic derivatives of fusidic acid and metergoline were synthesized 
and evaluated for antimycobacterial activity against the H37Rv strain of Mtb and 
antiplasmodial activity against the NF54 strain of P. falciparum.  
Fusidic acid derivatives were synthesized by 
performing various structural modifications at 
C-21 (SAR 1), C-3 (SAR 2) and C-16 (SAR 3) 
positions (Figure 1). C-21 derivatives were 
obtained by replacing the C-21 carboxyl group 
of fusidic acid with various bioisosteres. These 
replacements led to derivatives with inferior 
antimycobacterial activity (MIC99 ≥ 20 µM) as 
compared to fusidic acid (MIC99 0.6 µM). 
However, 2 out of these 28 compounds (3.15 and 3.18) displayed moderate activity (MIC99 
10 µM) and cytotoxicity (IC50 CHO 88.3 and 92.2 µM, respectively). On the other hand, most 
of these derivatives showed a 2-35 fold increase in antiplasmodial activity as compared to 
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fusidic acid (IC50 59 µM) and were also found to be non-cytotoxic. The antimycobacterial 
and antiplasmodial data of C-21 fusidic acid derivatives suggest that the carboxylic acid 
group is essential for its antimycobacterial activity but not for antiplasmodial activity. The C-
3 derivatives were obtained by replacing the C-3 hydroxyl group with various carboxylic and 
silicate esters as well as keto and oxime functionalities. C-3 derivatives exhibited more potent 
antimycobacterial activity as compared to C-21 derivatives, with 9 out of 14 derivatives 
displaying MIC99 ≤ 5 µM. One of these derivative, the C-3 triisopropoxy silicate ester of 
fusidic acid (3.42, MIC99 2.5 µM), demonstrated a superior in vivo (mouse) pharmacokinetic 
profile with higher concentrations achieved in blood, a longer half-life, and a lower clearance 
rate relative to fusidic acid. Similar to C-21 derivatives, structural modifications at the C-3 
position also resulted in improved antiplasmodial activity as compared to fusidic acid. The C-
16 derivatives were obtained by replacing the C-16 acetoxy group with methoxy and ethoxy 
groups. The antimycobacterial activity of the ethoxy derivative (MIC99 0.8 µM) was found to 
be comparable to fusidic acid (MIC99 0.6 µM). Seven miscellaneous derivatives with 
modifications at more than one diversity site of fusidic acid were also obtained. 
Antimycobacterial evaluation of these compounds indicated that the lipophilic side chain, 
carboxylic acid, and C-16 substitution are essential for antimycobacterial activity. 
Antiplasmodial evaluation revealed that C-3, C-11-diacetoxy fusidic acid methyl ester (3.56, 
IC50 0.4 µM) has superior antiplasmodial activity with no cytotoxicity.  
In addition, two separate in silico approaches were applied to fusidic acid. In one approach, a 
3D-QSAR pharmacophore model was developed based on the antiplasmodial activity of 61 
previously synthesized fusidic acid derivatives. This model was used as the 3D-structural 
search query to screen a fusidic acid-based combinatorial library. Eight virtual hit compounds 
were synthesized, including C-21 amide and C-3 ether fusidic acid derivatives. All 
synthesized hit compounds showed superior antiplasmodial activity relative to fusidic acid. 
Two C-21 amide derivatives (4.7 and 4.8) displayed significant activity against the CQ-
sensitive NF54 strain (IC50 values of 0.3 µM and 0.7 µM, respectively) and the CQ-resistant 
K1 strain (IC50 0.2 µM), and were also found to be non-cytotoxic. In another approach, 2D 
fingerprint and 3D shape similarity searches were performed on an in-house database using 
fusidic acid as the query compound. The database included 708 steroid-type natural products 
or their semi-synthetic derivatives with defined chemical structures and stereochemistry. This 
study was conducted with the aim of finding structurally similar compounds that may display 
similar biological activities as that of fusidic acid. Selected hit compounds were evaluated for 
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in vitro biological activity. Twelve out of 27 hit compounds displayed antiplasmodial activity 
(IC50 ˂ 25 µM). However, these compounds did not show any antimycobacterial activity 
except 4.16 and 4.26 (MIC99 80 µM).  
Metergoline derivatives were synthesized by 
replacing the benzyl carbamate (CBz) group 
with various aromatic, heteroaromatic and 
aliphatic amide moieties (Figure 2). Nine out of 
23 compounds exhibited antimycobacterial 
activity with MIC99 < 50 µM. The decanamide 
derivative of metergoline (5.23, MIC99 9.4 µM, 
IC50 CHO 86.6 µM) was found to have a superior antimycobacterial activity and cytotoxicity 
profile relative to metergoline (MIC99 25 µM, IC50 CHO 16.6 µM). Further, three derivatives, 
5.3 (IC50 1.3 μM), 5.9 (IC50 2.5 μM) and 5.25 (IC50 1.2 μM) were found to have slightly 
improved antiplasmodial activity relative to metergoline (IC50 3.7 μM). Compound 5.25 was 
found to be the most active derivative with an encouraging selectivity index value of 13. The 
antimycobacterial and antiplasmodial data of metergoline and its derivatives suggest that the 
benzyl carbamate group of metergoline is not required for activity and its substitution with 
other moieties may result in compounds with improved antimycobacterial and / or 
antiplasmodial activity.  
Overall, this work demonstrates the potential of fusidic acid and metergoline as a promising 
novel antimycobacterial and antiplasmodial templates for repositioning purposes. 
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Chapter 1 
Introduction 
Tuberculosis (TB) and malaria still remain among the major causes of death worldwide, 
particularly in developing countries. In spite of a number of drugs developed for TB and 
malaria, treatments are still challenged by drug resistance, extended treatment duration (TB), 
toxicity profile, and side effects that make these drugs unsatisfactory. Therefore, new drugs 
are needed that can successfully combat the aforementioned challenges. 
This chapter provides a brief introduction of TB and malaria. It also describes currently used 
anti-TB and antimalarial drugs, existing TB and malaria treatment regimens, as well as 
challenges associated with these treatments. New pipeline drugs developed to combat the 
current treatment challenges are also briefly described. 
1.1 Tuberculosis (TB) 
1.1.1  Disease and epidemiology  
TB is a contagious airborne disease responsible for ill health among millions of people each 
year. TB ranks as the second leading cause of death from an infectious disease worldwide, 
after the human immunodeficiency virus (HIV). According to the latest World Health 
Organization (WHO) report on TB1 collected from 205 countries and territories, an estimated 
9.6 million people developed TB in 2014 and 1.5 million died from the disease, 0.4 million of 
whom were HIV-positive. Further, the highest occurrence of TB cases (86%) was reported in 
Asia and the African region, while smaller proportions of cases also occurred in the Eastern 
Mediterranean (8%), European (3%) and American (3%) regions. Figure 1.1 shows the global 
estimated TB incidences in 2014. 
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Figure 1.1: Global estimated TB incidences in 20141 
TB infections in humans are primarily caused by Mycobacterium tuberculosis (Mtb), which 
was discovered by Robert Koch in 1882. Mtb is a slow growing, aerobic, non-motile, rod-
shaped bacterium (Figure 1.2). This gram-positive bacterium is enclosed by a thick and 
impermeable cell wall which is made up of peptidoglycans, arabinogalactans, and unusual 
lipids such as mycolic acids, with an outer cover of non-covalently linked proteins and 
polysaccharides. This unusual cell wall structure is believed to be the potential cause of Mtb 
virulence and dormancy.2,3 
 
 
Figure 1.2: Typical rod-shaped cells of Mtb4 
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TB typically affects the lungs (pulmonary TB) but the bacterium can also enter the blood 
stream and infect other parts of the body (non-pulmonary TB), which occurs in over 15% of 
patients. TB in the human body resides either as active TB or latent TB. Active TB is 
contagious, symptomatic and can cause the death of a person if not treated at the right time 
with appropriate medication. Symptoms of active TB include fever, loss of weight and 
appetite, as well as organ specific symptoms such as lung pain and coughing up 
blood/sputum. TB can also lie dormant where the human immune system keeps it under 
control without completely eliminating it. This is called latent TB, which is non-contagious 
and asymptomatic. TB resides as latent TB in 90-95% of infected individuals and only 5-10% 
develop active TB at some stage of their lives.5,6 Co-infection with HIV further complicates 
TB. HIV infection makes the individual more susceptible to TB infection and can also 
activate a latent infection. This co-infection causes both TB and HIV to progress more 
rapidly. 7–9 
1.1.2 Transmission and pathogenesis 
Through coughing and sneezing by an individual with active TB, Mtb is released into the air 
in the form of aerosols. These Mtb containing aerosols can then be inhaled by other 
individuals.10 Lungs are the primary site of infection where Mtb bacilli are phagocytized by 
alveolar macrophages. These cells are programmed to combat microbial intruders and to, 
ultimately, destroy them. However, some Mtb bacilli manage to escape eradication by 
macrophages and survive within these cells.11,12 Mtb multiplies in these cells and is released 
upon death of the macrophages. These bacilli may spread by way of lymphatic channels or 
through the bloodstream to more distant tissues and organs (including areas of the body in 
which TB is most likely to develop such as regional lymph nodes, apex of the lung, kidneys, 
brain and bone). This process of dissemination primes the immune system for a systemic 
response in which the infected macrophages together with T-lymphocytes and other 
mononuclear cells mature into a solid granuloma, the hallmark of TB.13 
It is believed that granulomas are structured clusters consisting of Mtb infected macrophages 
surrounded by different types of immune cells, in particular macrophages and T-lymphocytes. 
The pathogen is controlled at this stage by the immune system in immuno-competent 
individuals. Mtb is more likely to lie in a dormant (latent infection) state in a solid granuloma 
and does not spread further as a result of which latent TB infection is established in immune-
competent individuals with a life-long risk of reactivation. However, in the presence of a 
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weakened immune system, macrophages are unable to capture Mtb bacilli in the form of a 
solid granuloma as a result of which Mtb bacilli multiply at higher rates leading to the 
development of active disease (Figure 1.3).3 
 
 
Figure 1.3: A schematic diagram showing the action of the host immune system against 
infection of Mtb14 
1.1.3 Anti-TB Drugs 
There are more than 20 drugs currently used in the treatment of TB. The WHO has classified 
the available TB drugs into five groups based on efficacy, potency, drug class and experience 
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of use (Figure 1.4). TB can be cured completely with a combination of these TB drugs if there 
is patient compliance. 
Group 1:  Isoniazid (INH), Rifampicin (RIF), Rifabutin, Rifapentine, Ethambutol (EMB), 
Pyrazinamide (PZA) 
Group 2: Aminoglycosides {Streptomycin (SM), Kanamycin, Amikacin}, Polypeptide 
(Capreomycin) 
Group 3: Fluoroquinolones (Levofloxacin, Moxifloxacin, Gatifloxacin, Ofloxacin) 
Group 4: Ethionamide, Prothionamide, D-Cycloserine, Terizidone, p-Aminosalicylic acid 
Group 5: Bedaquiline (TMC-207), Delamanid (OPC-67683), Linezolid, Clofazimine,   
Amoxicillin/Clavulanate, Imipenem/Cilastatin, Meropenem, Thioacetazone, 
Clarithromycin 
 
Figure 1.4: Classification of anti-TB drugs15 
 
All group 1 drugs, as well as streptomycin from group 2, are used as first-line drugs for the 
treatment of TB. Active TB infection that can be treated with these drugs is called drug-
susceptible TB (DS-TB). These drugs were discovered between the 1950s and 1960s and 
since then have been used successfully in the treatment of DS-TB. Two new RIF analogues, 
rifabutin and rifapentine, have also been developed and can be used as an alternative to RIF. 
All these drugs are administered orally except streptomycin which is given intramuscularly or 
intravenously. Chemical structures of the first-line drugs are displayed in Figure 1.5. 
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Figure 1.5: First-line anti-TB drugs 
Drugs placed in groups 2 (except SM), 3 and 4 in Figure 1.4 are second-line drugs in TB and 
are used to treat drug-resistant TB (DR-TB). These consist of orally administered 
fluoroquinolones, injectable drugs such as kanamycin, amikacin, capreomycin, and oral 
bacteriostatic drugs such ethionamide, prothionamide, D-cyclocerine, teridizone and para-
amino salicylic acid. Structures of the second-line drugs are displayed in Figure 1.6.  
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Figure 1.6: Second-line anti-TB drugs 
Poor management of chemotherapy and poor patient compliance have contributed to the 
appearance of drug-resistant strains of Mtb [multi drug-resistant (MDR) and extensively drug-
resistant (XDR) TB].16 According to the latest WHO report, 3.3% of new and 20% of 
previously treated TB cases have MDR-TB and 9.7% of MDR-TB patients have XDR-TB.1 
DR-TB is called MDR-TB when it is resistant to at least INH and RIF, the two most 
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important first-line drugs used in the treatment of TB.17  DR-TB is called XDR-TB when it is 
resistant to INH and RIF as well as any of the fluoroquinolones and the injectable drugs 
(amikacin, kanamycin or capreomycin).17  
Group 5 in Figure 1.4 comprises third-line anti-TB drugs which can be used to treat DR-TB if 
recommended drugs cannot be provided for some reason. Many of these drugs such as 
linezolid, amoxicillin, imipenem, meropenem and clofazimine are already in use to treat other 
bacterial infections. However, there is limited data available concerning their efficacy in TB 
and/or long-term safety in humans. Therefore, these drugs are not recommended by the WHO 
for routine use. Most of these drugs, with the exception of bedaquiline and delamanid, are not 
registered for treatment, making their use ‘off-label’. Chemical structures of third-line drugs 
are presented in Figure 1.7.  
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Figure 1.7: Third-line anti-TB drugs 
 
A brief description of the mechanisms of action of the above-mentioned anti-TB drugs and 
Mtb genes involved in drug resistance is given in Table 1.1.  
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Table 1.1: Anti-TB drugs, their mode of action and main Mtb genes involved in resistance 
Drug Mechanism of  Action Mtb genes  References 
First-line drugs  
Orally administered  
Isoniazid Prodrug which is activated by Mtb 
catalase-peroxidase encoded by the 
katG gene and targets Enoyl-[acyl-
carrier-protein] reductase (InhA) 
resulting in inhibition of mycolic acid 
synthesis. 
katG, inhA 18–21 
Rifampicin 
Rifabutin, 
Rifapentine 
Inhibit Mtb RNA synthesis by binding 
to the β-subunit of the Mtb RNA 
polymerase. 
rpoB 22–24 
Ethambutol Inhibits arabinosyl transferase, encoded 
by embB gene, an enzyme involved in 
the synthesis of arabinogalactan of cell 
wall. 
embB 25–27 
Pyrazinamide Prodrug is activated by pyrazinamidase 
encoded by pncA gene into pyrazinoic 
acid which after initial efflux from the 
cell gets reabsorbed under acidic pH 
and accumulates in the membrane, 
disturbing membrane potential. 
pncA 28–32 
Injectable    
Streptomycin Binds to the 30S subunit of the 
ribosome at the ribosomal protein S12 
and the 16S rRNA, thereby inhibiting 
protein synthesis 
rpsL and rrs 
encoding for 
S12 and 16S 
rRNA, 
respectively 
33–35 
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Table 1.1: Continued… 
Second-line drugs  
Injectable  
Kanamycin 
Amikacin 
Binds to 16S rRNA of 30S ribosome 
subunit resulting in inhibition of protein 
synthesis. 
rrs 36,37 
Capreomycin Binds to intersubunit bridge B2a 
between 30S and 50S ribosomal 
subunits, inhibits protein synthesis. 
tlyA encoding 
rRNA 2-O′ 
methyltransfer
ase 
38 
Fluoroquinolones (FQs)  
Levofloxacin, 
Moxifloxacin, 
Gatifloxacin 
Ofloxacin 
Inhibit DNA gyrase (topoisomerase II) 
and topoisomerase IV, thereby blocking 
DNA replication and transcription. 
gyrA 39,40 
Oral bacteriostatic  
Ethionamide 
Prothionamide 
Prodrug which is activated by flavin 
monooxygenase encoded by etaA or 
ethA and targets Enoyl-[acyl-carrier-
protein] reductase (InhA) thereby 
inhibiting mycolic acid synthesis. 
etaA or ethA, 
inhA 
 
 
41–44 
D-Cycloserine 
Terizidone 
Inhibit d-alanine racemase (AlrA) and 
d-alanine:d-alanine ligase (Ddl) 
involved in the synthesis of 
peptidoglycan of Mtb cell wall. 
Over 
expression of 
alrA, Ddl 
genes 
45,46 
p-Aminosalicylic acid Inhibit folic acid biosynthesis and 
uptake of iron. 
thyA, 47 
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Table 1.1: Continued… 
Third-line drugs  
Bedaquiline (TMC-207) Inhibits mycobacterial ATP (adenosine 5’-triphosphate) 
synthase, an enzyme that is essential for the generation of 
energy in Mtb. 
48 
Delamanid (OPC-67683) Prodrug which is activated by an F420-deazaflavin 
dependent nitroreductase and thereby inhibits the 
synthesis of mycobacterial cell wall components: 
methoxy mycolic acid and ketomycolic acid. 
49,50 
Linezolid Binds to the 23S rRNA of 50S ribosome subunit, inhibits 
protein synthesis. 
51 
Clofazimine Appears to kill Mtb through prodrug action that involves 
a redox cycling pathway. As demonstrated in M. 
smegmatis, the drug is reduced by NDH-2 enzyme 
(NADH:quinone oxidoreductase) and produces reactive 
oxygen species upon subsequent reoxidation by O2  
52 
Amoxicillin/Clavulanate Inhibits peptidoglycan synthesis.* 53 
Imipenem/Cilastatin Inhibits peptidoglycan synthesis.* 54 
Meropenem Inhibits peptidoglycan synthesis.* 54 
Thioacetazone Inhibits mycolic acid synthesis.* 55 
Clarithromycin Inhibits protein synthesis by binding to the 23S rRNA of 
50S ribosomal subunit.* 
56 
* Proposed mechanism of action in Mtb based on the mechanism of action in bacteria 
1.1.4 Treatment 
The current anti-TB therapy recommended by the WHO is called DOTS (directly observed 
treatment, short course). It requires the administration of four drugs: Isoniazid (INH), 
Rifampicin (RIF), Pyrazinamide (PZA) and Ethambutol (EMB) or Streptomycin (SM). These 
drugs may possess bactericidal and/or sterilizing activity individually to varying degrees, but, 
in combination, are highly effective against all populations (fast-replicating, slow-replicating 
and non-replicating or dormant) of Mtb. All these drugs (INH, RIF, PZA, EMB or SM) are 
administered for the first two months of treatment followed by four months of treatment with 
a combination of INH and RIF. These drugs destroy Mtb in all growth stages in the initial two 
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months of treatment. In the additional four months, RIF kills any residual dormant bacilli and 
INH kills any RIF-resistant mutants that commence replication.57 This regimen is more than 
40 years old and is currently implemented for the treatment of pulmonary TB and most forms 
of extra-pulmonary TB, regardless of HIV status.1,5 
Treatment of latent TB infection (LTBI) is essential to control and eliminate TB as it 
considerably reduces the risk of progress of TB infection to disease. Recommended latent TB 
treatment includes (1) INH at a dose of 300 mg daily for at least 6 months and preferably for 
9 months; or (2) INH and rifapentine each at a dose of 900 mg weekly for 3 months; or (3) 
RIF at a dose of 600 mg daily for 4 months. INH at a dose of 300 mg for 9 months is highly 
effective and is the preferred regimen for HIV-infected people taking antiretroviral 
medication, and children aged 2–11 years. INH and rifapentine, each at a dose of 900 mg 
weekly for 3-4 months, is another effective regimen option for otherwise healthy patients 
aged ≥ 12 years.5 
The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: 
Pyrazinamide (PZA); a fluoroquinolone; a parenteral agent (typically amikacin or 
kanamycin); ethionamide (or prothionamide); and either D-cycloserine or p-aminosalicylic 
acid, with preference for D-cycloserine. Such therapy should be administered for at least 20 
months in patients who have not received previous treatment for MDR-TB and for up to 30 
months in those who have received previous treatment. Because of limited data, there is no 
separate recommended treatment regimen for XDR-TB. A regimen similar to MDR-TB is 
used for patients with XDR-TB.5,15  
1.1.5 Challenges 
There are several major challenges associated with current TB treatment.6,58 The cure rates 
with the standard first-line regimen are quite high (exceeding 90%) when delivered under 
DOTS, a program promoted by WHO. This includes direct observation of patient 
consumption of the TB medications by trained personnel. However, there is poor patient 
compliance due to many factors such as the cost of drugs, side effects, long treatment 
duration and the number of drug doses required. This has led to suboptimal responses (failure 
and relapse), the emergence of resistance (MDR- and XDR-TB), and continuous spread of the 
disease. Second-line drugs which are used to treat MDR- and XDR-TB are not available 
everywhere especially in poor nations and are less effective, more expensive, more toxic, and 
require a longer treatment duration than first-line drugs.  
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The frequent co-infection of TB in HIV patients further complicates the selection of an 
appropriate treatment regimen. Additional pill burden of anti-TB drugs with HIV medications 
diminishes compliance in patients. Another major concern in the treatment of TB/HIV co-
infections is the drug-drug interaction involving RIF and the antiretroviral protease inhibitors. 
RIF is a potent cytochrome P450 3A4 enzyme inducer. Administering RIF along with  
antiretroviral protease inhibitors increases the metabolism of these protease inhibitors 
resulting in decreased therapeutic concentrations.59,60 Consequently, RIF should not be used 
in HIV patients who are under treatment with protease inhibitors. In addition to HIV, patients 
with diabetes are at increased risk of developing active TB, and have higher rates of treatment 
failure and death, even when placed on appropriate TB treatment.61–63 
Treatment of latent TB infection is equally important as it may substantially reduce the risk of 
developing active TB. However, the most preferred prophylactic treatment of latent TB (9-
month with 300 mg isoniazid daily) is quite long and shows poor adherence. 
The above-mentioned challenges emphasize the urgent need to develop new anti-TB drugs 
which can shorten the duration of TB treatment, reduce dosing frequency, have an acceptable 
toxicity profile, target MDR and XDR strains, be co-administered with HIV drugs, and be 
effective against latent TB.  
1.1.6 New anti-TB drugs in the pipeline 
Many novel compounds or repurposed drugs have been revealed in the past few decades with 
anti-TB activity and some of them have reached clinical trial stages. Figure 1.8 displays the 
current progress of anti-TB agents or drugs at various preclinical and clinical stages.  
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Figure 1.8: Current progress of anti-TB agents or drugs at preclinical and clinical stages 64 
For the first time in more than 40 years, two new anti-TB drugs, bedaquiline and delamanid, 
have been approved for MDR-TB. However, both drugs have only received conditional 
approval65–67and can be used as a part of combination regimen for treating adult pulmonary 
MDR-TB only when MDR-TB is in severe form or when other recommended regimens 
cannot be provided. Bedaquiline (or TMC-207, Figure 1.7) is a diarylquinoline with a novel 
mechanism of action and acts on both replicating and dormant mycobacteria. It specifically 
inhibits mycobacterial ATP (adenosine 5’-triphosphate) synthase, an enzyme that is essential 
for the generation of energy in Mtb.48 Delamanid (Figure 1.7) is a nitroimidazole prodrug, 
which is activated by an F420-deazaflavin dependent nitroreductase. It acts by inhibiting the 
synthesis of mycobacterial cell wall components methoxy mycolic acid and ketomycolic 
acid.49,50 The approval of bedaquline and delamanid is based on limited phase II clinical data 
in patients with pulmonary MDR-TB and on a review of the safety data gathered in these 
studies. Various safety and efficacy trials of delamanid and bedaquiline when added to short 
MDR-TB regimens of nine and six month’s duration are going on in Phase III.68–70 
Delamanid, due to its manageable side effects,50 is also being evaluated against MDR-TB in 
children.71 
Pretomanid or PA-824 (Figure 1.9), like delamanid, is another nitroimidazole prodrug that 
requires intracellular activation by an F420-deazaflavin-dependent nitroreductase. Activation 
produces a des-nitro metabolite that generates reactive nitrogen species (including NO) 
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leading to a decrease in intracellular ATP causing anaerobic killing (similar to the action of 
cyanide).72 Besides being effective in anaerobic conditions, PA-824 also kills aerobically by 
inhibiting cell wall mycolic acid biosynthesis.73 With its dual mode of action, the drug is 
effective against drug- susceptible and drug- resistant TB.  
Three pretomanid-containing combination regimens are in phase II and III clinical trials for 
the treatment of both drug- susceptible and drug- resistant TB.1,64 In one regimen, pretomanid 
in combination with moxifloxacin and PZA has shown active bactericidal activity in phase II 
trials over two months against both drug-susceptible and MDR-TB. The bactericidal activity 
was found to be significantly superior when compared with the standard combination therapy 
(INH, RIF, PZA, EMB) against drug-susceptible TB. The regimen has now advanced to the 
phase III clinical trial stage. Another regimen containing pretomanid, bedaquiline and 
linezolid, is in phase III for evaluation of safety and efficacy against XDR-TB. A pretomaind-
bedaquiline-PZA combination is also being tested in phase II against drug-susceptible TB and 
against drug-resistant TB with addition of moxifloxacin. 
Rifapentine (Figure 1.5), a RIF derivative, displays better pharmacokinetic properties relative 
to RIF such as increased half-life and decreased CYP3A4 induction. Rifapentine has been 
shown as a potential substitute for RIF.74,75 A new combination containing rifapentine and 
moxifloxacin is also in phase III clinical trials to assess the efficacy of this regimen for less 
than two months in patients with drug-susceptible TB.76  
The ethylenediamine derivative SQ109 (Figure 1.9) is structurally related to EMB but has a 
different mechanism of action thereby displaying activity against EMB-resistant Mtb strains. 
This drug targets the Mtb transmembrane transporter protein encoded by the mycobacterial 
membrane protein large 3 (MmpL3) gene, and interferes with cell wall assembly.77 SQ109 is 
currently in phase II clinical trials. Other phase II candidates are the oxazolidinones: 
linezolid, its thiomorpholine analogue PNU-100480 (sutezolid) and AZD5847, which inhibit 
protein biosynthesis via binding to the 23S rRNA of the 50S ribosome subunit.  
Many drugs have progressed to the preclinical development stage (Figure 1.9). These include 
a caprazamycin derivative CPZEN-45, two DprE1 inhibitors benzothiazinones (BTZ043 and 
PBTZ169), a spectinomycin derivative 1599, a dipiperidine derivative SQ609, a capuramycin 
derivative SQ641, a DprE1 Inhibitor TBA-7371, a leucyl-tRNA synthetase inhibitor GSK-
070 and a riminophenazine derivative TBI-166.64 An imidazopyridine Q203 has advanced to 
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the phase I stage for the evaluation of safety, tolerability and pharmacokinetics of single 
doses of Q203 in healthy volunteers.78 Figure 1.10 summarizes targets of existing anti-TB 
drugs (purple) as well as those of current pipeline drugs (red). 
 
Figure 1.9: Chemical structures of clinical and preclinical candidates for the treatment of TB 
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Figure 1.10: Targets of existing (purple) and pipelined (red) anti-TB drugs79 
In summary, TB is occurring in more than 200 countries worldwide, killing one and half 
million people each year. Current TB treatment is faced with many challenges such as poor 
patient compliance due to administration of multiple drugs and longer treatment durations, 
emergence of Mtb resistant strains, and TB/HIV co-infections. New anti-TB drugs with novel 
mechanisms of action are thus needed to overcome these challenges and to achieve global 
control of TB. 
1.2 Malaria  
1.2.1 Disease and epidemiology  
Malaria is transmitted in nearly 100 countries worldwide. According to latest estimates 
released by WHO,80 around 214 million cases of malaria occurred in 2015 and the disease led 
to nearly half a million deaths worldwide. Malaria is most prevalent in Africa which alone 
accounted for 88% of all malaria cases and 90% of all malaria deaths in 2015. The remaining 
cases of malaria have been reported in South-East Asia and the Eastern Mediterranean 
Regions with 10% and 2% of all malaria cases, respectively. 
Malaria in humans is transmitted by the bite of a female Anopheles mosquito infected by a 
parasite called Plasmodium.81 Five Plasmodium species are responsible for causing malaria in 
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humans. These are P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi.82 P. 
falciparum, among these, is the most virulent and is mainly found in Africa where it is the 
primary cause of malaria morbidity and mortality. In regions outside Africa, South-East Asia 
and South America, substantial cases of infections occur due to P. vivax species.80 The 
virulence of P. vivax is due to the dormant liver stage of the parasite that can later activate 
and cause the disease months after the mosquito bite. Infections due to P. malariae and P. 
ovale are less common. P. malariae is located worldwide in Africa, South-East Asia and 
South America while P. ovale infections mainly occur in Africa. Similar to P. vivax, P. ovale 
also produces dormant liver stage parasites causing malaria months after the mosquito bite. P. 
knowlesi causes malaria mainly among monkeys but cases of human infections have been 
reported in certain forested areas of South-East Asia in recent years.80,83 
Malaria can be uncomplicated or severe malaria based on the parasite burden in the host. 
Uncomplicated malaria can be caused by all the above five Plasmodium species. Symptoms 
of uncomplicated malaria are non-specific and frequently include fever, and chills 
accompanied by headache, fatigue, abdominal discomfort, muscle and joint aches and 
vomiting. These symptoms should be diagnosed quickly if a person is living or has travelled 
to a malaria endemic region. Severe malaria is caused only by P. falciparum. In the absence 
of prompt treatment, the parasite burden continues to grow and uncomplicated malaria can 
progress to severe malaria. The main symptoms of severe malaria include coma (cerebral 
malaria), severe anaemia, hypoglycaemia, metabolic acidosis, acute renal failure or acute 
pulmonary oedema. Severe malaria is diagnosed when one of these symptoms occur with no 
other obvious cause accompanied by the presence of P. falciparum parasites in that region. 
1.2.2 Transmission and Pathology 
The life cycle of the Plasmodium parasite is divided between the female Anopheles mosquito 
and human (Figure 1.11).84,85 The Plasmodium parasites are found as "sporozoites" in the 
salivary glands of an infected mosquito. When the mosquito bites a human, the sporozoites 
are released into the human’s bloodstream. Sporozoites are rapidly taken up by the liver cells, 
where they multiply and develop into schizonts over the next one or two weeks.86 This is 
called the exoerythrocytic stage of infection and is asymptomatic. This process occurs with 
all Plasmodium species, except with P. vivax and P. ovale which can become dormant in the 
liver as ‘hypnozoites’ and cause malaria by invading the bloodstream weeks or even years 
later, causing clinical symptoms of malaria without a recent mosquito bite.87–89  
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Schizonts rupture to release merozoites into the bloodstream where they invade 
erythrocytes.86 Within the erythrocytes, merozoites successively mature from ring forms to 
trophozoites and then to multinucleated schizonts (over 48 hours for P. falciparum, P. vivax 
and P. ovale, 72 hours for P. malariae and 24 hours for P. knowlesi).90 These schizonts then 
rupture and release more merozoites in the blood which then infect more blood cells. This 
cycle of asexual multiplication is repeated and is known as the erythrocytic stage of the 
infection. Rupturing of schizonts releases parasites and host cellular material into the blood 
stream. This activates macrophages to release pro-inflammatory cytokines which cause fever 
and other pathological effects.  
Within some infected blood cells, Plasmodium enters a sexual multiplication cycle.  The 
merozoites develop into sexual forms of the parasite called gametocytes. Gametocyte-
containing blood cells circulate in the bloodstream. When a mosquito feeds on infected 
human blood, it ingests the blood cells which burst in the mosquito’s gut, thus releasing the 
gametocytes. These then develop further into mature sex cells called gametes. Male and 
female gametes fuse to form diploid zygotes, which develop into actively moving ookinetes 
that burrow into the mosquito midgut wall and form oocysts. Growth and division of each 
oocyst produces thousands of active haploid forms called sporozoites. After one or two weeks 
(time frame depends on Plasmodium species), the oocyst bursts and releases sporozoites into 
the body cavity of the mosquito, from where they travel to and invade the mosquito’s salivary 
glands. The cycle of human infection re-starts when the mosquito bites again.85,91,92 
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Figure 1.11: Life cycle of Plasmodium parasite93 
Upon invasion of the erythrocytes, the parasite degrades and consumes intracellular 
components, primarily haemoglobin. The parasite degrades haemoglobin in the food vacuole 
into heme (iron porphyrin) and globulin (protein), which are important sources of iron and 
amino acids, respectively, and are utilised in the synthesis of various parasitic proteins. Heme 
as such is toxic for the parasite as it can generate free radicals and reactive oxygen species 
which can degrade plasmodial proteins, lipids and DNA molecules. Therefore, Plasmodium 
detoxifies this iron-rich compound by polymerising it into the crystalline hemozoin (malaria 
pigment). Quine, chloroquine (CQ), mefloquine and other related drugs target the parasite 
through inhibition of hemozoin formation. 
1.2.3 Antimalarial drugs  
Total eradication of malaria can potentially be achieved by the effective prevention and 
treatment of malaria. Prevention of malaria can be further achieved by 1) control of the vector 
mosquito Anopheles and 2) chemoprophylaxis and chemoprevention. Deployment of long-
lasting-insecticide-treated mosquito nets, application of mosquito repellents to the skin, 
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spraying of the user-friendly insecticides in houses, buildings and agriculture in areas of 
moderate or high transmission have all substantially contributed to the decrease in malaria 
morbidity and mortality, by controlling the bite of vector mosquito Anopheles. Once the 
clinical symptoms develop and the patient is diagnosed with malaria, treatment of the disease 
becomes necessary with the available antimalarial drugs. The available antimalarial drugs can 
be classified as following. 
1. Quinolines: Quinine, CQ, piperaquine, amodiaquine, mefloquine, primaquine 
2. Aryl amino alcohols: halofantrine, lumenfantrine 
3. Sulfones and sulfonamides: Dapsone and sulfadoxine (Type 1 antifolates) 
4. Guanidines and diaminopyrimidines: Proguanil, chloroproguanil, pyrimethamine 
(Type 2 antifolates) 
5. Naphthoquinones: Atovaquone 
6. Artemisinin derivatives or peroxides: artemether, arteether, artesunate, artelinic acid 
7. Antibiotics: Tetracycline, doxycycline, clindamycin 
Another way of classifying the above-mentioned antimalarial drugs is based on the specific 
stage of the Plasmodium life cycle at which the drug shows its antimalarial action. Drugs that 
eliminate developing or dormant liver forms, such as primaquine, are called tissue 
schizonticides. Drugs that act on the blood forms of the parasite (erythrocytic parasites) and 
thereby terminate clinical attacks of malaria are called blood schizonticides. These are the 
most important drugs in anti-malarial chemotherapy. All above-mentioned drugs except 
primaquine possess this activity. P. vivax and P. Ovale infections not only require the cure of 
blood stage infection but also require the prevention of relapse by the killing of hypnozoites 
and therefore need both tissue schizonticides and blood schizonticides. This treatment method 
is known as radical cure of malaria. Drugs that kill sexual stages of the parasite i.e. 
gametocytes and prevent transmission are called gametocides. Complete and effective 
treatment of malaria requires drugs with activity at all growth stages of the parasite. Figure 
1.12 displays the chemical structures of currently used antimalarial drugs. 
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Figure 1.12: Chemical structures of currently used antimalarial drugs 
Quinine is one of the oldest antimalarial agents. It was first isolated from the cinchona tree in 
1820. Quinine was later replaced with a safer drug, a 4-aminoquinoline: CQ, and is now used 
to treat severe cases of malaria.94 CQ was introduced in the 1940s and resistance emerged 
approximately 10 years after its introduction. CQ is also used as the first-line treatment of P. 
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vivax infections; however, the prevalence of CQ-resistant P. vivax is increasing. Nevertheless, 
the efficacy, affordability and safety, even during pregnancy, made it the gold standard 
treatment of malaria for many years.95 CQ is still used as first-line drug in most African 
countries. Amodiaquine is another 4-aminoquinoline which has been in use for more than 70 
years. Amodiaquine has a short half-life of 3 h, thus the antimalarial activity is thought to be 
exerted by the primary metabolite, monodesethylamodiaquine, which has a half-life of 9-18 
days.96 The 4-methanol quinoline: mefloquine and the two aryl amino alcohols: halofantrine 
and lumenfantrine are used to treat CQ-resistant malaria. 
All the above-mentioned quinolines and aryl amino alcohols are blood schizontocides and are 
used in the treatment of clinical infections due to P. falciparum.97The 8-aminoquinoline 
primaquine, which is a tissue schizontocide, is not used in curing P. falciparum malaria but it 
is the only approved therapy for the treatment of P. vivax dormant liver stages.98 
CQ, due to its weakly basic nature (pKa values at 8.1 and 10.2), can diffuse freely across 
membranes at the neutral pH of the blood. However, due to the acidic nature of the parasite’s 
food vacuole, it becomes diprotonated and trapped inside this compartment. This allows CQ 
to accumulate in large quantities in the food vacuole where it binds to heme dimer and 
prevents polymerisation of heme into hemozoin, resulting in death of the parasite. 
Mechanisms of action of other quinolines and aryl amino alcohols are not much clear. 
However, they all have been  proposed to inhibit heme detoxification based on the similarity 
in their chemical structures and some in vitro studies.97,99,100 
Atovaquone is a hydroxynaphthoquinone analogue and is used in combination with proguanil 
as ‘Malarone’, mainly as a prophylactic medication for tourists. Atovaquone has been shown 
to inhibit the respiratory chain of plasmodial mitochondria at the cytochrome bc1 complex by 
mimicking the natural substrate, ubiquinone. 101,102 
The antifolate drugs inhibit two key enzymes in the folate biosynthesis pathway in plasmodia 
and are accordingly classified as type 1 and type 2 antifolate drugs depending upon the 
enzyme they inhibit. Type 1 antifolates inhibit the dihydropteroate synthase enzyme 
(PfDHPS) and include sulfadoxine and dapsone. Type 2 antifolates inhibit the dihydrofolate 
reductase enzyme (PfDHFR) and include pyrimethamine and proguanil. Antifolate drugs are 
highly effective when used in combination. The drug combination sulfadoxine-
pyrimethamine, named as ‘Fansidar’, was introduced in 1970s after the emergence of CQ-
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resistant parasites and was highly effective, cheap and well-tolerated with good compliance 
rates due to being administered in a single dose. However, resistance of Plasmodium to these 
antifolates emerged quickly after their introduction. Therefore, the sulfadoxine-
pyrimethamine combination is now primarily used as an intermittent preventative malaria 
treatment during pregnancy and to a lesser extent for the treatment of malaria infection. The 
other combination dapsone-proguanil, named as ‘Lapdap’, is no longer recommended as 
dapsone causes hemolysis in G6PD-deficient patients.103 
The most recent and effective class of antimalarial drugs is the peroxides, which include 
artemisinin and its derivatives (dihydroartemisinin, artemether, arteether, artesunate and 
artelinic acid). They have tissue, blood-schizontocidal and gametocidal activity and therefore 
eliminate all stages of the parasite. Artemisinin is a natural product isolated from the 
Artemisia annua plant (Chinese wormwood). Artemisinins display a unique trioxane structure 
with an endoperoxide bond that is mandatory for antimalarial activity. The mechanism of 
action of artemisinin is not fully understood but the prevailing theory is that the endoperoxide 
bridge is cleaved reductively by Fe(II) of heme proteins, leading to the formation of reactive 
carbon radicals that subsequently alkylate essential biomolecules.104,105  
Antibiotics such as tetracycline, doxycycline and clindamycin are quite effective, albeit slow-
acting antimalarials. Due to their slow action, these antibiotics are used in combination with 
more rapidly acting drugs like quinine. These antibiotics target the parasite apicoplast, a 
nonphotosynthetic plastid organelle, unique to plasmodia and other apicomplexan parasites. 
In Plasmodium species, the apicoplast appears to be essential for the synthesis of fatty acids, 
isoprenoids and heme.106 The apicoplast expresses its own genome, which encodes a small set 
of genes (approximately 30). The apicoplast proteome is thus supplemented by as many as 
500 nucleus-encoded apicoplast-targeted proteins. Antibiotics disrupt the apicoplast 
translation machinery during the first replication cycle delivering non-functional apicoplasts 
into the progeny during the second cycle. This results in the interruption import or export of 
new nuclear and apicoplast-encoded proteins during the second cycle, resulting in death of 
the parasites. However, during this first cycle, these antibiotics do not affect the apicoplast 
metabolic functions, especially those catalyzed by nuclear-encoded proteins, since they are 
already present in the apicoplast at the time of the antibacterial exposure. This explains the 
delayed death effect (DDE) of these antibiotics.107,108                                                        
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1.2.4 Treatment 
The WHO has provided guidelines for treating P. falciparum malaria based on the severity of 
the disease which can be uncomplicated or severe P. falciparum malaria.109  
Following artemisinin combination therapies (ACTs) are recommended for the treatment of 
uncomplicated P. falciparum malaria over a period of three days:  
1. Artemether plus lumefantrine 
2. Artesunate plus amodiaquine 
3. Artesunate plus mefloquine 
4. Dihydroartemisinin plus piperaquine 
5. Artesunate plus sulfadoxine-pyrimethamine 
ACT can be orally administered to all children and adults except pregnant women in their 
first trimester. Seven day treatment of quinine plus clindamycin has been recommended for 
pregnant women in the first trimester. ACT therapy is also recommended in uncomplicated 
malaria caused by species other than P. falciparum. Patients with P. vivax or P. ovale 
infections should be given a primaquine treatment after ACT to eradicate hypnozoites.  
Severe P. falciparum malaria treatment is started with intravenous or intramuscular injection 
of artesunate for at least 24 h and until the patient can tolerate oral medication. After the 
patient has received parenteral therapy and is now able to tolerate oral medication, treatment 
is completed with 3 days of ACT. Use of intramuscular artemether is recommended if 
artesunate is unavailable and intramuscular quinine dihydrochloride when both artesunate and 
artemether are unavailable. This treatment of severe malaria is given regardless of adults, 
infants or pregnant women.  
1.2.5 Challenges 
P. falciparum has developed resistance to quinolines and related analogues, to antifolates, to 
inhibitors of electron transport and, more recently, to artemisinins.97,110–113 Therefore, new 
medicinal agents with novel mechanisms of action are needed to overcome the problem of 
resistance. 
ACTs are the current standard of care for uncomplicated malaria. Artemisinin and its 
derivatives have a fast onset of action but short half-lives (t1/2 = 0.5-4 h) and rapid clearance. 
Therefore, artemisinins are combined with slow-clearing drugs like lumefantrine (t1/2 = 3-4 
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days) and piperaquine (t1/2 = 8-16 days) to kill residual parasites. New drugs are needed, 
which possess potencies similar to artemisinins but with longer half-lives. 
For complete eradication of malaria, drugs are needed that can eliminate liver stage 
hypnozoites, block transmission of the parasite by acting on gametocytes and are active in the 
mosquito stages of the parasite.  Primaquine is the only drug approved to eliminate 
hypnozoites and is also active against mature gametocytes. There is no drug currently 
registered to target mosquito stages. Patient compliance to the current treatment is poor due to 
multiple doses, adverse reactions, costliness and unavailability of the drugs in poor 
communities. 
In order to overcome the above-mentioned challenges, new drugs should be efficacious 
against drug-resistant strains, provide cure within a reasonable time (ideally three days or 
less) to ensure good compliance, be safe, be suitable for small children and pregnant women, 
have appropriate formulations for oral use and, above all, be affordable. 
1.2.6 Antimalarials in the pipeline 
As of March 2016, there are 9 antimalarial compounds being evaluated in humans for safety, 
pharmacokinetics and efficacy. In addition, 9 compounds are in preclinical studies for their 
evaluation as potential candidates to go further in human trials.  Most of these compounds 
possess novel mechanisms of action and thus evade drug resistance (Figure 1.13 and 1.14). A 
brief description of these preclinical and clinical candidates is given below.   
Primaquine is the only available drug so far that can prevent relapse due to P. vivax malaria. 
A new 8-aminoquinoline named tafenoquine has been developed that has shown activity 
against P.vivax life cycle including dormant forms. The drug is in Phase III trials to 
investigate a single dose treatment for relapsing P. vivax malaria.114  
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Figure 1.13: Global pipeline of preclinical and clinical antimalarial candidates115 
The problem of short half-lives for artemisinins can be overcome by improving both 
metabolic stability and aqueous solubility. A new endoperoxide OZ439, has been developed, 
which show greater metabolic stability and improved aqueous solubility. OZ439 is a 1,2,4-
trioxolane analogue containing adamantyl and 4-morpholinoethoxyphenylcyclohexyl 
moieties. This drug maintains activity across all asexual blood stages of the parasite such as 
rings, trophozoites and schizonts. This compound has a half-life of 25-30 h which has not 
been achieved with any other artemisinin derivative. The extended half-life and better 
solubility has improved the oral pharmacokinetic profile of OZ439.116 OZ439 has completed 
phase IIa trials for acute, uncomplicated malaria in patients with P. falciparum or P. vivax 
malaria monoinfection117,118  and is currently in phase IIb studies to determine the efficacy in 
combination with piperaquine for uncomplicated P. falciparum malaria.119 CDRI 97/78 is 
another 1,2,4-trioxolane derivative which has been found to be safe with an average half-life 
of 5 h, in a single ascending dose safety and pharmacokinetics study conducted in healthy 
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volunteers.120 CDRI 97/78 exerts its action by rapidly converting into its active alcohol 
metabolite arising from hydrolysis or metabolism of the ester group. 
 
Figure 1.14: Chemical structures of preclinical and clinical antimalarial candidates 
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Two novel molecules developed by Novartis, a spiroindolone KAE609 and an 
imidazolopiperazine KAF156, are also in phase II trials to assess safety and efficacy in P. 
falciparum or P. vivax malaria monoinfection.121 KAE609 inhibits the P-type cation 
transporter ATPase 4 (PfATP4), which regulates sodium concentration in the parasite 122 
while KAF156 targets the P. falciparum cyclic amine resistance locus (Pfcarl) gene that 
encodes a transmembrane protein believed to play a role in protein folding within the 
endoplasmic reticulum.123 Further, KAF156 was found to be completely protective as a single 
oral dose of 10 mg/kg when administered prophylactically in a sporozoite challenge mouse 
model.123 Based on this preclinical study, sporozoite challenge study in human volunteers is 
ongoing in order to evaluate the potential of KAF156 as a chemoprophylactic agent in 
malaria.115 
A triazolopyrimidine derivative DSM265 is one more candidate in phase II. DSM265 is a 
selective inhibitor of P. falciparum dihydroorotate dehydrogenase (DHODH). DHODH is 
involved in the biosynthesis of pyrimidines, which are important components of DNA and 
RNA. DSM265, thus, has the potential to prevent and cure malaria by targeting the ability of 
the parasite to replicate both in liver and blood stages.124 DSM 412, obtained by replacing the 
SF5-phenyl group of DSM265 with a CF3-pyridyl, is another member of this series which has 
reached preclinical trials.  
Other preclinical and clinical candidates include a P. falciparum phosphatidylinositol 4-
kinase (PfPI4K) inhibitor MMV048, a peptidomimetic protease inhibitor ACT-451840, three 
PfATP4 enzyme inhibitors SJ733, PA92 and GSK030, a P. falciparum dihydrofolate 
reductase (PfDHFR) inhibitor P218, a P. falciparum eukaryotic elongation factor 2 (PfeEF2) 
inhibitor DDD498, a V-type H+ ATPase inhibitor MMV 253, and three candidates, JPC2997, 
AN762 and GSK692, with unknown mechanisms of action.115  
In summary, malaria is being transmitted worldwide in nearly 100 countries causing half a 
million deaths each year. The emergence of resistant strains of P. falciparum has hindered 
current antimalarial treatment and global control of the disease. New drugs with novel 
mechanisms of action are required to overcome resistance and contribute to the eradication 
agenda. 
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1.3 Conclusion 
The high epidemiology of TB and malaria, and emerging drug resistance in both diseases 
necessitates the discovery of new agents with novel mechanisms of action. This project, 
therefore, seeks to contribute to this aspect and is an attempt to identify novel agents effective 
against TB and / or malaria using approaches underpinned by medicinal chemistry.  
Chapter 2 provides a discussion of drug repositioning/ repurposing as an approach to fast-
track the process of drug discovery and development, and its application in the field of 
chemotherapy for TB and malaria.  
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Chapter 2 
Drug Repositioning/Repurposing 
As explained in chapter 1, there is a need for the development of novel agents to overcome 
drug resistance and other challenges associated with the treatment of TB and malaria. The 
development of a new drug is a lengthy and costly process; therefore, the need for approaches 
that can save both time and money has been emphasised within this area of research. Drug 
repositioning and/or repurposing is one such approach. This chapter describes the application 
of drug repositioning within the context. 
2.1 Drug repositioning/repurposing as an approach in drug discovery 
The development of a new drug begins with the discovery of new hits. These hits are 
optimized by medicinal chemistry approaches to find new drug candidates which are then 
tested in various preclinical and clinical trials before entering the market. This process is quite 
lengthy and typically takes 12-14 years or sometimes even longer, and involves immense 
effort and money. Therefore, efforts to accelerate the drug discovery process have been the 
focus within this field of research.  
One of the strategies to accelerate the drug development process is called drug repositioning 
or repurposing.1 The two terms ‘repositioning’ and ‘repurposing’ have been used 
interchangeably but their individual meanings are different.  “Drug repurposing” is applied to 
existing drugs, which can be used for a new indication without any chemical modification. 
Changes are made by optimising only the doses in preclinical and clinical stages. On the other 
hand, ‘drug repositioning’ is a broader term and refers to the chemical modification of a pre-
existing drug. This term can also be applied to drugs, which have been rescued from phase III 
or IV clinical stages. Briefly, drug repositioning/repurposing allows pre-existing drugs to be 
used for indications that were not their initial target. The benefit of applying such an approach 
is that the pharmacokinetic and safety profiles of these drugs are already known and, 
therefore, this substantially reduces the money and time involved in new drug development. 
Several examples can be found in medicine history that supports this concept. For example, 
as described in Table 2.1, methotrexate was initially used to treat cancer but has also been 
shown to be useful in the treatment of rheumatoid arthritis; minoxidil was initially used in the 
treatment for hypertension but subsequently used to treat hair loss; sildenafil was successfully 
repurposed from a drug prescribed for hypertension to a drug now prescribed for erectile 
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dysfunction; thalidomide was initially developed as a sedative, analgesic and antiemetic to 
treat morning sickness and is now successfully used in the treatment of multiple myeloma.1,2  
Table 2.1: Examples of drug repositioning/repurposing2 
Drug Original indication New indication Year* 
Amphetamine Stimulant Hyperkinesis in children (attention 
deficit hyperactivity disorder, 
ADHD) 
1943 
Allopurinol Tumor lysis syndrome Gout 1967 
Zidovudine Cancer HIV/AIDS 1985 
Minoxidil Hypertension Hair loss (Alopecia) 1988 
Bupropion Depression Smoking cessation 1997 
Sibutramine Depression Obesity 1997 
Finasteride Benign prostatic 
hyperplasia 
Alopecia 1997 
Methotrexate Cancer Rheumatoid arthritis 1999 
Fluoxetine Depression Premenstrual dysphoric disorder 2000 
Atomoxetine Parkinson’s disease ADHD 2002 
Thalidomide Morning sickness Multiple myeloma 2003 
Cymbalta Depression Diabetic peripheral neuropathy 2004 
Topiramate Epilepsy Migraine 2004 
Paclitaxel Cancer Restenosis 2004 
Sildenafil Angina Erectile dysfunction 2005 
Requip Parkinson’s disease Restless legs 2005 
Lumigan Glaucoma Hypotrichosis simplex 2009 
Dapoxetine Analgesia and depression Premature ejaculation 2009 
Milnacipran Depression Fibromyalgia syndrome 2009 
Phentolamine Hypertension Dental anesthesia reversal agent 2009 
Lidocaine Local anesthetic Arrhythmia 2010 
Mifepristone Pregnancy termination Cushing’s syndrome 2012 
* Year of first approval in new indication 
Many drugs display off-target activity that often results in undesirable side effects. A drug 
can affect multiple targets or an individual target can be involved in multiple biological 
pathways. In addition, similarities in biochemical pathways, cell biology and biological 
processes can also be seen in different diseases. Knowledge of additional targets of a drug, 
the role of these targets in different biological pathways, as well as similarity in cell biology 
and biological processes in different diseases can help researchers identify potential drug 
candidates for repositioning/repurposing.  
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Based on the above discussion, there are two basic approaches for drug 
repositioning/repurposing (Figure 2.1): (1) discovering a new target for a known drug, (ii) 
discovering the role of a known target in a new indication.  
A simple and common procedure, which is usually followed to identify potential drug 
candidates for repositioning is the phenotypic whole cell screening against an indication, 
followed by target investigation. 
 
Figure 2.1: Approaches for drug repositioning/repurposing.3 
2.2 Drug repositioning/repurposing in tuberculosis (TB) 
Many drugs have either been, or shown the potential to be, repositioned in TB. Some of these 
drugs are merely the outcomes of expansion of their antibacterial spectrum while others have 
come from totally different indications.  
The best example of drug repositioning for TB exists in the form of fluoroquinolones (Figure 
2.2).4,5 Fluoroquinolones are DNA gyrase inhibitors and were originally introduced for the 
treatment of several bacterial infections, for example, bone and joint infections, skin 
infections, urinary tract infections, serious ear infections, bronchitis, and pneumonia. 
Fluoroquinolones have been successfully included in the WHO recommended treatment 
regimen for MDR-TB. All fluoroquinolones currently in use are synthetic derivatives of the 
parent compound nalidixic acid, which was discovered as a by-product during purification of 
the antimalarial drug chloroquine in 19626 and has been used to treat urinary tract infections.7 
New fluoroquinolones have been obtained through structural modifications of nalidixic acid 
(Figure 2.2), yielding far more potent and broad-spectrum antibiotics.8   
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Figure 2.2: Chemical structures of repositioned fluoroquinolones for the treatment of TB 
Since the successful repositioning of fluoroquinolones, many other antibiotics have been 
explored in TB. Linezolid (Figure 2.3), a third-line anti-TB drug, belongs to oxazolidinone 
class of antibiotics and is a protein synthesis inhibitor. Linezolid was originally introduced for 
the treatment of various infections caused by methicillin-, vancomycin- and penicillin-
resistant bacterial strains.9 The broad-spectrum activity of linezolid was then explored in TB 
bacteria.  After successful in vitro and in vivo evaluations in the mouse model, linezolid was 
also found efficacious and tolerable in MDR-TB patients. Due to toxicity issues, such as 
anaemia, and peripheral and optic neuropathy,10 the use of linezolid is limited to selected 
cases of drug-resistant TB when fewer treatment options are available. The high efficacy of 
linezolid led researchers to investigate the oxazolidinone class of antibiotics. Newer 
oxazolidinone derivatives PNU-100480 and AZD5847 with superior in vitro activity and in 
vivo efficacy11,12 have been developed and are expected to possess superior safety profiles 
compared to linezolid. Likewise, two newly-developed candidates PA-824 and OPC-67683 
(Figure 2.3) have been repositioned from the antibiotic metronidazole. These drugs possess 
activity against both anaerobic and aerobic Mtb through a dual mechanism of action, as 
follows: (i) killing anaerobic Mtb by generating reactive nitrogen species during activation by 
a F420-deazaflavin dependent nitroreductase; and, (ii) killing aerobic Mtb by inhibiting cell 
wall mycolic acid biosynthesis.13,14 The precursor metronidazole, itself is highly active 
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against Mtb15 and has been reported to prevent reactivation of latent TB in the macaques 
model.16  
 
Figure 2.3: Chemical structures of repositioned anti-TB drugs and potential repositioning 
candidates  
The anti-leprosy drug clofazimine (Figure 2.3) is successful in treating MDR- and XDR-TB. 
Clofazimine is a riminophenazine derivative that appears to kill Mtb by affecting intracellular 
redox cycling.17 In addition, clofazimine has also been shown to reverse the inhibitory effect 
of Mtb on the phagocyte’s intracellular killing mechanisms.18 Although the efficacy and role 
of clofazimine is not fully established, the regimens including clofazimine are able to shorten 
the treatment of MDR- and XDR-TB.19 In addition to clofazimine, many riminophenazine 
derivatives possess high bactericidal and sterilizing activity against TB both in vitro and in 
vivo in mouse models of TB. However, the unwelcome skin pigmentation caused by the use 
of riminophenazines hinders the development of this class of drugs.20,21 Efforts have been 
made to identify riminophenazine derivatives with improved physicochemical and 
pharmacokinetic properties that will avoid discoloration of the skin, but fight TB with 
efficacy that is similar to clofazimine. One such derivative, TB1-166, is in preclinical trials.22  
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Thioridazine (Figure 2.3) is an antipsychotic drug that has also shown promising in vitro and 
in vivo (mouse model) activity against MDR- and XDR-TB.23 It also possess in vitro activity 
against dormant forms of Mtb suggesting that it could also be used for latent TB therapy, 
either alone or in combination with existing anti-TB drugs.24  
In addition to the above drugs, many other drugs have been identified with promising in vitro 
activity against sensitive as well as resistant Mtb strains (Figure 2.4). For example, a novel 
candidate and anti-helminthic drug, pyrvinium pamoate, possesses strong inhibitory effects 
(MIC 310 nM) against the H37Rv strain of Mtb.25 Disulfiram, which has been in use since the 
1940s to treat chronic alcoholism, has shown complete inhibition of H37Rv growth at 5.26 
µM. The drug has also shown the same level of inhibition against clinical isolates and MDR 
and XDR strains of Mtb, and remarkable bactericidal activity in an in vivo experiment on 
guinea pigs.26 A trimethoprim-sulfamethoxazole combination (Co-trimoxazole), which is 
used as a prophylactic agent to treat non-tuberculosis bacterial infections in HIV-infected 
patients, has been found active against 100 wild type, MDR and XDR Mtb isolates with in 
vitro MIC distribution ranging from 0.125/2.4 to 2/38 µg/ml.27 The anti-protozoal drug 
nitazoxanide is active against replicating and non-replicating forms of Mtb. Since any attempt 
to raise resistant mutant Mtb strains for this drug failed, the drug is thought to have a novel 
mechanism of action through which it bypasses resistance. 28 The antimalarial drug 
mefloquine has been shown to be active in vitro with an average MIC of 21 µM against more 
than hundred sensitive and resistant Mtb strains.29 The drug has also shown good activity in 
macrophages.30  
 
Chapter 2: Drug Repositioning/Repurposing 
 
48 
 
 
Figure 2.4: Chemical structures of new promising candidates with effective in vitro activity 
against Mtb  
2.3 Drug repositioning/repurposing in malaria 
There are examples in malaria which show that the drug repositioning approach has made 
useful contributions to antimalarial drug development. Several broad spectrum antibiotics are 
effective antimalarial drugs in certain settings. For example, a synthetically derived 
tetracycline doxycycline, which has been in use as a broad spectrum antibiotic since 1967, 
has been successfully repositioned for chemoprophylaxis and treatment of malaria.  Likewise 
clindamycin, a lincosamide antibiotic, which was originally used for acne treatment and 
numerous other applications since 1940, is now used clinically for the treatment of malaria 
These antibiotics, due to their delayed death effect31 (killing Plasmodium parasites in the 
second replication cycle which leads to delayed clearance of the parasite), are usually 
combined with rapid-acting standard antimalarials such as chloroquine (CQ) and quinine 
during treatment.  
A number of sulphonamide-containing drugs are in the clinic for the treatment of a wide 
range of human diseases, including kidney disease, glaucoma, epilepsy, obesity and cancer.32 
Sulphonamides that target the folate biosynthesis pathway in bacteria have been evaluated as 
antimalarials since the same pathway is also present in Plasmodia. One such sulphonamide, 
sulphadoxine, originally developed as an antibacterial, has been used in combination therapy 
to treat P. falciparum infections. Sulfadoxine in combination with pyrimethamine, under the 
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name ‘Fansidar’, is used as an intermittent preventive treatment of malaria during pregnancy. 
This combination is also used in the treatment of uncomplicated malaria in combination with 
artesunate.33  Likewise, another sulphonamide, sulfamethoxazole, in combination with 
trimethoprim, under the name ‘Co-trimoxazole’,34 is currently recommended by the WHO as 
prophylaxis against opportunistic infections (malaria and several bacterial infections) in HIV-
infected patients.35,36  
 
Figure 2.5: Chemical structures of repositioned antimalarial drugs  
Since the successful repositioning of the above drugs, a number of FDA-approved drugs as 
well as those where clinical development has been discontinued before approval, have been 
screened for antiplasmodial activity. For example, screening of a library of 2,687 compounds 
containing 1,937 FDA-approved and 750 other compounds in clinical development identified 
the antiplasmodial activity of astemizole (a histamine H1 antagonist) with an IC50 value of 
227 nM against the 3D7 P. falciparum strain37. Unfortunately, this drug could not be 
repositioned in malaria because of side effects linked to QT prolongation. Screening of 
another library of 1,037 existing drugs provided decoquinate (an antiprotozoal used in 
veterinary medicine) with potent activity against Plasmodium liver stages both in vitro and in 
vivo.38 In addition to liver stage activity (IC50 2.6 nM), the drug has also been shown to be 
potent against the blood (IC50 10 nM) and sexual stages (IC50 36 nM) of the parasite. The 
drug acts by selectively and specifically inhibiting the parasite’s mitochondrial bc1 complex, 
with little cross-resistance with the antimalarial drug atovaquone, with a similar mechanism 
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of action. With such activity, decoquinate warrants further exploitation as a potent 
antimalarial compound. 
Emetine dihydrochloride hydrate is another anti-protozoal drug with potent inhibitory 
properties against drug sensitive (IC50 1 nM, 3D7 strain) and drug resistant (IC50 47 nM, K1 
strain) strains of P. falciparum. 39 Emetine dihydrochloride hydrate is a natural product which 
was developed for the treatment of intestinal and tissue amoebiasis but the use of this drug is 
restricted to severe cases because of its potential side effects such as nausea and vomiting 
following oral administration, and serious cardiotoxicity produced at high dose ranges.40 The 
above-mentioned in vitro IC50 values of emetine against P. falciparum are much lower than 
those determined against various Entamoeba species (IC50 26-60 μM)
41 which suggests that 
emetine may not produce potential toxicity at the doses required for malaria treatment. 
Further, the semisynthesis of a less toxic and equipotent anti-amoebic derivative of emetine 
dehydroemetine42 indicates that emetine can be derivatized to reduce its toxic effects. All 
these studies suggest that emetine and its semisynthetic derivatives are worth investigating in 
malaria.  
A phenotypic screening of 100 registered drugs has identified the in vitro antiplasmodial 
activity of the tricyclic antidepressants promazine, fluphenazine and nortriptyline. These 
drugs have shown potent in vitro P. falciparum activity against the K1 strain with an average 
IC50 value of 523 nM
43 and have previously been shown to reverse chloroquine resistance in 
P. falciparum in vitro and in monkey studies.44 Additionally, a recent publication has 
described tricyclic antidepressant drugs as blocking agents for Plasmodium oocyst 
development and transmission.45 With such activities, this class of antidepressants needs 
further investigation in malaria. In addition to tricyclic antidepressants, the same screening 
has also identified four antifungal azole derivatives, clotrimazole, econazole, miconazole and 
tioconazole (Figure 2.6), to be active against the K1 strain  of P. falciparum with IC50 values 
of 110, 320, 490 and 630 nM respectively.43   
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Figure 2.6: Chemical structures of drugs with potent in vitro activity in malaria 
From the above discussion, it is clear that drug repositioning/repurposing can be adopted as a 
useful strategy to accelerate drug discovery in TB and malaria. Potential candidates for 
repositioning can be identified using high-throughput screening (HTS) platforms. Subsequent 
medicinal chemistry approaches can be applied to such candidates in order to have them 
suitably repositioned for the treatment of TB and/or malaria. 
The present study focuses on two candidates for repositioning: fusidic acid (an antibiotic 
drug) and metergoline (an antipsychotic drug). The antimycobacterial activities of these 
candidates were identified from a HTS conducted by the Tuberculosis Antimicrobial 
Acquisition Coordinating Facility (TAACF). The respective antiplasmodial activities have 
also been reported. It was therefore envisioned that these compounds could be used as 
effective templates for the synthesis of more potent derivatives. A brief description of these 
drugs is given below. 
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2.4 Fusidic acid 
Fusidic acid (Figure 2.7) is a naturally occurring steroid-based narrow spectrum antibiotic. It 
was first isolated from the fungus Fusidium coccineum by Godtfredsen in 196246 at Leo 
laboratories in Ballerup, Denmark and has since 1962 been used in the clinical treatment of 
both topical and systemic infections caused by staphylococci.47–51 The drug is approved as its 
sodium salt, sodium fusidate, in many countries including South Korea, Japan, UK, Canada, 
Europe, Australia, New Zealand, Thailand, India and Taiwan, and is in clinical development 
in the Unites States.52–54The clinical value of fusidic acid is a result of its excellent 
distribution in various tissues, low degree of toxicity and allergic reactions, and the absence 
of cross-resistance with other clinically used antibiotics. 
 
Figure 2.7: Structure of fusidic acid 
Fusidic acid is most potent against Staphylococcus aureus and Staphylococcus epidermidis, 
including methicillin-resistant strains. It also shows activity against several other Gram-
positive species and Gram-negative Neisseria species.48,51,55–58 The antimicrobial spectrum of 
fusidic acid is given in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Drug Repositioning/Repurposing 
 
53 
 
Table 2.2: Antimicrobial spectrum of fusidic acid59 
Microorganisms In vitro MIC90 (µg/ml) 
Gram-positive  
Staphylococcus aureus 
(methicillin-susceptible) 
0.06 
Staphylococcus aureus  
(methicillin-resistant) 
0.12 
Staphylococcus epidermidis 
(methicillin-susceptible) 
0.25 
Staphylococcus epidermidis 
(methicillin-resistant) 
0.50 
Corynebacterium diptheriae 0.0044 
Clostridium tetani 0.05 
Clostridium perfringens 0.5 
Propionibacterium acnes 1.0 
Other Corynebacterium spp. 2.0 
Clostridium difficile 2.0 
Other Clostridium spp. ≤ 1.0 
Staphylococcus saprophyticus 3.12 
Streptococcus faecalis 6.25 
Streptococcus pyogenes 12.5 
Streptococcus pneumoniae 25.0 
Gram-negative  
Neisseria meningitidis 0.12 
Legionella pneumophila ≤ 0.25  
Neisseria gonorrhoeae 1.0 
Bacteroides fragilis 2.0 
Other Bacteroides species ≤ 2.0 
 2.4.1 SAR studies on fusidic acid 
Fusidic acid represents the fusidane class of antibiotics and is the most potent member of its 
familiy. Unlike regular tetracyclic triterpenes and sterols, the fusidanes possess an unusual 
stereochemistry of the tetracyclic ring system. Rings A, B and C are arranged in a trans-syn-
trans manner in contrast to usual trans-anti-trans arrangement in tetracyclic triterpenes and 
sterols. This unusual trans-syn-trans arrangement forces ring B to have a boat conformation 
(Figure 2.8).60 Fusidanes, therefore, do not possess any steroid like hormonal activity.  
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Figure 2.8: Trans-syn-trans arrangement of tetracyclic ring system of fusidic acid 
The antibacterial structure-activity relationship (SAR) of fusidic acid has been extensively 
studied by Leo Pharma and a number of derivatives have been prepared (Figure 2.9). These 
structural modifications on fusidic acid include replacing the carboxylic acid group with 
esters and amides; hydrogenations of C-24,25 and C-17,20 double bonds; substitution 
reactions at C-24,25 double bond;  ozonolysis of the C-24,25 and C-17,20 double bonds and 
introduction of other side chains;  cyclopropanation of the C-17,20 double bond; C-3 ester 
and amine derivatives; as well as C-16 ester, ether and thioether derivatives. However, none 
of these derivatives displayed better antibacterial activity compared to fusidic acid.60–66 
SAR studies of fusidic acid have shown that the tetracyclic skeleton, lipophilic side-chain and 
the carboxylic acid group at C-20 are essential for its biological activity. The orientation of 
the lipophilic side-chain, rather than the double bond at C-17, is crucial to the antibacterial 
activity. 
In order to investigate whether or not the C17,20 double bond is required for activity, four 
stereoisomers (17R,20S), (17R,20R), (17S,20S) and (17S,20R) were prepared by reducing this 
double bond. One stereoisomer (17S,20S) was equipotent to fusidic acid, whereas others had 
low or no antibacterial activity in comparison to fusidic acid.64 The 17S,20S-methanofusidic 
acid derivative of fusidic acid was obtained by replacing the C17,20 double bond with a 
cyclopropane ring and has activity comparable to fusidic acid.63 A conformational analysis to 
obtain correlation between low energy conformations and antibacterial activity of these 
derivatives demonstrated that the double bond between C-17 and C-20 is not essential for 
antibacterial activity, but rather that the carboxyl group and the lipophilic side chain must be 
oriented in a constrained conformational space similar to that of fusidic acid. 
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Figure 2.9: Structure-activity relationship of fusidic acid64  
2.4.2 Mechanism of action of fusidic acid in bacteria 
The synthesis of new proteins in living cells occurs in the ribosome. The elongation factor G 
(EF-G) plays an important role in the elongation phase of protein synthesis by catalysing the 
translocation of the peptidyl transfer RNA (tRNA) from the A-site to the P-site of the 
ribosome. EF-G binds to the ribosome in a complex with guanosine triphosphate (GTP). 
Hydrolysis of GTP to guanosine 5′-diphosphate (GDP) leads to the translocation step of 
protein synthesis, which is followed by dissociation of the EF-G–GDP complex from the 
ribosome. Fusidic acid binds with high affinity to the EF-G–GDP after the hydrolysis of GTP 
and prevents the release of the EF-G–GDP complex from the ribosome, thereby interfering 
with and obstructing protein synthesis (Figure 2.10).67,68 
 
Figure 2.10: Inhibition of protein synthesis by fusidic acid68  
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2.5 Metergoline 
Metergoline (Figure 2.11) is a semisynthetic ergoline alkaloid and was first described in 
1965.69 Metergoline has a number of applications as a serotonin antagonist and dopamine 
agonist, both in human and veterinary medicine. Metergoline is a nonspecific serotonin 
antagonist binding several 5-HT receptor subtypes (5HT1, 5HT2, 5HT7) with high affinity (Ki 
< 10 nM).70 Metergoline also has dopamine agonist properties, possibly due to serotonergic 
modulation of dopaminergic systems. It is marketed mostly in Europe and is used clinically 
for the management of disorders associated with hyperprolactinemia, and in the prophylaxis 
of migraine headaches.71–73  Metergoline has also been investigated for the management of 
certain psychiatric disorders in which 5-HT has been implicated, including seasonal 
depression,70 obsessive-compulsive disorder,74 carbon dioxide-induced anxiety,75 and 
premenstrual syndrome.76 It has also been used in veterinary medicine as a pregnancy 
termination drug for dogs.77 
 
Figure 2.11: Structure of metergoline 
Besides its antipsychiatric properties, metergoline has been documented to have in vitro 
antifungal activity (MIC80 4 µg/ml) against clinical isolates of Candida krusei.
78 The 
proposed mechanism of action is the inhibition of extracellular phospholipase secretion, a 
well-known virulence factor in Candida, which degrades the cell membrane of host tissue. 
The same study has also shown the in vitro synergistic interaction of metergoline with other 
antifungal agents such as amphotericin B and fluconazole.  
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2.6 Research question 
The research question that this study aims to answer is whether it will be possible to identify 
new analogues of fusidic acid and metergoline that display potent 
antimycobacterial/antiplasmodial activity and favourable pharmacokinetic properties. 
2.7 Aim 
To explore structure-activity relationship (SAR) studies of fusidic acid and metergoline as 
antimycobacterial/ antiplasmodial agents. 
2.8 Specific objectives 
I. To synthesize semisynthetic derivatives of fusidic acid and metergoline and evaluate 
these derivatives in vitro as antimycobacterial and/or antiplasmodial agents  
II. To evaluate selected derivatives for in vivo pharmacokinetic (PK) studies 
III. To apply in silico tools to build a pharmacophore model based on the antiplasmodial 
SAR of synthesized fusidic acid derivatives and use the model to design new fusidic 
acid derivatives 
IV. To apply in silico similarity search tools to identify fusidic acid-like compounds that 
possess antimycobacterial and/or antiplasmodial activities from an in-house database 
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Chapter 3 
Synthesis, structure-activity relationship and biological evaluation 
of fusidic acid derivatives 
3.1 Introduction 
This chapter describes the synthesis of fusidic acid derivatives. It then reports and discusses 
the characterization of the target compounds followed by a discussion of their in vitro 
antimycobacterial, antiplasmodial and cytotoxic activity profile. The in vivo mouse 
pharmacokinetic data of some representative compounds are also reported.  
3.2 Rationale 
A High-Throughput Screen (HTS) conducted by the Tuberculosis Antimicrobial Acquisition 
Coordinating Facility (TAACF) revealed the antimycobacterial activity of fusidic acid with 
an IC90 of 0.6 μg/ml (1.2 µM) against the H37Rv strain of Mtb.
1 The antimycobacterial 
activity of fusidic acid against clinical isolates has also been revealed in the literature.2 
Fusidic acid was tested in vitro against 170 clinical Mtb isolates of which 151 were 
susceptible to first-line drugs (SM, INH, RIF and EMB) and 19 were resistant to one or more 
first-line drugs. Only 3 out of 170 isolates were found to be resistant to fusidic acid while the 
remaining 167 isolates displayed MIC90 ≤ 31 µM. Moreover, fusidic acid did not show cross-
resistance with first-line drugs.2 
In summary, the in vitro effect of fusidic acid on Mtb is promising. Coupled with the 
excellent pharmacokinetic properties of fusidic acid in humans and the novelty in its 
mechanism of action, this makes fusidic acid a promising new antimycobacterial scaffold for 
repositioning via medicinal chemistry approaches.  
Apart from its antimycobacterial activity, fusidic acid has also shown in vitro antiplasmodial 
activity with an IC50 value of 52.8 µM against the D10 strain of P. falciparum.
3 Although this 
IC50 value is high, fusidic acid also has the potential for repositioning in malaria through 
semisynthesis. Therefore, the synthesized derivatives of fusidic acid were also evaluated 
against P. falciparum. 
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3.3 Fusidic acid derivatives for structure-activity relationship (SAR) studies 
The SAR studies performed by Leo pharma on fusidic acid as an antibacterial agent were 
described in Chapter 2. These studies have shown that the tetracyclic skeleton and the 
carboxylic acid group are essential for its antibacterial activity. The C-16 acetoxy, as well as 
the C-3 and C-11 hydroxyl groups are also important for activity but can be replaced with 
other functional groups such as esters, ethers, thioethers, keto, amines, oximes, halogen, and 
sulfoxide.4 Based on this antibacterial SAR, three sites in fusidic acid were chosen for initial 
antimycobacterial SAR studies as shown in Figure 3.1. 
 
 
 
Figure 3.1: Proposed initial antimycobacterial SAR studies   
SAR 1 includes replacement of the C-21 carboxylic acid with various bioisosteres such as 
esters, amides, sulfonamides, hydrazides, sulfonyl hydrazides and oxadiazoles. Bioisosteres 
are generally defined as those atoms or groups or molecules that exhibit similar volume, 
shape, and/or physicochemical properties, and whose replacement retains the biological 
activity of compounds.5 Bioisosteric replacement of a carboxylic acid group is a widely used 
approach within medicinal chemistry in order to improve properties such as bioavailability, 
selectivity, and potency of a lead compound. In addition, ester, amide, and hydrazide 
derivatives may act as stable molecules or as prodrugs that can generate fusidic acid in vivo. 
Replace carboxylic acid 
with various bioisosteres 
SAR 3 
Replace with ethers 
SAR 2 
Replace with carboxylic esters, silicates,  
as well as keto and oxime functionalities 
SAR 1 
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SAR 2 includes replacement of the C-3 OH group with other functional groups. The C-3 OH 
can be selectively derivatized as the C-11 OH is sterically hindered due to the chair-boat-
chair arrangement of the tetracyclic ring system of fusidic acid (Figure 3.2).6 Therefore, the 
C-3 OH is much more reactive than the C-11 OH.  In this study, the C-3 OH group was 
replaced with various carboxylic and silicate esters as well as with keto and oxime 
functionalities.  
SAR 3 includes replacement of the C-16 acetoxy group with ethers. 
In addition to the above, fusidic acid derivatives with modifications at more than one site 
(termed as miscellaneous derivatives) were also synthesized. 
 
Figure 3.2: Chair-boat-chair arrangement of tetracyclic ring system of fusidic acid 
3.4 Chemical synthesis 
3.4.1 Synthesis of C-21 fusidic acid derivatives (SAR 1) 
Synthetic routes used to synthesize C-21 derivatives of fusidic acid are outlined in Schemes 
3.1-3.3.7   Synthesis of various ester, amide and sulfonamide derivatives is shown in Scheme 
3.1. Fusidic acid methyl ester 3.2 was obtained by heating commercially available fusidic 
acid (3.1, 4500USD/100g from Ava Chem Scientific) with methyl iodide in the presence of 
the inorganic base K2CO3 in DMF.  Reaction of 3.1 with ammonium chloride using PyBOP-
HOBt as a coupling reagent furnished fusidic acid amide 3.3.8 Likewise, EDCI-mediated 
coupling of 3.1 with cyanamide and 5-aminotetrazole furnished amide derivatives 3.4 and 
3.5, respectively. Amide derivatives 3.6-3.9 were obtained through the coupling of 3.1 with a 
corresponding amine in the presence of EDCI using DMAP as a catalyst. Likewise, an EDCI-
DMAP mediated coupling of 3.1 with the respective sulfonamide furnished sulfonamide 
derivatives 3.10-3.12.  
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Scheme 3.1: Reagents and conditions: (a) K2CO3, CH3I, DMF, 50 
oC, 3 h; (b) PyBOP, HOBt, 
DIPEA, NH4Cl, DMF, 25 
oC, 16 h for compound 3.3; (c) RNH2, EDCI, HOBt, DIPEA, 
DCM, 25 oC, 24 h for compounds 3.4 and 3.5; (d) RNH2, EDCI, DMAP, DCM, 25 
oC, 16 h, 
for compounds 3.6-3.9; (e) RSO2NH2, EDCI, DMAP, DCM, 25 
oC, 48 h 
Various hydrazide and sulfonyl hydrazide derivatives of fusidic acid were synthesized as 
shown in Scheme 3.2. Fusidic  acid hydrazide 3.138 was synthesized by reacting 3.1 with 
hydrazine hydrate using EDCI-HOBt as a coupling agent. Hydrazide derivative 3.14 was 
obtained by the reaction of 3.1 with thiophene-2-carbohydrazide in the presence of the 
coupling reagent TBTU, while derivative 3.15 was obtained by the reaction of 3.1 with 
isoniazid in the presence of n-propanephosphonic acid anhydride (T3P) as the coupling agent. 
Synthesis of hydrazide derivatives 3.16 and 3.17 was accomplished by refluxing 3.13 with 3- 
or 4- pyridinecarboxaldehyde, respectively, in ethanol for 8 h. Sulfonylhydrazide derivatives 
(3.18-3.23) were obtained by reacting 3.13 with the respective sulfonyl chloride (aliphatic 
sulfonyl chlorides with varying carbon chain lengths for 3.18-3.21 and 4-substituted aromatic 
sulfonyl chlorides for 3.22-3.23) using pyridine as a base and solvent. 
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Scheme 3.2: Reagents and conditions: (f) EDCI, HOBt, acetonitrile, 25 oC, 3 h, 
NH2NH2.H2O, 25 
oC, 16 h; (g) RSO2Cl, pyridine, 25 
oC, 1-3 h; (h) 3-or 4-
pyridinecarboxaldehyde, ethanol, 85 oC, 8 h; (i) Isoniazid, T3P (50% w/v solution in DMF), 
Et3N, DCM, 0 
oC - 25 oC, 5 h; (j) Thiophene-2-carbohydrazide, TBTU, DIPEA, DMF, 25 oC, 
16 h  
Various oxadiazole derivatives were synthesized as shown in Scheme 3.3. Reaction of 3.1 
with the respective aliphatic and aromatic amidoximes in the presence of EDCI-HOBt in 
acetonitrile furnished intermediates, which upon reaction with sodium acetate in ethanol 
under microwave irradiation furnished 3-substituted-1,2,4-oxadiazole derivatives 3.24-3.27. 
The synthesis of 2-oxo-1,3,4-oxodiazole 3.28 was accomplished by reacting compound 3.13 
with CDI and Et3N at 25 
oC in THF  (Scheme 3.3). On the other hand, the reaction of 3.13 
with carbon disulphide and potassium hydroxide in refluxing ethanol furnished 2-thioxo-
1,3,4-oxadiazole 3.29.  
Chapter 3: Synthesis, structure-activity relationship and biological evaluation of fusidic acid 
derivatives 
 
69 
 
All target compounds were purified using column chromatography and fully characterized by 
analytical and spectroscopic techniques. Table 3.1 reports the isolated yields and melting 
points of the target compounds. Some of these derivatives were obtained in relatively poor 
yields either due to formation of undesired side products (3.5, 3.7-3.8, 3.20, and 3.24-3.27) or 
due to incomplete conversion of the starting material into product (3.9). Detailed synthetic 
procedures are described in Chapter 7. 
 
Scheme 3.3: Reagents and conditions: (k) (1) EDCI, HOBt, acetonitrile, 25 oC, 3 h, 
amidoxime, 80 oC, 12 h, (2) NaOAc, ethanol, MW, 100 oC, 2 h; (l) CDI, Et3N, THF, 0 
oC - 25 
oC, 16 h; (m) CS2, KOH, ethanol, reflux, 16 h 
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Table 3.1: Isolated yields and melting points of C-21 fusidic acid derivatives 
Compound Yield (%) Mp (oC) Compound Yield (%) Mp (oC) 
3.1 - 203-205 3.16 63 230-232 
3.2 92 166-168 3.17 63 159-161 
3.3 31 223-225 3.18 44 125-127 
3.4 53 142-144 3.19 45 127-129 
3.5 29 > 280 3.20 25 125-127 
3.6 67 216-218 3.21 71 121-123 
3.7 25 162-164 3.22 46 220-222 
3.8 18 195-197 3.23 65 230-232 
3.9 18 178-180 3.24 24 152-154 
3.10 31 214-216 3.25 23 126-128 
3.11 38 229-231 3.26 14 110-112 
3.12 30 232-234 3.27 20 86-88 
3.13 98 128-130 3.28 24 137-139 
3.14 50 144-146 3.29 56 130-132 
3.15 46 189-191    
 
3.4.1.1 Mechanism of T3P-mediated coupling 
n-Propanephosphonic acid anhydride is popularly known as T3P.9 T3P is a phosphorus-based 
six-membered cyclic anhydride in which the P and O atoms are alternatively linked to each 
other, with each P atom bearing a n-propyl group (Figure 3.3). T3P is mainly employed as a 
coupling and dehydrating agent. However, due to the facile nature of the -P-O-P- bond, T3P 
shows exceptional reactivity towards a wide range of nucleophiles. As such, T3P has also 
found use in various other reactions such as functional group transformations, 
rearrangements, heterocycle synthesis and catalysis. It is mostly available as 50% (w/w) 
solution in ethyl acetate or DMF. Owing to increased sensitivity towards water, T3P can be 
easily removed from the reaction by extracting with water. The mechanism of peptide 
coupling of fusidic acid (R1COOH) with various amines (R2-NH2) in the presence of T3P is 
shown in Figure 3.3. The reaction occurs by attack of the carboxylate ion on a P atom of T3P, 
thus opening the P-O-P ring and converting the O atom of the carboxylate ion into a good 
leaving group. Excess T3P and the un-cyclised by-product are removed by aqueous work-up. 
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Figure 3.3: The mechanism for T3P coupling reaction9 
3.4.1.2 Characterization of C-21 derivatives 
All fusidic acid derivatives were characterized using 1H NMR, 13C NMR and mass 
spectroscopy (MS). Proton assignments were made with the help of 1H-1H COSY spectra.  
The 1H NMR spectrum of fusidic acid was recorded in CDCl3 and is shown in Figure 3.4. The 
characteristic proton signals of fusidic acid appeared at δ 5.88 (d, J = 8.4 Hz, H-16), 5.10 (t, J 
= 7.2 Hz, H-24), 4.34 (m, H-11), 3.76 (m, H-3), 3.07-3.04 (m, H-13), 1.96 (s, OAc), 1.67 (s, 
CH3-27), 1.60 (s, CH3-26), 1.38 (s, CH3-30), 0.98 (s, CH3-19), 0.92 (d, J = 5.9 Hz, CH3-28), 
and 0.91 (s, CH3-18) ppm. Remaining protons of the tetracyclic ring system of fusidic acid, as 
well as the H-22 and H-23 protons appeared in the aliphatic region 2.52-1.02 ppm (Figure 
3.4).  
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Figure 3.4: 1H NMR spectrum (CDCl3, 400MHz) of fusidic acid  
The 13C NMR spectrum of fusidic acid (Figure 3.5) depicted 31 distinct signals corresponding 
to 31 carbon atoms. Six signals appeared in the aromatic region 175-120 ppm. Signals at 
174.0 and 170.5 ppm correspond to two carbonyl carbons of the -COOH and -OAc groups 
respectively, while signals at 150.9, 132.6, 129.5, 123.0 ppm correspond to C-17, C-25, C-20 
and C-24 respectively. Twenty five signals appeared in the aliphatic region 75-15 ppm. The 
C-16, C-3 and C-11 carbons appeared at 74.4, 71.4, and 68.2 ppm respectively while C-13 
appeared at 44.3 ppm.  The remaining carbon atoms appeared in the aliphatic region 50-15 
ppm. The 1H and 13C NMRs of fusidic acid were further verified in comparison with those 
reported in the literature.10 
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Figure 3.5: 13C NMR spectrum (CDCl3, 100 MHz) of fusidic acid 
All C-21 derivatives depicted similar chemical shifts in their 1H and 13C NMR spectra along 
with additional proton signals representing the attached moiety. Both 1H and 13C NMR 
spectra of the C-21 derivatives can be described overall by considering representative 
examples (3.14 and 3.16) from the series of compounds. 
The 1H NMR spectrum of compound 3.14 was recorded in CDCl3 at 400 MHz and is 
displayed in Figure 3.6. This compound was obtained by the coupling of fusidic acid with 
thiophene-2-carbohydrazide. Two broad singlets corresponding to two -CONH protons at 
8.83 ppm and 8.48 ppm indicated the formation of the hydrazide carbonyl group. Further, two 
doublets at 7.64 ppm and 7.55 ppm, as well as a triplet at 7.10 ppm, corresponding to H-31, 
H-33 and H-32, respectively, indicated incorporation of the thiophene moiety into the fusidic 
acid structure.  The remaining proton signals appeared in regions similar to fusidic acid. 
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 Figure 3.6: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.14 
Further, the 13C NMR spectrum of 3.14 (Figure 3.7) depicted an additional carbon signal in 
the carbonyl region at 159.1 ppm, as well as 4 signals in the aromatic region at 135.4, 132.7, 
131.0 and 127.8 ppm. These 5 additional signals indicated the presence of the thiophene-2-
carbohydrazide moiety in the structure. Overall, the 13C NMR of 3.14 depicted 36 distinct 
signals corresponding to 36 carbon atoms.  Additionally, the MS displayed mass peaks at 641 
[M+H] and 581 [M-OAc], as expected, which further supported the formation of the desired 
compound. Based on 1H, 13C and MS spectra, structure 3.14 was assigned to this compound.  
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Figure 3.7: 13C NMR spectrum (CDCl3, 100 MHz) of compound 3.14 
Compound 3.16 was obtained by refluxing fusidic acid hydrazide 3.13 with 3-
pyridinecarboxaldehyde in ethanol. The characteristic feature of the 1H NMR spectrum 
(Figure 3.8) is the presence of additional peaks in the aromatic region at 8.84 (s, H-35), 8.56 
(d, J = 5.2 Hz, H-34), 8.30 (d, J = 8.1 Hz, H-32), 8.13 (s, H-31) and 7.49 (dd, J = 8.0 and 4.9 
Hz, H-33) ppm, which confirmed the coupling of compound 3.13 with 3-
pyridinecarboxaldehyde. This type of coupling also delivered a mixture of E/Z isomers 
around the newly formed C=N double bond. This can be determined based on the splitting of 
some signals, as highlighted in Figure 3.8.  
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Figure 3.8: 1H NMR spectrum (CD3OD, 400 MHz) of compound 3.16 
Further, the 13C NMR spectrum (Figure 3.9) displayed 6 signals in the aromatic region at 
150.0, 148.3, 144.6, 134.5, 130.9 and 124.1 ppm, in addition to the expected signals for 
fusidic acid. These 6 additional signals indicated the presence of the 3-pyridyl moiety in the 
structure. Splitting of signals was also observed in the spectrum confirming the formation of 
E/Z isomers. Additionally, the MS displayed mass peaks at 620 [M+H] and 560 [M-OAc] as 
expected, which further confirmed the formation of the desired compound. Based on 1H, 13C 
and MS spectra, structure 3.16 was assigned to this compound. 
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Figure 3.9: 13C NMR spectrum (CD3OD, 100 MHz) of compound 3.16 
3.4.2 Synthesis of C-3 fusidic acid derivatives (SAR 2) 
Synthetic routes used to synthesize C-3 derivatives of fusidic acid are outlined in Scheme 3.4-
3.5. Short, medium and long chain aliphatic C-3 carboxylic esters of fusidic acid were 
synthesized under two different conditions depending upon availability of the starting 
materials. Ester derivatives 3.3011 and 3.32 were synthesized by the reaction of fusidic acid 
(3.1) with the corresponding anhydride using pyridine as base and solvent, while 3.31 and 
3.33-3.35 were synthesized by the reaction of fusidic acid with the corresponding carboxylic 
acid using the coupling reagent T3P in the presence of pyridine. 
C-3 oximes 3.37-3.39 were synthesized by irradiating a mixture of 3-keto fusidic acid (3.36)12 
and the respective hydroxyl amine hydrochloride under microwave irradiation at 80 oC in the 
presence of NH4OAc. Oximes were obtained as a mixture of E- and Z-isomers. 3-Keto fusidic 
acid was synthesized from fusidic acid using the Jones reagent as an oxidising agent. 
Oxidation of fusidic acid with the Jones reagent yielded both mono (3-keto, 3.36) as well as 
disubstituted (3,11-diketo 3.54) derivatives, which explains the low yield of 3-keto fusidic 
acid (3.36, 33%, Table 3.2). 3-Keto fusidic acid was also reduced to 3-epi fusidic acid (3.40) 
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using NaBH4 in methanol. This reaction yielded both fusidic acid as well as its epimer 3.40, 
which led to the poor yield of 3.40. 
Three silicate esters of fusidic acid (3.41-3.43) were synthesized by reacting the relevant 
trialkoxychlorosilane with fusidic acid at 0 oC for 1 h in the presence of imidazole as base and 
DMF as solvent  (Scheme 3.5). Trialkoxychlorosilanes were prepared in house by dropwise 
addition of the respective alcohols to a solution of SiCl4 in pentane at 25 
oC for 1 h and used 
without purification.13 Silicate ester 3.43 was obtained in relatively poor yield due to 
formation of undesired side products. 
All target compounds were purified using column chromatography and fully characterized by 
analytical and spectroscopic techniques. Table 3.2 reports the isolated yields and melting 
points of target compounds. Detailed synthetic procedures are described in Chapter 7. 
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Scheme 3.4: Reagents and conditions: (a) (RCO)2O, pyridine, 25 
oC, 3 h for compounds 3.30 
and 3.32; (b) ROOH, T3P (50% w/v solution in DMF), pyridine, 0 oC – 25 oC, 16 h for 
compounds 3.31 and 3.33-3.35; (c) Jones reagent, acetone, 0 oC, 40 min; (d) RONH2.HCl, 
NH4OAc, ethanol, MW, 80 
oC, 20 min; (e) NaBH4, methanol, 25 
oC, 3 h 
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Scheme 3.5: Reagents and conditions: (f) ClSi(OR)3, Imidazole, DMF, 0 
oC, 1 h 
 
Table 3.2: Isolated yields and melting points of C-3 derivatives 
Compound Yield (%) Mp (oC) 
3.30 58 112-114 
3.31 56 93-95 
3.32 66 162-164 
3.33 56 118-120 
3.34 62 167-169 
3.35 63 Oil 
3.36 33 119-121 
3.37 23 149-151 
3.38 59 176-178 
3.39 51 176-178 
3.40 25 211-213 
3.41 50 72-74 
3.42 35 70-72 
3.43 23 Oil 
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3.4.2.1 Characterization of C-3 derivatives 
3.4.2.1.1 C-3 caboxylic esters 
1H and 13C NMR spectra of C-3 carboxylic esters of fusidic acid can be described by using a 
representative compound 3.31 from this series. Compound 3.31 was prepared by reacting 
fusidic acid with propanoic acid in the presence of T3P and pyridine. The characteristic 
feature of the 1H NMR spectrum is the downfield shift of the H-3 proton from 3.76 ppm (in 
fusidic acid) to 4.95 ppm (in 3.31), indicating the successful coupling of propanoic acid to the 
C-3 OH of fusidic acid to form an ester bond. Additional peaks in the aliphatic region 
(highlighted in Figure 3.10) at 2.36 (q, J = 7.6 Hz, H-32) and 1.16 (t, J = 7.6 Hz, H-33) ppm 
indicated incorporation of an aliphatic chain in the structure of fusidic acid.  
 
 
Figure 3.10: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.31 
Further, the appearance of an additional peak at 173.2 ppm in the 13C NMR spectrum of 3.31 
indicated the presence of an additional carbonyl group (C-31, Figure 3.11), while the 
appearance of two additional peaks in the aliphatic region at 27.4 ppm and 9.4 ppm indicated 
the presence of two additional aliphatic carbons (C-32 and C-33) in the structure. The spectral 
data was well supported by MS, which displayed mass peaks at 573 [M+1], 595 [M+23] and 
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513 [M-OAc]. On the basis of spectral data, structure 3.31 was assigned to this compound. 
All C-3 ester derivatives (3.30-3.35) displayed similar patterns in their 1H, 13C and MS 
spectra. 
 
 
Figure 3.11: 13C NMR spectrum (CDCl3, 100 MHz) of compound 3.31 
3.4.2.1.2 C-3 oximes 
C-3 oxime derivatives 3.37-3.39 were prepared by the coupling of 3-keto fusidic acid (3.36) 
with O-alkylhydroxylamines. The 1H NMR spectrum of 3.38 (a member of this series) is 
described in Figure 3.12. The characteristic features of the 1H spectrum are the disappearance 
of the H-3 proton of fusidic acid from 3.76 ppm and the appearance of a singlet at 3.82 ppm 
corresponding to =N-OCH3, indicating the successful coupling of O-methylhydroxylamine 
with 3.36. Formation of E/Z isomers is also observed in the 1H spectrum as indicated by the 
splitting of singlet of =N-OCH3.  
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Figure 3.12: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.38 
The 1H spectrum was well supported by the corresponding 13C NMR spectrum (Figure 3.13). 
A shift in the C-3 signal from 71.4 ppm (in fusidic acid) to 161.9 (in 3.38) and the appearance 
of an additional signal at 61.1 ppm, corresponding to the carbon of =N-OCH3, was observed 
in the spectrum. Further, the MS of the compound displayed mass peaks at 544 [M+H], 566 
[M+23] and 484 [M-OAc], as expected. On the basis of all spectral data obtained, the 
structure as depicted in 3.38 was assigned to this compound. Other members of the series 
(3.37, 3.39) depicted similar patterns in their 1H, 13C and MS spectra. 
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Figure 3.13: 13C NMR spectrum (CDCl3, 100 MHz) of compound 3.38 
3.4.2.1.3 C-3 silicates 
The NMR spectra of C-3 silicates are described by using compound 3.42 as a representative 
from this series. The 1H NMR spectrum of this compound was recorded in CDCl3 at 400 
MHz (Figure 3.14). The characteristic feature of the spectrum is the slight downfield shift of 
the H-3 proton from 3.76 ppm (in fusidic acid) to 3.99 ppm (in 3.42), indicating the 
successful coupling of tripropoxychlorosilane with the C-3 OH of fusidic acid to form a 
silicate ester bond. The appearance of additional signals (highlighted in Figure 3.14) at 4.23 
ppm (heptet of 3H due to the -CH of the isopropoxysilicate group, H-31) and 1.19 ppm 
(doublet of 18H due to the -CH3 of the isopropoxysilicate group, H-32) indicated the 
successful incorporation of the triisopropoxysilicate moiety at the C-3 position of fusidic acid. 
All other protons showed a similar pattern to that observed for fusidic acid.  
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Figure 3.14: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.42 
The 1H NMR spectrum was well supported by the corresponding 13C NMR spectrum which 
depicted additional signals at 65.7 and 25.4 ppm, indicating three -CH carbons and six -CH3 
carbons of the isopropoxysilicate group (Figure 3.15). Further, the MS of the compound 
displayed mass peaks at 721 [M+1] and 661 [M-OAc], as expected. On the basis of spectral 
data obtained, structure 3.42 was assigned to this compound. Other silicate derivatives (3.41, 
3.43) depicted similar patterns in their 1H, 13C and MS spectra. 
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Figure 3.15: 13C NMR spectrum (CDCl3, 100 MHz) of compound 3.42 
3.4.3 Synthesis of C-16 fusidic acid derivatives (SAR 3) 
C-16 derivatives of fusidic acid were synthesized as described in Scheme 3.6.11,14 Synthesis 
commenced with protection of the C-3 OH group using acetic anhydride in pyridine to obtain 
the C-3 acetoxy derivative 3.30. The C-16 acetoxy group was then selectively hydrolysed by 
heating 3.30 with saturated aq. NaHCO3 under microwave irradiation at 100 
oC to obtain 
intermediate 3.44 with inversion of configuration at C-16 (β-acetoxy to α-OH). The 
carboxylic group of 3.44 was then protected by reacting with chloromethyl pivalate to obtain 
pivaloyloxymethyl ester 3.45, followed by bromination with CBr4/PPh3 to afford intermediate 
3.46 with inversion of configuration (α-OH to β-bromo). The β-bromo intermediate 3.46 was 
converted to the α-bromo derivative 3.47 by stirring it with tetrabutylammonium bromide in 
acetonitrile at 25 oC for 65 h. Compound 3.47 was then reacted with the respective alcohols in 
the presence of Ag2CO3 to afford the C-16 ether derivatives which, upon hydrolysis with 5 N 
aq. NaOH, provided target compounds 3.48-3.49. Intermediates as well as target compounds 
were purified using column chromatography and fully characterized by analytical and 
spectroscopic techniques. Table 3.3 reports the isolated yields and melting points of the 
intermediate and target compounds. Detailed synthetic procedures are described in Chapter 7. 
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Scheme 3.6: Reagents and conditions: (a) (Ac)2O, pyridine, 25 
oC, 3 h; (b) Sat. aq.NaHCO3, 
MW, 100 oC, 10 min; (c) ClCH2OCOC(CH3)3, Et3N, DMF, 25 
oC, 16 h; (d) PPh3, CBr4, 
benzene, 25 oC, 1 h; (e) Bu4N
+Br-, acetonitrile, 25 oC, 65 h; (f) ROH, Ag2CO3, 25 
oC, 16 h,  5 
N aq. NaOH, 80 oC, 1 h 
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Table 3.3: Isolated yields and melting points of C-16 derivatives 
Compound Yield (%) Mp (oC) 
3.44 37 ND 
3.45 49 Oil 
3.46 68 Oil 
3.47 83 Oil 
3.48 35 139-141 
3.49 37 177-179 
                                          ND = Not determined 
3.4.3.1 Characterisation of C-16 derivatives 
The spectral data of C-16 derivatives can be explained by using the C-16 ethoxy derivative 
(3.49) as a representative example of the series. The characteristic feature of the 1H NMR 
spectrum (Figure 3.16) is the upfield shift of H-16 from 5.88 ppm (in fusidic acid) to 4.45 
ppm (in 3.49) and the disappearance of the -OAc peak from 1.96 ppm. Further, the 
appearance of three additional peaks, two mutiplets of H-31 at 3.66-3.59 and 3.42-3.35 ppm 
and a triplet (J = 7.0 Hz) of H-32 at 1.20 ppm, confirmed the incorporation of the ethoxy 
group at the C-16 position.  
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Figure 3.16: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.49 
The 1H NMR spectrum was well supported by the corresponding 13C NMR spectrum (Figure 
3.17), which showed the disappearance of the C=O group of –OAc moiety from 170.6 ppm 
and the appearance of the C-31 of the ethoxy group at 80.6 ppm. Other carbon signals were 
found at their expected positions with minor shifts. Further, the MS of the compound 
displayed mass peaks at 503 [M+1] and 443 [M-OAc], as expected. On the basis of spectral 
data obtained, the structure 3.49 was assigned to this compound. The C-16 methoxy 
derivative 3.48 depicted a similar pattern in its 1H, 13C and MS spectra. 
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Figure 3.17: 13C NMR spectrum (CDCl3, 100 MHz) of compound 3.49 
3.4.4 Synthesis of miscellaneous derivatives 
Some fusidic acid derivatives with modification at more than one site were also synthesized 
and included under the miscellaneous category (Scheme 3.7). Compound 3.50 was obtained 
by hydrogenation of the double bond between C-24 and C-25 of fusidic acid bioisostere 3.18 
in the presence of H2/Pd-C in ethanol. Compound 3.51 was obtained by hydrolysis of 3.18 in 
the presence of K2CO3 in methanol. Ozonolysis of fusidic acid (3.1) generated an aldehyde 
3.52 and a ketone 3.53.15 C-3,C-11-diketo derivative 3.54, which was obtained as a by-
product during Jones oxidation of fusidic acid to generate 3-keto fusidic acid (Scheme 3.4), 
has also been included in the miscellaneous category. The derivative 3.55 was obtained by 
heating fusidic acid with acetic anhydride in the presence of pyridine under microwave 
irradiation at 80 oC. Further heating of 3.55 with methyl iodide at 50 oC in the presence of 
K2CO3 provided the methyl ester derivative 3.56. Target compounds were purified using 
column chromatography and fully characterized by analytical and spectroscopic techniques. 
Table 3.4 reports the isolated yields and melting points of target compounds. Some of these 
derivatives were obtained in relatively poor yields either due to the formation of undesired 
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side products (3.52 and 3.53) or due to incomplete conversion of the starting material into 
product (3.51). Detailed synthetic procedures are described in Chapter 7. 
 
Scheme 3.7: Reagents and conditions: (a) H2/Pd-C, ethanol, 25 
oC, 16 h; (b) K2CO3, 
methanol, 25 oC, 24 h; (c) O3/PPh3, DCM, -78 
oC to 25 oC, 2 h; (d) (Ac)2O, pyridine, MW, 80 
oC, 1.5 h; (e) K2CO3, CH3I, DMF, 50 
oC, 3 h 
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Table 3.4: Isolated yields and melting points of miscellaneous derivatives 
Compound Yield (%) Mp (oC) 
3.50 58 198-200 
3.51 22 169-171 
3.52 27 237-239 
3.53 26 92-94 
3.54 45 192-194 
3.55 35 305-307 
3.56 72 259-261 
3.4.4.1 Characterisation of miscellaneous derivatives 
The 1H and 13C NMR spectra of one of the miscellaneous derivatives (compound 3.51) are 
described below. The characteristic features of the 1H NMR spectrum of 3.18 (Figure 3.18) 
are the appearance of two -NH protons at 7.79 ppm and 6.89 ppm, as well as the appearance 
of the -SO2CH3 signal at 3.00 ppm. These proton signals confirmed incorporation of the 
methyl sulfonyl hydrazide moiety into fusidic acid at the C-21 position.  
 
Figure 3.18: 1H NMR spectrum (CDCl3, 400 MHz) of compound 3.18 
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The 1H spectrum of 3.51 showed the disappearance of the -OAc signal from 2.01 ppm and an 
upfield shift of H-16 from 5.74 ppm to 4.79 ppm (Figure 3.19). 
 
Figure 3.19: 1H NMR spectrum (CD3OD, 400 MHz) of compound 3.51 
The 1H NMR spectrum was well supported by the corresponding 13C NMR spectrum (Figure 
3.20), which showed the disappearance of the C=O group of the -OAc moiety in the carbonyl 
region. Further, MS of the compound displayed mass peaks at 567 [M+1] and 507 [M-OAc], 
as expected. On the basis of the spectral data obtained, structure 3.51 was assigned to this 
compound.  
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Figure 3.20: 13C NMR spectrum (CD3OD, 100 MHz) of compound 3.51 
3.5 Biological results and discussion 
Synthesized derivatives were screened in vitro against the H37Rv strain of Mtb at the Institute 
of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, South 
Africa. The MIC99 (minimum concentration required to inhibit the growth of 99% of the 
bacterial population) was determined for each compound and a maximum concentration limit 
was set at 160 µM. Rifampicin and kanamycin, were used as reference drugs. These 
derivatives were also evaluated for cytotoxicity against the Chinese Hamster Ovarian (CHO) 
mammalian cell line, and their half minimal inhibitory concentration (IC50) was determined. 
Emetine was used as reference drug in this assay. 
In vitro antiplamodial activities (IC50) were determined against the chloroquine (CQ)-
sensitive NF54 strain of P. falciparum at the Swiss Tropical and Public Health Institute, 
Basel, Switzerland. CQ and artesunate were used as the reference drugs.  
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3.5.1 C-21 fusidic acid derivatives 
3.5.1.1 Antimycobacterial activity 
The antimycobacterial activity (MIC99) of fusidic acid (3.1) was found to be 0.6 µM (Table 
3.5). All fusidic acid bioisosteres exhibited poor antimycobacterial activity as compared to 
fusidic acid, with MIC99 values ranging from 10 to >160 µM (Table 3.5).  
The effect of acyclic bioisosteric replacement of the carboxylic acid group was investigated 
through derivatives 3.2-3.23. Replacing the -COOH group with -COOCH3 and -CONH2 
groups (3.2-3.3, MIC99 >160 µM) diminished the activity. Most of the substituted amide 
derivatives (3.4-3.9, Table 3.5) showed improved activity as compared to the unsubstituted 
amide derivative 3.3 but were found to be far less active as compared to fusidic acid. Among 
sulfonamide derivatives (3.10-3.12), alkyl (3.10) and unsubstituted aromatic (3.11) 
derivatives were found to be either poorly active or inactive at the highest concentration 
tested. The substitution of the phenyl ring in 3.11 restored the activity and the resulting 3,4-
difluorophenylsulfonamide derivative 3.12 was found to be the most active among amide and 
sulphonamide derivatives, displaying antimycobacterial activity with a MIC99 value of 20 
µM. Among hydrazide derivatives (3.13-3.17), compound 3.15, which is a conjugate of 
fusidic acid and the antituberculosis drug isoniazid, was found to be the most active, 
displaying a MIC99 value of 10 µM with encouraging cytotoxicity (IC50 CHO 88.3 µM). Two 
more hydrazide derivatives 3.16 and 3.17 containing N-pyridin-3-ylmethylene and N-pyridin-
4-ylmethylene group, respectively, also showed an improvement in antimycobacterial activity 
(MIC99 of 20 µM). Among the sulfonylhydrazide derivatives (3.18-3.23), aromatic 
derivatives (3.22-3.23) were found to be inactive as compared to aliphatic derivatives (3.18-
3.21). Further, among aliphatic derivatives, activity decreased with an increase in the carbon 
chain length from methyl (3.18, MIC99 10 µM) to butyl (3.21, MIC99 160 µM). The methane 
sulfonyl hydrazide derivative 3.18 was found to be the most active, displaying a MIC99 value 
of 10 µM with encouraging cytotoxicity at IC50 92.2 µM. 
Replacement of the carboxylic acid group of fusidic acid with less acidic and similar 
molecular-size cyclic bioisosteres, such as an oxadiazole, was also explored. Oxadiazole rings 
can exist in three regioisomeric forms; 1,2,4-oxadiazoles, 1,3,4-oxadiazoles and 1,2,5-
oxadiazoles, the first two being the most common and recurrent motifs in drug-like 
molecules. However, these two isomeric forms offer different physiochemical profiles in 
terms of lipophilicity, aqueous solubility, metabolic stability and, hERG activity, thereby 
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resulting in diverse biological activities.16 Five oxadiazole bioisosteres were synthesized and 
included the 1,2,4-oxadiazole derivatives 3.24-3.27, the 5-oxo-1,3,4-oxadiazole derivative 
3.28 and the 5-thioxo-1,3,4-oxadiazole derivative 3.29. However, all of these derivatives were 
found to be either poorly active or inactive.  
In summary, bioisosteric replacement of the carboxylic acid group of fusidic acid resulted in 
poor antimycobacterial activity as compared to fusidic acid. However, two compounds 3.15 
and 3.18 showed moderate activity (MIC99 10 µM) and reasonably low cytotoxicity (IC50 
88.3 µM and 92.2 µM, respectively).  
 
Table 3.5: In vitro antimycobacterial activity (H37Rv strain), antiplasmodial activity (NF54 
strain) and cytotoxicity (CHO cell line) of C-21 fusidic acid bioisosteres 
 
Compound                  R 
MIC99 H37Rv 
(µM) 
IC50 NF54 
(µM) 
IC50 CHO 
 (μM) 
3.1  0.6 59.0 >194.0 
3.2  >160 4.7 ND 
3.3  >160 35.9 113.0 
3.4  40 10.8 >185.0 
3.5 
 
 
40 
 
>15 
 
>171.0 
3.6 
 
         >160 11.9 ND 
3.7 
 
>160 >18 ND 
3.8 
 
40 3.0 ND 
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3.9 
 
40 10.5 ND 
3.10 
 
 
80 
 
>15 
 
>169.0 
3.11 
 
 
>160 
 
>15 
 
96.1 
3.12 
 
20 7.3 81.4 
3.13  40 21.3 112.0 
3.14 
 
 
40 8.4 78.8 
3.15 
 
 
10 
 
 
3.2 
 
 
 
88.3 
 
3.16 
 
 
20 
 
 
8.4 
 
 
 
ND 
3.17 
 
 
20 
 
 
2.0 
 
 
 
ND 
 
3.18 
 
 
10 14.7 92.2 
3.19 
 
 
40 12.4 77.3 
3.20 
 
 
40 5.7 79.7 
3.21 
 
 
160 8.0 49.9 
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3.22 
 
 
>160 13.4 48.2 
3.23 
 
 
>160 31.3 53.2 
3.24 
 
 
>160 3.8 47.8 
3.25 
 
 
>160 1.9 71.7 
3.26 
 
 
80 2.1 68.2 
3.27 
 
 
>160 1.7          77.4 
3.28 
 
 
80 9.2          82.0 
3.29 
 
             
80 7.0          70.0 
 Rifampicin 0.005    
 Kanamycin 3.2    
 CQ  16 nM  
 Artesunate  4 nM  
 Emetine   0.4 
           CQ = chloroquine; ND = Not determined  
3.5.1.2 Antiplasmodial activity  
The IC50 value of fusidic acid (3.1) against the NF54 strain of P. falciparum was found to be 
59 µM, which is comparable to that reported for the D10 strain (52.8 µM). Most of the fusidic 
acid bioisosteres exhibited micromolar potencies, with 24 out of the 28 compounds displaying 
IC50 values between 1.7-35.9 µM.
7 Additionally, these derivatives were found to have low 
cytotoxicity against the CHO cell line. 
Replacing the carboxylic acid group with a methyl ester augmented the antiplasmodial 
activity by 12-fold (3.2, IC50 4.7 µM). Among amide derivatives, unsubstituted amide 
Chapter 3: Synthesis, structure-activity relationship and biological evaluation of fusidic acid 
derivatives 
 
99 
 
derivative 3.3 exhibited a 2-fold increase in activity (IC50 35.9 µM) compared to fusidic acid 
(Table 3.5). Substitution with an amide group brought improvement in antiplasmodial activity 
in most of the derivatives with 4-hydroxy piperidine amide (3.8, IC50 3.0 µM) being the most 
active. Among the sulfonamide derivatives (3.10-3.12), alkyl (3.10) and unsubstituted 
aromatic (3.11) derivatives were found to be inactive at the highest concentration tested (>15 
µM). On the other hand, substitution of the phenyl ring restored the activity as demonstrated 
by the 3,4-difluorophenylsulfonamide derivative 3.12 (IC50 7.3 µM), displaying an 8-fold 
increase in activity compared to fusidic acid. 
Among the hydrazide and sulfonyl hydrazide derivatives (3.13-3.23), substituted derivatives 
(3.14-3.23) demonstrated superior activity compared to the unsubstituted derivative 3.13, 
with the exception of compound 3.23, which displayed inferior antimycobacterial activity to 
3.13. Further, among sulfonylhydrazides, the antiplasmodial activity of the aliphatic 
derivatives (3.14-3.21) increased from 14.7 µM to 5.7 µM, which coincided with an increase 
in carbon chain length from methyl to propyl. This activity then decreased with insertion of 
one more -CH2- spacer or due to substitution with an aromatic ring. The N-pyridin-4-
ylmethylene fusidic acid hydrazide 3.17 was found to be the most active (IC50 2.0 µM) 
among all the hydrazide derivatives and demonstrated a 29-fold increase in activity compared 
to fusidic acid.  
Among cyclic bioisosteres, 1,2,4-oxadiazole derivatives 3.24-3.27 substituted at the 3-
position with aliphatic and aromatic substituents displayed superior antiplasmodial activity 
(15-35 fold higher) relative to fusidic acid. Introduction of a 4-fluorophenyl group at the 3-
position of the 1,2,4-oxadiazole ring (3.19, IC50 1.7 µM) conferred a 35-fold increase in 
activity. Two other cyclic bioisosteres, the 5-oxo-1,3,4-oxadiazole derivative 3.20 (IC50 9.2 
µM) and its thio analogue 3.21 (IC50 7.0 µM), also showed improvement in antiplasmodial 
activity by 6- and 8-fold, respectively, but were found to be less active than 1,2,4-oxadiazole 
derivatives. 
In summary, bioisosteric replacement of the carboxylic acid group of fusidic acid led to a 2-
35 fold increase in  antiplasmodial activity, and the best activity was observed with 1,2,4-
oxadiazoles.  
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Overall, the decreased in vitro antimycobacterial activity of C-21 derivatives on replacement 
of the carboxylic acid group of fusidic acid with other moieties suggests that the free 
carboxylic group is essential for antimycobacterial activity. This is consistent with its 
antibacterial activity where a free carboxylic acid is reported to be essential.4  On the other 
hand, the improved antiplasmodial activity suggests that the free carboxylic acid is not 
essential for antiplasmodial activity.  
3.5.2 C-3 fusidic acid derivatives 
3.5.2.1 Antimycobacterial activity 
A total of fourteen C-3 derivatives of fusidic acid were evaluated against the H37Rv strain of 
Mtb (Table 3.6). Most of the derivatives displayed antimycobacterial activity at 
concentrations ≤ 20 µM. Nine out of 14 derivatives displayed activity at concentrations ≤ 5 
µM. 
C-3 carboxylic esters were synthesized by reacting fusidic acid with aliphatic carboxylic 
acids with short, medium and long alkyl carbon chains (3.30-3.35). C-3 acetoxy fusidic acid 
(3.30), the shortest carbon chain ester derivative, exhibited moderate activity (MIC99 20 µM). 
As the carbon chain length was increased beyond this, the antimycobacterial activity was 
found to improve up to a certain chain length (3.30-3.32) and then decreased with further 
increase in chain length (3.33-3.35). The C-3 butyrate derivative 3.32 was found to be the 
most active and non-cytotoxic, displaying antimycobacterial activity with a MIC99 value of 
1.25 µM and cytotoxicity with an IC50 value of 170 µM. C-3 propionate (3.31), pentanoate 
(3.33) and heptanoate (3.34) derivatives also displayed good activities with MIC99 values of 
2.5 µM, 2.5 µM and 5 µM, respectively. Derivatives 3.33 and 3.34 were also evaluated for 
cytotoxicity and were found to have low cytotoxicity (Table 3.6). The long carbon chain 
ester, the decanoate derivative 3.35, was found to be inactive suggesting that a long carbon 
chain is not tolerated.  
C-3 oximes were synthesized by reacting 3-keto fusidic acid (3.36) with various hydroxyl 
amines. Among these derivatives, 3-keto fusidic acid was found to be the most active with a 
MIC99 value of 1.25 µM (Table 3.6). The unsubstituted 3-oxime derivative 3.37 also 
exhibited good antimycobacterial activity with a MIC99 value of 2.5 µM. However, 
substituted oximes: 3-O-methyl oxime 3.38 (MIC99 20 µM) and 3-O-benzyl oxime 3.39 
(MIC99 40 µM), showed inferior activity. The active derivatives, 3.36 and 3.37, were also 
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evaluated for cytotoxicity against the CHO cell line and were found to be non-cytotoxic. 3-
Epifusidic acid (3.40, with inversion of configuration at C-3 OH group) was also investigated 
and was found to be far less active (MIC99 11.4 µM) as compared to fusidic acid (MIC99 0.6 
µM), suggesting that inversion of stereochemistry at the C-3 position of fusidic acid reduces 
the antimycobacterial activity significantly. However, the presence of a double bond at the C-
3 position is well tolerated, as demonstrated by the antimycobacterial activities of 3- keto 
(3.36) and unsubstituted 3-oxime derivatives (3.37). 
Silicate esters of fusidic acid were synthesized based on the prodrug approach. It was 
hypothesized that these derivatives would revert back to fusidic acid through hydrolysis. 
Moreover, orthosilicic acid [Si(OH)4], the eventual stoichiometric by-product of silicate ester 
cleavage, is not associated with any significant toxicity as indicated by a number of studies.17–
19 Two out of three silicate esters, triethoxy silicate ester 3.41 and trioctyloxy silicate ester 
3.43, exhibited antimycobacterial activity comparable to fusidic acid, displaying MIC99 
values of 0.2 and 0.3 µM, respectively. Triisopropoxy silicate ester 3.42 exhibited relatively 
lower activity (MIC99 2.5 µM) compared to the above silicate derivatives. An increase in in 
vitro antimycobacterial activity of silicate esters may also be attributed to the hydrophobic 
nature of these compounds, which facilitates penetration through Mtb cell wall. Further, all 
these silicate esters were found to be relatively non-cytotoxic against the CHO cell line 
(Table 3.6). 
3.5.2.2 Antiplasmodial activity  
Most of the C-3 derivatives exhibited better antiplasmodial activity than fusidic acid (Table 
3.6). C-3 carboxylic esters exhibited variable antiplasmodial activity ranging from 6.6-56 
µM. The activity was found to increase with an increase in the carbon chain length and the 
decanoate derivative (3.35, MIC99 6.6 µM) was found to be the most active showing a 9-fold 
increase in antiplasmodial activity compared to fusidic acid (MIC99 59 µM).  
A similar trend was observed with C-3 oxime derivatives where antiplasmodial activity 
improved with increase in lipophilicity from unsubstituted oxime (3.37, IC50 > 19 µM) to 3-
O-benzyl oxime (3.39, IC50 3.4 µM). Conversion of the C-3 OH group of fusidic acid to the 
corresponding C-3 keto derivative (3.36, IC50 8.2 µM) resulted in a 7-fold increase in activity. 
3-Epi fusidic acid (3.40) also resulted in a 1.8-fold improvement in activity. This suggests 
that the orientation of C-3 OH group has little effect on antiplasmodial activity. This is in 
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contrast to antimycobacterial activity, which was found to decrease with inversion of the C-3 
OH configuration. 
Among silicates, triisopropoxy silicate 3.42 displayed better antiplasmodial activity compared 
to the other two silicate derivatives (Table 3.6).  
In summary, C-3 derivatives were obtained by substitution of the C-3 OH group with various 
moieties such as esters, oximes and silicates. These C-3 derivatives exhibited better 
antimycobacterial activity as compared to C-21 derivatives, with 9 out of 14 derivatives 
displaying MIC99 ≤ 5 µM. Further, these derivatives also showed improved antiplasmodial 
activity which, as with C-21 derivatives, was found to increase with lipophilicity. The in vitro 
antimycobacterial and antiplasmodial results obtained for 3-epifusidic acid (3.40) suggest that 
inversion of configuration at the C-3 position may significantly reduce the antimycobacterial 
activity, but this has little effect on antiplasmodial activity. However, a double bond at the C-
3 position is well tolerated. 
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Table 3.6: In vitro antimycobacterial activity (H37Rv strain), antiplasmodial activity (NF54 
strain) and cytotoxicity (CHO cell line) of C-3 fusidic acid derivatives 
 
 
Compound                  R 
MIC99 H37Rv 
(µM) 
IC50 NF54 
(µM) 
IC50 CHO 
(μM) 
3.1  
0.6 59.0 >194.0 
3.30  
20 56 ND 
3.31  
2.5            19 ND 
3.32  
1.25 14.9 170 
3.33  
2.5 7.5 74.4 
3.34             5.0 7.9 36.2 
3.35  >160 6.6 ND 
3.36  1.25 8.2 >194 
3.37  2.5 >19 164 
3.38  20 4.6 ND 
3.39  40 3.4 ND 
3.40  11.4 31.6 >194.0 
3.41 
 
0.2 10 79.5 
3.42 
 
2.5 4.6 115 
3.43 
 
0.3 >11 >107 
 Rifampicin 0.005    
 Kanamycin 3.2    
 CQ  16 nM  
 Artesunate  4 nM  
 Emetine   0.4 
CQ = chloroquine; ND = Not determined 
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3.5.3 C-16 fusidic acid derivatives 
Two C-16 ether derivatives (3.48 and 3.49) were also evaluated for antimycobacterial and 
antiplasmodial activity (Table 3.7). Antimycobacterial activity of the C-16-ethoxy derivative 
(3.49, MIC99 0.8 µM) was found to be comparable to fusidic acid, while the C-16-methoxy 
derivative (3.48, MIC99 18.7 µM) displayed inferior activity. The antiplasmodial activity of 
these two derivatives, however, did not show much improvement.  
Table 3.7: In vitro antimycobacterial activity (H37Rv strain), antiplasmodial activity (NF54 
strain) of C-16 fusidic acid derivatives 
 
 
Compound                  R 
MIC99 H37Rv 
(µM) 
IC50 NF54 
(µM) 
3.1 COCH3 0.6 59.0 
3.48 CH3 18.7 29.0 
3.49 C2H5 0.8 48.1 
 Rifampicin 0.005   
 Kanamycin 3.2   
 CQ  16 nM 
 Artesunate  4 nM 
               CQ = chloroquine 
3.5.4 Miscellaneous derivatives 
Derivatives with modifications at more than one site of fusidic acid have been included under 
the miscellaneous category. The biological results of these miscellaneous derivatives are 
reported in Table 3.8. Compound 3.50, which was obtained by hydrogenation of the double 
bond at the C-24,25 position of fusidic acid bioisostere 3.18 showed antimycobacterial 
activity, antiplasmodial activity and cytotoxicity similar to 3.18. This suggests that saturation 
of the C-24,25 double bond does not affect the antimycobacterial/antiplasmodial activity. 
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Another derivative 3.51, which was obtained by hydrolysis of the C-16 acetoxy group of 
3.18, resulted in reduced antimycobacterial activity and cytotoxicity, indicating the 
importance of the C-16 acetoxy group. The ketone derivative 3.53, obtained during 
ozonolysis of fusidic acid, did not show antimycobacterial activity at the highest 
concentrations tested. This complete loss of the side chain and the carboxylic acid group 
resulting in complete loss of activity indicates the importance of the side chain and the 
carboxylic acid group for antimycobacterial activity. C-3,C-11-diketo fusidic acid (3.54, 
MIC99 11.9 µM)  displayed lower antimycobacterial activity as compared to C-3 keto fusidic 
acid (3.36, MIC99 1.25 µM). Likewise, C-3,C-11-diacetoxy fusidic acid  (3.55, MIC99 52.5 
µM) also displayed lower antimycobacterial activity as compared to C-3 acetoxy fusidic acid 
(3.30, MIC99 20 µM). These results indicate that C-3,C-11 disubstitution is not tolerated for 
antimycobacterial activity. A methyl ester of 3.55 further reduced the antimycobacterial 
activity resulting in an inactive compound 3.56. 
Similar to C-21 and C-3 fusidic acid derivatives, the antiplasmodial activity of these 
miscellaneous derivatives was also found to increase with increase in lipophilicity. The most 
lipophilic derivative 3.56 was found to be the most active, displaying an IC50 of 0.4 µM. 
Further, the antiplasmodial activity of 3.53 (IC50 90.8 µM), though found to be lower than 
fusidic acid, was, however, retained in the absence of the side chain and -COOH group. This 
suggests that fusidic acid derivatives with different functionalities at this site can be explored 
as potential antiplasmodial agents. 
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Table 3.8: In vitro antimycobacterial activity (H37Rv strain), antiplasmodial activity (NF54 
strain) and cytotoxicity (CHO cell line) of miscellaneous fusidic acid derivatives 
Compound                  Structure 
MIC99H37Rv 
(µM) 
IC50 NF54 
(µM) 
IC50 CHO 
(μM) 
3.1 Fusidic acid 0.6 59.0 >194.0 
3.50 
 
10 ˃ 16 97.8 
3.51 
 
40 ˃ 16 32.0 
3.52 
 
40 43.4 ND 
3.53 
 
>160 90.8 ND 
3.54 
 
 
 
 
11.9 10.3 ND 
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3.55 
 
        52.5 2.9 ND 
3.56 
 
>125 0.4 >163 
 Rifampicin 0.005    
 Kanamycin 3.2    
 CQ  16 nM  
 Artesunate  4 nM  
 Emetine   0.4 
CQ = chloroquine; ND = Not determined 
3.5.5 In vivo pharmokinetics study of some representative fusidic acid derivatives 
Based on the in vitro data, the in vivo pharmacokinetic properties of some of the derivatives 
were evaluated in mice in order to determine the suitability of these compounds as potential 
candidates to be evaluated for efficacy in a mouse model of tuberculosis. The 
pharmacokinetic parameters of these compounds are described in Table 3.9 and Figure 3.21 
shows a concentration-time curve plotted for these derivatives. 
Fusidic acid has a short half-life (0.42 h) in mice as reported in a recent study,20 which can 
also be seen from its pharmacokinetic parameters in Table 3.9. Among all tested compounds, 
the triisopropoxy silicate 3.42 showed a better pharmacokinetic profile than fusidic acid, with 
higher concentrations achieved in blood, a longer half-life, and lower clearance rate after oral 
as well as intravenous administration (Table 3.9, Figure 3.21). This derivative was found to 
be relatively stable in vivo and did not act as a prodrug, as hypothesized initially. However, 
the silicate derivative 3.41 acted as a prodrug as it was completely converted into fusidic acid 
within 30 min after intravenous administration. All other derivatives showed similar or poorer 
pharmacokinetic profiles when compared to fusidic acid.  
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Table 3.9: Pharmacokinetic parameters of fusidic acid derivatives in mice 
 Oral administration: 20 mg/kg Intravenous administration: 5 mg/kg 
Compound 
AUC0-inf  
(min.µmol/L) 
tmax 
(h) 
Cmax   
(µg/L) 
t1/2 
(h) 
AUC0-inf  
(min.µmol/L) 
Vd 
(L/kg) 
Cl 
(ml/min/kg) 
t1/2 
(h) 
F 
(%) 
3.1 
Fusidic acid 
351.6 0.5 745.3 1.00 238.4 3.6 37.3 0.21 37 
3.37 1064.3 0.5 5 496.7 0.58 748.4 0.8 12.7 0.75 38 
3.18 349.3 0.7 1206.7 1.57 275.4 0.9 24.4 0.41 23 
3.50 178.6 0.7 412.7 1.82 571.9 1.2 38.9 0.36 6 
3.41 248.7 0.5 1450.0 1.34 ND ND ND ND ND 
3.42 2171.5 2.3 2496.7 5.05 1312.5 3.7 4.9 4.7 41 
AUC0-inf  = Area under the concentration-time curve extrapolated to infinity; Cmax = Maximum concentration of 
a drug in the body; tmax =  Time taken to reach the maximum concentration; t1/2 (h) = Half-life in hours; Vd = 
Volume of distribution; Cl = Rate of clearance of a drug from the body; F = Bioavailbility  
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Figure 3.21: Concentration-time curves of fusidic acid derivatives; per oral (P.O) and 
intravenous (I.V) 
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3.6 Conclusion 
Although fusidic acid has shown potent in vitro antimycobacterial activity this has not 
translated into activity in vivo in Mtb infected mice. It was hypothesized that subjecting 
fusidic acid to semisynthesis may generate derivatives with in vivo efficacy. In an attempt to 
achieve this objective, fusidic acid derivatives were synthesized by structural modifications at 
the C-21, C-3 and C-16 positions. C-21 derivatives were obtained by replacing the C-21 
carboxyl group of fusidic acid with various bioisosteres. This approach led to derivatives with 
far lower antimycobacterial activity compared to fusidic acid, with most of the derivatives 
displaying MIC99 values ≥ 20 µM. However, two derivatives, a fusidic acid-isoniazid 
conjugate 3.15, and methane sulfonyl hydrazide bioisostere 3.18 showed respectable activity 
each with MIC99 values of 10 µM. The decreased in vitro antimycobacterial activity of C-21 
derivatives on replacement of the carboxyl group of fusidic acid with other moieties suggests 
that the free carboxyl group is essential for antimycobacterial activity. C-3 derivatives were 
obtained by replacing the C-3 OH group with its epimer (as epifusidic acid), various 
carboxylic and silicate esters as well as oxime and keto functionalities. C-3 derivatives 
exhibited better antimycobacterial activity compared to the C-21 derivatives, with 9 out of 14 
derivatives displaying antimycobacterial (MIC99) activity ≤ 5 µM. Further, the in vitro 
antimycobacterial activity of 3-epifusidic acid (3.40) suggests that the inversion of 
configuration at the C-3 position may significantly reduce the antimycobacterial activity of 
fusidic acid derivatives. The C-16 ether derivatives 3.48 and 3.49 were obtained by replacing 
the C-16 acetoxy group with methoxy and ethoxy groups, respectively. The ethoxy derivative 
3.48 showed antimycobacterial activity comparable to fusidic acid. Seven miscellaneous 
derivatives with modifications at more than one site of fusidic acid were also obtained. 
Antimycobacterial evaluation of these compounds indicated that the lipophilic side chain, 
carboxylic acid, and the C-16 substitution are essential for antimycobacterial activity.  
Some of the fusidic acid derivatives (3.18, 3.37, 3.41, 3.42 and 3.50) were evaluated for in 
vivo pharmacokinetic properties in mice. Among these, the triisopropoxy silicate 3.42 showed 
a better pharmacokinetic profile than that of fusidic acid, with higher concentrations achieved 
in blood, a longer half-life (5 h versus 1 h after oral administration), and a lower clearance 
rate. The derivative was found to be stable in vivo and did not act as a prodrug. All other 
derivatives showed similar or poorer pharmacokinetic profiles when compared to fusidic acid.  
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In addition, the reported in vitro antiplasmodial activity of fusidic acid prompted 
antiplasmodial evaluation of the synthesized derivatives. The derivatives were tested against 
the NF54 strain of P. falciparum, and most of them displayed better IC50 values compared to 
fusidic acid. The antiplasmodial activity was found to increase with an increase in 
lipophilicity and the C-3, C-11-dicaetyl fusidic acid methyl ester 3.56 (IC50 0.4 µM) was 
found to be the most active. Further, antiplasmodial data for fusidic acid derivatives suggest 
that, unlike antimycobacterial activity, a free carboxyl group is not required for 
antiplasmodial activity.  
3.7 References 
(1)  National Center for Biotechnology Information. PubChem BioAssay Database; 
AID=1332, https://pubchem.ncbi.nlm.nih.gov/bioassay/1332 (accessed May 10, 2016). 
(2)  Cicek-Saydam, C.; Cavusoglu, C.; Burhanoglu, D.; Hilmioglu, S.; Ozkalay, N.; Bilgic, 
A. In Vitro Susceptibility of Mycobacterium Tuberculosis to Fusidic Acid. Clin. 
Microbiol . Infect. 2001, 7, 700–702. 
(3)  Johnson, R. A.; McFadden, G. I.; Goodman, C. D. Characterization of Two Malaria 
Parasite Organelle Translation Elongation Factor G Proteins: The Likely Targets of the 
Anti-Malarial Fusidic Acid. PLoS ONE 2011, 6, e20633. 
(4)  Duvold, T.; Sørensen, M. D.; Bjorkling, F.; Henriksen, A. S.; Rastrup-Andersen, N. 
Synthesis and Conformational Analysis of Fusidic Acid Side Chain Derivatives in 
Relation to Antibacterial Activity. J. Med. Chem. 2001, 44, 3125–3131. 
(5)  Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in 
Drug Design. J. Med. Chem. 2011, 54, 2529–2591. 
(6)  Godtfredsen, W. O.; Daehne, V. W.; Tybring, L.; Vangedal, S. Fusidic Acid 
Derivatives. I. Relationship between Structure and Antibacterial Activity. J. Med. 
Chem. 1966, 9, 15–22. 
(7)  Kaur, G.; Singh, K.; Pavadai, E.; Njoroge, M.; Espinoza-moraga, M.; Kock, C. De; 
Smith, P. J.; De, S. W.; Chibale, K. Synthesis of Fusidic Acid Bioisosteres as 
Antiplasmodial Agents and Molecular Docking Studies in the Binding Site of 
Elongation Factor-G. Med.Chem.Commun. 2015, 6, 2023–2028. 
(8)  Acornley, J. E.; Bessell, C. J.; Bynoe, M. L.; Godtfredsen, W.; Knoyle, J. M. Antiviral 
Activity of Sodium Fusidate and Related Compounds. Br. J. Pharmac. Chemother. 
1967, 31, 210–220. 
Chapter 3: Synthesis, structure-activity relationship and biological evaluation of fusidic acid 
derivatives 
 
112 
 
(9)  Basavaprabhu, Vishwanatha, T. M.; Panguluri, N. R.; Sureshbabu, V. V. 
Propanephosphonic Acid Anhydride ( T3P ® ) - A Benign Reagent for Diverse 
Applications Inclusive of Large-Scale Synthesis. Synthesis 2013, 45, 1569–1601. 
(10)  Rastrup-andersen, N.; Duvold, T. Spectral Assignments and Reference Data 
Reassignment of the 1 H NMR Spectrum of Fusidic Acid and Total Assignment of 1 H 
and 13 C NMR Spectra of Some Selected Fusidane Derivatives. Magn. Reson. Chem. 
2002, 40, 471–473. 
(11)  Duvold, T.; Bretting, C. A. S.; Rasmussen, P. A. ; Bouerat, L.; Thorhauge, J. Novel 
Fusidic Acid Derivatives. WO2005007669 A1, 2005. 
(12)  Duvold, T. Novel Polyaminated Fusidic Acid Derivatives. WO2002077007 A2, 2002. 
(13)  Wohl, A. R.; Michel, A. R.; Kalscheuer, S.; Macosko, C. W.; Panyam, J.; Hoye, T. R. 
Silicate Esters of Paclitaxel and Docetaxel: Synthesis, Hydrophobicity, Hydrolytic 
Stability, Cytotoxicity, and Prodrug Potential. J. Med. Chem. 2014, 57, 2368–2379. 
(14)  Von Daehne, W.; Rasmussen, P. R. l6-Ethers Of Fusidic Acid Derivatives. 
US4060606, 1977. 
(15)  Janssen, G.; Vanderhaeghe, H. Modification of the Side Chain of Fusidie Acid 
(Ramycin). J. Med. Chem. 1967, 10, 205–208. 
(16)  Bostro, J.; Hogner, A.; Llina, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in 
Medicinal Chemistry. J. Med. Chem. 2012, 55, 1817–1830. 
(17)  Anglin, E. J.; Cheng, L.; Freeman, W. R.; Sailor, M. J. Porous Silicon in Drug 
Delivery Devices and Materials. Adv. Drug Deliv. Rev. 2008, pp 1266–1277. 
(18)  Marcofranco, J. E.; Torres, V. E.; Nixon, D. E.; Wilson, D. M.; James, E. M.; 
Bergstralh, E. J.; Mccarthy, J. T. Oxalate, Silicon and Vanadium in Acquired Cystic 
Kidney-Disease. Clin. Nephrol. 1991, 35, 52–58. 
(19)  Gitelman, H. J.; Alderman, F.; Perry, S. J. Renal Handling of Silicon in Normals and 
Patients with Renal Insufficiency. Kidney int. 1992, 42, 957–959. 
(20)  Murphy, T.M.; Little, S.; Wu, R.; Slee, A.; Fernandes, P. Assessment of In Vivo 
Activity of CEM-102 (Fusidic Acid) in Murine Infection Models (Poster Presentation). 
http://www.cempra.com/common/pdf/Posters/Assessment of In Vivo Activity of 
CEM-102 in Murine.pdf (accessed Jun 20, 2016).  
 
 
  
Chapter 4: Use of in silico tools to design fusidic acid derivatives and to identify new fusidic 
acid-like compounds 
 
113 
 
Chapter 4 
Use of in silico tools to design fusidic acid derivatives and to 
identify new fusidic acid-like compounds 
4.1 Introduction 
This chapter introduces the use of in silico tools to design new fusidic acid derivatives and 
fusidic acid-like compounds. It is divided into two sections. The first section describes the 
building of a pharmacophore model based on the antiplasmodial activities of previously 
synthesized fusidic acid derivatives. This model was used to design new fusidic acid 
derivatives, which were then synthesized and subjected to in vitro biological evaluation. In 
the second section, the application of 2D and 3D similarity search methods to identify fusidic 
acid-like compounds from an in-house database is described.  
4.2 Rationale  
Ligand-based (LBVS) and structure-based (SBVS) virtual screening (VS) techniques are 
well-established computational tools used in the modern drug discovery process to identify 
new hit compounds, as well as facilitate hit-to-lead and lead optimization efforts for a 
particular molecular target.1–4 SBVS, such as structure-based 3D pharmacophore modelling 
and molecular docking, uses the 3D structure of a biological target. On the other hand, LBVS, 
such as ligand-based 3D pharmacophore modelling and 2D/3D similarity search methods, 
become the approach of choice when the biological target is not known or its 3D structure is 
not available. Since the biological targets of fusidic acid in Mtb and P. falciparum are not 
known, LBVS was the focus.  
The ligand-based 3D pharmacophore modelling superimposes a set of active compounds and 
extracts the common chemical features that are essential for their biological activity. By 
deriving a 3D pharmacophore model from a set of known active compounds and validating it 
on various active and inactive compound data sets, the model can then be used for virtual 
screening of a library of compounds in a database to identify new hit compounds. Application 
of such a technique prior to synthesis not only reduces the number of compounds for 
synthesis but also increases the % hit rate.  The ligand-based 3D pharmacophore approach has 
been widely reported in literature for its use in identifying new hit compounds for a particular 
target. In this study, a 3D-QSAR pharmacophore model was derived based on the 
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antiplasmodial activities of fusidic acid derivatives synthesized in our lab and has been 
utilized to design new potent fusidic acid derivatives. 
Similarity searching is another commonly used LBVS that does not require the 3D structure 
of a biological target. It is based on searching a database for compounds that most closely 
(structurally) resemble a given query compound. This query compound can represent a 
natural product or a known inhibitor of a target protein, or even a patented compound. The 
fundamental assumption is that the compounds that are structurally similar to the active query 
compound are likely to have similar properties, especially in terms of biological activity, as 
defined by the Similarity Property Principle.5 Different types of 2D fingerprint methods and 
3D shape similarity search methods are available in various drug discovery software 
packages. 2D similarity methods account for structural and/or topological features and the 
overlap between fingerprints of the query and the database compounds is quantified as a 
measure of molecular similarity.6 3D shape similarity methods measure overlapping volumes 
by comparing molecular conformations of the query and database compounds.7 These 2D and 
3D similarity search methods can use fusidic acid as a query compound to identify more 
fusidic acid-like compounds from a database. Since these compounds have a similar structure 
to fusidic acid, they may possess similar biological activities with a possibility of sharing the 
same biological target. 
4.3 3D-QSAR Pharmacophore model 
The purpose of this study was to derive a 3D-QSAR pharmacophore model based on the 
antiplasmodial activities of some previously synthesized fusidic acid derivatives and then use 
the model to design new fusidic acid derivatives.  
4.3.1 Materials and methods 
Data set: Sixty one compounds with available IC50 values, determined against the NF54 
strain of P. falciparum, were used to build the 3D-QSAR model. In order to build and 
validate the pharamacophore model, the data was divided into two sets: a training set of 29 
compounds and a test set of 32 compounds. The training set compounds were selected in such 
a way that they contained information in terms of both their structural features and biological 
activity ranges. Structures of the training set and test set compounds are shown in Table 4.1 
and Table 4.2 respectively.  
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Table 4.1: Chemical structures of the training set compounds with IC50 values 
 
S. No. X Y IC50 NF54 
(nM) 
S. No. X Y IC50 NF54 
(nM) 
1 COOH 
 
390 12 
 
OH 2900 
2 
 
           OH 500 13 
 
OH 3240 
3 COOH 
 
1060 14 COOH 
 
3430 
4 
 
OH 1200 15 
 
OH 3600 
5 
 
OH 1400 16 
 
OH 3800 
6 COOH 
 
1520 17 COOH 
 
4650 
7 
 
OH 1730 18 COOH 
 
6630 
8 COOH 
 
1960 19 
 
OH 7040 
9 
 
OH 2000 20 COOH 
 
8220 
10 COOH 
 
2600 21 
 
OH 8420 
11 
 
OH 2600 22 
 
OH 9230 
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Table 4.1: Continued… 
S. No. X Y IC50 NF54 
(nM) 
S. No. X Y IC50 NF54 
(nM) 
 
23 
 
 
OH 
 
13584 
 
27 
 
 
43400 
 
24 
 
 
OH 
 
14700 
 
28 
 
COOH 
 
OH 
 
59000 
 
25 
 
-CONHNH2 
 
OH 
 
21300 
 
29 
 
 
91000 
26 -CONH2 OH 35900  
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Table 4.2: Chemical structures of the test set compounds with IC50 values 
 
S. No. X Y 
IC50 NF54 
(nM) 
S. No. X Y 
IC50 NF54 
(nM) 
30 
 
OH 59 39 
 
OH 1800 
31 
 
OH 120 40 
 
OH 1890 
32 
 
OH 121 41 
 
OH 2000 
33 
 
OH 136 42 
 
OH 2090 
34 
 
OH 340 43 
 
OH 2100 
35 
 
OH 708 44 
 
OH 2300 
36 
 
OH 1074 45 
 
OH 2400 
37 
 
OH 1225 46 
 
OH 2400 
38 
 
OH 1464 47 
 
OH 2600 
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Table 4.2: Continued… 
S. No. X Y 
IC50 NF54 
(nM) 
S. No. X Y 
IC50 NF54 
(nM) 
48 
 
OH 2900 55 COOH -OCOC4H9 7450 
49 
 
OH 3000 56 COOH -OCOC6H13 7920 
50 
 
OH 3200 57 
 
OH 8040 
51 -COOC2H5 OH 3400 58 
 
OH 13370 
52 
 
OH 3500 59 COOH -OCOC3H7 14880 
53 -COOC8H17 OH 4600 60 COOH -OCOC2H5 19030 
54 
 
OH 4700 61 COOH -OCOCH3 56020 
 
3D-QSAR pharmacophore generation: The ‘HypoGen’ algorithm of Discovery Studio 4.0 
was employed to build a 3D-QSAR pharmacophore model with a set of selected 29 training 
set compounds (Table 4.1). Different possible conformations for each training set compound 
were generated using the ‘Best’ conformation method with the maximum number of 
conformations set to 255. These conformations were created within a relative energy 
threshold of 10 kcal/mol. The ‘Feature Mapping’ protocol was used to identify the common 
features present in active compounds and, accordingly, HB_acceptor, HB_donor, 
Hydrophobic and Ring aromatic were selected as key input pharmacophore features for the 
generation of the pharmacophore model. All other parameters were used at their default 
values except the uncertainty value which was set at 1.5. The ‘HypoGen’ algorithm generated 
a set of 10 pharmacophore hypotheses with corresponding statistical parameters such as cost 
values, root mean square deviation (RMSD), correlation coefficient and fit values. The best 
quality hypothesis was selected based on these parameters.   
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Validation of the pharmacophore model: In addition to having good statistical data, a good 
pharmacophore model should also be able to accurately predict the activity of compounds and 
retrieve active compounds from the database. Therefore, to check the reliability of the 
selected model, the model was validated using various techniques, such as Fischer’s 
randomization method, test set validation, and inactive set validation.  
Combinatorial library design: In order to identify hit compounds, the best pharmacophore 
model after validation was used as the 3D structural search query to screen a combinatorial 
library. The library was generated using the ‘Enumerate Library from Ligands’ protocol of 
Discovery Studio 4.0. A conformational ensemble of each library compound was then 
generated in the ‘Generate Conformation’ program, setting the confirmation method to ‘Best’, 
the maximum number of conformations to 255, and the relative energy threshold to 
10kcal/mol. All these conformations were used in the virtual screening, which was performed 
using the ‘Ligand Pharmacophore Mapping’ program with the ‘Flexible’ fit method. The 
selection of compounds for synthesis was based on their fit value computed by the 
pharmacophore model in the virtual screening. Selected hit compounds were synthesized and 
evaluated for biological activity.  
4.3.2 Results and discussion 
4.3.2.1 Pharmacophore modelling 
As mentioned in materials and methods (Section 4.3.1), the ‘HypoGen’ algorithm of 
Discovery Studio 4.0 generated a set of 10 pharmacophore hypotheses with corresponding 
statistical parameters such as cost values, root mean square deviation (RMSD), correlation 
coefficient and fit values. The best quality hypothesis was selected based on these parameters 
using Debnath’s analysis.8  The statistical parameters of these 10 pharmacophore are shown 
in Table 4.3. 
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Table 4.3: Statistical results of the 10 pharmacophore hypotheses generated by ‘HypoGen’ 
algorithm 
Hypothesis 
Total 
Cost 
aCost 
Difference 
bRMSD 
Correlation 
Training Set 
cFeatures 
Correlation 
Test Set 
Hypo 1 115.806 111.46 1.30259 0.919356 HY, HY, HY, RA 0.619677 
Hypo 2 118.772 108.49 1.34949 0.913164 HY, HY, HY, RA 0.832466 
Hypo 3 127.014 100.25 1.63088 0.870076 HY, HY, HY, RA 0.433590 
Hypo 4 127.593 99.668 1.64589 0.86748 HY, HY, HY, RA 0.574456 
Hypo 5 127.798 99.463 1.52039 0.888284 HY, HY, HY, RA 0.629285 
Hypo 6 131.349 95.912 1.73001 0.852355 HY, HY, HY, RA 0.366060 
Hypo 7 132.382 94.879 1.74801 0.849004 HY, HY, HY, RA 0.273861 
Hypo 8 136.537 90.724 1.81551 0.836014 HBA, HY, HY, 
RA 
0.583952 
Hypo 9 137.504 89.757 1.80439 0.838285 HBA, HY, HY, 
RA 
0.594138 
Hypo 10 138.409 88.852 1.81525 0.836151 HBA, HY, HY, 
RA 
0.465832 
aCost difference between the null and the total cost; The null cost, the fixed cost and the configuration cost are 
227.261, 87.4891 and 17.7258, respectively; bRMSD = root mean square deviation; cAbbreviation used for 
features: HBA = hydrogen bond acceptor,  HY =  hydrophobic, and RA =  ring aromatic 
According to Debnath’s analysis, the best pharmacophore model should have the highest cost 
difference, a good correlation coefficient, the least RMSD, and the lowest total cost values. 
Cost difference represents the difference between the null and total cost of hypothesis. The 
cost values of 10 pharmacophore models ranged from 115.806 to 138.409 (Table 4.3). Out of 
these 10 hypotheses, Hypo 1 and Hypo 2 showed lower cost values (115.806 - Hypo 1, 
118.772 - Hypo 2) compared to the other hypothesis. The correlation coefficient is based on 
linear regression derived from the geometric fit index. A higher correlation coefficient stands 
for better predictive ability of the model. The correlation coefficients for Hypo 1 and Hypo 2 
were 0.919356 and 0.913164, respectively, which were prominently higher than other 
hypotheses. The RMSD factor represents the deviation of the predicted activity value from 
the experimental value; therefore, a lower RMSD value further supports the predictive ability 
of the model. The RMSD values of Hypo 1 (1.30259) and Hypo 2 (1.34949) were found to be 
Chapter 4: Use of in silico tools to design fusidic acid derivatives and to identify new fusidic 
acid-like compounds 
 
121 
 
lower than other models. Both of the hypotheses also showed the same pharmacophore 
features: 3 hydrophobic regions and one aromatic ring feature. The selection of the best 
model for virtual screening was performed after checking the reliability of these two models 
on the test set. The highest correlation coefficient in the test set was obtained for Hypo 2 
(0.832466) while Hypo 1 showed a correlation coefficient of 0.619677. However, none of the 
other 8 pharmacophore models showed a correlation coefficient close to Hypo 2. The 
correlation coefficient values for all the 10 pharmacophore models in the test set are also 
shown in Table 4.3. Consequently, Hypo 2 was selected for virtual screening. Figure 4.1 
represents the best HypoGen model-Hypo 2, and mapping of Hypo 2 with one of the most 
active (1, IC50 = 390 nM) and the least active (29, IC50 = 91000 nM) compounds from the 
training set. The most active compound (1) overlapped with all four pharmacophore features 
of Hypo 2 and showed the highest fit value of 3.69. On the other hand, the least active 
compound (29) missed one ring aromatic and one hydrophobic feature of Hypo 2 and thus 
showed the lowest fit value of 1.53. The fit values and the predicted IC50 values of all the 
training set compounds, as computed by Hypo 2, are shown in Table 4.4. Figure 4.2 shows 
the plot of the correlation between the experimental and predicted activity of these 
compounds. 
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A. B. 
                
 
C. 
                                            
Figure 4.1: Pharmacophore models based on fusidic acid derivatives generated by HypoGen;  
A. The best HypoGen model, Hypo 2; B. Mapping of Hypo 2 with one of the most active 
compounds (IC50 = 390 nM) from the training set; C. Mapping of Hypo 2 with one of the 
least active compounds (IC50 = 91000 nM) from the training set; Pharmacophore features are 
color-coded: orange for ring aromatic (RA) and cyan for hydrophobic (HY)  
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Table 4.4: Experimental (Exp IC50) and predicted (Pred IC50) IC50 values of the training set 
compounds based on best pharmacophore hypothesis Hypo 2 
S. No. 
d Fit 
Value 
Exp IC50 
(nM) 
Pred IC50 
(nM) 
e Error S. No. 
d Fit 
Value 
Exp IC50 
(nM) 
Pred IC50 
(nM) 
e Error 
1 3.69 390 500 +1.3 16 3.04 3800 2200 -1.7 
2 3.14 500 1800 +3.6 17 2.98 4700 2600 -1.8 
3 3.52 1100 750 -1.4 18 2.53 6600 7300 +1.1 
4 3.05 1200 2200 +1.8 19 2.18 7000 16000 +2.3 
5 3.14 1400 1800 +1.3 20 2.11 8200 19000 +2.3 
6 3.13 1500 1800 +1.2 21 2.85 8400 3500 -2.4 
7 3.13 1700 1800 +1.1 22 2.11 9200 19000 +2.1 
8 3.01 2000 2400 +1.2 23 2.38 14000 10000 -1.3 
9 3.03 2000 2300 +1.2 24 2.11 15000 19000 +1.3 
10 3.13 2600 1800 -1.4 25 2.11 21000 19000 -1.1 
11 2.75 2600 4400 +1.7 26 2.11 36000 19000 -1.9 
12 2.96 2900 2700 -1.1 27 1.63 43000 57000 +1.3 
13 3.03 3200 2300 -1.4 28 2.11 59000 19000 -3.1 
14 3.06 3400 2100 -1.6 29 1.53 91000 73000 -1.2 
15 3.06 3600 2100 -1.7      
d Fit value indicates how well the features in the pharmacophore overlap the chemical features in the molecule; 
eDivision of higher value of experimental/predicted IC50 by lower predicted/experimental IC50 value; ‘+’ 
indicates that the predicted IC50 is higher than the experimental IC50, ‘–’ indicates that the predicted IC50 is 
lower than the experimental IC50, a value of 1 indicates that the predicted IC50 is equal to the experimental IC50 
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                                                     Experimental Activity (pIC50) 
Figure 4.2: Plot of the correlation (R) between the experimental activity and the activity 
predicted by Hypo 2 for the training set compound 
The selected model ‘Hypo 2’ was subjected to a reliability check using three techniques- 
Fischer’s randomization test, test set validation, and inactive set validation. Fischer’s 
randomization test validates the correlation between the chemical structures and the 
biological activity of the compounds. In this technique, the activity data is randomised among 
the training set compounds and new pharmacophore hypotheses are generated under the same 
features and parameters as used in the original hypothesis generation. If these random 
pharmacophores show similar or better statistics, such as cost values and correlation 
coefficients, than the original hypothesis, then the original hypothesis is considered as 
generated by chance. Fischer’s randomization test was performed simultaneously during the 
original hypothesis generation. A confidence level of 95% was selected, which generated 19 
random pharmacophore hypotheses. The lower correlation coefficients and the higher total 
cost values of these 19 hypotheses as compared to Hypo2 indicated that the Hypo 2 has not 
been generated by chance (Figure 4.3).  
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Figure 4.3: Total cost (above) and correlation (below) values of all pharmacophore models at 
95% confidence level 
A validation process using a test set of 32 fusidic acid derivatives (not included in the training 
set) was performed on the entire 10 hypotheses. A conformational space for 32 test set 
compounds was prepared in the same manner as in the pharmacophore generation process. 
The ‘Ligand pharmacophore mapping’ protocol was used for predicting the activity of all test 
set compounds. The highest correlation between the experimental and the predicted activity  
for the test set compounds was obtained in the case of Hypo 2 (Table 4.3) showing that Hypo 
2 fits, not only for training set compounds, but also for other fusidic acid derivatives. Table 
4.5 shows experimental and predicted IC50 values of the test set compounds. Figure 4.4 
represents the plot of the correlation between the experimental and predicted activity by Hypo 
2 for the test set compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
Hypo
total 
cost
random
1
random
2
random
3
random
4
random
5
random
6
random
7
random
8
random
9
random
10
random
11
random
12
random
13
random
14
random
15
random
16
random
17
random
18
random
19
Hypo1 115.81 163.3 163.53 126.19 159.92 152.66 127.35 151.08 142.45 179.81 153.6 160.33 159.64 150.27 143.94 124.26 133.94 178.64 160.53 155.54
Hypo2 118.77 182.32 178.17 167.61 184.05 166.83 168.79 193.18 146.77 185.28 169.59 169.09 179.01 166.72 167.95 160.23 147.25 179.82 172.28 175.83
Hypo3 127.01 184.95 178.88 168.26 204.51 166.84 174.69 202.37 175.83 211.68 195.75 170.69 182.8 166.83 191.65 171.76 153.31 209.83 173.82 176.72
Hypo4 127.59 185.83 183.79 171.98 204.88 170.36 175.85 205.11 178.48 213.45 198.57 179.81 182.83 171.81 198.6 181.27 156.91 212.58 177.45 179.13
Hypo5 127.8 186.04 184.12 172.89 206.64 167.29 175.85 205.12 185.4 217.02 201.43 182.98 184.5 176.07 199.69 185.66 158.88 212.62 179.19 182.56
Hypo6 131.35 187.38 184.5 173.06 208.13 171.26 176.56 205.96 190.1 217.24 209.63 185.6 185.86 182.05 200.13 188.77 159.58 213.21 179.71 186.26
Hypo7 132.38 188.75 190.8 174.94 210 175.64 176.79 206.38 192.44 218.31 209.85 188.18 186.4 182.56 200.81 190.19 159.77 213.52 180.08 187.85
Hypo8 136.54 188.82 192.91 175.69 212.75 175.91 177.02 206.16 193.66 218.69 209.95 190.57 193.56 183.21 201.03 190.26 161.56 214.41 181.07 189.23
Hypo9 137.5 189.49 193.56 175.73 212.88 177.45 178.93 207.84 194.45 218.7 213.59 195.14 193.75 185.34 201.39 190.7 164.46 214.68 181.54 190.18
Hypo10 138.41 190.42 193.91 177.33 214.58 179.1 180.44 210.18 197.64 219.52 214.27 199.31 194.7 187.64 201.76 190.88 167.07 214.83 184.1 190.39
Hypo Correlation
Random 
1
Random 
2
Random 
3
Random 
4
Random 
5
Random 
6
Random 
7
Random 
8
Random 
9
Random 
10
Random 
11
Random 
12
Random 
13
Random 
14
Random 
15
Random 
16
Random 
17
Random 
18
Random 
19
Hypo 1 0.919356 0.71528 0.73123 0.86894 0.7497 0.77185 0.8655 0.77196 0.8083 0.64836 0.77379 No data 0.74594 0.7813 0.8016 0.87526 0.8412 0.65124 0.7386 0.7556
Hypo 2 0.913164 0.63279 0.66196 0.71992 0.6563 0.70818 0.7113 0.57287 0.7896 0.62162 0.70597 0.6965 0.66394 0.7114 0.7039 0.73723 0.7899 0.63866 0.6857 0.6749
Hypo 3 0.870076 0.61198 0.67045 0.70121 0.5089 0.71166 0.6899 0.52074 0.6698 0.48622 0.56819 0.6988 0.64413 0.7125 0.5833 0.69905 0.7664 0.48058 0.675 0.6685
Hypo 4 0.86748 0.63272 0.65487 0.68292 0.5182 0.70413 0.6893 0.50268 0.6531 0.48716 0.57353 0.6585 0.65923 0.693 0.5663 0.63855 0.752 0.46403 0.6668 0.6595
Hypo 5 0.888284 0.63378 0.64515 0.69381 0.4978 0.70638 0.6894 0.54165 0.6343 0.45039 0.56585 0.6417 0.63376 0.675 0.5502 0.62156 0.7459 0.47047 0.6531 0.6485
Hypo 6 0.852355 0.63359 0.64063 0.69709 0.5056 0.70282 0.6892 0.54237 0.6039 0.46027 0.51207 0.6262 0.62788 0.6449 0.544 0.61854 0.741 0.4564 0.6507 0.64
Hypo 7 0.849004 0.60469 0.61121 0.68755 0.4909 0.68422 0.6878 0.52519 0.5822 0.47508 0.47955 0.6232 0.63481 0.6486 0.5523 0.61061 0.7408 0.46543 0.6523 0.6103
Hypo 8 0.836014 0.60973 0.60323 0.66642 0.499 0.68683 0.6829 0.54054 0.5721 0.45294 0.49222 0.6112 0.6013 0.6459 0.5546 0.60446 0.7317 0.43755 0.6427 0.6262
Hypo 9 0.838285 0.61924 0.60774 0.68662 0.4537 0.67097 0.6799 0.52724 0.5972 0.46192 0.47725 0.5984 0.59975 0.6261 0.5477 0.6042 0.7224 0.43553 0.638 0.6146
Hypo 10 0.836151 0.5993 0.59014 0.67162 0.4827 0.65833 0.66 0.50991 0.5564 0.41496 0.46608 0.5624 0.5886 0.6271 0.5453 0.59976 0.7143 0.44228 0.6329 0.602
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Table 4.5: Experimental (Exp IC50) and predicted (Pred IC50) IC50 values of the test set 
compounds against Hypo 2 
S. No. 
d Fit 
Value 
Exp IC50 
(nM) 
Pred IC50 
(nM) 
e Error S. No. 
d Fit 
Value 
Exp IC50 
(nM) 
Pred IC50 
(nM) 
e Error 
30 3.55 59 694 +11.76 46 2.94 2400 2852 +1.19 
31 3.53 120 720 +6.00 47 3.08 2600 2026 -1.28 
32 3.63 121 580 +4.79 48 2.92 2900 2964 +1.02 
33 4.04 136 222 +1.63 49 3.11 3000 1912 -1.57 
34 3.49 340 785 +2.31 50 3.13 3200 1822 -1.76 
35 3.18 708 1792 +2.53 51 3.09 3400 2010 -1.69 
36 3.13 1074 1833 +1.71 52 2.95 3500 2741 -1.28 
37 3.18 1225 1639 +1.34 53 2.94 4600 2805 -1.64 
38 3.12 1464 1860 +1.27 54 2.75 4700 4350 -1.1 
39 3.07 1800 2090 +1.16 55 3.07 7450 2079 -3.58 
40 3.11 1890 1924 +1.02 56 2.96 7920 2668 -2.97 
41 3.53 2000 724 -2.76 57 3.01 8040 2398 -3.35 
42 3.04 2090 2220 +1.06 58 2.99 13370 2490 -5.37 
43 3.01 2100 2426 +1.16 59 3.03 14880 2275 -6.54 
44 3.15 2300 1742 -1.32 60 2.99 19030 2586 -7.36 
45 3.09 2400 1988 -1.21 61 2.28 56020 12871 -4.35 
d Fit value indicates how well the features in the pharmacophore overlap the chemical features in the molecule; 
eDivision of higher value of experimental/predicted IC50 by lower predicted/experimental IC50 value; ‘+’ 
indicates that the predicted IC50 is higher than the experimental IC50, ‘–’ indicates that the predicted IC50 is 
lower than the experimental IC50, a value of 1 indicates that the predicted IC50 is equal to the experimental IC50 
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Experimental Activity (pIC50) 
Figure 4.4: Plot of the correlation (R) between the experimental activity and the activity 
predicted by Hypo 2 for the test set molecules 
The ability of Hypo 2 to reject inactive compounds was also validated by screening a set of 
four inactive fusidic acid derivatives (IC50 > 100 µM) which were predicted to be inactive by 
Hypo 2. Hypo 2, after validation, was used to screen a fusidic acid-based combinatorial 
library.  
A general structure representing the library design is shown in Figure 4.5. 
 
Figure 4.5: A combinatorial library design for fusidic acid derivatives. 
A total of 120 compounds were screened through Hypo 2 using the ‘Ligand Pharmacophore 
Mapping’ protocol, which computed a fit value for each library compound. The selection of 
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hit compounds was based on these fit values. The threshold for the fit value was decided from 
the fit values of the two most active compounds (compounds 1 and 2, Table 4.4) used in 3D-
QSAR pharmacophore model generation. Accordingly, compounds with fit values > 3 were 
prioritized and 8 compounds were selected for synthesis. These 8 hits include derivatization 
either at the C-21 carboxylic acid to make C-21 amide derivatives of fusidic acid or at the C-3 
position to make C-3 ethers. The chemical structures of the compounds with their fit value 
and predicted value of activity are shown in Figure 4.6. 
Fit value: 4.00 
Predicted activity: 242 nM 
 
Fit value: 3.98 
Predicted activity: 256 nM 
 
Fit value: 3.87 
Predicted activity: 334 nM 
Fit value: 3.77 
Predicted activity: 420 nM 
Fit value: 3.53 
Predicted activity: 728 nM 
 
Fit value: 3.89 
Predicted activity: 315 nM 
 
Fit value: 3.90 
Predicted activity: 307 nM 
 
Fit value: 3.40 
Predicted activity: 966 nM 
 
Figure 4.6: Structures of hit compounds selected for synthesis with fit values and predicted 
activity 
4.3.2.2 Synthesis of hit compounds (4.1-4.8) 
Two different synthetic routes (Scheme 4.1) were adopted for synthesis. Compounds 4.4-4.8 
were synthesized by the reaction of fusidic acid (3.1) with the corresponding amine using T3P 
(50% w/v in DMF) as a coupling reagent. All these compounds were obtained in good to very 
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good yields (70-89%). However, compounds 4.7 (20%) and 4.8 (25%) were obtained in poor 
yields as reactions did not proceed to completion and fusidic acid was recovered in these 
reactions. Synthesis of compounds 4.1-4.3 was achieved in 3 steps. Fusidic acid was first 
protected as pivaloyloxymethyl ester to yield 4.0. This intermediate was then heated with the 
corresponding benzyl halides at 130 oC using DIPEA as a base. This reaction yielded both C-
3-mono substituted (4.1a-4.3a) as well as C-3,C-11-disubstituted products, which were 
separated by silica gel column chromatography. Finally, the pivaloyloxymethyl group of 
4.1a-4.3a was removed using K2CO3 in methanol, yielding target compounds 4.1-4.3. 
Detailed synthetic procedures are described in the experimental section (Chapter 7). All 
compounds were well characterised by 1H NMR, 13C NMR and mass spectroscopy. Purities 
were checked by LCMS and found to be greater than 95%. Table 4.6 reports the yields of 
isolated intermediates while Table 4.7 reports the isolated yields and melting points of the 
target compounds. 
 
Scheme 4.1: (a) ClCH2OCOC(CH3)3, Et3N, DMF, 25 
oC, 36 h; (b) R1-Cl or R1-Br, DIPEA, 
16 h, 130 oC; (c) K2CO3, Methanol, 25 
oC, 2.5 h; (d) R-NH2, Et3N, DCM, T3P (50% w/v 
solution in DMF), 0 oC - 25 oC, 5 h  
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Table 4.6: Yields of isolated intermediates 
Compound R1 Yield (%) 
4.0  H 93 
4.1a 
 
45 
4.2a 
 
31 
4.3a 
 
62 
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Table 4.7: Isolated yields and melting points of synthesized fusidic acid derivatives 
 
Compound R R1 Yield* (%) Mp (
oC) 
4.1 OH 
 
89 301-303 
4.2 OH 
 
78 271-273 
4.3 OH 
 
82 206-208 
4.4 
 
H 74 195-197 
4.5 
 
H 70 106-108 
4.6 
 
H 70 110-112 
4.7 
 
H 20 127-129 
4.8 
 
H 25 250-252 
*Yields are reported for the final step of synthesis 
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4.3.2.3 Antiplasmodial activity 
Synthesized hit compounds were screened for in vitro antiplasmodial activity against the CQ-
sensitive NF54 strain of P. falciparum. CQ and artesunate were used as the reference drugs. 
The most active compounds were screened for cytotoxicity against the Chinese Hamster 
Ovarian (CHO) mammalian cell line.  
The antiplasmodial activity (IC50 value) of fusidic acid was found to be 59 µM. All 
synthesized compounds were found to be more active than fusidic acid with IC50 values 
ranging from 0.3 to 9.2 µM (Table 4.8). C-21 amide derivatives 4.4-4.8 displayed better 
activities than C-3 ether derivatives 4.1-4.3. Among C-21 derivatives, the antiplasmodial 
activity of the compounds improved significantly when the -CH2 of benzyl was removed 
(compound 4.8) or substituted for a hydrogen atom (compound 4.7). The IC50 values for these 
two compounds were also found to be close to those predicted by the pharmacophore model 
(Figure 4.6). However, IC50 values for other compounds were found to be higher than those 
predicted by the pharmacophore model. This suggests that a new series of hits with C-21 
phenyl amide derivatives in place of the benzyl amide derivatives may be useful. However, a 
substituent at the 4-position of the benzyl group had no effect on antiplasmodial activity. 
Compounds 4.7 (IC50 0.3 µM) and 4.8 (IC50 0.7 µM) were found to be the most active. These 
two compounds also showed potent in vitro activity against the CQ-resistant K1 strain with 
IC50 values of 0.2 µM each and were also found to be non-cytotoxic on CHO cell line (Table 
4.9).  
4.3.2.4 Antimycobacterial activity 
As mentioned in chapter 3, fusidic acid possesses potent in vitro antimycobacterial activity. 
Therefore, the compounds were additionally screened against the H37Rv strain of Mtb to 
determine their MIC99 values (Table 4.8). However, none of the compounds displayed 
antimycobacterial activity even at the highest concentrations tested (125 µM). 
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Table 4.8: In vitro antiplasmodial (NF54 strain) and antimycobacterial activity (H37Rv 
strain) of fusidic acid derivatives 
 
Compound R R1 
IC50 NF54 
(µM)  
MIC99 H37Rv 
 (µM)   
Fusidic acid 
3.1 
OH H 59 0.6 
4.1 OH 
 
6.4 >125 
4.2 OH 
 
7.6 >125 
4.3 OH 
 
9.2 >125 
4.4 
 
H 2.7 >125 
4.5 
 
H 5.9 >125 
4.6 
 
H 3.6 >125 
4.7 
 
H 0.3 >125 
4.8 
 
H 0.7 >125 
 CQ  16 nM  
 Artesunate  4 nM  
 Rifampicin   0.005 
 Kanamycin   3.2 
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Table 4.9: In vitro antiplasmodial activity and cytotoxicity of the most active hit compounds  
Compound IC50 NF54 
(µM) 
IC50 K1 
(µM) 
IC50 CHO 
(µM) 
4.7 0.3 0.2 >153 
4.8 0.7 0.2 134 
CQ 16 nM 215 nM  
Artesunate 4 nM 2.6 nM  
Emetine   0.05 
                               CQ = Chloroquine 
4.4 2D and 3D similarity searches for the identification of fusidic acid-like   
compounds as antiplasmodial agents 
The purpose of this study was to search for new fusidic acid-like compounds using 2D and 
3D similarity search methods using an in-house database. For this, fusidic acid was used as 
the ‘query compound’ in order to search for similar compounds from the database. These 
compounds, according to the Similarity Property Principle, may show similar biological 
activity.  
4.4.1 Materials and Methods 
Database: The database used was built in-house. It consisted of 708 steroid-type natural 
products or their semisynthetic derivatives with defined chemical structures and 
stereochemistry. 
2D fingerprints: Thirteen fingerprint methods are available in Discovery Studio 4.0: one 
MDL PublicKeys and 12 extended-connectivity fingerprints. Extended-connectivity 
fingerprints are circular topological fingerprints and their generation process systematically 
records the neighbourhood of each non-hydrogen atom into multiple circular layers up to a 
given bond diameter.6 The extended connectivity fingerprints are further subgrouped into 
three ECFPs (ECFP_2, ECFP_4, ECFP_6), three FCFPs (FCFP_2, FCFP_4, FCFP_6), three 
ECFCs (ECFC_2, ECFC_4, ECFC_6) and three FCFCs (FCFC_2, FCFC_4, FCFC_6). 
ECFPs (atom-types) and FCFPs (functional class) consider only the presence or absence of a 
feature while ECFCs and FCFCs also consider as many times a feature appears, the numeric 
2, 4 and 6 represent bond diameter length or maximum number of bonds considered. In this 
experiment, three fingerprints were generated using FCFP_2, ECFC_4 and FCFC_4 methods. 
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Ligand preparation: Ligands were prepared in order to remove any duplicates from the 
database using the method ‘Prepare Ligands’ in Discovery Studio 4.0. Ligands were prepared 
in 2D coordinates and ionisation/tautomerisation/isomerisation options were switched off.  
Similarity coefficient: The Tanimoto coefficient (Tc) was calculated to measure similarity 
between the query and the database compounds. Tc is generally defined as the fraction of 
features common between two compounds to the total number of features present in two 
compounds. The value of Tc lies between 0 and 1 where 0 stands for ‘not similar’ and 1 
stands for ‘highly similar’. 
3D shape: Besides structural/topological features, molecular shapes/conformations were also 
compared between the database molecules and the query molecule (Fusidic Acid). A ‘Phase-
Shape’ screening was performed by Maestro 8.0, Schrodinger. According to the author4, 
Phase-Shape considers volume overlapping of all the conformations of a molecule with the 
query molecule and returns an aligned structure, which shows the best overlap with the query. 
Four different Phase-Shape methods are available in this software: Shape_none, 
Shape_mmod., Shape_ele, Shape_pharm. Shape_none computes volume overlaps only and 
does not discriminate between the different atoms. Shape_mmod computes volume overlaps 
only between atoms that have the same macromodel atom type. Shape_ele and Shape_pharm 
also consider atom-related information in their calculations. Shape_ele computes volume 
overlaps only between atoms of the same element. Shape_pharm computes volume overlaps 
between atoms that have the same pharmacophore type such as acceptor and donor. Out of 
these four Phase-Shape screening methods, we chose Shape_ele and Shape_pharm methods. 
Ligand preparation: The query compound, as well as all the database compounds, were 
prepared by ‘LigPrep’ in Maestro. OPLS_2005 was selected as force field. Epik was chosen 
to generate all possible protonation states of the compounds at a pH from 5.0 to 9.0. The 
remaining parameters were used at their default values. A conformational search was then 
performed using ‘ConfGen’ in the fast search mode and different energy conformations of the 
query and the database compounds were generated. Only the lowest energy conformation of 
the query was allowed to screen the database. 
Similarity coefficient: Like Tanimoto, the value of ‘shape similarity coefficient’ also lies 
between 0 and 1 where 0 stands for ‘not similar’ and 1 stands for ‘highly similar’.  
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4.4.2 Results and discussion  
4.4.2.1 Similarity searching 
A similarity search of an in-house database containing 708 steroid-type natural products or 
their semisynthetic derivatives with defined chemical structures and stereochemistry was 
performed using fusidic acid as a query compound. 2D as well as 3D similarity search 
methods were applied to find compounds with a similar structure or shape as that of fusidic 
acid. Instead of focussing on one single 2D or 3D method, a combination of these was 
preferred. Furthermore, instead of opting for one fingerprint method from 2D methods, a 
combination of FCFP_2, ECFC_4 and FCFC_4 was preferred. Similarly, a combination of 
Shape_ele and Shape_pharm was applied from 3D methods. A work flow leading to the 
selection of hit compounds from the database using the two similarity search protocols is 
shown in Figure 4.7. Twenty five top ranked compounds from each 2D fingerprint method 
were selected which makes Tc threshold values of 0.66, 0.60 and 0.92 for FCFP_2, ECFC_4 
and FCFC_4, respectively. Similarly, 20 top ranked compounds from each 3D method were 
selected which makes a cut-off value of 0.69 for Shape_ele and 0.39 for Shape_pharm.  
After combining all the top ranked compounds resulting from 2D/3D similarity searches and 
removing any duplicates found, Log P filter was applied to the compounds. Log P values 
were computed using StarDrop 5.5 and any compound having Log P > 5.5 owing to undesired 
lipophilicity was eliminated. Finally, 27 hit compounds were selected and screened for 
antiplasmodial activity.  
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Figure 4.7: Flow diagram for in silico selection process 
4.4.2.2 Antiplasmodial activity 
Antiplasmodial activities (IC50 values) for all the compounds were determined against the 
NF54 strain of P. falciparum. IC50 value of fusidic acid (3.1) was found to be 59 µM (Table 
4.10). Twelve out of 27 compounds were found to be active with IC50 < 25 µM. However, 
none of the compounds except fusidic acid was tested beyond this concentration. Compound 
4.13 (Cucurbitacin B) was found to be the most active with an IC50 value of 1.4 µM. Five 
compounds, 4.9, 4.11, 4.21, 4.30 and 4.32 exhibited activity below 10 µM with IC50 values of 
2.9 µM, 1.8 µM, 3.4 µM, 7.0 µM and 6.0 µM, respectively. Six compounds (4.12, 4.23, 4.24, 
4.25, 4.27 and 4.35) were found to have activity between 10-25 µM (Table 4.10). Similarity 
search methods provided 12 compounds, with superior antiplasmodial activity than fusidic 
acid. The most active compounds 4.9, 4.11, 4.13 and 4.21 were further screened for in vitro 
cytotoxicity against the CHO cell line and found to have IC50 values of 55.2 µM, 8.5 µM, 2.0 
µM and 141 µM respectively (Table 4.10). An increase in cytotoxicity with increasing 
activities was observed in the three cucurbitacin derivatives 4.9 (Cucurbitacin A), 4.11 
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(Cucurbitacin C) and 4.13 (Cucurbitacin B) which indicate that an increasing activity from 
4.9 to 4.11 to 4.13 may be due to increased cytotoxicity of these compounds. 
4.4.2.3 Antimycobacterial activity  
Since fusidic acid displays potent in vitro activity against Mtb, the compounds were also 
screened for antimycobacterial activity. MIC99 values of all the compounds were determined 
against the H37Rv strain of Mtb (Table 4.10). A maximum concentration limit was set at 160 
µM. MIC99 of fusidic acid was found to be 0.6 µM. Only two compounds (4.16 and 4.26) 
were found to possess some antimycobacterial activity (80 µM each). Although none of the 
compounds showed promising antimycobacterial activity, 4.16 and 4.26 could be good 
candidates for chemical modifications to achieve derivatives with improved activities.  
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Table 4.10: Chemical structures and biological activities of the hit compounds 
Compound Structure 
MIC99H37Rv 
(µM) 
IC50NF54    
(μM) 
IC50CHO 
(μM) 
3.1 Fusidic Acid 0.6 59 194 
 
4.9 
 
 
>160 
 
2.9 
 
55.2 
 
 
4.10 
 
 
 
>160 
 
 
>25 
 
 
ND 
 
 
4.11 
 
 
 
>160 
 
 
1.8 
 
 
8.5 
 
 
4.12 
 
 
 
>160 
 
 
24 
 
 
ND 
 
 
4.13 
 
 
 
>160 
 
 
1.4 
 
 
2.0 
 
 
4.14 
 
 
 
>160 
 
 
>25 
 
 
ND 
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Table 4.10: Continued… 
Compound  Structure MIC99H37Rv 
(µM)  
IC50NF54 
(μM) 
IC50CHO  
 (μM) 
 
 
 
4.15 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.16 
 
 
 
 
80 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.17 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.18 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.19 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.20 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
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Table 4.10: Continued… 
Compound  Structure MIC99H37Rv 
(µM)  
IC50NF54 
(μM) 
IC50CHO 
(μM) 
 
 
 
4.21 
 
 
 
 
>160 
 
 
 
3.4 
 
 
 
141 
 
 
 
4.22 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.23 
 
 
 
 
>160 
 
 
 
13.0 
 
 
 
ND 
 
 
 
4.24 
 
 
 
 
>160 
 
 
 
21.4 
 
 
 
ND 
 
 
 
4.25 
 
 
 
 
>160 
 
 
 
18.6 
 
 
 
ND 
 
 
4.26 
 
 
 
80 
 
 
>25 
 
 
ND 
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Table 4.10: Continued… 
Compound Structure MIC99H37Rv 
(µM) 
IC50NF54    
(μM) 
IC50CHO 
(μM) 
 
 
4.27 
 
 
 
>160 
 
 
19.8 
 
 
ND 
 
 
4.28 
 
 
 
>160 
 
 
>25 
 
 
ND 
 
 
 
4.29 
 
 
 
 
>160 
 
 
 
>25 
 
 
 
ND 
 
 
 
4.30 
 
 
 
 
>160 
 
 
 
7.0 
 
 
 
ND 
 
 
4.31 
 
 
 
>160 
 
 
>25 
 
 
ND 
 
 
 
4.32 
 
 
 
 
>160 
 
 
 
6.0 
 
 
 
ND 
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Table 4.10: Continued… 
Compound  Structure MIC99H37Rv 
(µM) 
IC50NF54    
(μM) 
IC50CHO 
(μM) 
 
 
4.33 
 
 
 
>160 
 
 
>25 
 
 
ND 
 
 
4.34 
 
 
 
>160 
 
 
>25 
 
 
ND 
 
 
4.35 
 
 
 
>160 
 
 
15.80 
 
 
ND 
 CQ  16 nM  
 Artesunate  4 nM  
 Rifampicin 0.005   
 Kanamycin 3.2   
 Emetine   0.05 
CQ = Chloroquine; ND = Not determined 
4.5 Conclusion 
Two different in silico approaches were used to design new fusidic acid derivatives. In one 
approach, a 3D-QSAR pharmacophore model based on the antiplasmodial activities of 61 
fusidic acid derivatives was developed using the ‘Hypogen’ program of Discovery Studio 4.0. 
After validating the reliability of the pharmacophore model using different methods, it was 
then used as 3D-query for virtual screening to search for potential hits from a fusidic acid-
based combinatorial library. Eight hit compounds were synthesized and evaluated for their 
antiplasmodial activity against the NF54 strain of P. falciparum. All compounds were found 
to be more active than fusidic acid. Compounds 4.7 and 4.8 displayed high activity with IC50 
values of 0.3 µM and 0.7 µM, respectively. Compounds 4.7 and 4.8 were non-cytotoxic and 
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also displayed potent in vitro activity against the resistant strain (K1) with IC50 values of 0.2 
µM each.  
In another approach, 2D fingerprint and 3D shape similarity searches were performed on an 
in-house database using fusidic acid as the query compound. The aim of the study was to find 
structurally similar compounds with similar biological activities as that of fusidic acid. 
Selected hit compounds were tested for antiplasmodial as well as antimycobacterial activities. 
Twelve out of the 27 compounds were found to possess antiplasmodial activities (IC50 < 25 
µM) superior to fusidic acid (IC50 59 µM). Only two compounds (4.16 and 4.26) were found 
to possess some antimycobacterial activity (80 µM each). Although none of the compounds 
showed promising antimycobacterial activity, it may be beneficial to consider compounds 
4.16 and 4.26 for chemical modification in an effort to generate derivatives with improved 
activities. Furthermore, the high structural similarity of these compounds indicates that they 
may have the same biological target as fusidic acid.  
4.6 References 
(1)  Braga, R. C.; Alves, V. M.; Silva, A. C.; Nascimento, M. N.; Silva, F. C.; Liao, L. M.; 
Andrade, C. H. Virtual Screening Strategies in Medicinal Chemistry: The State of the 
Art and Current Challenges. Curr. Top. Med. Chem. 2014, 14, 1899–1912. 
(2)  Ghoneim, O. M.; Ibrahim, D. A.; El-deeb, I. M.; Ha, S.; Booth, R. G. A Novel 
Potential Therapeutic Avenue for Autism : Design , Synthesis and Pharmacophore 
Generation of SSRIs with Dual Action. Bioorg. Med. Chem. Lett. 2011, 21, 6714–
6723. 
(3)  Lionta, E.; Spyrou, G.; Vassilatis, D. K.; Cournia, Z. Structure-Based Virtual 
Screening for Drug Discovery : Principles , Applications and Recent Advances. Curr. 
Top. Med. Chem. 2014, 14, 1923–1938. 
(4)  Hu, G.; Kuang, G.; Xiao, W.; Li, W.; Liu, G.; Tang, Y. Performance Evaluation of 2D 
Fingerprint and 3D Shape Similarity Methods in Virtual Screening. J. Chem. Inf. 
Model. 2012, 52, 1103–1113. 
(5)  Concepts and Applications of Molecular Similarity; Mark A. Johnson (Editor), G. M. 
M. (Editor), Ed.; 1990. 
(6)  Rogers, D.; Hahn, M. Extended-Connectivity Fingerprints. J. Chem. Inf. Model. 2010, 
50, 742–754. 
(7)  Good, A. C.; Richards, W. G. Excplicit Calculation of 3{D} Molecular Similarity. 
Perspect. Drug Discovery Des. 1998, 9-11, 321–338. 
Chapter 4: Use of in silico tools to design fusidic acid derivatives and to identify new fusidic 
acid-like compounds 
 
145 
 
(8)  Debnath, A. K. Generation of Predictive Pharmacophore Models for CCR5 
Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class 
of HIV-1 Entry Inhibitors. J. Med. Chem. 2003, 46, 4501–4515. 
(9)  Maggiora, G.; Vogt, M.; Stumpfe, D.; Bajorath, J. Molecular Similarity in Medicinal 
Chemistry. J. Med. Chem. 2014, 57, 3186–3204.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5: Synthesis, characterization and biological evaluation of metergoline derivatives 
 
146 
 
Chapter 5 
Synthesis, characterization and biological evaluation of 
metergoline derivatives 
5.1 Introduction 
This chapter describes the design and synthesis of new metergoline derivatives. It then reports 
and discusses the characterization of the target compounds by 1H and 13C NMR. It further 
discusses the antimycobacterial, antiplasmodial and cytotoxicity profiles of metergoline 
derivatives.  
5.2 Rationale 
As mentioned earlier in Chapter 2, metergoline is an antipsychotic drug belonging to the 
ergoline family of compounds. It is used in a variety of medical applications as a serotonin 
antagonist and dopamine agonist, both in human and veterinary medicine. A High-
Throughput Screen (HTS) conducted by the Tuberculosis Antimicrobial Acquisition 
Coordinating Facility (TAACF) revealed that metergoline displays antimycobacterial activity 
with an IC90 = 6.0 μg/ml (15 µM) against the H37Rv strain of Mtb.
1 In addition, a quantitative 
HTS on a National Institute of Health (NIH) molecular library to obtain delayed death 
inhibitors of the apicoplast of P. falciparum showed that metergoline also displays 
antiplasmodial activity with an IC50 of 7.4 µM.
2  
The above-mentioned data was the basis for the hypothesis that structural modifications of 
metergoline might result in derivatives with improved antimycobacterial and/or 
antiplasmodial activity. Metergoline is attractive template for repositioning because it has 
previously not been explored within the context of TB or malaria. Optimised derivatives of 
this compound might reveal a novel mode of action that circumvents drug resistance which is 
one of the main focus areas of current antituberculosis and antimalarial drug development 
efforts.  
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5.3 Synthesis of metergoline derivatives 
Metergoline can be chemically viewed as benzyl carbamate (CBz) protected amine with an 
ergoline backbone in which the benzyl carbamate group can be easily deprotected and 
replaced with a number of other functionalised aliphatic, aromatic and heteroaromatic 
moieties. In the present study, the ergoline backbone of metergoline was retained and the 
benzyl carbamate group was replaced with various aliphatic, aromatic and heteroaromatic 
amides.3 
 
Figure 5.1: Synthetic strategy to obtain new metergoline derivatives3 
Structural modification of metergoline (5.1) commenced with the removal of the benzyl 
carbamate group using Pd/C as a catalyst in methanol at 25 oC to afford the key amine 
intermediate 5.2 (Scheme 5.1). The intermediate 5.2 was then used as a scaffold for various 
amide derivatives, which were synthesized either through EDCI-HOBt coupling of the amine 
5.2 with various carboxylic acids or by reacting it directly with respective acid chlorides (5.6, 
5.7, 5.15, 5.20 and 5.22) in the presence of an appropriate base. Substituted aromatic, 
heteroaromatic and aliphatic (acyclic and cyclic) carboxylic acids were used in these 
reactions to obtain the corresponding amide derivatives of metergoline and, subsequently, to 
study the effect of the amide moiety on the antimycobacterial and antiplasmodial activities. 
Table 5.1 shows isolated yields and melting points of synthesized metergoline derivatives.  
 
Chapter 5: Synthesis, characterization and biological evaluation of metergoline derivatives 
 
148 
 
 
Scheme 5.1: (a) Methanol, H2, 10% Pd/C (50% moisture), 25 
oC, 16 h;  (b)  RCOOH, EDCI, 
HOBt, DIPEA, DCM, 25 oC, 24 h or RCOCl, DCM, 25 oC, 3 h 
Table 5.1: Isolated yields and melting points of synthesized metergoline derivatives 
Compound R 
Yield* 
(%) 
Mp (oC) Compound R 
Yield* 
(%) 
Mp (oC) 
5.1 Metergoline - 148-150 5.8 
 
72 192-194 
5.24 Amine 95 151-153 5.9 
 
26 195-197 
5.3 
 
35 224-226 5.105 
 
45 178-180 
5.4 
 
66 180-182 5.115 
 
23 218-220 
5.5 
 
63 183-185 5.125 
 
50 168-170 
5.6 
 
53 139-141 5.13 
 
51 202-204 
5.7 
 
41 160-162 5.14 
 
35 168-170 
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Table 5.1: Continued… 
Compound R 
Yield* 
(%) 
Mp (oC) Compound R 
Yield* 
(%) 
Mp (oC) 
5.155 CH3 43 191-193 5.21 (CH2)5CH3 49 146-148 
5.165 CH2CH3 67 185-187 5.22 (CH2)6CH3 53 141-143 
5.17 (CH2)2CH3 71 169-171 5.23 (CH2)8CH3 64 138-140 
5.18 C(CH3)3 50 102-104 5.24 
 
63 145-147 
5.19 (CH2)3CH3 91 166-168 5.25 
 
41 124-126 
5.20 (CH2)4CH3 52 133-135     
* Yields are reported for the final step of synthesis 
5.4 Mechanism of EDCI-HOBt mediated amide coupling 
EDCI [1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide] is a water soluble carbodiimide 
which is commercially available as an HCl salt. It is commonly used as coupling reagent for 
amide bond formation between a carboxylic acid and an amine. HOBt (1-
Hydroxybenzotrizole) is commercially available as monohydrate and is the most usual 
combination with EDCI. The mechanism of coupling through EDCI-HOBt is well-known and 
widely reported in the literature.6 Reaction of a carboxylic acid (RCOOH) with an EDCI is 
believed to involve a labile O-acylisourea, which reacts with 1 eq. of HOBt to form an active 
ester of carboxylic acid. EDCI is converted into a urea by-product.  The active ester then 
reacts with 1 eq. of an amine (amine intermediate 5.2 in this case) to form the corresponding 
amide derivative. HOBt is recovered in the end. This mechanism is described in Figure 5.2. 
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Figure 5.2: Known mechanism for an EDCI-HOBt coupling reaction7  
5.5 Characterization of the synthesized metergoline derivatives 
All synthesized metergoline derivatives were characterized using 1H NMR, 13C NMR and 
mass spectroscopy (MS). Proton assignments were made with the help of 1H-1H COSY 
spectrum. 
All synthesized metergoline derivatives were obtained from a common amine intermediate 
5.2. 1H NMR of the intermediate was recorded in CDCl3 at 400 MHz and is displayed in 
Figure 5.3. The spectrum shows 4 characteristic signals corresponding to the indole region: a 
triplet at 7.18 ppm, two doublets at 7.10 and 6.92, and a singlet at 6.72 ppm.  Two singlets at 
3.74 and 2.52 ppm correspond to two methyl groups attached to N1 and N6 nitrogen atoms, 
respectively, with the methyl group at N1 being more downfield as it is attached to an 
aromatic nitrogen. A broad singlet at 2.37 ppm corresponds to NH2 protons while protons of –
CH2 (H-17) attached to NH2 appear in the region between 2.80-2.69 ppm. Other aliphatic 
protons displayed signals in the region 1.00-3.50 ppm. This NMR spectral data was 
confirmed by comparing with that reported in the literature.4 Additionally, the mass spectrum 
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of 5.2 displayed a base peak at 270 [M+H], which further supported the formation of this 
intermediate.   
 
Figure 5.3: 1H NMR spectrum (CDCl3, 400 MHz) of the intermediate 5.2 
The intermediate 5.2 was reacted with various carboxylic acids or acid chlorides to obtain the 
target compounds. The 1H NMR of one of the target compounds (5.5) is shown in Figure 5.4. 
Disappearance of NH2 protons at 2.37 ppm (Figure 5.3) and appearance of a broad triplet at 
6.48 ppm indicated the formation of an amide bond. The formation of this amide bond was 
also accompanied by a downfield shift of H-17 protons from 2.80-2.69 ppm (in 5.2) to 3.50-
3.46 ppm (in 5.5). The appearance of four additional signals in the aromatic region of 5.5 
indicated incorporation of the 3-chlorophenyl moiety. The protons of the 3-chlorophenyl 
moiety also showed meta coupling in addition to ortho coupling. Instead of appearing as a 
singlet, H-18 appeared as a triplet with J = 1.8 Hz due to meta coupling with H-19 and H-21. 
Similarly, H-19 appeared as doublet of doublet of doublets (ddd) with J = 8.0, 2.1, 1.1 Hz due 
to one ortho coupling with H-20 and two meta couplings with H-18 and H-21. H-21also 
appeared as ddd with J = 7.7, 1.7, 1.1 Hz due to one ortho coupling with H-20 and two meta 
couplings with H-18 and H-19. H-20 appeared as triplet with J = 7.8 Hz due to two ortho 
protons H-19 and H-21. All other proton signals showed a chemical shift similar to those 
observed in the intermediate 5.2. 
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Figure 5.4: 1H NMR (CDCl3, 400 MHz) spectrum of compound 5.5 
Furthermore, the 13C NMR spectrum showed a signal at δ 166.3 ppm indicating the presence 
of a carbonyl carbon in the structure (Figure 5.5). The appearance of six additional signals in 
the aromatic region at 136.5, 133.1, 131.5, 129.9, 127.3 and 124.9 ppm supported the 
incorporation of the 3-chlorophenyl moiety. Overall, the 13C NMR of 5.5 depicted 24 distinct 
signals corresponding to 24 carbon atoms.  Additionally, the mass spectrum displayed a mass 
peak at 408 [M+H], as expected, which further supported the formation of 5.5. 
Proton signals of 
3-chlorophenyl moiety 
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Figure 5.5: 13C NMR (CDCl3, 100 MHz) spectrum of compound 5.5  
Target compounds 5.3-5.14 depicted a similar pattern to 5.5 in their respective 1H and 13C 
NMR spectra. In compounds 5.15-5.25, an aliphatic moiety was incorporated in place of the 
aromatic moiety and therefore, their 1H NMR spectra displayed additional signals in the 
aliphatic region. Similar changes were also observed in the respective 13C NMR spectra. 
However, the fragmentation pattern in the mass spectra remained unchanged for all target 
compounds. 
The 1H NMR data for one of the aliphatic amides (5.22) is shown in Figure 5.6.  The 
disappearance of NH2 protons at 2.37 ppm (Figure 5.3) and appearance of a broad triplet at 
5.60 ppm in 5.22 indicated the formation of an amide bond, which was also accompanied by a 
downfield shift of H-17 protons from 2.80-2.69 ppm (in 5.2) to 3.30-3.26 ppm (in 5.22). 
Furthermore, the appearance of two triplets at 2.21 (J = 7.4 Hz, 2H, 2×H-18) and 0.88 (J = 
6.9 Hz, 3×H-24), and two multiplets at 1.70-1.62 (m, 2H, 2×H-19) and 1.36-1.25 (m, 8H, 
2×H-20, 2×H-21, 2×H-22, 2×H-23), indicated incorporation of the n-octyl group. All other 
proton signals showed a chemical shift similar to those observed in the intermediate 5.2.  
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Figure 5.6: 1H NMR (CDCl3, 400 MHz) spectrum of compound 5.22  
The 1H NMR spectrum was further supported by the 13C NMR spectrum, which depicted a 
signal at 173.2 ppm indicating the presence of carbonyl carbon in the structure (Figure 5.7). 
Appearance of seven additional signals in the aliphatic region at 36.9, 31.7, 29.3, 29.0, 25.8, 
22.6 and 14.0 ppm supported the incorporation of an n-octyl group. Overall, the 13C NMR of 
5.22 depicted 25 distinct signals corresponding to 25 carbon atoms.  Additionally, the mass 
spectrum showed a mass peak at 396 [M+H], as expected, which further supported the 
formation of 5.22.  
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Figure 5.7: 13C NMR (CDCl3, 100 MHz) spectrum of compound 5.22  
5.6 Biological results and discussion  
All synthesized compounds were evaluated for their antimycobacterial and antiplasmodial 
activity, as well as for cytotoxicity.  
5.6.1 Antimycobacterial activity 
Compounds were screened in vitro against the H37Rv strain of Mtb at the National Institute 
of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH). The 
MIC99 was determined for each compound. A maximum concentration limit was set at 50 
µM. Rifampicin and kanamycin, were used as reference drugs.  
Nine out of 23 amide derivatives exhibited MIC99 values ranging from 9.4 to 37 µM (Table 
5.2).  The MIC99 of metergoline (5.1) was found to be 25 µM in the same assay. Intermediate 
5.2, obtained after the removal of benzyl carbamate group from metergoline (Scheme 5.1), 
was also tested and found to be inactive, suggesting the importance of the benzyl carbamate 
group of metergoline for activity. Among mono-substituted amide derivatives (5.3-5.9), 3- 
and 4-chloro derivatives displayed superior activity (MIC99 37 μM) relative to the 2-chloro 
derivative, which was found to be inactive at 50 µM. These results indicated a preference for 
meta- and para-substitutions over ortho substitution. Among di-substituted derivatives, 
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compound 5.8 (3-CF3,4-Cl) was found to be the most active with a MIC99 of 19 μM. With the 
exception of 5.8, all other aromatic amide derivatives displayed inferior activity relative to 
metergoline. Heteroaromatic amides (5.10-5.14) displayed no activity at the highest 
concentration tested. 
Aliphatic amide derivatives with varying carbon chain lengths (5.15-5.23, Table 5.2) showed 
varying activity. Derivatives with short (from acetamide 5.15 to butanamide 5.17), branched 
(tertiary butanamide 5.18) and medium (pentanamide 5.19 and hexanamide 5.20) carbon 
chain lengths were found to be inactive. However, as the carbon chain length was increased 
further (5.21-5.23), activity also improved. Octanamide 5.22 (MIC99 19 µM) and decanamide 
5.23 (MIC99 9.4 µM) derivatives were found to have superior activity relative to metergoline. 
Compound 5.23 was the least cytotoxic as indicated by a high IC50 value of 86.6 µM against 
the CHO cell line as compared to metergoline (IC50 16.6 µM).  Cyclopentyl amide (5.24) and 
heterocyclic alkyl amide (5.25) derivatives were in active at the highest concentration tested 
(MIC99 ˃ 50 µM).   
To summarise, decanamide 5.23 with an MIC99 9.4 µM was found to be the most active 
among all amide derivatives of metergoline and also displayed less cytotoxicity (IC50 CHO 
86.6 µM) as compared to metergoline. Two more compounds, octanamide 5.22 and 3-CF3,4-
Cl-disustituted phenyl amide 5.8 with MIC99 of 19 µM each, also displayed better activity 
than metergoline but were found to be cytotoxic (IC50 CHO 4.6 and 4.4 µM, respectively). 
Data concerning the antimycobacterial activity of metergoline derivatives suggest that the 
benzyl carbamate group of metergoline is not necessary for activity.  
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Table 5.2: In vitro antimycobacterial activity (H37Rv strain), antiplasmodial activity (NF54 
strain) and cytotoxicity (CHO cell lines) of metergoline derivatives 
 
Compound R 
MIC99 H37Rv 
(µM) 
IC50 NF54 
(µM) 
IC50 CHO 
(μM) 
SI* 
5.1 Metergoline 25 3.7 16.6 4.5 
5.2 Amine >50 3.6 26.1 7.0 
5.3 
 
37 1.3 4.3 3.0 
5.4 
 
>50 14.6 25.0 2.0 
5.5 
 
37 4.9 4.7 1.0 
5.6 
 
25 4.8 3.8 1.0 
5.7 
 
37 8.3 7.5 1.0 
5.8 
 
19 5.3 4.4 0.8 
5.9 
 
25 2.5 11.2 4.5 
5.10 
 
>50 17.4 162 9.0 
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Table 5.2: Continued… 
Compound R 
MIC99 H37Rv 
(µM) 
IC50 NF54 
(µM) 
IC50 CHO 
(μM) 
SI* 
5.11 
 
>50 17.5 161 9.0 
5.12 
 
>50 11.4 112 10 
5.13 
 
>50 8.4 163.5 20 
5.14 
 
>50 27.4 ND ND 
5.15 CH3 >50 199 ND ND 
5.16 CH2CH3 >50 40.3 ND ND 
5.17 (CH2)2CH3 >50 32.1 ND ND 
5.18 C(CH3)3 >50 89.1 ND ND 
5.19 (CH2)3CH3 >50 18.7 105.0 6.0 
5.20 (CH2)4CH3 >50 28.6 ND ND 
5.21 (CH2)5CH3 37 9.1 8.9 1.0 
5.22 (CH2)6CH3 19 3.9 4.6 1.0 
5.23 (CH2)8CH3 9.4 5.2 86.6 17 
5.24 
 
>50 4.3 143.6 33 
5.25 
 
>50 1.2 16.6 13 
 Rifampicin 0.005    
 Kanamycin 3.2    
 CQ  16 nM   
 Artesunate  4 nM   
 Emetine   0.05  
*SI = (selectivity index) = IC50CHO/IC50NF54; ND = Not determined; CQ = Chloroquine 
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5.6.2 Antiplasmodial activity 
As mentioned earlier, metergoline showed antiplasmodial activity (IC50 7.4 μM) in a 
quantitative HTS conducted by the NIH. This prompted the evaluation of all synthesized 
metergoline derivatives for in vitro antiplasmodial activity against the CQ-sensitive NF54 
strain of P. falciparum. CQ and artesunate were used as the reference drugs (Table 5.2). 
The IC50 of metergoline was found to be 3.7 μM with a selectivity index (SI) value of 4.5. 
The amine intermediate 5.2, obtained after the removal of benzyl carbamate group from 
metergoline, showed activity (IC50 3.6 μM) comparable to that of metergoline (IC50 3.7 μM), 
suggesting that the benzyl carbamate group of metergoline may not contribute to the observed 
antiplasmodial activity. Most of the amide derivatives exhibited micromolar potencies, with 
17 of the 23 compounds displaying IC50 values between 1.2 μM and 20 μM (Table 5.2). 
Introduction of the 4-chlorophenyl group as in compound 5.3 resulted in improved 
antiplasmodial activity (IC50 1.3 μM) relative to metergoline. The activity of this derivative 
was compared to that of its regioisomers [2-chloro 5.4 (IC50 14.6 μM) and 3-chloro 5.5 (IC50 
4.9 μM)], as well as with dichloro-substituted amide derivatives [3,4-dichloro 5.6 (IC50 4.8 
μM) and 2,4-dichloro 5.7 (IC50 8.3 μM)]. Compound 5.3 was found to be the most active 
among them. These results indicated a preference for the para-substituted phenyl ring over 
the ortho-, meta- and di-substituted phenyl rings. Further, among di-substituted aromatic 
amides, 3-CF3,4-NO2 substituted derivative 5.9 (IC50 2.5 μM) displayed a slightly improved 
activity and comparable cytotoxicity to metergoline. Heteroaromatic amides (5.10-5.14) 
showed relatively higher IC50 values ranging from 8.4 to 27.4 μM (Table 5.2). These results 
indicated that heteroaromatic amides are not tolerated.  
Short to medium chain aliphatic amide derivatives, 5.15-5.20, showed much lower 
antiplasmodial activity as compared to metergoline (Table 5.2). However, as the chain length 
was increased further, 5.21-5.23, the activity also increased and octanamide derivative 5.22 
was found to be the most active with an IC50 value of 3.9 μM, which is comparable to 
metergoline. The cyclopentyl amide derivative 5.24 also showed activity similar to 
metergoline (IC50, 4.3 μM) and had a much better SI value of 33. Heterocyclic alkyl amide 
5.25 showed the best activity (IC50 1.2 μM) when compared to metergoline and all other 
derivatives, with a SI of 13.  
In summary, removal of the benzyl carbamate group from metergoline did not alter its 
antiplasmodial activity, suggesting that the benzyl carbamate group is not required for 
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antiplasmodial activity. Most of the amide moieties substituted for the benzyl carbamate 
group resulted in either comparable or reduced activities. However, three derivatives 5.3, 5.9 
and 5.25 resulted in improved activities. The derivative 5.25 was found to be the most active 
of all with an IC50 of 1.2 μM with a SI value of 13.  
5.7 Conclusion 
A series of new metergoline derivatives was synthesized to establish the potential of 
metergoline to act as a template for new antimycobacterial and/or antiplasmodial derivatives. 
In these semisynthetic derivatives, the ergoline part of metergoline was retained and the 
benzyl carbamate group was replaced with various aromatic, heteroaromatic and aliphatic 
amides. All synthesized compounds were evaluated for antimycobacterial activity against the 
H37Rv strain of Mtb, antiplasmodial activity against the NF54 strain of P. falciparum, as well 
as cytotoxicity against the CHO cell line. 
Nine out of 23 amide derivatives exhibited antimycobacterial activity (MIC99 < 50 µM). 3-
CF3,4-Cl-disustituted aromatic amide 5.8 (MIC99 19 µM), octanamide 5.22 (MIC99 19 µM), 
and decanamide 5.23 (MIC99 9.4 µM) showed higher antimycobacterial activity than 
metergoline (MIC99 25 µM). Decanamide derivative 5.23 was found to have superior 
antimycobacterial activity with an improved cytotoxicity profile as compared to metergoline 
and all other derivatives. Most of these amide derivatives also exhibited micromolar potencies 
against the NF54 strain of P. falciparum, with 17 of the 23 compounds having IC50 values 
between 1.2 μM and 20 μM. Three derivatives 5.3, 5.9 and 5.25 displayed improved 
antiplasmodial activities as compared to metergoline. Compound 5.25 was found to be the 
most active of all with an IC50 1.2 μM. This compound also had an encouraging SI value of 
13. 
The antimycobacterial and antiplasmodial data suggests that the benzyl carbamate group of 
metergoline is not required for activity and its substitution with other moieties may result in 
compounds with improved antimycobacterial and/or antiplasmodial activity. Over all, this 
work shows the potential of metergoline for repositioning in TB and /or malaria via medicinal 
chemistry approaches.  
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Chapter 6 
Summary, conclusion and recommendations for future work 
6.1 General 
Drug resistance and other challenges associated with existing TB and malaria treatments have 
necessitated the development of novel agents. The process of new drug development can 
potentially be accelerated by applying drug repositioning approaches. This study focussed on 
the repositioning of two drugs, an antibacterial agent fusidic acid and an antipsychotic agent 
metergoline, in TB and/or malaria. New semisynthetic derivatives of fusidic acid and 
metergoline were synthesized and biologically evaluated for antimycobacterial and 
antiplasmodial activities.  In addition, in silico tools were applied to fusidic acid with the aim 
of identifying new fusidic acid-like compounds, which possess antimycobacterial and/or 
antiplasmodial activity.  
6.2 Fusidic acid derivatives 
Fusidic acid is a naturally-occurring antibiotic and is mainly used in the treatment of 
staphylococcal bacterial infections. Fusidic acid was identified with potent in vitro 
antimycobacterial activity (IC90 1.2 µM, H37Rv strain of Mtb) in a High-Throughput Screen 
(HTS) conducted by the Tuberculosis Antimicrobial Acquisition Coordinating Facility 
(TAACF). It is also reported to have activity against a range of sensitive and resistant clinical 
isolates of Mtb. The aforementioned data prompted the synthesis of fusidic acid derivatives 
and their evaluation as antimycobacterial agents. Apart from its antimycobacterial activity, 
fusidic acid has also shown antiplasmodial activity (IC50 52.8 µM, D10 strain of P. 
falciparum) as reported in the literature. Although this IC50 value is high, fusidic acid also has 
the potential for repositioning in malaria through semisynthesis. Therefore, the synthesized 
derivatives of fusidic acid were also evaluated against P. falciparum. 
Fusidic acid derivatives were synthesized by performing various structural modifications at 
C-21, C-3 and C-16 positions as reflected in SAR 1, SAR 2, and SAR 3 studies in Chapter 3. 
The chemistry involved various types of reactions, mainly including amide coupling, 
esterification, cyclization, substitution, condensation, and oxidation. All the synthesized 
target compounds were characterized by 1H, 13C NMR and MS. Purities of these compounds 
were determined by HPLC or LCMS and found to be more than 95%.  
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C-21 derivatives were obtained by replacing the C-21 carboxyl group of fusidic acid with 
various bioisosteres. In total, twenty eight compounds were evaluated for antimycobacterial 
activity against the H37Rv strain of Mtb and antiplasmodial activity against the NF54 strain 
of P. falciparum. These replacements led to lower antimycobacterial activity (MIC99 ≥ 20 
µM) as compared to fusidic acid (MIC99 0.6 µM). However, two compounds, fusidic acid-
isoniazid conjugate 3.15 and methane sulfonyl hydrazide derivative 3.18, displayed moderate 
activity (MIC99 10 µM) and reasonably low cytotoxicity (IC50 CHO 88.3 and 92.2 µM, 
respectively). Further, most of these derivatives showed a 2-35 fold increase in 
antiplasmodial activity compared to fusidic acid (IC50 59 µM) and were also found to have 
low cytotoxicity. The antimycobacterial and antiplasmodial data of C-21 fusidic acid 
derivatives suggest that the carboxylic acid group is essential for its antimycobacterial 
activity but not for antiplasmodial activity.  
C-3 derivatives were obtained by replacing the C-3 hydroxyl group of fusidic acid with 
various carboxylic and silicate esters, as well as with keto and oxime functionalities. C-3 
derivatives exhibited much potent antimycobacterial activity as compared to C-21 derivatives, 
with 9 out of 14 derivatives displaying MIC99 ≤ 5 µM. Similar to C-21 derivatives, structural 
modifications at the C-3 position also resulted in improved antiplasmodial activity as 
compared to fusidic acid. Further, the in vitro antimycobacterial (MIC99 11.4 µM) and 
antiplasmodial (IC50 31.6 µM) results of 3-epifusidic acid (3.40) suggests that inversion of 
configuration at the C-3 position significantly reduces the antimycobacterial activity of 
fusidic acid, but has little effect on the antiplasmodial activity. The antimycobacterial and 
antiplasmodial activities of keto (3.36) and oxime derivatives (3.37-3.39) suggest that these 
functionalities are tolerated at the C-3 position. 
C-16 derivatives were obtained by replacing the C-16 acetoxy group of fusidic acid with 
methoxy and ethoxy groups. The antimycobacterial activity of the ethoxy derivative (3.49, 
MIC99 0.8 µM) was found to be comparable to fusidic acid (MIC99 0.6 µM).  
Seven miscellaneous derivatives with modifications at more than one site of fusidic acid were 
also obtained. Antimycobacterial evaluation of these compounds indicated that the lipophilic 
side chain, the carboxylic acid group, and C-16 substitution are essential for 
antimycobacterial activity. Antiplasmodial evaluation revealed that C-3, C-11-diacetoxy 
fusidic acid methyl ester (3.56, IC50 0.4 µM) has superior antiplasmodial activity with no 
cytotoxicity.  
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Some of the fusidic acid derivatives (3.18, 3.37, 3.41, 3.42 and 3.50) were also evaluated for 
in vivo pharmacokinetics in mice. Among these, the C-3 triisopropoxy silicate derivative 
(3.42) showed an improved pharmacokinetic profile relative to fusidic acid, with higher 
concentrations achieved in blood, a longer half-life (5 h vs 1 h after oral administration), and 
a lower clearance rate. All other derivatives showed similar or poorer pharmacokinetic 
profiles when compared to fusidic acid.  
6.3 In silico tools 
Two separate in silico approaches were applied to fusidic acid. In one approach, a 3D-QSAR 
pharmacophore model was developed based on the antiplasmodial activity of 61 previously 
synthesized fusidic acid derivatives. This model was used as the 3D-structural search query to 
screen a fusidic acid based combinatorial library. Eight hit compounds were synthesized, 
including C-21 amide and C-3 ether fusidic acid derivatives. Chemistry mainly involved O-
alkylation and amide coupling reactions. These compounds were evaluated for antiplasmodial 
activity against the NF54 strain of P. falciparum. All hit compounds showed superior 
antiplasmodial activity relative to fusidic acid. Two C-21 amide derivatives (4.7 and 4.8) 
displayed significant activity against the CQ-sensitive NF54 strain (IC50 values of 0.3 µM and 
0.7 µM, respectively) and the CQ-resistant K1 strain (IC50 0.2 µM), and were also found to be 
non-cytotoxic against the CHO cell line. 
In another approach, 2D fingerprint and 3D shape similarity searches were performed on an 
in-house database using fusidic acid as the query compound. The database included 708 
steroid-type natural products or their semisynthetic derivatives with defined chemical 
structures and stereochemistry. This study was conducted with the aim of finding structurally 
similar compounds with similar biological activities to fusidic acid. Selected hit compounds 
were evaluated for in vitro biological activity. Twelve out of 27 hit compounds displayed 
superior antiplasmodial activity (IC50 < 25 µM) as compared to fusidic acid. However, these 
compounds did not show any antimycobacterial activity except 4.16 and 4.26 (MIC99 80 µM).  
6.4 Metergoline derivatives 
Metergoline is an antipsychotic drug belonging to ergoline family and is used in a variety of 
medical applications as serotonin antagonist and dopamine agonist, both in human and 
veterinary health. A HTS conducted by the TAACF revealed the antimycobacterial activity of 
metergoline (IC90 15 µM, H37Rv strain of Mtb). In addition, a quantitative HTS on a NIH 
molecular library to obtain delayed death inhibitors of the malaria parasite plastid found 
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metergoline to have antiplasmodial activity with an IC50 of 7.4 µM. The above data prompted 
the synthesis of metergoline derivatives and their evaluation as 
antimycobacterial/antiplasmodial agents. 
Metergoline was subjected to semisynthesis, in which its benzyl carbamate (CBz) group was 
removed to obtain an amine intermediate. This amine intermediate was then used to 
synthesize various aromatic, heteroaromatic and aliphatic amide derivatives. Chemistry 
mainly involved amide coupling using EDCI-HOBt as the coupling reagent. Synthesized 
derivatives were characterized by 1H, 13C NMR and MS, and evaluated for antimycobacterial 
activity against the H37Rv strain of Mtb, antiplasmodial activity against the NF54 strain of P. 
falciparum and cytotoxicity against the CHO cell line. Nine out of 23 compounds exhibited 
antimycobacterial activity with MIC99 < 50 µM. The decanamide derivative (5.23, MIC99 9.4 
µM, IC50 CHO 86.6 µM) was found to have a superior antimycobacterial activity and 
cytotoxicity profile relative to metergoline (MIC99 25 µM, IC50 CHO 16.6 µM). Further, most 
of these amide derivatives also exhibited micromolar potencies against the NF54 strain of P. 
falciparum, with 17 of the 23 compounds having IC50 values between 1.2 μM and 20 μM. 
Three derivatives, 5.3 (IC50 1.3 μM), 5.9 (IC50 2.5 μM) and 5.25 (IC50 1.2 μM) were found to 
have superior antiplasmodial activity as compared to metergoline (IC50 3.7 μM). Compound 
5.25 was found to be the most active derivative with an encouraging selectivity index value of 
13. The antimycobacterial and antiplasmodial data of metergoline and its derivatives suggest 
that the benzyl carbamate group of metergoline is not required for activity and its substitution 
with other moieties may result in compounds with improved antimycobacterial and/or 
antiplasmodial activity.   
Overall, this study demonstrates the potential of fusidic acid and metergoline as a promising 
novel antimycobacterial and antimalarial templates for repositioning purposes. 
6.5 Recommendations for future work 
In case of fusidic acid, three C-3 silicate ester derivatives were synthesized based on the 
hypothesis that these derivatives would revert back to fusidic acid through hydrolysis. Two 
silicate derivatives, triethoxy silicate ester 3.41 and trioctyloxy silicate ester 3.43 exhibited 
comparable antimycobacterial activity to fusidic acid, with MIC99 values of 0.2 and 0.3 µM, 
respectively. This in vitro activity data suggests that these derivatives may be hydrolysed to 
fusidic acid either in the culture medium or inside the cell. LC-MS analysis of the culture 
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medium and Mtb lysate incubated with the silicate esters needed to be performed in order to 
generate data to confirm or disprove this hypothesis.   
The antimycobacterial activity of a fusidic acid bioisostere 3.11 increased sharply from MIC99 
> 160 μM to MIC99 20 μM, by adding fluorine atoms at the 3 and 4-positions of the phenyl 
group (3.12, Figure 6.1). Further structural modification around the phenyl group of 3.11 can 
be performed, either by adding substituents (for example Cl, OCF3, Me, and OMe) at 3- 
and/or 4- positions of the phenyl group, or by replacing the phenyl group with various 
heterocyclic moieties. 
Two C-16 ether derivatives of fusidic acid were obtained by replacing the acetoxy group with 
methoxy and ethoxy groups. The C-16 ethoxy derivative (3.49) was found to be equipotent to 
fusidic acid. This suggests that this site needs to be explored with various aliphatic or 
aromatic ether, thioether, ester and oxime moieties (Figure 6.1). 
 
Figure 6.1: Future recommendations to obtain new fusidic acid derivatives  
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Removal of the carboxylic acid bearing lipophilic side chain (ketone derivative 3.53) did not 
significantly diminish the antiplasmodial activity when compared to fusidic acid (IC50 90.8 vs 
59 μM). This suggests that further exploration of this site of fusidic acid by structural 
modification is warranted. The ketone derivative 3.53 can be condensed with various amines 
to obtain oxime derivatives or can also undergo reductive amination to produce amine 
derivatives (Figure 6.2). Likewise, 3-keto fusidic acid (3.36) can also be subjected to 
reductive amination to obtain various aliphatic, aromatic and heteroaromatic amine 
derivatives (Figure 6.2). 
 
Figure 6.2: Future recommendations to obtain new fusidic acid derivatives  
In case of metergoline, replacement of the CBz group of metergoline with various amide 
moieties generated some derivatives with improved antimycobacterial or antiplasmodial 
activity. However, further improvement in antimycobacterial or antiplasmodial activity is 
needed. From a SAR point of view, the amide group of active derivatives can be replaced 
with other functional groups such as sulphonamide or amino groups, in an effort to improve 
the antimycobacterial or antiplasmodial activity of these derivatives (Figure 6.3).  
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Figure 6.3: Future recommendations to obtain new metergoline derivatives 
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Chapter 7 
Experimental 
7.1 General  
Fusidic acid was purchased from Ava Chem Scientific while metergoline and all other 
reagents were purchased from Sigma Aldrich. All solvents used for reactions, such as DMF, 
methanol, ethanol, acetonitrile and pyridine, were purchased from Sigma Aldrich and were 
anhydrous. Solvents like ethyl acetate (EtOAc), hexane, dichloromethane (DCM) and 
methanol, used for extraction and column chromatography purification purposes, were 
purchased from Kimix Chemicals and were of AR grade. Solvents and ammonium acetate 
used for HPLC and LC-MS purposes were bought from Sigma Aldrich (ammonium acetate 
and DMSO), Merck (glacial acetic acid) and Microsep (acetonitrile and methonol), and were 
of HPLC grade. 
7.2 Synthetic procedure, physical and spectroscopic characterization of target    
compounds 
All target compounds and intermediates were characterised by 1H NMR, 13C NMR and MS. 
1H and 13C NMR spectra were recorded on a Bruker 400 spectrometer. The 1H NMR data are 
reported as follows: chemical shift in parts per million (δ) downfield of tetramethylsilane 
(TMS), multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, dd = 
doublet of doublets, ddd doublet of doublet of doublets, dt =doublet of triplets, h = heptet, and 
m = multiplet), coupling constant (Hz), and integrated value. The 13C NMR spectra were 
measured with complete proton decoupling.  
Purities were determined either by high performance liquid chromatography (HPLC) or liquid 
chromatography - mass spectrometery (LC-MS) as described below. The purities of all 
compounds were found to be ≥ 95%. 
HPLC: Compound purity was determined by Waters HPLC system using X-bridge C18 5µm 
column (4.6 x 150 mm) as stationary phase. Mobile phase consisted of 10 mM ammonium 
acetate in HPLC grade water (A) and acetonitrile (B). This mobile phase was delivered at a 
flow rate of 1.20 mL/min in gradient mode set to initially run at 75% A, then linearly 
increased to 100% B over 9 min and held constant for another 5 min and then decreased to 
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25% B over next 6 min to give total run time of 20 min. A photodiode array (PDA) detector 
was used and set to monitor wavelength at 254 nm. 
LC-MS: LC-MS analysis was performed using an Agilent® 1260 Infinity Binary Pump, 
Agilent® 1260 Infinity Diode Array Detector (DAD), Agilent® 1290 Infinity Column 
Compartment, Agilent® 1260 Infinity Standard Autosampler, and a Agilent® 6120 
Quadrupole (single) mass spectrometer, equipped with APCI and ESI multimode ionisation 
source. Stationary phase:  Agilent Poroshell 120 C18 reversed phase column (3.0×50 mm) 
containing 2.7 μm particles. Mobile phase: 10 mM ammonium acetate in water (A) and 10 
mM ammonium acetate in methanol (B); flow rate: 1.0 mL/min in gradient mode set to 
initially run at 10% B for 0.5 min, then linearly increased to 90% B over 2 min and held 
constant for another 3.5 min. The column was subsequently re-equilibrated to starting mobile 
phase composition for 2 min to give total run time of 8 min. Column temperature was 
maintained at 40 οC. The diode array detector was programmed to monitor absorption over 
the wavelength range of 190-600 nm.  
Masses of some of the compounds were also determined by JEOL JMS–GCMS–GCMAT II 
GCMS mass spectrometer. 
Melting points were obtained from a Reichert-Jung Thermovar hot-stage microscope 
apparatus and are uncorrected. 
Thin layer chromatographic (TLC) was performed on aluminium-backed pre-coated silica gel 
60 plates purchased from Merck. Spots were visualised using UV (254/366 nm) light as well 
as anisaldehyde stain.  
7.2.1 Chapter 3 
7.2.1.1 C-21 Fusidic acid derivatives 
Fusidic acid methyl ester (3.2)1  
K2CO3 (1.06 g, 7.67 mmol) was added to a solution of 
fusidic acid (3.1) (2.0 g, 3.87 mmol) in DMF (10 ml), 
followed by addition of methyl iodide (0.36 ml, 5.80 
mmol). Resulting reaction mixture was then heated at 50 
oC for 3 h. After completion of reaction (TLC), reaction 
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mixture was diluted with EtOAc (100 ml) and washed with water (3×100 ml). The organic 
layer was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The 
yellowish product was stirred in n-pentane for 30 min to obtain  3.2 as a white solid (1.9 g, 
92%); Rf 0.5 (60% EtOAc:hexane); Mp. 166-168 
οC; 1H NMR (400 MHz, CDCl3) δ 5.83 (d, J 
= 8.4 Hz, 1H, H-16), 5.07 (t, J = 7.2 Hz, 1H, H-24), 4.33 (m, 1H, H-11), 3.73 (m, 1H, H-3), 
3.63 (s, 3H, OCH3), 3.04-3.01 (m, 1H, H-13), 2.51-2.36 (m, 2H, 2×H-22), 2.32-2.27 (m, 1H, 
H-12), 2.19-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.95 (s, 3H, OAc), 1.88-1.70 (m, 4H, 
2×H-2, H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.58 (s, 3H, CH3-26), 1.58-1.47 (m, 4H, H-1, H-
4, H-6 and H-9), 1.37 (s, 3H, CH3-30), 1.27-1.24 (m, 1H, H-15), 1.16-1.05 (m, 2H, H-6 and 
H-7), 0.96 (s, 3H, CH3-19), 0.91-0.90 (m, 6H, CH3-18 and CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ  170.7, 170.3, 148.1, 132.5, 130.4, 123.1, 74.4, 71.4, 68.2, 51.3, 49.3, 48.7, 43.9, 
39.4, 39.0, 37.0, 36.3, 36.0, 35.6, 32.3, 30.2, 29.9, 28.9, 28.3, 25.7, 23.9, 22.9, 20.9, 20.8, 
17.7 (2C) and 15.9; LC-MS (ESI): m/z 553 [M+23]+, 471 [M-OAc]+; purity (LC-MS): 97% (tr 
= 3.62 min).  
Fusidic acid amide (3.3)2 
NH4Cl (1.9 g, 35 mmol), DIPEA (6 ml, 35 mmol) and HOBt 
(1.2 g, 8.7 mmol) were added to a solution of fusidic acid 
(3.1) (3 g, 5.8 mmol) in DMF (10 ml), and the reaction 
mixture stirred at 25 oC for 15 min. This was followed by 
addition of benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) (4.53 g, 8.7 mmol) and the 
resulting reaction mixture was further stirred at 25 oC for 16 
h. After completion of reaction (TLC), reaction mixture was 
diluted with EtOAc (150 ml) and washed with water (3×150 
ml). The organic layer was dried over anhydrous magnesium sulfate, filtered and 
concentrated in vacuo. Purification by flash chromatography on 100-200 silica gel using 
EtOAc:hexane as eluent afforded product 3.3 as a white solid (0.93 g, 31%); Rf 0.5 (90% 
EtOAc:hexane); Mp. 223-225 οC; 1H NMR (400 MHz, CDCl3) δ 5.74 (d, J = 8.4 Hz, 1H, H-
16), 5.42 (br s, 2H, NH2), 5.09 (t, J = 6.8 Hz, 1H, H-24), 4.34 (m, 1H, H-11), 3.75 (m, 1H, H-
3), 3.01-2.98 (m, 1H, H-13), 2.55-2.47 (m, 1H, H-22), 2.38-2.33 (m, 1H, H-22), 2.31-2.26 (m, 
1H, H-12), 2.20-2.08 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.02 (s, 3H, OAc), 1.89-1.73 (m, 
4H, 2×H-2, H-7 and H-12), 1.68 (s, 3H, CH3-27), 1.61 (s, 3H, CH3-26), 1.58-1.49 (m, 4H, H-
1, H-4, H-6 and H-9), 1.37 (s, 3H, CH3-30), 1.30-1.27 (m, 1H, H-15), 1.17-1.08 (m, 2H, H-6 
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and H-7), 0.97 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.92 (d, J = 6.8 Hz, CH3-28); 
13C NMR 
(100 MHz, CDCl3) δ 173.6, 171.0, 142.5, 133.9, 132.6, 123.2, 73.7, 71.3, 68.3, 60.3, 49.3, 
48.7, 43.2, 39.5, 39.2, 37.1, 36.2, 35.6, 32.4, 30.3, 29.9, 29.3, 27.9, 25.6, 24.1, 22.7, 20.7 
(2C), 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 516 [M+H]+, 456 [M-OAc]+; purity (HPLC): 
96% (tr = 18.53 min). 
General synthetic procedure for compounds 3.4 and 3.5  
Cyanamide (in case of 3.4) and 5-aminotetrazole (in case of 3.5) (2.0 eq.), EDCI (1.20 eq.), 
HOBt (1.20 eq.) and DIPEA (3.0 eq.) were added to a solution of fusidic acid (3.1) (1.0 eq.) 
in DCM (20 ml), and the resulting reaction mixture was stirred at 25 oC for 24 h. After 
completion of reaction (TLC), reaction mixture was diluted with DCM (15 ml) and washed 
with water (3×15 ml), dried over anhydrous magnesium sulfate, filtered and concentrated in 
vacuo. Purification by flash chromatography on 100-200 silica gel using methanol:DCM as 
eluent afforded respective products. 
N-cyanofusidic acid amide (3.4)  
White solid (0.10 g obtained from 0.18 g of 3.1, 53%); Rf 
0.3 (8% Methanol:DCM); Mp. 142-144 οC; 1H NMR (400 
MHz, CDCl3) δ 5.71 (d, J = 8.4 Hz, 1H, H-16), 5.09 (t, J = 
6.8 Hz, 1H, H-24), 4.36 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.04-3.01 (m, 1H, H-13), 2.55-2.47 (m, 1H, H-22), 2.27-
2.24 (m, 2H, H-12 and H-22), 2.17-2.12 (m, 5H, H-1, H-5, 
H-15 and 2×H-23), 2.06 (s, 3H, OAc), 1.85-1.82 (m, 4H, 
2×H-2, H-7 and H-12), 1.70 (s, 3H, CH3-27), 1.62 (s, 3H, 
CH3-26), 1.58-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.39 
(s, 3H, CH3-30), 1.27-1.23 (m, 1H, H-15), 1.13-1.11 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-
19), 0.93-0.92 (m, 6H, CH3-18 and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 170.8 (2C), 
147.4, 133.5, 129.8, 122.5, 106.7, 73.8, 71.5, 68.3, 49.5, 48.7, 43.6, 39.5, 39.0, 36.8, 36.5, 
35.8, 35.1, 31.9, 30.1, 29.7, 29.1, 28.1, 25.7, 23.8, 23.2, 20.8, 20.7, 17.8, 17.7 and 15.8; LC-
MS (ESI): m/z 563 [M+23]+, 481 [M-OAc]+; purity (LC-MS): 96% (tr = 3.85 min). 
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N-(2H-tetrazol-5-yl)fusidic acid amide (3.5) 
White solid (0.10 g obtained from 0.3 g of 3.1, 29%); Rf 
0.2 (8% Methanol:DCM); Mp. ˃280 οC; 1H NMR (400 
MHz, DMSO-d6) δ 10.96 (br s, 1H, CONH), 5.63 (d, J = 
8.8 Hz, 1H, H-16), 5.07 (t, J = 6.8 Hz, 1H, H-24), 4.13 (m, 
1H, H-11), 4.05 (d, J = 3.5 Hz, 1H, OH), 3.95 (d, J = 3.1 
Hz, 1H, OH), 3.48 (m, 1H, H-3), 2.92-2.89 (m, 1H, H-13), 
2.49-2.42 (m, 1H, H-22), 2.29-2.20 (m, 2H, H-12 and H-
22), 2.13-1.95 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.72-
1.60 (m, 5H, H-2, H-12 and OAc), 1.58 (s, 3H, CH3-27), 
1.51 (s, 3H, CH3-26), 1.49-1.28 (m, 6H, H-1, H-2, H-4, H-6, H-7 and H-9), 1.26 (s, 3H, CH3-
30), 1.08-1.04 (m, 1H, H-15), 1.00-0.97 (m, 2H, H-6 and H-7), 0.86 (s, 3H, CH3-19), 0.82 (s, 
3H, CH3-18), 0.76 (d, J = 6.6 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CD3OD) δ 170.6 (2C), 
152.0, 145.0, 132.4, 132.2, 122.8, 73.9, 71.0, 67.1, 54.1, 49.4, 48.5, 43.3, 39.3, 38.8, 36.8, 
36.4, 35.8, 35.4, 31.4, 29.6, 28.9, 27.4, 24.4, 22.4 (2C), 20.9, 19.1, 16.5 (2C) and 15.0; LC-
MS (ESI): m/z 606 [M+23]+, 524 [M-OAc]+; purity (LC-MS): 99% (tr = 3.92 min). 
General synthetic procedure for compounds 3.6-3.9  
Respective amine (1.5 eq.), EDCI (1.5 eq.) and 4-(dimethylamino)pyridine (DMAP) (0.4 eq.) 
were added to a solution of fusidic acid (3.1) (1.0 eq.) in DCM (5 ml). The reaction mixture 
was stirred at 25 oC for 16 h. After completion of reaction (TLC), reaction mixture was 
diluted with DCM (20 ml) and washed with water (3×15 ml). Organic layer was then dried 
over anhydrous magnesium sulfate, filtered and concentrated in vacuo. Purification by flash 
chromatography on 100-200 silica gel using methanol:DCM as eluent afforded products 3.6-
3.9. 
N-(2-morpholinoethyl)fusidic acid amide (3.6)  
White solid (0.163 g obtained from 0.2 g of 3.1, 
67%); Rf 0.1 (100% EtOAc); Mp. 216-218 
oC; 1H 
NMR (400 MHz, CDCl3) δ 5.73 (d, J = 7.3 Hz, 
1H, H-16), 5.08 (t, J = 7.0 Hz, 1H, H-24), 4.33 
(m, 1H, H-11), 3.76 (m, 5H, H-3, 2×H-34 and 
2×H-35), 3.45-3.37 (m, 1H, H-31), 3.27-3.16 (m, 
1H, H-31), 3.01-2.97 (m, 1H, H-13), 2.61-2.42 
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(m, 7H, H-22, 2×H-32, 2×H-33 and 2×H-36), 2.38-2.25 (m, 2H, H-12 and H-22), 2.20-2.05 
(m, 5H, H-1, H-5, H-15 and 2×H-23), 1.98 (s, 3H, OAc), 1.88-1.71 (m, 4H, 2×H-2, H-7 and 
H-12), 1.67 (s, 3H, CH3-27), 1.59 (s, 3H, CH3-26), 1.59-1.47 (m, 4H, H-1, H-4, H-6 and H-
9), 1.38 (s, 3H, CH3-30), 1.25-1.21 (m, 1H, H-15), 1.15-1.05 (m, 2H, H-6 and H-7), 0.96 (s, 
3H, CH3-19), 0.93 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 171.2, 170.8, 141.3, 135.5, 132.2, 123.4, 73.6, 71.3, 68.3, 66.4, 56.8, 53.3, 53.1 
(2C), 49.3, 48.6, 43.2, 39.5, 39.3, 37.0, 36.2, 36.1, 35.6, 35.1, 32.4, 30.3, 30.0, 29.3, 27.9, 
25.7, 24.1, 22.7, 21.1, 20.8, 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 629 [M+1]+, 569 [M-
OAc]+, 651 [M+23]+; purity (LC-MS): 97% (tr = 4.12 min). 
N-(2-hydroxyethyl)fusidic acid amide (3.7) 
White solid (0.080 g obtained from 0.3 g of 3.1, 
25%); Rf 0.3 (100% EtOAc); Mp. 162-164 
oC; 1H 
NMR (400 MHz, CD3OD) δ 5.79 (d, J = 8.5 Hz, 1H,  
H-16), 5.16 (t, J = 7.1 Hz, 1H, H-24), 4.33 (m, 1H, H-
11), 3.68 (m, 1H, H-3), 3.59 (t, J = 6.2 Hz, 2H, H-32), 
3.38-3.32 (m, 1H, H-31), 3.20-3.14 (m, 1H, H-31),  
3.08-3.05 (m, 1H, H-13), 2.63-2.55 (m, 1H, H-22), 
2.31-2.09 (m, 7H, H-1, H-5, H-12, H-15, H-22 and 
2×H-23), 1.99 (s, 3H, OAc), 1.89-1.72 (m, 4H, 2×H-2, H-7, H-12), 1.70 (s, 3H, CH3-27), 1.64 
(s, 3H, CH3-26), 1.62-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.41 (s, 3H, CH3-30), 1.25-1.10 
(m, 3H, H-6, H-7, H-15), 1.02 (s, 3H, CH3-19), 0.97 (s, 3H, CH3-18), 0.92 (d, J = 6.8 Hz, 3H, 
CH3-28); 
13C NMR (100 MHz, CD3OD) δ 173.2, 171.0, 141.9, 134.3, 131.8, 123.1, 73.8, 
71.0, 67.2, 60.1, 49.3, 48.4, 43.1, 41.6,  39.3, 38.9, 36.8, 36.4, 35.9, 35.4, 31.5, 29.6 (2C), 
29.0, 27.3, 24.4, 22.4, 22.3, 20.9, 19.7, 16.4 (2C) and 15.0; LC-MS (ESI): m/z 500 [M-OAc]+, 
582 [M+23]+; purity (LC-MS): 96% (tr = 4.03 min). 
N-(4-hydroxypiperidin-1-yl)fusidic acid amide 
(3.8) 
White solid (0.105 g obtained from 0.5 g of 3.1, 
18%); Rf 0.3 (100% EtOAc); Mp. 195-197 
oC; 1H 
NMR (400 MHz, CDCl3) δ 5.47 (dd, J = 8.6, 4.7 Hz 
1H, H-16), 5.05 (t, J = 7.1 Hz, 1H, H-24), 4.41-4.24 
(m, 2H, H-11 and H-33), 3.86-3.70 (m, 3H, H-3, H-
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31 and H-35), 3.40-3.15 (m, 2H, H-31 and H-35), 3.00-2.96 (m, 1H, H-13), 2.40-2.34 (m, 2H, 
2×H-22), 2.31-2.25 (m, 1H, H-12), 2.20-2.03 (m, 9H, H-1, H-5, H-15, 2×H-23, 2×H-32 and 
2×H-34), 1.96 (s, 3H, OAc), 1.89-1.69 (m, 4H, 2×H-2, H-7 and H-12), 1.65 (s, 3H, CH3-27), 
1.58 (s, 3H, CH3-26), 1.57-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.36 (s, 3H, CH3-30), 1.20-
1.15 (m, 1H, H-15), 1.13-1.03 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-
18), 0.89 (d, J = 6.9 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 170.9, 170.2, 139.9, 
133.6, 132.4, 123.3, 72.9, 71.3, 68.3, 67.7, 49.3, 49.0, 43.7, 42.9 (2C), 39.5, 39.4, 38.6, 36.9, 
36.3, 36.0, 35.5, 35.0, 33.9, 32.1, 30.2, 29.9, 27.7, 25.6, 23.9, 22.9, 21.1, 20.8, 17.9, 17.6 and 
15.9; LC-MS (ESI): m/z 540 [M-OAc]+, purity (LC-MS): 98% (tr = 4.56 min). 
N-(3-hydroxyazetidin-1-yl)fusidic acid amide (3.9) 
White solid (0.060 g obtained from 0.3 g of 3.1, 
18%); Rf 0.1 (80% EtOAc:hexane); Mp. 178-180 
oC; 
1H NMR (400 MHz, CDCl3) δ 5.79 (d, J = 8.7 Hz, 
1H, H-16), 5.06 (t, J = 7.1 Hz, 1H, H-24), 4.42 (m, 
1H, H-32), 4.34 (m, 1H, H-11), 4.27-4.15 (m, 2H, H-
31 and H-33), 4.02-3.81 (m, 2H, H-31 and H-33), 
3.75 (m, 1H, H-3), 3.00-2.96 (m, 1H, H-13), 2.51-
2.40 (m, 1H, H-22), 2.35-2.25 (m, 2H, H-12 and H-
22), 2.21-2.07 (m, 5H, H-1, H-5, H-15 and 2×H-23), 
2.05 (s, 3H, OAc), 1.89-1.72 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.60 (s, 
3H, CH3-26), 1.62-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.24-1.20 (m, 
1H, H-15), 1.16-1.07 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.96 (s, 3H, CH3-18), 0.92 
(d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 172.0, 171.8, 141.6, 132.4, 
131.7, 123.3, 73.1, 71.4, 68.3, 62.2, 60.7, 58.1, 49.4, 48.8, 43.3, 39.5, 39.3, 37.0, 36.3, 36.1, 
35.5, 32.3, 30.3, 29.9, 29.4, 27.7, 25.7, 24.0, 22.8, 21.3, 20.8, 17.9, 17.5 and 15.9; LC-MS 
(ESI): m/z 512 [M-OAc]+, purity (LC-MS): 94% (tr = 4.55 min). 
General synthetic procedure for compounds 3.10-3.12 
Respective sulphonamide (1.50 eq.), EDCI (1.50 eq.) and DMAP (0.4 eq.) were added to a 
solution of fusidic acid (3.1) (1.0 eq.) in DCM (10 ml) and reaction mixture was stirred at 25 
oC for 48 h. After completion of reaction (TLC), solvent was removed in vacuo and the 
residue was taken in EtOAc (25 ml). The organic phase was washed with water (3×15 ml), 
dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. Purification by 
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flash chromatography on 100-200 silica gel using methanol:DCM as eluent afforded products 
3.10-3.12. 
N-(methylsulfonyl)fusidic acid amide (3.10) 
White solid (0.108 g obtained from 0.3 g of 3.1, 31%); Rf 
0.4 (5% Methanol:DCM); Mp. 214-216 οC; 1H NMR (400 
MHz, CDCl3) δ 5.79 (d, J = 8.4 Hz, 1H, H-16), 5.10 (t, J = 
6.7 Hz, 1H, H-24), 4.34 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.08-3.05 (m, 1H, H-13), 2.75 (s, 3H, H-31), 2.42-2.40 (m, 
2H, H-12 and H-22), 2.34-2.30 (m, 1H, H-22), 2.21-2.09 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 2.02 (s, 3H, OAc), 1.93-
1.73 (m, 4H, 2×H-2, H-7 and H-12), 1.68 (s, 3H, CH3-27), 
1.62 (s, 3H, CH3-26), 1.58-1.50 (m, 4H, H-1, H-4, H-6 and 
H-9), 1.38 (s, 3H, CH3-30), 1.34-1.30 (m, 1H, H-15), 1.17-1.07 (m, 2H, H-6 and H-7), 0.98 
(s, 3H, CH3-19), 0.93-0.91 (m, 6H, CH3-28 and CH3-18); 
13C NMR (100 MHz, CDCl3) δ 
170.9, 164.7, 153.1, 132.5, 129.1, 123.0, 74.1, 71.3, 68.2, 49.2, 48.8, 44.6, 43.3, 39.5, 39.1, 
37.1, 36.3, 36.1, 35.4, 32.5, 30.3, 30.0, 29.0, 28.8, 25.7, 24.2, 22.6, 21.1, 20.7, 18.0, 17.8 and 
15.9; LC-MS (ESI): m/z 594 [M+H]+, 534 [M-OAc]+; purity (LC-MS): 98% (tr = 4.11 min). 
N-(phenylsulfonyl)fusidic acid amide (3.11) 
White solid (0.10 g obtained from 0.2 g of 3.1, 
38%); Rf 0.4 (5% Methanol:DCM); Mp. 229-231 
οC; 1H NMR (400 MHz, CDCl3) δ 8.49 (br s, 1H, 
NH), 8.08 (d, J = 7.5 Hz, 2H, H-31), 7.62 (t, J = 
7.3 Hz, 1H, H-33), 7.53 (t, J = 7.3 Hz, 2H, H-32), 
5.65 (d, J = 8.4 Hz, 1H, H-16), 4.98 (t, J = 6.8 Hz, 
1H, H-24), 4.33 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
2.99-2.97 (m, 1H, H-13), 2.41-2.34 (m, 1H, H-22), 
2.23-2.08 (m, 5H, H-1, H-5, H-12, H-22 and H-23), 1.92-1.88 (m, 2H, H-15 and H-23), 1.85 
(s, 3H, OAc), 1.76-1.72 (m, 4H, 2×H-2, H-7 and H-12), 1.65 (s, 3H, CH3-27), 1.60-1.53 (m, 
4H, H-1, H-4, H-6 and H-9), 1.47 (s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.30-1.26 (m, 1H, 
H-15), 1.12-1.09 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.92 (d, J = 6.8 Hz, 3H, CH3-
28), 0.89 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 170.7, 167.7, 146.7, 138.8, 133.8, 
133.6, 132.0, 128.8 (2C), 128.5 (2C), 122.6, 73.7, 71.4, 68.2, 49.2, 48.6, 43.7, 39.5, 39.1, 
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37.0, 36.2, 36.0, 35.5, 32.3, 30.2, 29.9, 29.1, 27.9, 25.6, 24.0, 22.8, 20.7 (2C), 17.9, 17.7 and 
15.9; LC-MS (ESI): m/z 678 [M+23]+, 596 [M-OAc]+; purity (LC-MS): 99% (tr = 4.32 min). 
N-(3,4-difluorophenylsulfonyl)fusidic acid amide (3.12) 
White solid (0.12 g obtained from 0.3 g of 3.1, 
30%); Rf 0.3 (4% Methanol:DCM); Mp. 232-234 
οC; 1H NMR (400 MHz, CDCl3) δ 8.55 (br s, 1H, 
NH), 7.97-7.92 (m, 1H, H-31), 7.89-7.87 (m, 1H, 
H-33), 7.35-7.29 (m, 1H, H-32), 5.65 (d, J = 8.1 
Hz, 1H, H-16), 4.99 (t, J = 6.8 Hz, 1H, H-24), 
4.34 (m, 1H, H-11), 3.76 (m, 1H, H-3), 3.01-2.98 
(m, 1H, H-13), 2.42-2.34 (m, 1H, H-22), 2.23-
2.09 (m, 7H, H-1, H-5, H-12, H-15, H-22 and 2×H-23), 1.95 (s, 3H, OAc), 1.75-1.69 (m, 4H, 
2×H-2, H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.61-1.54 (m, 4H, H-1, H-4, H-6 and H-9), 1.50 
(s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.32-1.28 (m, 1H, H-15), 1.16-1.07 (m, 2H, H-6 and 
H-7), 0.97 (s, 3H, CH3-19), 0.92 (d, J = 7.0 Hz, 3H, CH3-28), 0.90 (s, 3H, CH3-18); 
13C NMR 
(100 MHz, CDCl3) δ 170.6, 167.8, 167.7, 152.6, 147.4, 131.8, 126.0, 122.5, 118.8, 118.6, 
118.0, 117.8, 73.7, 71.4, 68.2, 49.3, 48.7, 43.8, 39.5, 39.2, 37.0, 36.2, 36.1, 35.5, 32.3, 30.3, 
29.9, 29.1, 28.0, 25.6, 24.0, 22.8, 20.8, 20.7, 17.9, 17.6 and 15.8; LC-MS (ESI): m/z 714 
[M+23]+, 632 [M-OAc]+; purity (LC-MS): 94% (tr = 4.36 min). 
Fusidic acid hydrazide (3.13)2 
HOBt (0.062 g, 0.44 mmol) and EDCI (0.085 g, 0.44 
mmol) were added to a solution of fusidic acid (3.1) (0.2 g, 
0.38 mmol) in acetonitrile (10 ml) and the reaction mixture 
was stirred at 25 oC for 3 h. Hydrazine hydrate (0.07 ml, 
1.52 mmol) was then added and the resulting reaction 
mixture was further stirred at 25 oC for 16 h. After 
completion of reaction (TLC), solvent was removed in 
vacuo and the residue was taken in EtOAc (25 ml). The 
organic phase was washed with water (3×15 ml), dried over anhydrous magnesium sulfate 
and concentrated in vacuo. Purification by flash chromatography on 100-200 silica gel using 
EtOAc:hexane mixture as eluent afforded product 3.13 as a white solid (0.2 g, 98%); Rf 0.2 
(90% EtOAc:hexane); Mp. 128-130 οC; 1H NMR (400 MHz, CDCl3) δ 8.26 (br s, 1H, NH), 
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7.75 (br s, 2H, NH2), 5.88 (d, J = 8.2 Hz, 1H, H-16), 5.10 (t, J = 6.8 Hz, 1H, H-24), 4.34 (m, 
1H, H-11), 3.76 (m, 1H, H-3), 3.07-3.04 (m, 1H, H-13), 2.48-2.43 (m, 2H, 2×H-22), 2.34-
2.31 (m, 1H, H-12), 2.21-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.88-
1.73 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.56-1.49 
(m, 4H, H-1, H-4, H-6 and H-9), 1.37 (s, 3H, CH3-30), 1.32-1.29 (m, 1H, H-15), 1.17-1.06 
(m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.93-0.91 (m, 6H, CH3-18 and CH3-28); 
13C 
NMR (100 MHz, CDCl3) δ 174.0, 170.5, 150.9, 132.6, 129.5, 123.0, 74.4 (2C), 71.4, 68.2, 
49.3, 48.7, 44.3, 39.5, 39.0, 37.0, 36.2, 36.1, 35.6, 32.3, 30.2, 29.9, 28.7, 28.4, 25.6, 22.8, 
20.8, 20.6, 17.9, 17.7 and 15.9; LC-MS (ESI): m/z 531 [M+H]+, 471 [M-OAc]+; purity 
(HPLC):  97% (tr = 18.44 min). 
N-(thiophene-2-carbonyl)fusidic acid hydrazide (3.14) 
Thiophene-2-carbohydrazide (0.03 g, 0.23 mmol), 
TBTU (0.07 g, 0.23 mmol) and DIPEA (0.1 ml, 
0.57 mmol) were added to a solution of fusidic 
acid (3.1) (0.1 g, 0.19 mmol) in DMF (3 ml) and 
the resulting reaction mixture was stirred at 25 oC 
for 16 h. After completion of reaction (TLC), 
reaction mixture was diluted with EtOAc (15 ml) 
and washed with water (3×15 ml), dried over 
anhydrous magnesium sulfate and concentrated in vacuo. Purification by flash 
chromatography on 100-200 silica gel using EtOAc:hexane as eluent afforded product 3.14 as 
a white solid (0.062 g, 50%); Rf 0.5 (60% EtOAc:hexane); Mp. 144-146 
οC; 1H NMR (400 
MHz, CDCl3) δ 8.83 (br s, 1H, NH), 8.48 (br s, 1H, NH), 7.64 (d, J = 4.0 Hz, 1H, H-31), 7.55 
(d, J = 4.9 Hz, 1H, H-33), 7.10 (t, J = 4.7 Hz, 1H, H-32), 5.80 (d, J = 8.1 Hz, 1H, H-16), 5.10 
(t, J = 6.8 Hz, 1H, H-24), 4.34 (m, 1H, H-11), 3.75 (m, 1H, H-3), 3.06-3.03 (m, 1H, H-13), 
2.54-2.49 (m, 1H, H-22), 2.38-2.35 (m, 1H, H-22), 2.32-2.29 (m, 1H, H-12), 2.20-2.10 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 1.98 (s, 3H, OAc), 1.88-1.74 (m, 4H, H-2, H-12, H-2 and 
H-7), 1.68 (s, 3H, CH3-27), 1.62 (s, 3H, CH3-26), 1.62-1.49 (m, 4H, H-1, H-4, H-6 and H-9), 
1.38 (s, 3H, CH3-30), 1.34-1.30 (m, 1H, H-15), 1.18-1.09 (m, 2H, H-6 and H-7), 0.98 (s, 3H, 
CH3-19), 0.96 (s, 3H, CH3-18), 0.92 (d, J = 6.9 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 170.9, 167.8, 159.1, 145.2, 135.4, 132.7, 132.3, 131.0, 129.4, 127.8, 123.1, 74.0, 
71.4, 68.2, 49.4, 48.7, 43.6, 39.5, 39.2, 37.0, 36.3, 36.0, 35.7, 32.2, 30.1, 29.9, 29.6, 28.1, 
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25.6, 23.9, 22.9, 21.0, 20.8, 17.9, 17.8 and 15.9; LC-MS (ESI): m/z 641 [M+H]+, 581 [M-
OAc]+; purity (HPLC): 98% (tr = 11.39 min). 
N-isonicotinoylfusidic acid hydrazide (3.15) 
Et3N (0.12 ml, 0.870 mmol) was added dropwise 
to a solution of fusidic acid (3.1) (0.150 g, 0.290 
mmol) and isoniazid (0.039 g, 0.290 mmol) in 
DCM (5 ml). Resulting reaction mixture was 
cooled to 0 oC in an ice bath and T3P solution 
(0.13 ml, 0.435 mmol, 50% w/v in DMF, d = 1.09 
g/ml) was added dropwise. Reaction mixture was 
then slowly warmed to 25 oC and stirred for 5 h. 
After completion of reaction (TLC), the reaction mixture was diluted with DCM (20 ml) and 
water (15 ml) and shaken well in a separating funnel. Organic layer was separated, dried over 
anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by 
column chromatography on 100-200 silica gel using EtOAc:hexane as eluent affording 3.15 
as a white solid (0.084 g, 46%); Rf 0.5 (10% Methanol:DCM); Mp. 189-191 
oC; 1H NMR 
(400 MHz, CD3OD) δ 8.70 (d, J = 6.1 Hz, 2H, 2×H-32), 7.80 (d, J = 6.1 Hz, 2H, 2×H-31), 
5.75 (d, J = 8.2 Hz, 1H, H-16), 5.18 (t, J = 7.1 Hz, 1H, H-24), 4.33 (m, 1H, H-11), 3.67 (m, 
1H, H-3), 3.11-3.08 (m, 1H, H-13), 2.65-2.57 (m, 1H, H-22), 2.37-2.13 (m, 7H, H-1, H-5, H-
12, H-15, H-22, 2×H-23), 1.97 (s, 3H, OAc), 1.92-1.71 (m, 4H, 2×H-2, H-7, H-12), 1.69 (s, 
3H, CH3-27), 1.67 (s, 3H, CH3-26), 1.64-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.41 (s, 3H, 
CH3-30), 1.34-1.30 (m, 1H, H-15), 1.19-1.09 (m, 2H, H-6 and H-7), 1.01 (s, 3H, CH3-19), 
0.97 (s, 3H, CH3-18), 0.90 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CD3OD) δ 
171.6, 171.4, 164.9, 149.5 (2C), 144.1, 140.9, 132.1, 131.8, 123.1, 121.8 (2C), 74.4, 71.0, 
67.1, 49.3, 48.3, 43.3, 39.3, 38.9, 36.8, 36.4, 36.0, 35.4, 31.5, 29.6 (2C), 29.5, 27.4, 24.4, 
22.4, 22.3, 20.9, 19.9, 16.7, 16.6 and 15.1; LC-MS (ESI): m/z 636 [M+H]+, 658 [M+23]+, 576 
[M-OAc]+; purity (HPLC): 96% (tr = 16.74 min). 
General synthetic procedure for compounds 3.16-3.17 
A solution of fusidic acid hydrazide (3.13) (0.150 g, 0.290 mmol) and pyridine-3-
carboxaldehyde or pyridine-4-carboxaldehyde (0.040 g, 0.377 mmol) in ethanol (2 ml) was 
refluxed in a sealed glass tube at 85 oC for 8 h. After completion of reaction (TLC), the 
reaction mixture was concentrated in vacuo and the residue was purified by column 
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chromatography on 100-200 silica gel using methanol:DCM as eluent affording products 
3.16-3.17. 
N-(pyridin-3-ylmethylene)fusidic acid hydrazide (3.16) 
White solid (0.110 g, 63%); Rf 0.2 (8% 
Methanol:DCM); Mp. 230-232 oC; A mixture of 
E/Z isomers; 1H NMR (400 MHz, CD3OD) δ 
8.84 (s, 1H, H-35, E/Z), 8.78 (s, 1H, H-35, E/Z),  
8.56 (d, J = 5.2 Hz, 1H, H-34, E/Z), 8.53 (d, J = 
5.2 Hz, 1H, H-34, E/Z), 8.30 (d, J = 8.1 Hz, 1H, 
H-32, E/Z), 8.06 (d, J = 8.1 Hz, 1H, H-32, E/Z), 
8.13 (s, 1H, H-31, E/Z), 7.96 (s, 1H, H-31, E/Z), 
7.49 (dd, J = 8.0 and 4.9 Hz, 1H, H-33), 5.83 (d, J = 8.8 Hz, 1H, H-16, E/Z), 5.57 (d, J = 8.8 
Hz, 1H, H-16, E/Z), 5.16 (t, J = 7.2 Hz, 1H, H-24), 4.35 (m, 1H, H-11), 3.67 (m, 1H, H-3), 
3.14-3.11 (m, 1H, H-13), 2.72-2.64 (m, 1H, H-22), 2.39-2.14 (m, 7H, H-1, H-5, H-12, H-15, 
H-22 and 2×H-23), 1.94-1.70 (m, 4H, 2×H-2, H-7 and H-12), 1.88 (s, 3H, OAc), 1.67 (s, 3H, 
CH3-27), 1.61 (s, 3H, CH3-26), 1.63-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.40 (s, 3H, CH3-
30), 1.22-1.18 (m, 1H, H-15), 1.17 -1.09 (m, 2H, H-6 and H-7), 1.01 (s, 3H, CH3-19), 0.97 (s, 
3H, CH3-18), 0.90 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CD3OD) δ 171.0, 
169.6, 150.0 (E/Z), 149.4 (E/Z), 148.3 (E/Z), 147.4 (E/Z), 145.2, 144.6, 134.5 (E/Z), 134.2 
(E/Z), 132.1 131.5, 130.9, 124.1, 123.2 (E/Z), 122.9 (E/Z), 74.2 (E/Z), 73.6 (E/Z), 71.0, 67.1, 
49.4, 48.5, 43.4 (E/Z), 42.7 (E/Z), 39.3, 38.7, 36.9, 36.4, 35.9, 35.4, 31.4, 29.6, 29.5 (E/Z), 
29.4 (E/Z), 28.9, 27.5 (E/Z), 27.0 (E/Z), 24.5, 22.5, 22.4, 21.0, 19.6 (E/Z), 19.3 (E/Z), 16.5, 
16.4 and 15.0; LC-MS (ESI): m/z 620 [M+H]+, 642 [M+23]+, 560 [M-OAc]+; purity (HPLC): 
98% (tr = 16.94 min). 
N-(pyridin-4-ylmethylene)fusidic acid hydrazide (3.17) 
White solid (0.110 g, 63%); Rf 0.2 (8% 
Methanol:DCM); Mp. 159-161 oC; A mixture of E/Z 
isomers; 1H NMR (400 MHz, CDCl3) δ 10.18 (s, 1H, 
NH, E/Z), 9.05 (s, 1H, NH, E/Z), 8.66 (br s, 2H, 
2×H-33), 8.24 (s, 1H, H-31, E/Z), 7.81 (s, 1H, H-31, 
E/Z), 7.61 (d, J = 4.4 Hz, 2H, 2×H-32, E/Z), 7.51 (d, 
J = 4.4 Hz, 2H, 2×H-32, E/Z), 5.76 (d, J = 8.1 Hz, 
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1H, H-16, E/Z), 5.63 (d, J = 8.1 Hz, 1H, H-16, E/Z), 5.10 (m, 1H, H-24), 4.38 (m, 1H, H-11), 
3.76 (m, 1H, H-3), 3.12-3.08 (m, 1H, H-13, E/Z), 3.03-2.99 (m, 1H, H-13, E/Z), 2.72-2.65 
(m, 1H, H-22), 2.57-2.10 (m, 7H, H-1, H-5, H-12, H-15, H-22 and 2×H-23), 1.93-1.73 (m, 
4H, 2×H-2, H-7 and H-12), 1.93 (s, 3H, OAc, E/Z), 1.91 (s, 3H, OAc, E/Z), 1.67-1.52 (m, 
10H, CH3-27, CH3-26, H-1, H-4, H-6 and H-9), 1.40 (s, 3H, CH3-30, E/Z), 1.38 (s, 3H, CH3-
30, E/Z), 1.23-1.20 (m, 1H, H-15), 1.16-1.07 (m, 2H, H-6 and H-7), 1.00-0.91 (m, 9H, CH3-
18, CH3-19 and CH3-28); 
13C NMR (100 MHz, CD3OD) δ 170.9, 169.8, 149.0 (2C), 145.5, 
144.8, 143.0, 132.2, 131.4, 123.2 (E/Z), 122.9 (E/Z), 121.6 (2C, E/Z), 121.1 (2C, E/Z), 74.2 
(E/Z), 73.6 (E/Z), 71.0, 67.1, 49.4 (E/Z), 49.0 (E/Z), 48.5, 43.4 (E/Z), 42.8 (E/Z), 39.3, 38.7, 
36.9, 36.4, 35.9, 35.4, 31.4, 29.6, 29.5 (E/Z), 29.3 (E/Z), 28.9, 27.5 (E/Z), 27.1 (E/Z), 24.5, 
22.5, 22.4, 21.0, 19.5 (E/Z), 19.3 (E/Z), 16.4 (2C), 15.0; LC-MS (ESI): m/z 620 [M+H]+, 642 
[M+23]+, 560 [M-OAc]+; purity (HPLC): 98% (tr = 16.98 min).  
General synthetic procedure for compounds 3.18-3.23  
To a solution of compound 3.13 (1.0 eq.) in pyridine (2-5 ml), respective sulfonyl chloride 
(1.0 eq.) was added and reaction mixture was stirred at 25 oC for 1-3 h. After completion of 
reaction (TLC), reaction mixture was diluted with EtOAc (25 ml) and washed with water 
(3×15 ml), dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by flash chromatography on 100-200 silica gel using EtOAc:hexane as eluent 
afforded products 3.18-3.23. 
N-methylsulfonylfusidic acid hydrazide (3.18) 
White solid (0.05 g obtained from 0.1 g of 3.13, 44%); 
Rf 0.4 (70% EtOAc:hexane); Mp. 125-127 
οC; 1H NMR 
(400 MHz, CDCl3) δ 7.79 (d, J = 3.7 Hz, 1H, NH), 6.89 
(d, J = 4.8 Hz, 1H, NH),  5.74 (d, J = 8.1 Hz, 1H, H-16), 
5.11 (t, J = 7.2 Hz, 1H, H-24), 4.35 (m, 1H, H-11), 3.76 
(m, 1H, H-3), 3.07-3.02 (m, 1H, H-13), 3.00 (s, 3H, 
SO2CH3), 2.52-2.45 (m, 1H, H-22), 2.37-2.26 (m, 2H, 
H-12 and H-22), 2.21-2.09 (m, 5H, H-1, H-5, H-15 and 
2×H-23), 2.01 (s, 3H, OAc), 1.91-1.73 (m, 4H, 2×H-2, H-7 and H-12), 1.69 (s, 3H, CH3-27), 
1.62 (s, 3H, CH3-26), 1.60-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.33-
1.27 (m, 1H, H-15), 1.18-1.05 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-
18), 0.93 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 170.8, 170.5, 146.0, 
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133.1, 131.7, 122.7, 73.8, 71.4, 68.3, 49.4, 48.8, 43.7, 39.6, 39.4, 39.2, 37.0, 36.3, 36.0, 35.4, 
32.1, 30.2, 29.8, 29.7, 28.2, 25.6, 24.0, 22.9, 21.1, 20.7, 17.9, 17.8 and 15.8; LC-MS (ESI): 
m/z 609 [M+H]+, 549 [M-OAc]+; purity (HPLC): 96% (tr = 13.94 min). 
 
N-ethylsulfonylfusidic acid hydrazide (3.19) 
White solid (0.16 g obtained from 0.3 g of 3.13, 
45%); Rf 0.5 (70% EtOAc:hexane); Mp. 127-129 
οC; 1H NMR (400 MHz, CDCl3) δ 8.23 (br s, 1H, 
NH), 7.13 (br s, 1H, NH), 5.74 (d, J = 8.2 Hz, 1H, 
H-16), 5.10 (t, J = 6.6 Hz, 1H, H-24), 4.37 (m, 1H, 
H-11), 3.76 (m, 1H, H-3), 3.17-3.07 (m, 2H, H-31), 
3.03-3.00 (m, 1H, H-13), 2.43-2.39 (m, 1H, H-22), 
2.33-2.24 (m, 2H, H-12 and H-22), 2.16-2.14 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 2.00 (s, 3H, OAc), 1.86-1.80 (m, 4H, 2×H-2, H-7 and H-
12), 1.68 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.57-1.51 (m, 4H, H-1, H-4, H-6 and H-9), 
1.43 (t, J = 7.3 Hz, 3H, H-32), 1.38 (s, 3H, CH3-30), 1.28-1.25 (m, 1H, H-15), 1.15-1.09 (m, 
2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.93-0.91 (m, 6H, CH3-18 and CH3-28); 
13C NMR 
(100 MHz, CDCl3) δ 171.0, 170.4, 145.3, 132.9, 131.9, 122.8, 73.8, 71.6, 68.3, 49.4, 48.7, 
46.4, 43.6, 39.6, 39.2, 36.9, 36.5, 35.8, 35.5, 31.8, 30.1, 29.7, 29.7, 28.2, 25.6, 23.7, 23.1, 
21.1, 20.9, 17.7(2C), 15.8 and 7.8; LC-MS (ESI): m/z 645 [M+23]+, 563 [M-OAc]+; purity 
(LC-MS): 96% (tr = 4.15 min). 
N-propylsulfonylfusidic acid hydrazide (3.20) 
White solid (0.15 g obtained from 0.5 g of 3.13, 
25%); Rf 0.4 (5% Methanol:DCM); Mp. 125-127 
οC; 1H NMR (400 MHz, CDCl3) δ 7.95 (br s, 1H, 
NH), 6.95 (br s, 1H, NH), 5.73 (d, J = 8.2 Hz, 1H, 
H-16), 5.10 (t, J = 6.8 Hz, 1H, H-24), 4.36 (m, 
1H, H-11), 3.76 (m, 1H, H-3), 3.08-2.99 (m, 3H, 
2×H-31 and H-13), 2.49-2.42 (m, 1H, H-22), 
2.35-2.25 (m, 2H, H-12 and H-22), 2.17-2.11 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 2.01 (s, 3H, OAc), 1.97-1.78 (m, 6H, 2×H-2, H-7, H-12 
and 2×H-32), 1.73 (s, 3H, CH3-27), 1.61 (s, 3H, CH3-26), 1.58-1.49 (m, 4H, H-1, H-4, H-6 
and H-9), 1.38 (s, 3H, CH3-30), 1.31-1.27 (m, 1H, H-15), 1.14-1.11 (m, 2H, H-6 and H-7), 
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1.05 (t, J = 7.3 Hz, 3H, H-33), 0.98 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.93 (d, J = 7.0 
Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 170.8, 170.4, 145.7, 133.1, 131.9, 122.7, 
73.8, 71.3, 68.3, 53.4, 49.3, 48.8, 43.7, 39.6, 39.2, 37.0, 36.3, 36.1, 35.5, 32.1, 30.2, 29.8, 
29.7, 28.1, 25.5, 23.9, 22.8, 21.1, 20.7, 17.9, 17.7, 17.0, 15.8 and 12.9; LC-MS (ESI): m/z  
659 [M+23]+, 577 [M-OAc]+; purity (LC-MS): 99% (tr = 4.20 min). 
N-butylsulfonylfusidic acid hydrazide (3.21) 
White solid (0.35 g obtained from 0.4 g of 3.13, 
71%); Rf 0.6 (70% EtOAc:hexane); Mp. 121-
123 οC; 1H NMR (400 MHz, CDCl3) δ 8.15 (br 
s, 1H, NH), 7.06 (br s, 1H, NH), 5.74 (d, J = 
8.2 Hz, 1H, H-16), 5.10 (t, J = 6.6 Hz, 1H, H-
24), 4.36 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.15-3.00 (m, 3H, 2×H-31 and H-13), 2.45-2.40 
(m, 1H, H-22), 2.35-2.24 (m, 2H, H-12 and H-
22), 2.16-2.11 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.01 (s, 3H, OAc), 1.93-1.71 (m, 6H, 
2×H-2, H-7, H-12 and 2×H-32), 1.68 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.59-1.49 (m, 
4H, H-1, H-4, H-6 and H-9), 1.47-1.41 (m, 2H, H-33), 1.38 (s, 3H, CH3-30), 1.29-1.25 (m, 
1H, H-15), 1.16-1.07 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.95-0.92 (m, 9H, CH3-18, 
CH3-28 and 3×H-34); 
13C NMR (100 MHz, CDCl3) δ 170.9, 170.4, 145.3, 132.9, 131.7, 
122.8, 73.7, 71.5, 68.3, 51.6, 49.4, 48.7, 43.6, 39.6, 39.2, 36.9, 36.4, 35.9, 35.5, 31.9, 30.2, 
29.7, 28.2, 25.6, 25.1, 23.8, 23.0, 21.5, 21.1, 20.8, 17.8 (C3), 15.8 and 13.4; LC-MS (ESI): 
m/z 673 [M+23]+, 591 [M-OAc]+; purity (LC-MS): 97% (tr = 4.47 min). 
N-(4-Methylphenylsulfonyl)fusidic acid hydrazide (3.22) 
White solid (0.03 g obtained from 0.05 g of 
3.13, 46%); Rf 0.3 (60% EtOAc:hexane); Mp. 
220-222 οC; 1H NMR (400 MHz, CDCl3) δ 
7.80 (d, J = 8.4 Hz, 2H, H-31), 7.70 (d, J = 
6.0 Hz, 1H, NH), 7.32 (d, J = 6.0 Hz, 1H, 
NH), 7.26 (d, J = 7.9 Hz, 2H, H-32), 5.54 (d, J 
= 8.2 Hz, 1H, H-16), 4.94 (t, J = 6.8 Hz, 1H, 
H-24), 4.30 (m, 1H, H-11), 3.75 (m, 1H, H-3), 
2.95-2.92 (m, 1H, H-13), 2.38 (s, 3H, H-33), 
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2.20-2.02 (m, 8H, H-1, H-5, H-12, H-15, 2×H-22 and 2×H-23), 2.00 (s, 3H, OAc), 1.88-1.72 
(m, 4H, 2×H-2, H-7 and H-12), 1.70 (s, 3H, CH3-27), 1.57 (s, 3H, CH3-26), 1.51-1.47 (m, 4H, 
H-1, H-4, H-6 and H-9), 1.33 (s, 3H, CH3-30), 1.27-1.24 (m, 1H, H-15), 1.14-1.04 (m, 2H, H-
6 and H-7), 0.96 (s, 3H, CH3-19), 0.91 (d, J = 6.2 Hz, 3H, CH3-28), 0.87 (s, 3H, CH3-18); 
13C 
NMR (100 MHz, CDCl3) δ 170.2, 169.6, 145.9, 144.8, 133.3, 132.7, 131.4, 129.5 (2C), 128.8 
(2C), 122.9, 73.9, 71.3, 68.2, 49.3, 48.8, 43.5, 39.5, 39.1, 37.1, 36.2, 36.1, 35.3, 32.4, 30.3, 
29.9, 29.5, 28.0, 25.7, 24.1, 22.6, 21.6, 21.0, 20.6, 17.9 (2C) and 15.8; LC-MS (ESI): m/z 685 
[M+H]+, 625 [M-OAc]+; purity (HPLC): 97% (tr = 12.56 min). 
N-(4-chlorophenylsulfonyl)fusidic acid hydrazide (3.23) 
White solid (0.093 g obtained from 0.108 g of 
3.13, 65%); Rf 0.5 (60% EtOAc:hexane); Mp. 
230-232 οC; 1H NMR (400 MHz, CDCl3) δ 
7.86 (d, J = 8.6 Hz, 2H, H-32), 7.62 (d, J = 
5.3 Hz, 1H, NH), 7.45 (d, J = 8.4 Hz, 2H, H-
31), 7.31 (d, J = 5.5 Hz, 1H, NH), 5.55 (d, J = 
8.4 Hz, 1H, H-16), 4.95 (t, J = 6.8 Hz, 1H, H-
24), 4.31 (m, 1H, H-11), 3.75 (m, 1H, H-3), 
2.97-2.94 (m, 1H, H-13), 2.18-2.06 (m, 8H, H-1, H-5, H-12, H-15, 2×H-22 and 2×H-23), 
2.00 (s, 3H, OAc), 1.91-1.74 (m, 4H, 2×H-2, H-7 and H-12), 1.71 (s, 3H, CH3-27), 1.58 (s, 
3H, CH3-26), 1.54-1.51 (m, 4H, H-1, H-4, H-6 and H-9), 1.34 (s, 3H, CH3-30), 1.29-1.26 (m, 
1H, H-15), 1.14-1.07 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.92 (d, J = 6.8 Hz, 3H, 
CH3-28), 0.89 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 170.3, 169.7, 146.3, 140.6, 
134.9, 133.0, 131.3, 130.2 (2C), 129.2 (2C), 122.6, 73.8, 71.3, 68.1, 49.2, 48.9, 43.6, 39.5, 
39.2, 37.1, 36.3, 36.0, 35.3, 32.5, 30.3, 29.9, 29.6, 28.0, 25.7, 24.1, 22.4, 21.1, 20.6, 18.0, 
17.9 and 15.8; LC-MS (ESI): m/z 722 [M+NH4]
+, 645 [M-OAc]+; purity (HPLC): 98% (tr = 
11.92 min). 
General synthetic procedure for compounds 3.24-3.27 
EDCI (1.15 eq.) and HOBt (1.20 eq.) were added to a solution of fusidic acid (3.1) (1.0 eq.) in 
acetonitrile (20 ml) and resulting reaction mixture was stirred at 25 oC for 3 h followed by the 
addition of respective amidoxime (1.10 eq.) and then reaction mixture was heated at 80 οC for 
12 h. After completion of reaction (TLC), solvent was removed in vacuo. The residue was 
taken in EtOAc (25 ml), washed with water (3×15 ml), dried over anhydrous magnesium 
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sulfate, filtered and concentrated in vacuo. Without further purification this intermediate and 
NaOAc (5.0 eq.) were taken in EtOH (20 ml) and irradiated in microwave at 100 οC for 2 h. 
After completion of reaction (TLC), solvent was removed in vacuo and residue was taken in 
EtOAc (25 ml), washed with water (2×15 ml), dried over anhydrous magnesium sulfate, 
filtered and concentrated in vacuo. Purification by flash chromatography on 100-200 silica 
gel using EtOAc:hexane as eluent afforded products 3.24-3.27. 
20-Decarboxy-20-(3-methyl-1,2,4-oxadiazol-5-yl)fusidic acid (3.24)  
White solid (0.090 g obtained from 0.35 g of 3.1, 24%); Rf 
0.8 (80% EtOAc:hexane); Mp. 152-154 οC; 1H NMR (400 
MHz, CDCl3) δ 5.96 (d, J = 8.2 Hz, 1H, H-16), 5.06 (t, J = 
6.8 Hz, 1H, H-24), 4.37 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.16-3.13 (m, 1H, H-13), 2.70-2.62 (m, 2H, 2×H-22), 2.41-
2.37 (m, 1H, H-12), 2.36 (s, 3H, H-31), 2.24-2.06 (m, 5H, 
H-1, H-5, H-15 and 2×H-23), 1.95-1.76 (m, 4H, 2×H-2, H-
7 and H-12), 1.71 (s, 3H, OAc), 1.64 (s, 3H, CH3-27), 1.60-
1.50 (m, 4H, H-1, H-4, H-6 and H-9), 1.57 (s, 3H, CH3-26), 1.40 (s, 3H, CH3-30), 1.35-1.32 
(m, 1H, H-15), 1.18-1.08 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 0.93-0.92 (m, 6H, 
CH3-18 and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 177.7, 170.0, 166.8, 152.7, 132.8, 
123.0, 122.6, 74.6, 71.3, 68.2, 49.2, 48.9, 44.8, 39.5, 39.0, 37.0, 36.2, 36.1, 35.7, 32.5, 30.3, 
30.0, 29.8, 28.2, 25.6, 24.2, 22.6, 20.7 (2C), 18.0, 17.7, 15.9 and 11.4; LC-MS (ESI): m/z 555 
[M+H]+; purity (HPLC): 96% (tr = 13.91 min).  
20-Decarboxy-20-(3-ethyl-1,2,4-oxadiazol-5-yl)fusidic acid (3.25) 
White solid (0.050 g obtained from 0.2 g of 3.1, 23%); Rf 
0.6 (80% EtOAc:hexane); Mp. 126-128 οC; 1H NMR (400 
MHz, CDCl3) δ 5.97 (d, J = 8.4 Hz, 1H, H-16), 5.07 (t, J = 
6.8 Hz, 1H, H-24), 4.37 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.16-3.14 (m, 1H, H-13), 2.72 (q, J = 7.5 Hz, 2H, H-31), 
2.68-2.63 (m, 2H, 2×H-22), 2.41-2.38 (m, 1H, H-12), 
2.24-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.98-1.77 
(m, 4H, 2×H-2, H-7 and H-12), 1.72 (s, 3H, OAc), 1.64 (s, 
3H, CH3-27), 1.64-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.57 (s, 3H, CH3-26), 1.40 (s, 3H, 
CH3-30), 1.32-1.29 (m, 4H, H-15 and 3×H-32), 1.19-1.06 (m, 2H, H-6 and H-7), 0.99 (s, 3H, 
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CH3-19), 0.93-0.92 (m, 6H, CH3-18 and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 177.6, 
171.3, 169.9, 152.7, 132.8, 123.0, 122.6, 74.5, 71.3, 68.3, 49.2, 48.9, 44.8, 39.5, 39.0, 37.1, 
36.3, 36.1, 35.7, 32.5, 30.3, 30.0, 29.9, 28.2, 25.6, 24.2, 22.6, 20.7 (2C), 19.6, 18.0, 17.7, 15.9 
and 11.4; LC-MS (ESI): m/z 569 [M+H]+, 509 [M-OAc]+; purity (HPLC): 98% (tr = 15.38 
min).  
20-Decarboxy-20-(3-propyl-1,2,4-oxadiazol-5-yl)fusidic acid (3.26) 
White solid (0.080 g obtained from 0.5 g of 3.1, 14%); Rf 
0.6 (70% EtOAc:hexane); Mp. 110-112 οC; 1H NMR 
(400 MHz, CDCl3) δ 5.97 (d, J = 8.2 Hz, 1H, H-16), 5.07 
(t, J = 6.8 Hz, 1H, H-24), 4.37 (m, 1H, H-11), 3.76 (m, 
1H, H-3), 3.17-3.14 (m, 1H, H-13), 2.68-2.65 (m, 4H, 
2×H-22 and 2×H-31), 2.42-2.38 (m, 1H, H-12), 2.24-
2.06 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.95-1.75 (m, 
6H, 2×H-2, H-7, H-12 and 2×H-32), 1.72 (s, 3H, OAc), 
1.64 (s, 3H, CH3-27), 1.60-1.51 (m, 4H, H-1, H-4, H-6 and H-9), 1.57 (s, 3H, CH3-26), 1.40 
(s, 3H, CH3-30), 1.36-1.33 (m, 1H, H-15), 1.19-1.08 (m, 2H, H-6 and H-7), 1.01-0.97 (m, 6H, 
CH3-19 and 3×H-33), 0.93-0.92 (m, 6H, CH3-28 and CH3-18); 
13C NMR (100 MHz, CDCl3) δ 
177.4, 170.2, 169.9, 152.5, 132.7, 123.2, 122.6, 74.6, 71.3, 68.3, 49.2, 48.9, 44.9, 39.5, 39.0, 
37.1, 36.3, 36.1, 35.7, 32.5, 30.3, 30.0, 29.9, 28.2, 27.9, 25.6, 24.2, 22.6, 20.7 (2C), 20.4, 
18.1, 17.7, 15.9 and 13.7; LC-MS (ESI): m/z 583 [M+H]+, 523 [M-OAc]+; purity (LC-MS): 
98% (tr = 4.33 min). 
20-Decarboxy-20-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)fusidic acid (3.27) 
White solid (0.10 g obtained from 0.4 g of 3.1, 20%); 
Rf 0.7 (50% EtOAc:hexane); Mp. 86-88 
οC; 1H NMR 
(400 MHz, CDCl3) δ 8.08 (dd, J = 8.8 and 5.3 Hz, 
2H, H-32), 7.16 (dd, J = 8.6 and 5.5 Hz, 2H, H-31), 
6.14 (d, J = 8.1 Hz, 1H, H-16), 5.10 (t, J = 6.8 Hz, 
1H, H-24), 4.39 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.23-3.20 (m, 1H, H-13), 2.74 (t, J = 7.7 Hz, 2H, 
2×H-22), 2.46-2.42 (m, 1H, H-12), 2.29-2.08 (m, 5H, 
H-1, H-5, H-15 and 2×H-23), 1.98-1.75 (m, 4H, 2×H-2, H-7 and H-12), 1.64 (s, 6H, OAc and 
CH3-27), 1.58 (s, 3H, CH3-26), 1.60-1.50 (m, 4H, H-1, H-4, H-6 and H-9), 1.42 (s, 3H, CH3-
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30), 1.40-1.37 (m, 1H, H-15), 1.22-1.09 (m, 2H, H-6 and H-7), 1.00 (s, 3H, CH3-19), 0.96 (s, 
3H, CH3-18), 0.93 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 177.8, 170.2, 
167.3, 165.7, 153.9, 133.0, 129.5, 129.4, 123.2, 122.8, 122.6, 116.1, 115.9, 74.7, 71.3, 68.2, 
49.2, 49.1, 45.2, 39.5, 39.0, 37.1, 36.2 (2C), 35.8, 32.4, 30.3, 30.0, 29.6, 28.4, 25.6, 24.2, 
22.7, 20.7 (2C), 18.1, 17.7 and 15.9; LC-MS (ESI): m/z 635 [M+H]+, 575 [M-OAc]+; purity 
(HPLC): 97% (tr = 16.80 min). 
20-Decarboxy-20-(5-hydroxy-1,3,4-oxadiazol-2-yl) fusidic acid (3.28) 
Et3N (0.1 ml, 0.72 mmol) was added to a solution of 
compound 3.13 (0.2 g, 0.38 mmol) in THF (10 ml) and 
reaction mixture was cooled to 0 οC followed by addition 
of 1,1’ carbonyldiimidazole (CDI) (0.092 g, 0.56 mmol). 
Reaction mixture was stirred at 0 οC for 5 h followed by 
further addition of Et3N (0.1 ml, 0.72 mmol) and CDI 
(0.092 g, 0.56 mmol). Reaction mixture was stirred at 25 
oC for 11 h and solvent was removed in vacuo. Residue 
was taken in EtOAc (15 ml) and washed with water 
(3×15 ml), dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. 
Purification by flash chromatography on 100-200 silica gel using EtOAc:hexane as eluent 
afforded product 3.28 as a white solid (0.052 g, 24%); Rf 0.5 (70% EtOAc: hexane); Mp. 137-
139 οC; 1H NMR (400 MHz, CDCl3) δ 5.86 (d, J = 8.2 Hz, 1H, H-16), 5.08 (t, J = 6.8 Hz, 1H, 
H-24), 4.37 (m, 1H, H-11), 3.77 (m, 1H, H-3), 3.12-3.09 (m, 1H, H-13), 2.59-2.52 (m, 1H, H-
22), 2.49-2.42 (m, 1H, H-22), 2.38-2.34 (m, 1H, H-12), 2.21-2.11 (m, 5H, H-1, H-5, H-15 
and 2×H-23), 1.92 (s, 3H, OAc), 1.89-1.75 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-
27), 1.62-1.50 (m, 7H, CH3-26, H-1, H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.36-1.33 (m, 
1H, H-15), 1.18-1.08 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-19), 0.93-0.92 (m, 6H, CH3-18 
and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 174.6, 170.3, 154.4, 151.5, 132.9, 122.5, 122.2, 
74.5, 71.4, 68.2, 49.2, 48.8, 44.8, 39.5, 39.1, 37.1, 36.2, 36.1, 35.7, 32.4, 30.3, 29.9, 28.5, 
28.1, 25.6, 24.2, 22.6, 20.9, 20.7, 18.1, 17.8 and 15.8; LC-MS (ESI): m/z 557 [M+H]+; purity 
(HPLC): 96% (tr = 12.91 min). 
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20-Decarboxy-20-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl) fusidic acid (3.29) 
Carbon disulfide (0.03 ml, 0.52 mmol) and KOH (0.026 g, 
0.47 mmol) were added to a solution of compound 3.13 
(0.25 g, 0.47 mmol) in ethanol (5 ml) at 0 οC and resulting 
reaction mixture was shifted to heating at 80 οC until 
reaction proceeds to completion. After completion of 
reaction (TLC, 16 h), solvent was removed in vacuo and 
diluted with EtOAc (15 ml). The organic phase was 
washed with water (3×15 ml), dried over anhydrous 
magnesium sulfate, filtered and concentrated in vacuo. Purification by flash chromatography 
on 100-200 silica gel using EtOAc:hexane as eluent afforded product 3.29 as a white solid 
(0.15 g, 56%); Rf 0.4 (90% EtOAc:hexane); Mp. 130-132 
οC; 1H NMR (400 MHz, CDCl3) δ 
11.97 (br s, 1H, NH), 5.86 (d, J = 8.2 Hz, 1H, H-16), 5.06 (t, J = 6.8 Hz, 1H, H-24), 4.37 (m, 
1H, H-11), 3.77 (m, 1H, H-3), 3.14-3.11 (m, 1H, H-13), 2.60-2.54 (m, 2H, 2×H-22), 2.38-
2.34 (m, 1H, H-12), 2.20-2.08 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.02-1.70 (m, 4H, 2×H-
2, H-7 and H-12), 1.89 (s, 3H, OAc), 1.65 (s, 3H, CH3-27), 1.61-1.50 (m, 7H, CH3-26, H-1, 
H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.35-1.31 (m, 1H, H-15), 1.17-1.07 (m, 2H, H-6 
and H-7), 0.98 (s, 3H, CH3-19), 0.93-0.91 (m, 6H, CH3-18 and CH3-28); 
13C NMR (100 
MHz, CDCl3) δ 170.6 (2C), 153.0 (2C), 133.0, 122.4, 121.0, 74.5, 71.5, 68.1, 49.3, 48.9, 45.1, 
39.5, 39.1, 37.0, 36.3, 36.0, 35.7, 32.1, 30.2, 29.8, 29.0, 28.1, 25.6, 24.0, 22.9, 20.9, 20.8, 
18.0, 17.8 and 15.9; LC-MS (ESI): m/z 595 [M+23]+, 513 [M-OAc]+; purity (LC-MS): 98% 
(tr = 4.55 min). 
7.2.1.2 C-3 Fusidic acid derivatives 
General synthetic procedure for compounds 3.30 and 3.32  
Fusidic acid (3.1) (1.0 eq.) was dissolved in a mixture of corresponding acid anhydride (5.5 
eq.) and pyridine (6.5 eq.) and the resulting reaction mixture was stirred at 25 oC for 3 h. 
After completion of reaction (TLC), water (25 ml) was added to the reaction mixture and 
aqueous layer was extracted with EtOAc (2×15 ml). Organic layer was washed with aq 0.5 M 
HCl (2×15 ml) to get rid of excess of pyridine. Organic layer was then dried over anhydrous 
sodium sulfate, filtered and concentrated in vacuo. The residue was purified on 100-200 silica 
gel using EtOAc: hexane as eluent to afford compound 3.30 and 3.32. 
 
Chapter 7: Experimental 
 
189 
 
General synthetic procedure for compounds 3.31 and 3.33-3.35 
T3P (2.0 eq., 50% w/v in DMF, d = 1.09 g/ml) was added dropwise to an ice cooled solution 
of fusidic acid (3.1) (1.0 eq.) and respective carboxylic acid (1.1 eq.) in pyridine. Reaction 
mixture was then slowly warmed to 25 oC and stirred for 16 h. After completion of the 
reaction (TLC), water (25 ml) was added to the reaction mixture and aqueous layer was 
extracted with EtOAc (2×15 ml). Organic layer was washed with aq 0.5 M HCl (2×15 ml) to 
remove excess of pyridine. Organic layer was dried over anhydrous sodium sulfate, filtered 
and concentrated in vacuo. The residue was purified by column chromatography on 100-200 
silica gel using EtOAc: hexane as eluent to afford compound3.31 and 3.33-3.35.  
3-Acetoxyfusidic acid (3.30)3 
White solid (0.126 g obtained from 0.2 g of 3.1, 58%); 
Rf 0.4 (50% EtOAc:hexane); Mp. 112-114 
oC; 1H NMR 
(400 MHz, CDCl3) δ 5.91 (d, J = 8.4 Hz, 1H, H-16), 
5.11 (t, J =7.2 Hz, 1H, H-24), 4.94 (m, 1H, H-3), 4.34 
(m, 1H, H-11), 3.08-3.04 (m, 1H, H-13), 2.53-2.42 (m, 
2H, 2×H-22), 2.35-2.30 (m, 1H, H-12), 2.22-2.05 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 2.07 (s, 3H, H-32), 
1.97 (s, 3H, OAc), 1.91-1.76 (m, 4H, 2×H-2, H-7 and H-
12), 1.68 (s, 3H, CH3-27), 1.63-1.53 (m, 4H, H-1, H-4, H-6 and H-9), 1.61 (s, 3H, CH3-26), 
1.38 (s, 3H, CH3-30), 1.36-1.32 (m, 1H, H-15), 1.20-1.02 (m, 2H, H-6 and H-7), 0.99 (s, 3H, 
CH3-19), 0.93 (s, 3H, CH3-18), 0.83 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 174.3, 170.9, 170.5, 151.1, 132.6, 129.6, 123.0, 74.4, 74.1, 68.3, 49.1, 48.8, 44.3, 
39.5, 39.0, 37.8, 36.9, 35.8, 34.8, 32.7, 31.1, 28.7, 28.4, 27.4, 25.7, 24.3, 22.5, 21.3, 20.6 
(2C), 18.1, 17.8 and 15.5; LC-MS (ESI): m/z 559 [M+1]+, 581 [M+23]+, 499 [M-OAc]+; 
purity (HPLC): 98% (tr = 12.56 min). 
3-Propionyloxyfusidic acid (3.31) 
White solid (0.310 g obtained from 0.5 g of 3.1, 
56%); Rf 0.5 (50% EtOAc:hexane); Mp. 93-95 
oC; 
1H NMR (400 MHz, CDCl3) δ 5.91 (d, J = 8.3 Hz, 
1H, H-16), 5.12 (t, J = 7.2 Hz, 1H, H-24),  4.95 (m, 
1H, H-3), 4.34 (m, 1H, H-11), 3.08-3.04 (m, 1H, H-
13), 2.51-2.42 (m, 2H, 2×H-22), 2.36 (q, J = 7.6 Hz, 
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2H, 2×H-32), 2.35-2.30 (m, 1H, H-12), 2.22-2.06 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.97 
(s, 3H, OAc), 1.89-1.78 (m, 4H, 2×H-2, H-7 and H-12), 1.73-1.52 (m, 4H, H-1, H-4, H-6 and 
H-9), 1.68 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.38 (s, 3H, CH3-30), 1.35-1.32 (m, 1H, H-
15), 1.19-1.03 (m, 2H, H-6 and H-7), 1.16 (t, J = 7.6 Hz, 3H, H-33), 0.99 (s, 3H, CH3-19), 
0.93 (s, 3H, CH3-18),  0.83 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 174.1, 
173.2, 170.5, 151.0, 132.6, 129.5, 123.0, 74.3, 73.8, 68.2, 49.1, 48.8, 44.3, 39.4, 39.0, 37.8, 
37.0, 35.7, 34.8, 32.8, 31.0, 28.8, 28.3, 28.1, 27.4, 25.7, 24.3, 22.5, 20.6, 20.5, 18.1, 17.7, 
15.5 and 9.4; LC-MS (ESI): m/z 573 [M+1]+, 595 [M+23]+, 513 [M-OAc]+; purity (HPLC): 
98% (tr = 13.20 min). 
3-Butyryloxyfusidic acid (3.32) 
White solid (3.0 g obtained from 4.0 g of 3.1, 
66%); Rf 0.5 (50% EtOAc:hexane) Mp. 162-164 
oC; 1H NMR (400 MHz, CDCl3) δ 5.90 (d, J = 8.3 
Hz, 1H, H-16), 5.10 (t, J = 7.2 Hz, 1H, H-24), 4.95 
(m, 1H, H-3), 4.34 (m, 1H, H-11), 3.07-3.03 (m, 
1H, H-13), 2.53-2.41 (m, 2H, 2×H-22), 2.35-2.29 
(m, 1H, H-12), 2.32 (t, 2H, J = 7.3 Hz, 2×H-32), 
2.22-2.03 (m, 5H, H-1, H-5, H-15 and 2×H-23), 
1.97 (s, 3H, OAc), 1.91-1.76 (m, 4H, 2×H-2, H-7 
and H-12), 1.72-1.52 (m, 6H, H-1, H-4, H-6, H-9 and 2×H-33), 1.68 (s, 3H, CH3-27), 1.60 (s, 
3H, CH3-26), 1.38 (s, 3H, CH3-30), 1.35-1.32 (m, 1H, H-15), 1.19-1.05 (m, 2H, H-6 and H-
7), 0.99 (s, 3H, CH3-19), 0.97 (t, J = 7.4 Hz, 3H, 3×H-34), 0.93 (s, 3H, CH3-18), 0.83 (d, J = 
6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 174.5, 173.4, 170.4, 151.2, 132.6, 
129.6, 123.0, 74.4, 73.8, 68.2, 49.1, 48.8, 44.3, 39.4, 39.0, 37.8, 36.9, 36.7, 35.7, 34.8, 32.7, 
31.0, 28.7, 28.3, 27.4, 25.6, 24.3, 22.5, 20.5 (2C), 18.6, 18.0, 17.7, 15.6 and 13.7; LC-MS 
(ESI): m/z 587 [M+1]+, 609 [M+23]+, 527 [M-OAc]+; purity (HPLC): 99% (tr = 13.94 min). 
3-Pentanoyloxyfusidic acid (3.33) 
White solid (1.3 g obtained from 2.0 g of 3.1, 
56%); Rf 0.6 (50% EtOAc:hexane) Mp. 118-
120 oC; 1H NMR (400 MHz, CDCl3) δ 5.90 (d, 
J = 8.4 Hz, 1H, H-16), 5.11 (t, J = 7.1 Hz, 1H, 
H-24), 4.94 (m, 1H, H-3), 4.34 (m, 1H, H-11), 
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3.07-3.03 (m, 1H, H-13), 2.49-2.45 (m, 2H, 2×H-22), 2.35-2.29 (m, 1H, H-12), 2.33 (t, J = 
7.4 Hz, 2H, 2×H-32), 2.22-2.04 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 
1.91-1.77 (m, 4H, 2×H-2, H-7 and H-12), 1.64-1.53 (m, 6H, H-1, H-4, H-6, H-9 and 2×H-
33), 1.67 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.40-1.32 (m, 3H, H-15 and 2×H-34), 1.38 
(s, 3H, CH3-30), 1.19-1.04 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 0.97-0.93 (m, 6H, 
CH3-18 and 3×H-35), 0.82 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 
174.2, 173.5, 170.4, 151.2, 132.6, 129.5, 123.0, 74.4, 73.8, 68.2, 49.1, 48.8, 44.3, 39.4, 39.0, 
37.8, 37.0, 35.7, 34.8, 34.5, 32.8, 31.0, 28.7, 28.3, 27.4, 27.3, 25.6, 24.3, 22.5, 22.3, 20.5 
(2C), 18.1, 17.7, 15.6 and 13.7; LC-MS (ESI): m/z 601 [M+1]+, 623 [M+23]+, 541 [M-OAc]+; 
purity (HPLC): 99% (tr = 14.37 min). 
3-Heptanoyloxyfusidic acid (3.34) 
White solid (0.380 g obtained from 0.5 g 
of 3.1, 62%); Rf 0.6 (50% 
EtOAc:hexane); Mp. 167-169 oC; 1H 
NMR (400 MHz, CDCl3) δ 5.91 (d, J = 
8.4 Hz, 1H, H-16), 5.11 (t, J = 7.2 Hz, 
1H, H-24), 4.95 (m, 1H, H-3), 4.34 (m, 
1H, H-11), 3.08-3.04 (m, 1H, H-13), 2.53-
2.42 (m, 2H, 2×H-22), 2.36-2.31 (m, 1H, 
H-12), 2.33 (t, J = 7.4 Hz, 2H, 2×H-32), 
2.22-2.05 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.97 (s, 3H, OAc), 1.89-1.77 (m, 4H, 2×H-2, 
H-7 and H-12), 1.72-1.53 (m, 6H, H-1, H-4, H-6, H-9 and 2×H-33), 1.68 (s, 3H, CH3-27), 
1.60 (s, 3H, CH3-26), 1.38 (s, 3H, CH3-30), 1.39-1.29 (m, 7H, H-15, 2×H-34, 2×H-35 and 
2×H-36), 1.19-1.04 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 0.93 (s, 3H, CH3-18), 0.89 
(t, J = 7.0 Hz, 3H, 3×H-37), 0.83 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 
173.5, 173.3, 170.5, 151.0, 132.6, 129.5, 123.0, 74.3, 73.8, 68.2, 49.1, 48.8, 44.3, 39.4, 39.0, 
37.9, 37.0, 35.7, 34.8, 34.7, 32.8, 31.5, 31.1, 28.8, 28.7, 28.3, 27.4, 25.6, 25.2, 24.4, 22.4 
(2C), 20.6, 20.5, 18.1, 17.7, 15.6 and 14.0; LC-MS (ESI): m/z 629 [M+1]+, 651 [M+23]+, 569 
[M-OAc]+; purity (HPLC): 99% (tr = 16.04 min). 
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3-Decanoyloxyfusidic acid (3.35) 
Colourless viscous oil (0.410 g 
obtained from 0.5 g of 3.1, 63%); 
Rf 0.8 (50% EtOAc:hexane); 
1H 
NMR (400 MHz, CDCl3) δ 5.90 
(d, J = 8.4 Hz, 1H, H-16), 5.10 (t, 
J = 7.2 Hz, 1H, H-24), 4.94 (m, 
1H, H-3), 4.34 (m, 1H, H-11), 
3.07-3.03 (m, 1H, H-13), 2.51-
2.43 (m, 2H, 2×H-22), 2.34-2.30 (m, 1H, H-12), 2.32 (t, J = 7.4 Hz, 2H, 2×H-32), 2.21-2.02 
(m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.91-1.77 (m, 4H, 2×H-2, H-7, H-
12), 1.72-1.52 (m, 6H, H-1, H-4, H-6, H-9 and 2×H-33), 1.68 (s, 3H CH3-27), 1.60 (s, 3H, 
CH3-26), 1.38 (s, 3H, CH3-30), 1.35-1.27 (m, 13H, H-15, 2×H-34, 2×H-35, 2×H-36, 2×H-37, 
2×H-38 and 2×H-39), 1.19-1.04 (m, 2H, H-6 and H-7), 0.99 (s, 3H, CH3-19), 0.93 (s, 3H, 
CH3-18), 0.88 (t, J = 6.9 Hz, 3H, 3×H-40), 0.82 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 
MHz, CDCl3) δ 174.1, 173.5, 170.4, 151.0, 132.6, 129.6, 123.0, 74.3, 73.8, 68.2, 49.1, 48.8, 
44.3, 39.4, 39.0, 37.8, 37.0, 35.7, 34.8, 34.7, 32.8, 31.8, 31.1, 29.4, 29.3, 29.2, 29.2, 28.7, 
28.3, 27.4, 25.6, 25.2, 24.4, 22.6, 22.5, 20.6, 20.5, 18.1, 17.7, 15.6 and 14.0; LC-MS (ESI): 
m/z 671 [M+1]+, 693 [M+23]+, 611 [M-OAc]+; purity (HPLC): 99% (tr = 17.48 min). 
3-Ketofusidic acid (3.36)4 
Jones’ reagent (0.8 ml) was added dropwise over 30 min to 
an ice cooled solution of fusidic acid (3.1) (2.0 g, 3.87 
mmol) in acetone (20 ml). Reaction was monitored by TLC. 
Reaction mixture was stirred at 0 oC for additional 10 min. 
Water (40 ml) was then added to the reaction mixture and 
aqueous layer was extracted with EtOAc (80 ml). Organic 
layer was then dried over anhydrous sodium sulfate, filtered 
and concentrated in vacuo. The residue was purified by 
column chromatography on 100-200 silica gel using EtOAc:hexane as eluent, affording 3.36 
as a white solid (0.650 g, 33%); Rf 0.4 (60% EtOAc:hexane); Mp. 119-121 
oC; 1H NMR (400 
MHz, CDCl3) δ 5.91 (d, J = 8.3 Hz, 1H, H-16), 5.10 (t, J = 7.2 Hz, 1H, H-24), 4.40 (m, 1H, 
H-11), 3.07-3.03 (m, 1H, H-13), 2.51-2.42 (m, 4H, 2×H-2 and 2×H-22), 2.41-2.04 (m, 7H, H-
1, H-4, H-5, H-12, H-15 and 2×H-23), 1.97 (s, 3H, OAc), 2.01-1.86 (m, 3H, H-1, H-7 and H-
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12), 1.68 (s, 3H, CH3-27), 1.67-1.63 (m, 2H, H-6 and H-9), 1.60 (s, 3H, CH3-26), 1.35-1.33 
(m, 1H, H-15), 1.31 (s, 3H, CH3-30), 1.27-1.13 (m, 2H, H-6 and H-7), 1.16 (s, 3H, CH3-19), 
1.02 (d, J = 6.6 Hz, 3H, CH3-28), 0.95 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 212.4, 
173.5, 170.4, 151.0, 132.7, 129.7, 122.9, 74.3, 68.1, 48.8, 48.4, 45.7, 45.4, 44.3, 39.4, 39.0, 
38.0, 36.9, 36.1, 35.4, 33.5, 28.7, 28.3, 25.7, 24.7, 22.6, 21.9, 20.6, 18.0, 17.7 and 12.3; LC-
MS (ESI): m/z 515 [M+H]+, 537 [M+23]+, 455 [M-OAc]+; purity (LC-MS): 97% (tr = 3.89 
min). 
General synthetic procedure for compounds 3.37-3.39 
A mixture of 3-keto fusidic acid 3.36 (1.0 eq.), hydroxyl amine hydrochloride (5 eq.) and 
ammonium acetate (5 eq.) was taken in ethanol (2-3 ml) in a microwave friendly vessel. The 
vessel was sealed and the reaction mixture was irradiated in microwave at 80 oC for 20 min. 
After completion of reaction (TLC), the reaction mixture was diluted with water (15 ml) and 
EtOAc (25 ml). EtOAc layer was separated, dried over anhydrous sodium sulfate, filtered and 
concentrated in vacuo. The residue was purified by column chromatography on 100-200 silica 
gel using EtOAc:hexane as eluent, affording target compound as a white solid. 
3-Hydroxyiminofusidic acid (3.37) 
White powder (0.071 g obtained from 0.3 g of 3.36, 
23%); Rf 0.6 (70% EtOAc:hexane); Mp. 149-151 
oC; A 
mixture of E/Z isomers; 1H NMR (400 MHz, CDCl3) δ 
5.90 (t, J = 8.4 Hz, 1H, H-16), 5.10 (t, J = 7.2 Hz, 1H, 
H-24), 4.36 (m, 1H, H-11), 3.20-3.15 (m, 1H, H-13, 
E/Z), 3.05-3.02 (m, 1H, H-13, E/Z), 2.79-2.69 (m, 1H, 
H-22), 2.56-2.45 (m, 3H, 2×H-2 and H-22), 2.35-2.00 
(m, 7H, H-1, H-4, H-5, H-12, H-15 and 2×H-23), 1.95 
(s, 3H, OAc), 1.91-1.54 (m, 5H, H-1, H-6, H-7, H-9 and H-12), 1.67 (s, 3H, CH3-27), 1.60 (s, 
3H, CH3-26), 1.40-1.30 (m, 4H, H-15 and CH3-30), 1.20-0.81 (m, 11H, H-6, H-7, CH3-18, 
CH3-19 and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 174.2, 170.6, 164.8, 150.0, 132.6, 
130.4, 123.0, 74.2, 68.1, 48.8, 48.5, 46.6, 45.1, 44.0, 39.4, 39.0, 37.3, 36.6, 36.0, 34.1, 33.2, 
28.8, 28.3, 25.7, 24.4, 22.7, 21.6, 20.6, 18.3, 17.8 and 14.4; LC-MS (ESI): m/z 470 [M-
OAc]+, 530 [M+H]+, 552 [M+23]+; purity (LC-MS): 97% (tr = 3.90 min). 
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3-Methoxyiminofusidic acid (3.38) 
White powder (0.251 g obtained from 0.4 g of 3.36, 
59%); Rf 0.5 (60% EtOAc/Hexane); Mp. 176-178 
oC; A 
mixture of E/Z isomers; 1H NMR (400 MHz, CDCl3) 
5.90 (t, J = 7.7 Hz, 1H, H-16), 5.09 (t, J = 7.2 Hz, 1H, 
H-24), 4.36 (m, 1H, H-11), 3.83  (s, 1H, =N-OCH3, 
E/Z), 3.82 (s, 1H, =N-OCH3, E/Z), 3.05-3.02 (m, 1H, 
H-13), 2.68-2.56 (m, 1H, H-22), 2.48-2.42 (m, 3H, 
2×H-2 and H-22), 2.36-1.99 (m, 7H, H-1, H-4, H-5, H-
12, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.92-1.44 (m, 5H, H-1, H-6, H-7, H-9 and H-12), 
1.67 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.38-1.34 (m, 4H, H-15 and CH3-30), 1.20-0.85 
(m, 11H, H-6, H-7, CH3-18, CH3-19 and CH3-28,); 
13C NMR (100 MHz, CDCl3) δ 174.1, 
170.4, 161.9, 151.6, 132.6, 129.9, 122.9, 74.3, 68.1, 61.1, 48.9, 48.5, 46.8, 45.2, 44.3, 39.4, 
39.0, 37.0, 36.8, 36.2, 35.4, 33.5, 28.7, 28.3, 25.7, 24.6, 22.5, 21.6, 20.6, 18.0, 17.7 and 14.5; 
LC-MS (ESI): m/z 484 [M-OAc]+, 544 [M+H]+, 566 [M+23]+; purity (LC-MS): 98% (tr = 
4.47 min). 
3-Benzyloxyiminofusidic acid (3.39) 
White solid (0.081 g obtained from 0.130 g of 
3.36, 51%); Rf 0.6 (60% EtOAc:hexane); Mp. 
176-178 oC; A mixture of E/Z isomers; 1H 
NMR (400 MHz, CDCl3) δ 7.38-7.25 (m, 5H, 
ArH), 5.91 (t, J = 7.7 Hz, 1H, H-16), 5.10 (t, J = 
7.3 Hz, 1H, H-24), 5.08 (d, J = 5.5 Hz, 2H, 
2×H-31), 4.35 (m, 1H, H-11), 3.14-3.08 (m, 1H, 
H-13, E/Z), 3.07-3.02 (m, 1H, H-13, E/Z), 2.69-
2.61 (m, 1H, H-22), 2.48-2.44 (m, 3H, 2×H-2 
and H-22), 2.39-1.99 (m, 7H, H-1, H-4, H-5, H-12, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 
1.92-1.44 (m, 5H, H-1, H-6, H-7, H-9 and H-12), 1.67 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-26), 
1.38-1.30 (m, 4H, H-15 and CH3-30), 1.20-0.79 (m, 11H, H-6, H-7, CH3-18, CH3-19 and 
CH3-28,); 
13C NMR (100 MHz, CDCl3) δ 174.4, 170.4, 162.6, 151.6, 132.6, 129.9, 128.2, 
128.2, 128.1, 127.8, 127.6, 127.5, 123.0, 75.4, 74.3, 68.1, 48.8, 48.5, 46.8, 45.2, 44.3, 39.4, 
39.0, 37.1, 36.8, 36.2, 35.4, 33.5, 28.7, 28.3, 25.7, 24.6, 22.5, 21.6, 20.6, 18.0, 17.7 and 14.5; 
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LC-MS (ESI): m/z 560 [M-OAc]+, 620 [M+H]+, 642 [M+23]+; purity (LC-MS): 98% (tr = 
5.64 min). 
3-Epifusidic acid (3.40)1 
NaBH4 (0.022 g, 0.582 mmol) was added portion wise to a 
solution of 3.36 (0.1 g, 0.194 mmol) in methanol (3 ml) at 
25 oC. Reaction mixture was then stirred for 3 h. After 
completion of the reaction (TLC), reaction mixture was 
acidified to pH = 1 by dropwise addition of 1 N aq. HCl. 
Methanol was then removed in vacuo and residue was 
dissolved in EtOAc (15 ml). The EtOAc layer was washed 
with water (10 ml), dried over anhydrous sodium sulfate, 
filtered and concentrated in vacuo. The crude product was purified by column 
chromatography on 100-200 silica gel using EtOAc:DCM as eluent, affording 3.40 as a white 
solid (0.025 g, 25%); Rf 0.5 (60% EtOAc/DCM); Mp. 211-213 
oC; 1H NMR (400 MHz, 
CD3OD) δ 5.81 (d, J = 8.5 Hz, 1H, H-16), 5.14 (t, J = 7.2 Hz, 1H, H-24), 4.31 (m, 1H, H-11), 
3.07-2.98 (m, 2H, H-3, H-13), 2.59-2.50 (m, 1H, H-22), 2.42-2.35 (m, 1H, H-22), 2.32-2.27 
(m, 1H, H-12), 2.19-2.01 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.91-1.72 
(m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.61 (s, 3H, CH3-26), 1.61-1.57 (m, 3H, 
H-1, H-6 and H-9), 1.40-1.29 (m, 1H, H-4), 1.33 (s, 3H, CH3-30), 1.26-1.22 (m, 1H, H-15), 
1.19-1.10 (m, 2H, H-6 and H-7), 1.02 (s, 3H, CH3-19), 0.94 (d, J = 6.5 Hz, 3H, CH3-28), 0.93 
(s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 172.8, 171.2, 147.2, 131.9, 130.9, 122.9, 
75.9, 74.3, 67.0, 49.0, 48.5, 43.6, 42.6, 39.7, 39.2, 38.6, 36.2, 36.1, 33.7, 32.0, 31.2, 28.5, 
27.9, 24.5, 23.0, 22.7, 21.1, 19.3, 16.6, 16.4 and 14.5; LC-MS (ESI): m/z 457 [M-OAc]+, 539 
[M+23]+; purity (LC-MS): 98% (tr = 4.71 min). 
General synthetic procedure for compounds 3.41-3.43 
Corresponding alcohol (3 eq.) was added dropwise to a solution of SiCl4 (1 eq.) in n-pentane 
at 25 oC under nitrogen atmosphere. Addition of alcohol was accompanied by frothing in the 
reaction indicating a rapid reaction between the alcohol and SiCl4. Reaction was stirred for 1 
h. The clear solution formed was concentrated in vacuo to obtain crude trialkoxychlorosilane 
which was used as such for next step. 
A solution of fusidic acid (3.1) (1 eq.) and imidazole (2 eq.) in DMF (5 ml) was cooled to 0 
oC under nitrogen atmosphere and trialkoxychlorosilane (3 eq., crude obtained above) was 
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added. Reaction was stirred at 0 oC for 1 h and monitored by TLC. After completion of 
reaction (TLC), reaction mixture was diluted with EtOAc (25 ml) and washed with water 
(3×15 ml). EtOAc layer was then dried over anhydrous sodium sulfate, filtered and 
concentrated in vacuo. Product was purified by column chromatography on 100-200 size 
silica gel using EtOAc:hexane as eluent, affording target compound as clear liquid (3.43) or 
white solid (3.41 and 3.42). 
3-Triethoxysilyloxyfusidic acid (3.41) 
White solid (0.330 g obtained from 0.5 g of 3.1, 
50%); Rf 0.5 (60% EtOAc:hexane); Mp. 72-74 
oC; 1H NMR (400 MHz, CDCl3) δ 5.89 (d, J = 8.3 
Hz, 1H, H-16), 5.10 (t, J = 7.2 Hz, 1H, H-24), 
4.34 (m, 1H, H-11), 4.00 (m, 1H, H-3), 3.85 (q, J 
= 7.0 Hz, 6H, 6×H-31), 3.07-3.04 (m, 1H, H-13), 
2.51-2.42 (m, 2H, 2×H-22), 2.36-2.31 (m, 1H, H-
12), 2.25-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-
23), 1.96 (s, 3H, OAc), 1.87-1.76 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.60 
(s, 3H, CH3-26), 1.57-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.36 (s, 3H, CH3-30), 1.34-1.30 
(m, 1H, H-15), 1.23 (t, J = 7.0 Hz, 9H, 9×H-32), 1.16-1.04 (m, 2H, H-6 and H-7), 0.97 (s, 3H, 
CH3-19), 0.92 (s, 3H, CH3-18), 0.90 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 174.3, 170.4, 151.3, 132.6, 129.5, 123.0, 74.4, 73.1, 68.3, 59.2 (3C), 49.1, 48.8, 
44.4, 39.4, 39.0, 37.1, 36.4, 36.3, 35.4, 33.0, 30.5, 30.2, 28.7, 28.4, 25.6, 24.2, 22.5, 20.5, 
20.4, 18.2(3C), 18.1, 17.7 and 16.2. LC-MS (ESI): m/z 619 [M-OAc]+; purity (LC-MS): 98% 
(tr = 5.17 min). 
3-Triisopropoxysilyloxyfusidic acid (3.42) 
White solid; (0.250 g obtained from 0.5 g of 3.1, 
35%); Rf 0.5 (60% EtOAc:hexane); Mp. 70-72 
oC; 
1H NMR (400 MHz, CDCl3) δ 5.89 (d, J = 8.3 Hz, 
1H, H-16), 5.10 (t, J = 7.2 Hz, 1H, H-24), 4.34 (m, 
1H, H-11), 4.23 (h, J = 6.1 Hz, 3H, 3×H-31), 3.99 
(m, 1H, H-3), 3.07-3.04 (m, 1H, H-13), 2.51-2.42 
(m, 2H, 2×H-22), 2.36-2.31 (m, 1H, H-12), 2.25-
2.02 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 
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3H, OAc), 1.91-1.73 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.60 (s, 3H, CH3-
26), 1.57-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.36 (s, 3H, CH3-30), 1.34-1.30 (m, 1H, H-
15), 1.19 (d, J = 6.1 Hz, 18H, 18×H-32), 1.14-1.03 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-
19), 0.92 (s, 3H, CH3-18), 0.90 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 
174.2, 170.4, 151.4, 132.6, 129.4, 123.0, 74.4, 72.9, 68.4, 65.7 (3C), 49.2, 48.8, 44.4, 39.4, 
39.0, 37.1, 36.4 (2C), 35.3, 33.1, 30.6, 30.0, 28.7, 28.4, 25.6, 25.4 (6C), 24.2, 22.5, 20.6, 20.4, 
18.1, 17.7 and 16.3; LC-MS (ESI): m/z 661 [M-OAc]+; purity (LC-MS): 99% (tr = 6.87 min). 
3-Trisoctyloxysilyloxyfusidic acid (3.43) 
Colourless viscous oil (0.210 g 
obtained from 0.5 g of 3.1, 23%); 
Rf 0.7 (50% EtOAc:hexane); 
1H 
NMR (400 MHz, CDCl3) δ 5.90 
(d, J = 8.3 Hz, 1H, H-16), 5.10 (t, 
J = 7.2 Hz, 1H, H-24), 4.34 (m, 
1H, H-11), 3.75 (t, J = 6.7 Hz, 6H, 
6×H-31), 3.99 (m, 1H, H-3), 3.07-
3.04 (m, 1H, H-13), 2.51-2.42 (m, 
2H, 2×H-22), 2.36-2.31 (m, 1H, 
H-12), 2.22-2.02 (m, 5H, H-1, H-
5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.87-1.75 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 
3H, CH3-27), 1.60 (s, 3H, CH3-26), 1.57-1.45 (m, 10H, H-1, H-4, H-6, H-9 and 6×H-32), 
1.36 (s, 3H, CH3-30), 1.34-1.25 (m, 31H, 30× H-33,34,35, 36, 37 and H-15), 1.14-1.03 (m, 
2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.92 (s, 3H, CH3-18), 0.90-0.87 (m, 12H, CH3-28 and 
9×H-38); 13C NMR (100 MHz, CDCl3)
 δ 173.9, 170.4, 151.4, 132.6, 129.4, 123.0, 74.4, 73.0, 
68.3, 63.6 (3C), 49.1, 48.8, 44.4, 39.4, 39.0, 37.2, 36.4, 36.3, 35.3, 33.2, 32.4 (3C), 31.8 (3C), 
30.6, 30.2, 29.4 (3C), 29.3 (3C), 28.7, 28.4, 25.7 (3C), 25.6, 24.4, 22.6 (3C), 22.4, 20.6, 20.4, 
18.1, 17.7, 16.3 and 14.1 (3C).  
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7.2.1.3 C-16 Fusidic acid derivatives 
3-Acetoxy-16-deacetoxy-16α-hydroxyfusidic acid (3.44)3 
A mixture of 3.30 (0.2 g) and sat. aq. NaHCO3 (2 ml) was 
irradiated in microwave at 100 oC for 10 min. Reaction 
mixture was then diluted with water (15 ml) and acidified 
with 1 N aq. HCl. The acidic layer was extracted with 
EtOAc (25 ml), dried over anhydrous sodium sulfate, 
filtered and concentrated in vacuo. Product was purified 
by column chromatography on 100-200 size silica gel 
using EtOAc:hexane as eluent, affording target compound 
as a white solid (0.070 g, 37%); Rf 0.3 (50% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 
5.12 (t, J = 7.2 Hz, 1H, H-24), 4.94 (m, 1H, H-3), 4.83 (t, J = 7.3 Hz, 1H, H-16), 4.33 (m, 1H, 
H-11), 3.34-3.31 (m, 1H, H-13), 2.48-2.44 (m, 2H, 2×H-22), 2.38-2.33 (m, 1H, H-12), 2.25-
1.98 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.07 (s, 3H, OAc), 1.84-1.50 (m, 8H, H-1, 2×H-2, 
H-4, H-6, H-7, H-9 and H-12), 1.68 (s, 3H, CH3-27), 1.61 (s, 3H, CH3-26), 1.45 (s, 3H, CH3-
30), 1.25-1.03 (m, 3H, H-6, H-7 and H-15), 0.97 (s, 3H, CH3-19), 0.82 (d, J = 6.7 Hz, 3H, 
CH3-28), 0.75 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 174.0, 171.0, 164.6, 132.4, 
127.6, 123.2, 74.1, 72.1, 68.4, 49.0, 47.4, 43.8, 39.5, 39.2, 37.6, 36.8, 35.9, 34.9, 32.5, 30.9, 
29.0, 28.3, 27.3, 25.6, 24.4, 22.6, 21.3, 20.6, 18.3, 17.8 and 15.4; LC-MS (ESI): m/z 499 [M-
OH]+, 539 [M+23]+. 
3-Acetoxy-16-deacetoxy-16α-hydroxyfusidic acid pivaloyloxymethyl ester (3.45)3 
Chloromethyl pivalate (0.19 ml, 1.25 mmol) was 
added to the solution of compound 3.44 (0.586 g, 
1.13 mmol) in DMF (3 ml). This was followed by 
dropwise addition of Et3N (0.32 ml, 2.27 mmol). 
Resulting reaction mixture was stirred at 25 oC for 
16 h. After completion of reaction (TLC), reaction 
mixture was diluted with EtOAc (25 ml) and 
washed with water (3×15 ml). EtOAc layer was 
then dried over sodium sulfate, filtered and concentrated in vacuo. Crude product was 
purified by column chromatography on 100-200 size silica gel using EtOAc:hexane as eluent, 
affording target compound as viscous yellow oil (0.350 g, 49%); Rf 0.6 (40% EtOAc:hexane); 
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1H NMR (400 MHz, CDCl3) δ 5.88 (d, J = 5.4 Hz, 1H, H-31), 5.81 (d, J = 5.4 Hz, 1H, H-31),  
5.08 (t, J = 7.2 Hz, 1H, H-24), 4.94 (m, 1H, H-3), 4.75 (t, J = 7.3 Hz, 1H, H-16),  4.31 (m, 
1H, H-11), 3.33-3.29 (m, 1H, H-13), 2.45-2.40 (m, 2H, 2×H-22), 2.36-2.28 (m, 1H, H-12), 
2.17-1.86 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.07 (s, 3H, OAc), 1.84-1.49 (m, 8H, H-1, 
2×H-2, H-4, H-6, H-7, H-9 and H-12), 1.67 (s, 3H, CH3-27), 1.59 (s, 3H, CH3-26), 1.45 (s, 
3H, CH3-30), 1.25-1.03 (m, 3H, H-6, H-7 and H-15), 1.21 (s, 9H, -OCOC(CH3)3), 0.97 (s, 3H, 
CH3-19), 0.82 (d, J = 6.7 Hz, 3H, CH3-28), 0.74 (s, 3H, CH3-18); LC-MS (ESI): m/z 613 [M-
OH]+. 
3-Acetoxy-16-deacetoxy-16β-bromofusidic acid pivaloyloxymethyl ester (3.46)5 
Compound 3.45 (0.4 g, 0.63 mmol) was dissolved in 
dry benzene (8 ml) and PPh3 (0.712 g, 2.71 mmol) and 
CBr4 (1.13 g, 3.40 mmol) were added at 25 
oC under 
nitrogen atmosphere. Resulting reaction mixture was 
stirred for 1 h. After completion of the reaction (TLC), 
ether (30 ml) was added and precipitated material was 
removed by filtration. Filtrate was concentrated in 
vacuo and residue was purified by column 
chromatography on 100-200 size silica gel using EtOAc:hexane as eluent, affording target 
compound as viscous yellow oil (0.3 g, 68%); Rf 0.6 (30% EtOAc:hexane); 
1H NMR (400 
MHz, CDCl3) δ 5.89 (d, J = 5.5 Hz, 1H, H-31), 5.84 (d, J= 5.5 Hz, 1H, H-31),  5.59 (d, J = 
8.8 Hz, 1H, H-16),  5.07 (t, J = 7.2 Hz, 1H, H-24), 4.95 (m, 1H, H-3), 4.32 (m, 1H, H-11), 
3.07-3.03 (m, 1H, H-13), 2.45-2.40 (m, 2H, 2×H-22), 2.36-2.32 (m, 1H, H-12), 2.19-1.97 (m, 
5H, H-1, H-5, H-15 and 2×H-23), 2.07 (s, 3H, OAc), 1.91-1.80 (m, 4H, 2×H-2, H-7 and H-
12), 1.68 (s, 3H, CH3-27), 1.63-1.52 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, CH3-26), 
1.34 (s, 3H, CH3-30), 1.25-1.03 (m, 3H, H-6, H-7 and H-15), 1.23 (s, 9H, -OCOC(CH3)3), 
1.20 (s, 3H, CH3-19), 1.00 (d, J = 6.7 Hz, 3H, CH3-28), 0.83 (s, 3H, CH3-18); 
13C NMR (100 
MHz, CDCl3) δ 170.8 (2C), 168.3, 152.5, 132.7, 131.7, 122.8, 80.0, 74.1, 68.2, 49.3, 48.6, 
48.4, 45.5, 42.6, 39.8, 38.8, 38.0, 37.1, 35.7, 34.4, 33.0, 31.2, 29.3, 28.0, 27.4, 26.9 (3C), 
25.7, 24.4, 22.2, 21.3, 20.4, 19.5, 17.8 and 15.5. 
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3-Acetoxy-16-deacetoxy-16α-bromofusidic acid pivaloyloxymethyl ester (3.47)5 
Compound 3.46 (0.3 g, 0.43 mmol) was dissolved 
in acetonitrile (3 ml) and tetra butyl ammonium 
bromide (0.3 g, 0.93 mmol) was added. Reaction 
mixture was then stirred at 25 oC for 65 h. 
Acetonitrile was then removed in vacuo. Residue 
was stirred with ether (25 ml) and precipitated 
tetra butyl ammonium bromide was removed by 
filtration. Filtrate was concentrated in vacuo to 
afford the target compound as viscous yellow oil, which was used directly for next step 
without further purification (0.250 g, 83%); Rf 0.6 (30% EtOAc:hexane); 
1H NMR (400 
MHz, CDCl3) δ 5.90 (d, J = 5.4 Hz, 1H, H-31), 5.82 (d, J = 5.4 Hz, 1H, H-31), 5.62 (t, J = 6.9 
Hz, 1H, H-16), 5.08 (t, J =7.3 Hz, 1H, H-24), 4.94 (m, 1H, H-3), 4.33 (m, 1H, H-11), 3.45-
3.41 (m, 1H, H-13), 2.44-2.40 (m, 2H, 2×H-22), 2.34-2.29 (m, 1H, H-12), 2.15-2.01 (m, 5H, 
H-1, H-5, H-15 and 2×H-23), 2.07 (s, 3H, OAc), 1.81-1.50 (m, 8H, H-1, 2×H-2, H-4, H-6, H-
7, H-9 and H-12), 1.67 (s, 3H, CH3-27), 1.59 (s, 3H, CH3-26), 1.45 (s, 3H, CH3-30), 1.25-1.04 
(m, 3H, H-6, H-7 and H-15), 1.23 (s, 9H, -OCOC(CH3)3), 0.98 (s, 3H, CH3-19), 0.83 (d, J = 
6.7 Hz, 3H, CH3-28), 0.77 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 170.9 (2C), 167.4, 
154.7, 132.6, 129.5, 123.0, 79.8, 74.0, 68.2, 50.6, 49.3, 48.7, 43.5, 41.9, 39.5, 38.8,  37.6, 
36.9, 35.8, 35.0, 32.5, 30.9, 28.6, 28.3, 27.3, 26.9 (3C), 25.7, 24.2, 22.8, 21.3, 20.6, 17.8, 17.3 
and 15.5. 
General synthetic procedure for compounds 3.48 and 3.49 
Ag2CO3 (2.0 eq.) was added to a solution of compound 3.47 (1.0 eq.) in 2-3 ml of respective 
alcohol (methanol for 3.48 and ethanol for 3.49) and reaction mixture was stirred in dark at 
25 oC for 16 h. After completion of reaction (TLC), reaction mixture was filtered to remove 
excess of Ag2CO3. The filtered solid was washed with 1 ml of respective alcohol and filtrates 
were combined.  5 N aq. NaOH was then added to the combined filtrate and resulting reaction 
mixture was heated at 80 oC for 1 h. Reaction mixture was then acidified with 5 N aq. HCl, 
diluted with water (10 ml) and extracted with EtOAc (25 ml). EtOAc layer was dried over 
anhydrous sodium sulfate, filtered and concentrated in vacuo. Crude product was purified by 
column chromatography on 100-200 size silica gel using EtOAc:hexane as eluent, affording 
target compounds as a white solid. 
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16-Deacetoxy-16β-methoxy fusidic acid (3.48)5 
White solid (0.025 g obtained from 0.1 g of 3.47, 
35%); Rf 0.5 (60% EtOAc:hexane); Mp. 139-141 
oC; 1H NMR (400 MHz, CDCl3) δ 5.11 (t, J =7.2 
Hz, 1H, H-24), 4.37 (d, J = 7.1 Hz, 1H, H-16), 
4.33 (m, 1H, H-11), 3.76 (m, 1H, H-3), 3.32 (s, 
3H, 3×H-31), 3.06-3.02 (m, 1H, H-13), 2.58-2.50 
(m, 1H, H-22), 2.47-2.40 (m, 1H, H-22), 2.35-2.30 
(m, 1H, H-12), 2.24-2.01 (m, 4H, H-1, H-5 and 
2×H-23), 1.92-1.71 (m, 5H, 2×H-2, H-7, H-12 and H-15), 1.67 (s, 3H, CH3-27), 1.62-1.50 
(m, 5H, H-1, H-4, H-6, H-9 and H-15), 1.60 (s, 3H, CH3-26), 1.38 (s, 3H, CH3-30), 1.23-1.05 
(m, 2H, H-6 and H-7), 0.98 (m, 6H, CH3-19,  CH3-18), 0.93 (d, J = 6.8 Hz, 3H, CH3-28); 
13C 
NMR (100 MHz, CDCl3) δ 171.5, 150.0, 133.6, 132.3, 123.3, 82.1, 71.4, 68.4, 56.6, 49.3, 
49.1, 43.8, 39.7, 37.2, 36.5, 35.9, 35.9, 34.7, 32.9, 30.4, 30.1, 29.6, 28.3, 25.6, 24.4, 22.3, 
20.6, 18.4, 17.8 and 15.9; LC-MS (ESI): m/z 457 [M-OCH3]
+, 511 [M+23]+; purity (LC-MS): 
98% (tr = 5.07 min). 
16-Deacetoxy-16β-ethoxyfusidic acid (3.49)5 
White solid (0.053 g obtained from 0.2 g of 3.47, 37%); Rf 
0.5 (60% EtOAc:hexane); Mp. 177-179 oC; 1H NMR (400 
MHz, CDCl3) δ 5.11 (t, J =7.2 Hz, 1H, H-24), 4.45 (d, J = 
7.1 Hz, 1H, H-16), 4.33 (m, 1H, H-11), 3.76 (m, 1H, H-3), 
3.66-3.59 (m, 1H, H-31), 3.42-3.35 (m, 1H, H-31), 3.06-
3.02 (m, 1H, H-13), 2.59-2.51 (m, 1H, H-22), 2.46-2.39 
(m, 1H, H-22), 2.35-2.30 (m, 1H, H-12), 2.22-2.01 (m, 4H, 
H-1, H-5, 2×H-23), 1.91-1.71 (m, 5H, 2×H-2, H-7, H-12, 
H-15,), 1.67 (s, 3H, CH3-27), 1.64-1.49 (m, 5H, H-1, H-4, H-6, H-9, H-15), 1.60 (s, 3H, CH3-
26), 1.37 (s, 3H, CH3-30), 1.20 (t, J =7.0 Hz, 3H, 3×H-32), 1.22-1.05 (m, 2H, H-6, H-7), 1.00 
(s, 3H, CH3-19), 0.98 (s, 3H, CH3-18), 0.93 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 171.9, 150.1, 133.6, 132.3, 123.3, 80.6, 71.4, 68.5, 64.8, 49.4, 49.1, 43.8, 39.7, 
37.2, 36.4, 36.0, 35.9, 35.2, 32.8, 30.4, 30.1, 29.6, 28.3, 25.6, 24.4, 22.3, 20.6, 18.4, 17.8, 
15.9 and 14.7; LC-MS (ESI): m/z 457 [M-OCH2CH3]
+, 525 [M+23]+; purity (LC-MS): 98% 
(tr = 5.23 min). 
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7.2.1.4 Miscellaneous fusidic acid derivatives 
24,25-Dihydro methylsulfonyl fusidic acid hydrazide (3.50) 
A solution of 3.18 (0.240 g, 0.395 mmol) in ethanol (30 
ml) was charged with 10% Pd/C (0.060 g, 50% 
moisture). The reaction mixture was stirred at 25 oC for 
16 h under a hydrogen atmosphere. Progress of the 
reaction was monitored by TLC. After completion of 
reaction, reaction mixture was filtered through a bed of 
celite and the filtrate was evaporated in vacuo to afford 
compound 3.50 which after trituration with n-pentane 
delivered a white solid (0.140 g, 58%); Rf 0.3 (90% EtOAc:hexane); Mp. 198-200 
οC; 1H 
NMR (400 MHz, CDCl3) δ 8.24 (br s, 1H, NH), 7.12 (br s, 1H, NH), 5.73 (d, J = 8.2 Hz, 1H, 
H-16), 4.37 (m, 1H, H-11), 3.76 (m, 1H, H-3), 3.05-3.01 (m, 1H, H-13), 3.01 (s, 3H, 
SO2CH3), 2.45-2.37 (m, 1H, H-22), 2.32-2.10 (m, 6H, H-1, H-5, H-12, H-15, H-22 and H-
25), 2.01 (s, 3H, OAc), 1.89-1.41 (m, 12H, H-1, 2×H-2, H-4, H-6, H-7, H-9, H-12, 2×H-23 
and 2×H-24), 1.38 (s, 3H, CH3-30), 1.29-1.06 (m, 3H, H-6, H-7 and H-15), 0.98 (s, 3H, CH3-
19), 0.94-0.91 (m, 6H, CH3-18, CH3-28), 0.87 (d, J = 6.6 Hz, 6H, CH3-26 and CH3-27); 
13C 
NMR (100 MHz, CDCl3) δ 170.8, 170.6, 145.1, 132.2, 73.8, 71.6, 68.4, 49.4, 48.7, 43.6, 39.5 
(2C), 39.2, 38.8, 36.9, 36.4, 35.8, 35.4, 31.9, 30.2, 29.9, 29.7, 27.7, 27.4, 23.8, 23.1, 22.5 
(2C), 21.2, 20.8, 17.8 and 15.8; LC-MS (ESI): m/z 633 [M+23]+, 551 [M-OAc]+; purity (LC-
MS): 97% (tr = 4.41 min) 
16-Deacetoxy-16β-hydroxymethanesulfonylfusidic acid hydrazide (3.51) 
K2CO3 (0.460 g, 3.328 mmol) was added to a solution 
of compound 3.18 (0.1 g, 0.164 mmol) in methanol and 
the resulting reaction mixture was stirred at 25 oC for 24 
h. After completion of the reaction (TLC), K2CO3 was 
removed by filtration and the resulting filtrate was 
concentrated in vacuo. Residue was purified by column 
chromatography on 100-200 size silica gel using 
EtOAc:hexane as eluent, affording target compound as 
a white solid (0.020 g, 22%); Rf 0.3 (5% Methanol:DCM); Mp. 169-171 
οC; 1H NMR (400 
MHz, CD3OD) δ 5.14 (t, J = 7.2 Hz, 1H, H-24), 4.79 (d, J = 8.5 Hz, 1H, H-16), 4.30 (m, 1H, 
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H-11), 3.67 (m, 1H, H-3), 3.07 (s, 3H, SO2CH3), 3.07-3.02 (m, 1H, H-13), 2.54-2.46 (m, 1H, 
H-22), 2.36-2.30 (m, 1H, H-22), 2.30-2.07 (m, 6H, H-1, H-5, H-15, H-12 and 2×H-23), 1.89-
1.71 (m, 4H, 2×H-2, H-7 and H-12), 1.68 (s, 3H, CH3-27), 1.62 (s, 3H, CH3-26), 1.62-1.46 
(m, 4H, H-1, H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.30-1.27 (m, 1H, H-15), 1.20-1.09 
(m, 2H, H-6 and H-7), 1.02 (s, 3H, CH3-19), 1.00 (s, 3H, CH3-18), 0.90 (d, J = 6.8 Hz, 3H, 
CH3-28); 
13C NMR (100 MHz, CD3OD) δ  172.4, 150.6, 131.8, 130.2, 123.0, 71.2, 71.0, 67.3, 
49.2, 48.5, 43.7, 40.6, 39.4 (2C), 36.7, 36.4, 36.1, 35.5, 31.6, 29.6 (2C), 29.0, 27.7, 24.5, 22.5, 
22.2, 20.9, 17.3, 16.5 and 15.0; LC-MS (ESI): m/z 589 [M+23]+, purity (LC-MS): 96% (tr = 
4.25 min). 
General synthetic procedure for compounds 3.52 and 3.53 
A solution of fusidic acid (3.1) (0.5 g, 0.97 mmol) in DCM (50 ml) was cooled to -78 οC and 
then ozone was purged through this solution until its colour turns to pale blue. Reaction was 
then shifted to 25 oC and PPh3 (0.64 g, 2.42 mmol) was added as a quencher. Reaction 
mixture was stirred at 25 oC for 2 h. After completion of reaction (TLC), it was washed with 
water (2×15 ml), dried over anhydrous magnesium sulfate and concentrated in vacuo. 
Purification by column chromatography on 100-200 silica gel using EtOAc:hexane as eluent 
afforded products 3.52 and 3.53. 
(Z)-2-((3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetoxy-3,11-dihydroxy-4,8,10,14-
tetramethyldodecahydro-1H-cyclopenta[a]phenanthren-17(2H,10H,14H)-ylidene)-5-
oxopentanoic acid (3.52)6 
White solid (0.13 g, 27%); Rf 0.1 (100% EtOAc); Mp. 237-
239 οC; 1H NMR (400 MHz, CDCl3) δ 9.78 (s, 1H, H-24), 
5.90 (d, J = 8.3 Hz, 1H, H-16), 4.34 (m, 1H, H-11), 3.76 (m, 
1H, H-3), 3.11-3.08 (m, 1H, H-13), 2.80-2.70 (m, 2H, 2×H-
22), 2.61-2.39 (m, 2H, 2×H-23), 2.32-2.27 (m, 1H, H-12), 
2.22-2.07 (m, 3H, H-1, H-5 and H-15), 1.98 (s, 3H, OAc), 
1.91-1.71 (m, 4H, 2×H-2, H-7 and H-12), 1.63-1.48 (m, 4H, 
H-1, H-4, H-6 and H-9), 1.38 (s, 3H, CH3-30), 1.34-1.31 (m, 
1H, H-15), 1.23-1.06 (m, 2H, H-6 and H-7), 0.98 (s, 3H, CH3-19), 0.93-0.91 (m, 6H, CH3-18 
and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 207.0, 170.4 (2C), 156.5, 127.8, 74.5, 71.5, 
68.1, 49.3, 48.9, 45.1, 39.5, 39.1, 37.0, 36.3, 36.0, 35.7, 32.1, 30.2, 29.8, 28.7, 28.4, 25.6, 
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22.9, 20.9, 20.8, 17.8 and 15.9; LC-MS (ESI): m/z 490 [M]+, purity (HPLC): 98% (tr = 15.68 
min). 
(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-3,11-dihydroxy-4,8,10,14-tetramethyl-17-
oxohexadecahydro-1H-cyclopenta[a]phenanthren-16-yl acetate (3.53)6 
White solid (0.10 g, 26%); Rf 0.5 (100% EtOAc); Mp. 92-
94 οC; 1H NMR (400 MHz, CDCl3) δ 5.31 (d, J = 7.0 Hz, 
1H, H-16), 4.36 (m, 1H, H-11), 3.75 (m, 1H, H-3), 3.05-
3.01 (m, 1H, H-13), 2.63-2.56 (m, 1H, H-12), 2.24-2.04 (m, 
3H, H-1, H-5 and H-15), 2.11 (s, 3H, OAc), 1.93-1.71 (m, 
4H, 2×H-2, H-7 and H-12), 1.65-1.46 (m, 4H, H-1, H-4, H-
6 and H-9), 1.49 (s, 3H, CH3-30), 1.43-1.40 (m, 1H, H-15), 1.27-1.12 (m, 2H, H-6 and H-7), 
0.97-0.93 (m, 9H, CH3-18, CH3-19 and CH3-28); 
13C NMR (100 MHz, CDCl3) δ 212.1, 
170.3, 72.1, 71.3, 67.4, 50.5, 47.5, 46.4, 39.9, 37.1, 36.5, 35.9, 35.8, 30.8, 30.2, 30.0, 29.9, 
23.4, 23.1, 20.8 (2C), 17.7 and 15.9; LC-MS (ESI): m/z 392 [M]+; purity (LC-MS): 98% (tr = 
5.10 min).  
3,11-Diketofusidic acid (3.54)1 
White solid (0.900 g, 45%); Rf 0.3 (60% EtOAc:hexane); 
Mp. 192-194 oC; 1H NMR (400 MHz, CDCl3) δ 5.93 (d, J = 
8.3 Hz, 1H, H-16), 5.08 (t, J = 7.4 Hz, 1H, H-24), 2.95-2.87 
(m, 1H, H-13), 2.77-2.65 (m, 2H, H-9 and H-12), 2.54-2.31 
(m, 4H, 2×H-2 and 2×H-22), 2.25-1.96 (m, 8H, 2×H-1, H-4, 
H-5, H-12, H-15 and 2×H-23), 1.99 (s, 3H, OAc), 1.84-1.78 
(m, 1H, H-7), 1.66 (s, 3H, CH3-27), 1.60-1.56 (m, 4H, H-6 
and CH3-26), 1.47-1.44 (m, 1H, H-15), 1.30-1.10 (m, 2H, H-
6 and H-7), 1.20 (s, 3H, CH3-30), 1.15 (s, 3H, CH3-19), 1.05 (d, J = 6.5 Hz, 3H, CH3-28), 
1.05 (s, 3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 215.6, 209.4, 173.6, 170.2, 148.1, 
133.1, 130.8, 122.4, 74.1, 58.2, 48.6, 47.0, 46.2, 44.8, 44.3, 40.7, 38.0, 36.6, 36.6, 33.3, 32.4, 
28.7, 27.9, 25.6, 23.9, 22.4, 21.2, 20.5, 17.7, 17.0 and 14.0; LC-MS (ESI): m/z 453 [M-
OAc]+, 535 [M+23]+; purity (LC-MS): 95% (tr = 4.72 min). 
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3,11-Diacetoxyfusidic acid (3.55)1 
A mixture of fusidic acid (3.1) (0.2 g, 0.39 mmol), acetic 
anhydride (0.4 ml, 3.9 mmol) and pyridine (0.3 ml, 3.9 
mmol) was taken in a microwave friendly vessel and 
irradiated in microwave at 80 oC for 1.5 h. After 
completion of the reaction (TLC), water (15 ml) was 
added to the reaction mixture and aqueous layer was 
extracted with EtOAc (2×15 ml). Organic layer was 
washed with aq 0.5 M HCl (2×15 ml) to get rid of excess 
of pyridine. Organic layer was then dried over anhydrous 
sodium sulfate, filtered and concentrated in vacuo. The residue was purified on 100-200 silica 
gel using EtOAc: hexane as eluent affording 3.55 as a brown solid (0.082 g, 35%); Rf 0.4 
(50% EtOAc:hexane); Mp. 305-307 oC; 1H NMR (400 MHz, CDCl3) δ 5.88 (d, J = 8.4 Hz, 
1H, H-16), 5.29 (m, 1H, H-11), 5.06 (t, J =7.2 Hz, 1H, H-24), 4.94 (m, 1H, H-3), 2.85-2.81 
(m, 1H, H-13), 2.44-2.39 (m, 3H, H-12 and 2×H-22), 2.23-1.99 (m, 5H, H-1, H-5, H-15 and 
2×H-23), 2.06 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.85-1.60 (m, 8H, H-1, 
2×H-2, H-4, H-6, H-7, H-9 and H-12), 1.67 (s, 3H, CH3-27), 1.57 (s, 3H, CH3-26), 1.37 (s, 
3H, CH3-30), 1.37-1.03 (m, 3H, H-6, H-7 and H-15), 0.99 (s, 3H, CH3-19), 0.95 (s, 3H, CH3-
18), 0.82 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 173.2, 170.6, 170.4, 
170.1, 149.9, 132.9, 129.9, 122.6, 74.2, 74.1, 70.6, 48.6, 48.0, 44.7, 39.6, 38.9, 37.7, 36.8, 
34.7, 32.6, 32.1, 29.7, 28.7, 28.1, 27.3, 25.6, 23.9, 22.4, 21.7, 21.2, 20.6, 20.4, 18.0, 17.6 and 
15.5; LC-MS (ESI): m/z 541 [M-OAc]+, 623 [M+23]+; purity (LC-MS): 98% (tr = 5.14 min). 
3,11-Diacetoxyfusidic acid methyl ester (3.56) 
Compound 3.55 (0.1 g, 0.166 mmol) was dissolved in 
DMF (2 ml) and K2CO3 (0.028 g, 0.202 mmol) was added 
followed by addition of methyl iodide (0.012 ml, 0.202 
mmol). Resulting reaction mixture was then heated at 50 
oC for 3 h. After completion of reaction (TLC), reaction 
mixture was diluted with EtOAc (15 ml) and washed with 
water (3×10 ml). Organic layer was separated, dried over 
anhydrous sodium sulfate, filtered and concentrated in 
vacuo. The yellowish product was stirred in n-pentane for 30 min to obtain  3.56 as a white 
solid (0.074 g, 72%); Rf 0.8 (50% EtOAc:hexane); Mp. 259-261 
οC; 1H NMR (400 MHz, 
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CDCl3) δ 5.84 (d, J = 8.4 Hz, 1H, H-16), 5.28 (m, 1H, H-11), 5.04 (t, J =7.3 Hz, 1H, H-24), 
4.92 (m, 1H, H-3), 3.64 (s, 3H, OCH3), 2.84-2.79 (m, 1H, H-13), 2.45-2.34 (m, 3H, H-12 and 
2×H-22), 2.22-1.95 (m, 5H, H-1, H-5, H-15 and 2×H-23), 2.05 (s, 3H, OAc), 2.02 (s, 3H, 
OAc), 1.98 (s, 3H, OAc), 1.85-1.59 (m, 8H, H-1, 2×H-2, H-4, H-6, H-7, H-9 and H-12), 1.66 
(s, 3H, CH3-27), 1.57 (s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.33-1.03 (m, 3H, H-6, H-7, H-
15), 0.98 (s, 3H, CH3-19), 0.93 (s, 3H, CH3-18), 0.82 (d, J = 6.6 Hz, 3H, CH3-28); 
13C NMR 
(100 MHz, CDCl3) δ 170.6, 170.4, 170.3, 170.0, 147.0, 132.7, 131.0, 122.7, 74.1 (2C), 70.6, 
51.4, 48.5, 48.0, 44.3, 39.6, 39.0, 37.7, 36.8, 34.7, 32.7, 32.1, 29.7, 28.9, 28.0, 27.3, 25.7, 
23.9, 22.4, 21.7, 21.2, 20.9, 20.4, 17.9, 17.6 and 15.5; LC-MS (ESI): m/z 555 [M-OAc]+, 637 
[M+23]+; purity (LC-MS): 96% (tr = 5.42 min). 
7.2.2 Chapter 4 
7.2.2.1 C-3 Ether derivatives of fusidic acid  
Fusidic acid pivaloyloxymethyl ester (4.0) 
Chloromethyl pivalate (0.17 ml, 1.13 mmol) was 
added to the solution of compound 3.1 (0.530 g, 
1.03 mmol) in DMF (3 ml). This was followed by 
dropwise addition of Et3N (0.43 ml, 3.09 mmol). 
Resulting reaction mixture was stirred at 25 oC for 
36 h. After completion of reaction (TLC), reaction 
mixture was diluted with EtOAc (25 ml) and 
washed with water (3×15 ml). EtOAc layer was 
then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Crude product 
was purified by column chromatography on 100-200 size silica gel using EtOAc:hexane as 
eluent, affording target compound as a white solid (0.6 g, 93%); Rf 0.6 (60% EtOAc:hexane); 
1H NMR (400 MHz, CDCl3) δ 5.85 (d, J = 8.4 Hz, 1H, H-16), 5.78 (d, J = 5.4 Hz, 1H, H-31), 
5.69 (d, J = 5.4 Hz, 1H, H-31), 5.07 (t, J =7.2 Hz, 1H, H-24), 4.33 (m, 1H, H-11), 3.74 (m, 
1H, H-3), 3.06-3.02 (m, 1H, H-13), 2.50-2.37 (m, 2H, 2×H-22), 2.33-2.28 (m, 1H, H-12), 
2.21-2.00 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.97 (s, 3H, OAc), 1.89-1.71 (m, 4H, 2×H-2, 
H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.61-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.58 (s, 3H, 
CH3-26), 1.38 (s, 3H, CH3-30), 1.31-1.28 (m, 1H, H-15), 1.20 (s, 9H, OCOC(CH3)3), 1.17-
1.03 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.91 (d, J = 6.7 Hz, 3H, CH3-28), 0.90 (s, 
3H, CH3-18); 
13C NMR (100 MHz, CDCl3) δ 177.0, 170.2, 168.1, 150.8, 132.6, 129.3, 122.9, 
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79.8, 74.3, 71.3, 68.2, 49.2, 48.7, 45.8, 44.3, 39.5, 39.0, 38.7, 37.1, 36.2, 35.6, 32.4, 30.3, 
30.0, 28.7, 28.2, 26.8 (3C), 25.6, 24.1, 22.7, 20.7 (2C), 17.9, 17.7 and 15.9. 
General synthetic procedure for compounds 4.1a-4.3a 
A mixture of compound 4.0 (1.0 eq.), respective 4-substitiuted benzyl bromide (3.0 eq.) and 
DIPEA (5.0 eq.) was heated in a closed vessel at 130 oC for 16 h. After completion of 
reaction (TLC), reaction mixture was loaded directly on column containing 100-200 silica gel 
and purified using DCM: hexane as eluent to afford required products. 
3-(4-Chlorobenzyloxy)fusidic acid pivaloyloxymethyl ester (4.1a) 
Colourless viscous oil (0.110 g, 45%); 
Rf  0.6 (25% EtOAc:hexane); 
1H NMR 
(400 MHz, CDCl3) δ 7.31-7.26 (m, 
4H, ArH), 5.86 (d, J = 8.4 Hz, 1H, H-
16), 5.79 (d, J = 5.4 Hz, 1H, H-31), 
5.70 (d, J = 5.4 Hz, 1H, H-31), 5.08 (t, 
J =7.2 Hz, 1H, H-24), 4.57 (d, J = 12.3 
Hz, IH, H-32), 4.32 (d, J = 12.3 Hz, 
1H, H-32), 4.32 (m, 1H, H-11), 3.36 
(m, 1H, H-3), 3.06-3.02 (m, 1H, H-13), 2.51-2.38 (m, 2H, 2×H-22), 2.34-2.29 (m, 1H, H-12), 
2.25-2.01 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.97 (s, 3H, OAc), 1.94-1.73 (m, 4H, 2×H-2, 
H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.63-1.46 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, 
CH3-26), 1.36 (s, 3H, CH3-30), 1.32-1.28 (m, 1H, H-15), 1.21 (s, 9H, OCOC(CH3)3), 1.17-
1.03 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.91 (s, 3H, CH3-18), 0.90 (d, J = 6.7 Hz, 
3H, CH3-28);
 13C NMR (100 MHz, CDCl3) δ 177.0, 170.2, 168.1, 150.8, 138.1, 132.8, 132.6, 
129.3, 128.6 (2C), 128.3 (2C), 122.9, 79.8, 78.7, 74.3, 69.9, 68.3, 49.2, 48.8, 44.3, 39.4, 39.0, 
38.7, 37.1, 37.0, 36.2, 35.5, 32.7, 30.9, 28.8, 28.2, 26.9 (3C), 25.7, 25.4, 24.3, 22.6, 20.8, 
20.6, 18.0, 17.7 and 16.2.  
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3-(4-Methoxybenzyloxy)fusidic acid pivaloyloxymethyl ester (4.2a) 
Colourless viscous oil (0.075 g, 31%); 
Rf  0.6 (25% EtOAc:hexane); 
1H 
NMR (400 MHz, CDCl3) δ 7.26 (d, J 
= 8.7 Hz, 2H, 2×H-34), 6.86 (d, J = 
8.7 Hz, 2H, 2×H-33), 5.86 (d, J = 8.4 
Hz, 1H, H-16), 5.79 (d, J = 5.3 Hz, 
1H, H-31), 5.70 (d, J = 5.3 Hz, 1H, 
H-31), 5.08 (t, J = 7.2 Hz, 1H, H-24), 
4.55 (d, J = 11.8 Hz, 1H, H-32), 4.32 
(m, 1H, H-11), 4.30 (d, J = 11.8 Hz, 1H, H-32), 3.80 (s, 3H, OCH3), 3.36 (m, 1H, H-3), 3.06-
3.02 (m, 1H, H-13), 2.51-2.38 (m, 2H, 2×H-22), 2.35-2.30 (m, 1H, H-12), 2.24-2.01 (m, 5H, 
H-1, H-5, H-15 and 2×H-23), 1.97 (s, 3H, OAc), 1.92-1.66 (m, 4H, 2×H-2, H-7 and H-12), 
1.67 (s, 3H, CH3-27), 1.58-1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, CH3-26), 1.36 
(s, 3H, CH3-30), 1.32-1.28 (m, 1H, H-15), 1.21 (s, 9H, OCOC(CH3)3), 1.18-1.00 (m, 2H, H-6 
and H-7), 0.97 (s, 3H, CH3-19), 0.90 (s, 3H, CH3-18), 0.89 (d, J = 6.7 Hz, 3H, CH3-28);
 13C 
NMR (100 MHz, CDCl3) δ  177.0, 170.2, 168.1, 158.8, 150.9, 132.6, 131.7, 129.3, 128.8 
(2C), 122.9, 113.6 (2C), 79.8, 78.0, 74.3, 70.2, 68.3, 55.2, 49.2, 48.8, 44.3, 38.7, 39.4, 39.0, 
37.1 (2C), 36.2, 35.4, 32.7, 30.9, 28.7, 28.2, 26.8 (3C), 25.6, 25.4, 24.3, 22.6, 20.8, 20.6, 18.0, 
17.7 and 16.1. 
3-(4-Methylbenzyloxy)fusidic acid pivaloyloxymethyl ester (4.3a) 
Colourless viscous oil (0.288 g, 62%); 
Rf  0.7 (25% EtOAc:hexane); 
1H NMR 
(400 MHz, CDCl3) δ 7.23 (d, J = 8.0 
Hz, 2H, 2×H-34), 7.13 (d, J = 8.0 Hz, 
2H, 2×H-33), 5.86 (d, J = 8.4 Hz, 1H, 
H-16), 5.79 (d, J = 5.4 Hz, 1H, H-31), 
5.70 (d, J = 5.4 Hz, 1H, H-31), 5.08 (t, 
J =7.2 Hz, 1H, H-24), 4.58 (d, J = 12.0 
Hz, H-32), 4.33 (d, J = 12.0 Hz, H-32), 
4.32 (m, 1H, H-11), 3.36 (m, 1H, H-3), 3.06-3.02 (m, 1H, H-13), 2.51-2.38 (m, 2H, 2×H-22), 
2.35-2.30 (m, 1H, H-12), 2.34 (s, 3H, 3×H-35), 2.26-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-
23), 1.97 (s, 3H, OAc), 1.94-1.70 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, CH3-27), 1.65-
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1.45 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.32-1.28 
(m, 1H, H-15), 1.21 (s, 9H, OCOC(CH3)3), 1.16-1.01 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-
19), 0.91 (s, 3H, CH3-18), 0.90 (d, J = 6.7 Hz, 3H, CH3-28);
 13C NMR (100 MHz, CDCl3) δ 
177.0, 170.2, 168.1, 150.9, 136.7, 136.6, 132.6, 129.3, 128.8 (2C), 127.4 (2C), 123.0, 79.8, 
78.2, 74.3, 70.5, 68.3, 49.2, 48.8, 44.3, 38.7, 39.4, 39.0, 37.1(2C), 36.2, 35.4, 32.8, 30.9, 28.8, 
28.2, 26.9 (3C), 25.7, 25.4, 24.3, 22.6, 21.1, 20.8, 20.6, 18.0, 17.7 and 16.1.  
General synthetic procedure for compounds 4.1-4.3 
K3CO3 (1.5 eq.) was added to the solution of compound (4.1a-4.3a) (1.0 eq.) in methanol (2 
ml) and reaction mixture was stirred at 25 oC for 2.5 h. After completion of reaction (TLC), 
reaction mixture was acidified to pH = 1 with 1 N aq. HCl and concentrated to remove 
methanol. Residue was diluted with DCM (25 ml) and water (15 ml). DCM layer was 
separated, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. 
Compound was stirred in n-pentane for 30 min and filtered to obtain pure product as a white 
solid.  
3-(4-Chlorobenzyloxy)fusidic acid (4.1) 
White solid (0.083 g obtained from 0.110 g of 
4.1a, 89%); Rf  0.2 (30% EtOAc:hexane); Mp. 
301-303 οC; 1H NMR (400 MHz, CDCl3) δ 
7.31-7.27 (m, 4H, ArH), 5.89 (d, J = 8.3 Hz, 
1H, H-16), 5.10 (t, J = 7.3 Hz, 1H, H-24), 4.58 
(d, J = 12.3 Hz, 1H, H-32), 4.32 (d, J = 12.3 
Hz, 1H, H-32), 4.34 (m, 1H, H-11), 3.36 (m, 
1H, H-3), 3.07-3.03 (m, 1H, H-13), 2.53-2.41 
(m, 2H, 2×H-22), 2.36-2.31 (m, 1H, H-12), 
2.25-2.02 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.95-1.74 (m, 4H, 2×H-2, 
H-7 and H-12), 1.68 (s, 3H, CH3-27), 1.65-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.60 (s, 3H, 
CH3-26), 1.37 (s, 3H, CH3-30), 1.34-1.30 (m, 1H, H-15), 1.18-1.01 (m, 2H, H-6 and H-7), 
0.98 (s, 3H, CH3-19), 0.92 (s, 3H, CH3-18), 0.90 (d, J = 6.7 Hz, 3H, CH3-28);
 13C NMR (100 
MHz, CDCl3) δ 173.8, 170.4, 151.3, 138.1, 132.8, 132.6, 129.4, 128.6 (2C), 128.3 (2C), 
123.0, 78.7, 74.4, 69.9, 68.4, 49.2, 48.8, 44.4, 39.4, 39.0, 37.1, 37.0, 36.2, 35.5, 32.7, 30.9, 
28.7, 28.4, 25.7, 25.4, 24.3, 22.6, 20.6, 20.6, 18.0, 17.7 and 16.2; LC-MS (ESI): m/z 581 [M-
OAc]+; purity (LC-MS): 98% (tr = 6.18 min). 
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3-(4-Methoxybenzyloxy)fusidic acid (4.2) 
White solid (0.050 g obtained from 0.075 g of 
4.2a, 78%); Rf  0.2 (30% EtOAc:hexane); Mp. 
271-273 oC; 1H NMR (400 MHz, CDCl3) δ 
7.26 (d, J = 8.7 Hz, 2H, 2×H-34), 6.87 (d, J = 
8.7 Hz, 2H, 2×H-33), 5.89 (d, J = 8.3 Hz, 1H, 
H-16), 5.10 (t, J = 7.2 Hz, 1H, H-24), 4.55 (d, 
J = 11.8 Hz, 1H, H-32), 4.33 (m, 1H, H-11), 
4.30 (d, J = 11.8 Hz, 1H, H-32), 3.80 (s, 3H, 
OCH3), 3.36 (m, 1H, H-3), 3.06-3.03 (m, 1H, 
H-13), 2.53-2.41 (m, 2H, 2×H-22), 2.36-2.31 (m, 1H, H-12), 2.24-2.02 (m, 5H, H-1, H-5, H-
15 and 2×H-23), 1.95 (s, 3H, OAc), 1.93-1.72 (m, 4H, 2×H-2, H-7 and H-12), 1.67 (s, 3H, 
CH3-27), 1.64-1.46 (m, 4H, H-1, H-4, H-6 and H-9), 1.60 (s, 3H, CH3-26), 1.37 (s, 3H, CH3-
30), 1.33-1.29 (m, 1H, H-15), 1.16-1.02 (m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.91 (s, 
3H, CH3-18), 0.89 (d, J = 6.7 Hz, 3H, CH3-28);
 13C NMR (100 MHz, CDCl3) δ  174.7, 170.5, 
158.8, 151.1, 132.6, 131.7, 129.6, 128.8 (2C), 123.0, 113.6 (2C), 78.0, 74.4, 70.2, 68.4, 55.2, 
49.2, 48.7, 44.3, 39.4, 38.9, 37.0 (2C), 36.2, 35.4, 32.7, 30.9, 28.7, 28.4, 25.7, 25.4, 24.3, 
22.7, 20.7, 20.6, 18.0, 17.7 and 16.1; LC-MS (ESI): m/z 577 [M-OAc]+; purity (LC-MS): 
96% (tr = 5.91 min). 
3-(4-Methylbenzyloxy)fusidic acid (4.3) 
White solid (0.200 g obtained from 0.288 g of 
4.2a, 82%); Mp. 206-208 oC; Rf  0.2 (30% 
EtOAc:hexane); 1H NMR (400 MHz, CDCl3) δ 
7.24 (d, J = 7.8 Hz, 2H, 2×H-34), 7.14 (d, J = 
7.8 Hz, 2H, 2×H-33),  5.89 (d, J = 8.3 Hz, 1H, 
H-16), 5.11 (t, J =7.2 Hz, 1H, H-24), 4.58 (d, J 
= 12.0 Hz, 1H, H-32), 4.33 (d, J = 12.0 Hz, 1H, 
H-32), 4.34 (m, 1H, H-11), 3.37 (m, 1H, H-3), 
3.07-3.04 (m, 1H, H-13), 2.51-2.41 (m, 2H, 2×H-22), 2.38-2.30 (m, 1H, H-12), 2.34 (s, 3H, 
3×H-35), 2.26-2.03 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.96 (s, 3H, OAc), 1.94-1.73 (m, 
4H, 2×H-2, H-7 and H-12), 1.68 (s, 3H, CH3-27), 1.63-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 
1.60 (s, 3H, CH3-26), 1.37 (s, 3H, CH3-30), 1.34-1.30 (m, 1H, H-15), 1.17-1.01 (m, 2H, H-6 
and H-7), 0.98 (s, 3H, CH3-19), 0.92-0.90 (m, 6H, CH3-18 and CH3-28);
 13C NMR (100 MHz, 
Chapter 7: Experimental 
 
211 
 
CDCl3) δ 174.6, 170.4, 151.4, 136.7, 136.6, 132.6, 129.5, 128.8 (2C), 127.4 (2C), 123.0, 78.2, 
74.4, 70.4, 68.4, 49.2, 48.7, 44.4, 39.4, 39.0, 37.0 (2C), 36.2, 35.4, 32.7, 30.9, 28.7, 28.4, 
25.6, 25.4, 24.3, 22.6, 21.1, 20.6, 20.5, 18.0, 17.7 and 16.1; LC-MS (ESI): m/z 561 [M-
OAc]+; purity (LC-MS): 97% (tr = 6.24 min). 
7.2.2.2 C-21 Amide derivatives of fusidic acid  
General synthetic procedure for compounds 4.4-4.8 
Et3N (3 eq.) was added dropwise to a solution of fusidic acid (3.1) (1 eq.) and respective 
amine (1.2 eq.) in DCM (5 ml). Resulting reaction mixture was cooled to 0 oC in an ice bath 
and T3P solution (1.5 eq., 50% w/v in DMF, d = 1.09 g/ml) was added dropwise. Reaction 
mixture was then slowly warmed to 25 oC and stirred for 5 h. After completion of reaction 
(TLC), the reaction mixture was diluted with DCM (20 ml) and water (15 ml) and shaken 
well in a separating funnel. Organic layer was separated, dried over anhydrous sodium 
sulfate, filtered and concentrated in vacuo. The residue was purified by column 
chromatography on 100-200 silica gel using EtOAc:hexane as eluent, affording target 
compound as a white solid. 
N-(4-chlorobenzyl)fusidic acid amide (4.4) 
White solid (0.183 g obtained from 0.2 g of 3.1, 
74%); Rf 0.3 (60% EtOAc:hexane); Mp 195-197 
oC; 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.6 
Hz, 2H, 2×H-33), 7.21 (d, J = 8.6 Hz, 2H, 2×H-32), 
5.74 (d, J = 8.2 Hz, 1H, H-16), 5.67 (dd, J = 6.8, 
4.5 Hz, 1H, NH), 5.06 (t, J =7.2 Hz, 1H, H-24), 
4.57 (dd, J = 14.5, 6.8 Hz, 1H, H-31), 4.32 (m, 1H, 
H-11), 4.06 (dd, J = 14.5, 6.8 Hz, 1H, H-31), 3.74 
(m, 1H, H-3), 2.98-2.95 (m, 1H, H-13), 2.55-2.2.47 (m, 1H, H-22), 2.40-2.33 (m, 1H, H-22), 
2.29-2.24 (m, 1H, H-12), 2.18-2.06 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.98 (s, 3H, OAc), 
1.90-1.70 (m, 4H, 2×H-2, H-7 and H-12), 1.63 (s, 3H, CH3-27), 1.62-1.48 (m, 4H, H-1, H-4, 
H-6 and H-9), 1.55 (s, 3H, CH3-26), 1.36 (s, 3H, CH3-30), 1.29-1.25 (m, 1H, H-15), 1.16-1.08 
(m, 2H, H-6 and H-7), 0.97 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, 
CH3-28); 
13C NMR (100 MHz, CDCl3) δ 171.1, 170.7, 142.0, 136.5, 135.5, 133.5, 132.5, 
129.4 (2C), 128.9 (2C), 123.2, 73.6, 71.3, 68.3, 49.2, 48.7, 43.3, 43.1, 39.5, 39.3, 37.1, 36.3, 
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36.1, 35.6, 32.6, 30.3, 30.0, 29.4, 28.0, 25.6, 24.2, 22.6, 21.0, 20.7, 17.8, 17.8 and 15.9; LC-
MS (ESI): m/z 580 [M-OAc]+, 662 [M+23]+; purity (LC-MS): 99% (tr = 5.51 min). 
N-(4-methoxybenzyl)fusidic acid amide (4.5)  
White solid (0.173 g obtained from 0.2 g of 3.1, 
70%); Rf 0.3 (60% EtOAc:hexane); Mp 106-108 
oC; 1H NMR (400 MHz, CDCl3) δ 7.20 (d, J = 7.9 
Hz, 2H, 2×H-33), 6.86 (d, J = 8.0 Hz, 2H, 2×H-
32), 5.72 (d, J = 8.2 Hz, 1H, H-16), 5.61 (t, J = 
4.7 Hz, 1H, NH), 5.06 (t, J = 7.2 Hz, 1H, H-24), 
4.51 (dd, J = 14.1, 5.8 Hz, 1H, H-31), 4.32 (m, 
1H, H-11), 4.06 (dd, J = 14.1, 5.8 Hz, 1H, H-31), 
3.79 (s, 3H, OCH3), 3.74 (m, 1H, H-3), 2.98-2.95 
(m, 1H, H-13), 2.55-2.47 (m, 1H, H-22), 2.40-2.33 (m, 1H, H-22), 2.29-2.24 (m, 1H, H-12), 
2.18-2.06 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.99 (s, 3H, OAc), 1.89-1.71 (m, 4H, 2×H-2, 
H-7 and H-12), 1.63 (s, 3H, CH3-27), 1.62-1.48 (m, 4H, H-1, H-4, H-6 and H-9), 1.56 (s, 3H, 
CH3-26), 1.35 (s, 3H, CH3-30), 1.29-1.26 (m, 1H, H-15), 1.16-1.05 (m, 2H, H-6 and H-7), 
0.96 (s, 3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.91 (d, J = 6.7 Hz, 3H, CH3-28); 
13C NMR (100 
MHz, CDCl3) δ 171.0, 170.8, 159.1, 141.6, 135.7, 132.4, 129.9, 129.4 (2C), 123.3, 114.2 
(2C), 73.7, 71.3, 68.3, 55.3, 49.2, 48.7, 43.3, 43.2, 39.5, 39.3, 37.1, 36.2, 36.1, 35.6, 32.5, 
30.3, 30.0, 29.4, 28.0, 25.6, 24.1, 22.6, 21.0, 20.7, 17.8, 17.8 and 15.9; LC-MS (ESI): m/z 576 
[M-OAc]+, 658 [M+23]+; purity (LC-MS): 97% (tr = 5.13 min). 
N-(4-methylbenzyl)fusidic acid amide (4.6) 
White solid (0.168 g obtained from 0.2 g of 3.1, 
70%); Rf 0.3 (60% EtOAc:hexane); Mp. 110-112 
oC; 
1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 8.2 Hz, 
2H, 2×H-33), 7.12 (d, J = 8.0 Hz, 2H, 2×H-32), 5.72 
(d, J = 8.2 Hz, 1H, H-16), 5.63 (dd, J = 6.4, 4.3 Hz, 
1H, NH), 5.07 (t, J =7.2 Hz, 1H, H-24), 4.54 (dd, J = 
14.3, 6.3 Hz, 1H, H-31), 4.32 (m, 1H, H-11), 4.06 
(dd, J = 14.3, 6.3 Hz, 1H, H-31), 3.74 (m, 1H, H-3), 
2.97-2.94 (m, 1H, H-13), 2.55-2.47 (m, 1H, H-22), 
2.40-2.33 (m, 1H, H-22), 2.32 (s, 3H, 3×H-35), 2.29-2.24 (m, 1H, H-12), 2.18-2.06 (m, 5H, 
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H-1, H-5, H-15 and 2×H-23), 1.98 (s, 3H, OAc), 1.89-1.69 (m, 4H, 2×H-2, H-7 and H-12), 
1.63 (s, 3H, CH3-27), 1.61-1.47 (m, 4H, H-1, H-4, H-6 and H-9), 1.56 (s, 3H, CH3-26), 1.36 
(s, 3H, CH3-30), 1.29-1.25 (m, 1H, H-15), 1.16-1.08 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-
19), 0.94 (s, 3H, CH3-18), 0.91 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, CDCl3) δ 
171.0, 170.7, 141.6, 137.3, 135.7, 134.8, 132.4, 129.4 (2C), 128.1 (2C), 123.3, 73.7, 71.3, 
68.3, 49.2, 48.7, 43.6, 43.2, 39.5, 39.3, 37.1, 36.2, 36.1, 35.6, 32.5, 30.3, 30.0, 29.4, 28.0, 
25.6, 24.1, 22.6, 21.0 (2C), 20.7, 17.8, 17.7 and 15.9; LC-MS (ESI): m/z 560 [M-OAc]+, 642 
[M+23]+; purity (LC-MS): 98% (tr = 5.39 min). 
N-(1-(4-Chlorophenyl)ethyl)fusidic acid amide (4.7)  
White powder (0.100 g obtained from 0.4 g of 3.1, 
20%); Rf 0.4 (60% EtOAc:hexane); Mp 127-129 
oC; 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 8.4 
Hz, 2H, 2×H-33), 7.22 (d, J = 8.4 Hz, 2H, 2×H-32), 
5.71 (d, J = 8.2 Hz, 1H, H-16), 5.52 (d, J = 7.9 Hz, 
1H, NH), 5.08 (t, J =6.8 Hz, 1H, H-24), 5.04-4.92 
(m, 1H, H-31), 4.31 (m, 1H, H-11), 3.73 (m, 1H, H-
3), 2.99-2.94 (m, 1H, H-13), 2.51-2.40 (m, 1H, H-
22), 2.35-2.29 (m, 1H, H-22), 2.27-2.24 (m, 1H, H-
12), 2.19-1.98 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.95 (s, 3H, OAc), 1.87-1.70 (m, 4H, 
2×H-2, H-7 and H-12), 1.66 (s, 3H, CH3-27), 1.59-1.41 (m, 4H, H-1, H-4, H-6 and  H-9), 
1.45 (d, J = 6.9 Hz, 3H, H-34). 1.57 (s, 3H, CH3-26), 1.34 (s, 3H, CH3-30), 1.30-1.25 (m, 1H, 
H-15), 1.15-1.03 (m, 2H, H-6 and H-7), 0.96 (s, 3H, CH3-19), 0.93-0.89 (m, 6H, CH3-18 and 
CH3-28); 
13C NMR (100 MHz, CDCl3) δ 170.8, 170.3, 142.0, 141.3, 135.7, 133.2, 132.5, 
128.8 (2C), 127.8 (2C), 123.3, 74.4, 71.3, 68.3, 49.2, 48.5, 48.4, 43.2, 39.5, 39.3, 37.0, 36.2, 
36.1, 35.7, 32.4, 30.2, 30.0, 29.5, 28.0, 25.7, 24.0, 22.7, 21.7, 21.3,  20.7, 18.0, 17.8 and 15.9; 
LC-MS (ESI): m/z 594 [M-OAc]+; purity (LC-MS): 96% (tr = 5.36 min). 
N-(4-chlorophenyl)fusidic acid amide (4.8) 
White solid (0.060 g obtained from 0.2 g of 3.1, 
25%); Rf 0.3 (60% EtOAc:hexane); Mp. 250-252 
oC; 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.9 
Hz, 2H, 2×H-32), 7.26 (d, J = 8.9 Hz, 2H, 2×H-
31), 7.15 (br s, 1H, NH),  5.76 (d, J = 8.5 Hz, 1H, 
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H-16), 5.11 (t, J =7.2 Hz, 1H, H-24), 4.36 (m, 1H, H-11), 3.74 (m, 1H, H-3), 3.06-3.03 (m, 
1H, H-13), 2.61-2.54 (m, 1H, H-22), 2.45-2.39 (m, 1H, H-22), 2.33-2.28 (m, 1H, H-12), 2.26-
2.09 (m, 5H, H-1, H-5, H-15 and 2×H-23), 1.91-1.72 (m, 4H, 2×H-2, H-7 and H-12), 1.73 (s, 
3H, OAc), 1.66 (s, 3H, CH3-27), 1.62-1.49 (m, 4H, H-1, H-4, H-6 and H-9), 1.59 (s, 3H, CH3-
26), 1.39 (s, 3H, CH3-30), 1.28-1.24 (m, 1H, H-15), 1.17-1.08 (m, 2H, H-6 and H-7), 0.98 (s, 
3H, CH3-19), 0.94 (s, 3H, CH3-18), 0.92 (d, J = 6.8 Hz, 3H, CH3-28); 
13C NMR (100 MHz, 
CDCl3) δ 170.6, 169.4, 142.9, 136.5, 135.0, 132.8, 129.1, 129.0 (2C), 123.2, 120.6 (2C), 73.7, 
71.3, 68.3, 49.4, 48.7, 43.2, 39.5, 39.3, 37.1, 36.3, 36.2, 35.6, 32.4, 30.3, 29.9, 29.3, 28.1, 
25.7, 24.1, 22.8, 20.8, 20.7, 17.9, 17.8 and 15.9; LC-MS (ESI): m/z 566 [M-OAc]+, 648 
[M+23]+; purity (LC-MS): 98% (tr = 5.66 min). 
7.2.3 Chapter 5 (Metergoline derivatives) 
(5R,8S,10R)-1,6-Dimethyl-8-aminomethyl-ergoline (5.2)7 
A suspension of metergoline (5.1) (1.0 g, 3.712 mmol) in 
methanol (30 ml) was charged with 10% Pd/C (50% moisture). 
The reaction mixture was stirred at 25 oC for 16 h under a 
hydrogen atmosphere. Progress of the reaction was monitored by 
TLC. After completion of reaction, reaction mixture was filtered 
through a bed of celite and the filtrate was evaporated in vacuo 
to afford compound 5.2 as yellow viscous oil which solidified on 
long standing in refrigerator. Yellow solid (0.630 g, 95%);  Mp. 
151-153 oC; 1H NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 7.10 (d, J = 8.2 
Hz, 1H, H-12), 6.92 (d, J = 7.1 Hz, 1H, H-14), 6.72 (s, 1H, H-2), 3.74 (s, 3H, N1-CH3), 3.38 
(dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.22-3.18 (m, 1H, H-7), 3.06-2.99 (m, 1H, H-10), 2.80-2.69 
(m, 4H, 2×H-17, H-4 and H-9), 2.52 (s, 3H, N6-CH3), 2.37 (br s, 2H, NH2), 2.24-2.18 (m, 1H, 
H-5), 2.14-2.04 (m, 1H, H-8), 2.00 (t, J = 11.3 Hz, 1H, H-7), 1.12 (q, J = 12.2 Hz, 1H, H-9); 
13C NMR (100 MHz, CDCl3) δ 134.6, 133.7, 126.7, 122.7, 122.4, 112.6, 111.0, 106.6, 67.7, 
61.8, 46.6, 43.2, 40.6, 39.2, 32.6, 32.2 and 27.0; LC-MS (ESI): m/z 270 [M+H]+; purity 
(HPLC): 99% (tr = 4.75 min). 
General Synthetic procedure for metergoline derivatives 
Procedure A 
Compound 5.2 (1.0 eq.), respective carboxylic acid (1.2 eq.) and HOBt (1.2 eq.) were 
dissolved in DCM. Diisopropylethylamine (3.0 eq.) was then added dropwise followed by 
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addition of EDCI (1.2 eq.). Reaction mixture was stirred at 25 oC for 24 h. After completion 
of reaction (TLC), reaction mixture was diluted with DCM and washed with water. Organic 
layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. 
Crude product was purified by column chromatography on 60-120 silica gel using 
methanol:DCM as eluent. 
Procedure B (for compounds 5.6, 5.7, 5.15, 5.20 and 5.22) 
A solution of compound 5.2 (1.0 eq.) and respective acid chloride (1.5 eq.) in DCM was 
stirred at 25 oC for 3 h. After completion of reaction (TLC), reaction mixture was diluted with 
DCM and washed with water. Organic layer after drying over anhydrous sodium sulfate was 
concentrated in vacuo. Crude product was purified by column chromatography on 60-120 
silica gel using methanol:DCM as eluent. 
(5R,8S,10R)-1,6-Dimethyl-8-(4-chlorobenzoyl)aminomethyl-ergoline (5.3) 
Off-white solid (0.070 g obtained from 0.130 g of 5.2, 
35%); Rf 0.5 (10% Methanol:DCM); Mp. 224-226 
oC; 
1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.6 Hz, 2H, 
2×H-18), 7.41 (d, J = 8.6 Hz, 2H, 2×H-19), 7.18 (t, J = 
7.1 Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.89 
(d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 6.37 (t, J = 
5.4 Hz, 1H, NH), 3.75 (s, 3H, N1-CH3), 3.52-3.42 (m, 
2H, 2×H-17), 3.38 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 
3.12-3.08 (m, 1H, H-7), 3.03-2.97 (m, 1H, H-10), 2.74-
2.67 (m, 2H, H-4 and H-9), 2.48 (s, 3H, N6-CH3), 2.31-2.22 (m, 1H, H-8), 2.22-2.16 (m, 1H, 
H-5), 2.06 (t, J = 11.3 Hz, 1H, H-7), 1.23 (q, J = 12.2 Hz, 1H, H-9); 13C NMR (100 MHz, 
CDCl3) δ 166.7, 137.7, 134.4, 133.1, 133.0, 128.8 (2C), 128.3 (2C), 126.4, 122.7, 122.5, 
112.5, 110.5, 106.9, 67.4, 61.5, 43.8, 43.2, 40.4, 36.7, 32.7, 32.1 and 26.9; LC-MS (ESI): m/z 
408 [M+H]+; purity (LC-MS): 99% (tr = 3.71 min).  
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(5R,8S,10R)-1,6-Dimethyl-8-(2-chlorobenzoyl)aminomethyl-ergoline (5.4) 
White solid (0.150 g obtained from 0.150 g of 5.2, 66%); 
Rf 0.5 (10% Methanol:DCM); Mp. 180-182 
oC; 1H NMR 
(400 MHz, CDCl3): δ 7.71-7.69 (m, 1H, H-18), 7.43-7.41 
(m, 1H, H-21), 7.39-7.32 (m, 2H, H-19 and H-20), 7.19 
(t, J = 7.1 Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 
6.90 (d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 6.31 (t, 
J = 5.4 Hz, 1H, NH), 3.76 (s, 3H, N1-CH3), 3.53-3.50 (m, 
2H, 2×H-17), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.19-
3.15 (m, 1H, H-7), 3.04-2.98 (m, 1H, H-10), 2.79-2.68 
(m, 2H, H-4 and H-9), 2.50 (s, 3H, N6-CH3), 2.34-2.23 (m, 1H, H-8), 2.22-2.16 (m, 1H, H-5), 
2.10 (t, J = 11.3 Hz, 1H, H-7), 1.26 (q, J = 12.3 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): 
δ 166.6, 135.2, 134.4, 133.1, 131.3, 130.5, 130.3, 130.2, 127.1, 126.5, 122.7, 122.5, 112.5, 
110.6, 106.8, 67.4, 61.5, 43.9, 43.3, 40.5, 36.6, 32.7, 32.2 and 26.9; LC-MS (ESI): m/z 408 
[M+H]+; purity (HPLC): 99% (tr = 12.89 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(3-chlorobenzoyl)aminomethyl-ergoline (5.5) 
White solid (0.143 g obtained from 0.150 g of 5.2, 63%); 
Rf 0.5 (10% Methanol:DCM); Mp. 183-185 
oC; 1H NMR 
(400 MHz, CDCl3): δ 7.81 (t, J = 1.8 Hz, 1H, H-18), 7.68 
(ddd, J = 7.7, 1.7, 1.1 Hz, 1H, H-21), 7.46 (ddd, J = 8.0, 
2.1, 1.1 Hz, 1H, H-19), 7.36 (t, J = 7.8 Hz, 1H, H-20), 
7.18 (t, J = 7.1 Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, 
H-12), 6.88 (d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 
6.48 (t, J = 5.4 Hz, 1H, NH), 3.75 (s, 3H, N1-CH3), 3.50-
3.46 (m, 2H, 2×H-17), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-
4), 3.18-3.14 (m, 1H, H-7), 3.11-3.04 (m, 1H, H-10), 2.81-2.69 (m, 2H, H-4 and H-9), 2.53 
(s, 3H, N6-CH3), 2.38-2.30 (m, 1H, H-8), 2.30-2.23 (m, 1H, H-5), 2.14 (t, J = 11.3 Hz, 1H, 
H-7), 1.25 (q, J = 12.3 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): δ 166.3, 136.5, 134.8, 
134.4, 133.1, 131.5, 129.9, 127.3, 126.5, 124.9, 122.7, 122.5, 112.5, 110.6, 106.8, 67.4, 61.5, 
43.9, 43.3, 40.6, 36.8, 32.7, 32.2 and 27.0; LC-MS (ESI): m/z 408 [M+H]+; purity (HPLC): 
98% (tr = 14.09 min). 
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(5R,8S,10R)-1,6-Dimethyl-8-(3,4-dichlorobenzoyl)aminomethyl-ergoline (5.6)  
Off-white solid (0.070 g obtained from 0.080 g of 5.2, 
53%); Rf 0.6 (10% Methanol:DCM); Mp. 139-141 
oC; 
1H NMR (400 MHz, CD3OD): δ 8.03 (d, J = 2.0 Hz, 
1H, H-18), 7.78 (dd, J = 8.4, 2.1 Hz, 1H, H-20), 7.64 
(d, J = 8.4 Hz, 1H, H-19), 7.13-7.11 (m, 2H, H-12 and 
H-13), 6.88 (d, J = 7.1 Hz, 1H, H-14), 6.84 (s, 1H, H-
2), 3.74 (s, 3H, N1-CH3), 3.57-3.41 (m, 4H, 2×H-17 
and H-4), 3.25-3.23 (m, 1H, H-7), 3.03-2.97 (m, 1H, H-
10), 2.80-2.68 (m, 2H, H-4 and H-9), 2.63 (s, 3H, N6-
CH3), 2.47-2.40 (m, 1H, H-5), 2.36-2.27 (m, 2H, H-7 and H-8), 1.25 (q, J = 12.3 Hz, 1H, H-
9); 13C NMR (100 MHz, CD3OD): δ 166.6, 135.4, 134.6, 134.3, 130.9, 130.4, 129.6, 129.2, 
126.7, 125.9, 123.0, 122.4, 112.4, 107.7, 107.1, 67.3, 59.8, 42.7, 40.8, 39.0, 35.1, 31.4, 30.8 
and 25.0; LC-MS (ESI): m/z 442 [M+H]+; purity (HPLC): 97% (tr = 14.16 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(2,4-dichlorobenzoyl)aminomethyl-ergoline (5.7) 
Off-white solid (0.120 g obtained from 0.180 g of 5.2, 
41%); Rf 0.6 (10% Methanol:DCM); Mp. 160-162 
oC; 
1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 8.3 Hz, 1H,  
H-20), 7.44 (d, J = 2.0 Hz, 1H, H-18), 7.33 (dd, J = 8.3, 
2.0 Hz, 1H, H-19), 7.19 (t, J = 7.1 Hz, 1H, H-13), 7.12 
(d, J = 8.2 Hz, 1H, H-12), 6.89 (d, J = 7.0 Hz, 1H, H-
14), 6.73 (s, 1H, H-2), 6.34 (t, J = 5.4 Hz, 1H, NH), 
3.76 (s, 3H, N1-CH3), 3.52-3.47 (m, 2H, 2×H-17), 3.39 
(dd, J = 14.7, 4.3 Hz, 1H and H-4), 3.17-3.13 (m, 1H, 
H-7), 3.03-2.97 (m, 1H, H-10), 2.77-2.67 (m, 2H, H-4 and H-9), 2.50 (s, 3H, N6-CH3), 2.34-
2.24 (m, 1H, H-8), 2.23-2.16 (m, 1H, H-5), 2.09 (t, J = 11.3 Hz, 1H, H-7), 1.26 (q, J = 12.2 
Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): δ 166.3, 136.8, 134.4, 133.4, 131.6, 130.9, 
130.5, 130.0, 127.5, 125.9, 123.0, 122.9, 112.9, 108.0, 107.5, 67.6, 60.3, 42.9, 41.8, 38.7, 
35.0, 32.8, 31.1 and 25.3; LC-MS (ESI): m/z 442 [M+H]+; purity (HPLC): 98% (tr = 14.12 
min). 
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(5R,8S,10R)-1,6-Dimethyl-8-(4-chloro-3-trifluoromethybenzoyl)aminomethyl-ergoline 
(5.8) 
White solid (0.192 g obtained from 0.150 g of 5.2, 
72%); Rf 0.5 (10% Methanol:DCM); Mp. 192-194 
oC; 
1H NMR (400 MHz, CDCl3): δ 8.20 (d, J = 2.1 Hz, 1H,  
H-18), 7.97 (dd, J = 8.3, 2.0 Hz, 1H, H-20), 7.54 (d, J = 
8.3 Hz, 1H, H-19), 7.19 (t, J =7.1 Hz, 1H, H-13), 7.12 
(d, J = 8.2 Hz, 1H, H-12), 6.95 (t, J = 5.4 Hz, 1H, NH), 
6.87 (d, J = 7.1 Hz, 1H, H-14), 6.74 (s, 1H, H-2), 3.76 
(s, 3H, N1-CH3), 3.58-3.45 (m, 2H, 2×H-17), 3.40 (dd, 
J = 14.7, 4.3 Hz, 1H, H-4), 3.30-3.26 (m, 1H, H-7), 
3.24-2.18 (m, 1H, H-10), 2.94-2.87 (m, 1H, H-4), 2.77-2.72 (m, 1H, H-9), 2.61 (s, 3H, N6-
CH3), 2.54-2.41 (m, 2H, H-5 and H-8), 2.29 (t, J = 11.5 Hz, 1H, H-7), 1.28 (q, J = 12.2 Hz, 
1H, H-9); 13C NMR (100 MHz, CDCl3) δ 165.5, 135.6, 134.4, 133.1, 131.7 (3C), 131.3 (2C), 
126.6, 126.2, 122.8 (2C), 112.7, 109.3, 107.2, 67.5, 61.1, 43.6, 42.5, 39.7, 35.9, 32.8, 31.8 
and 26.2; LC-MS (ESI): m/z 476 [M+H]+; purity (LC-MS): 99% (tr = 4.16 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(4-nitro-3-trifluoromethylbenzoyl)aminomethyl-ergoline 
(5.9) 
Yellow solid (0.050 g obtained from 0.108 g of 5.2, 
26%); Rf 0.5 (10% Methanol:DCM); Mp. 195-197 
oC; 
1H NMR (400 MHz, CDCl3): δ 8.30 (d, J = 1.5 Hz, 
1H, H-18), 8.15 (dd, J = 8.3, 1.6 Hz, 1H, H-20), 7.86 
(d, J = 8.3 Hz, 1H, H-19), 7.16 (t, J = 7.1 Hz, 1H, H-
13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 7.01 (t, J = 5.4 Hz 
1H, NH), 6.86 (d, J = 7.1 Hz, 1H, H-14), 6.74 (s, 1H, 
H-2), 3.75 (s, 3H, N1-CH3), 3.56-3.44 (m, 2H, 2×H-
17), 3.38 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.17-3.13 
(m, 1H, H-7), 3.08-3.01 (m, 1H, H-10), 2.76-2.70 (m, 2H, H-4 and H-9), 2.52 (s, 3H, N6-
CH3), 2.43-2.32 (m, 1H, H-8), 2.28-2.22 (m, 1H, H-5), 2.12 (t, J = 11.4 Hz, 1H, H-7), 1.24 (q, 
J = 12.4 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3) δ 164.3, 149.4, 138.4, 134.4, 132.3, 
131.7 (2C), 127.2, 126.3, 125.2 (2C), 122.7 (2C), 112.5, 109.9, 107.1, 67.4, 61.2, 44.2, 43.0, 
40.2, 36.2, 32.7, 32.0 and 26.6; LC-MS (ESI): m/z 487 [M+H]+; purity (LC-MS): 97% (tr = 
3.49 min). 
Chapter 7: Experimental 
 
219 
 
(5R,8S,10R)-1,6-Dimethyl-8-(nicotinoyl)aminomethyl-ergoline (5.10)8 
Light-yellow solid (0.050 g obtained from 0.080 g of 5.2,  
45%); Rf 0.5 (20% Methanol:DCM); Mp. 178-180 
oC; 1H 
NMR (400 MHz, CDCl3): δ 9.05 (s, 1H, H-21), 8.72 (d, J 
= 4.8 Hz, 1H, H-20), 8.16 (dt, 1H, J = 8.0, 1.9 Hz, 1H, H-
18), 7.38 (dd, J = 7.9, 4.8 Hz, 1H, H-19), 7.18 (t, J = 7.1 
Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.89 (d, J 
= 7.1 Hz, 1H, H-14), 6.77 (t, J = 5.4 Hz, 1H, NH), 6.73 
(s, 1H, H-2), 3.75 (s, 3H, N1-CH3), 3.59-3.45 (m, 2H, 
2×H-17), 3.40 (dd, J = 14.6, 4.3 Hz, 1H, H-4), 3.25-3.21 
(m, 1H, H-7), 3.16-3.10 (m, 1H, H-10), 2.85-2.72 (m, 2H, H-4 and H-9), 2.57 (s, 3H, N6-
CH3), 2.46-2.31 (m, 2H, H-5 and H-8), 2.21 (t, J = 11.5 Hz, 1H, H-7), 1.28 (q, J = 12.4 Hz, 
1H, H-9); 13C NMR (100 MHz, CDCl3): δ 165.9, 152.2, 148.0, 135.1, 134.4, 132.3, 130.2, 
126.3, 123.5, 122.8, 122.7, 112.6, 109.8, 107.0, 67.5, 61.2, 43.6, 42.8, 40.0, 36.3, 32.7, 31.9 
and 26.5; LC-MS (ESI): m/z 375 [M+H]+; purity (HPLC): 98% (tr = 10.67 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(isonicotinoyl)aminomethyl-ergoline (5.11)8 
Off-white solid (0.032 g obtained from 0.1 g of 5.2, 23%); 
Rf 0.4 (15% Methanol:DCM); Mp. 218-220 
oC; 1H NMR 
(400 MHz, CDCl3): δ 8.75 (d, J = 4.5 Hz, 2H, 2×H-19), 
7.65 (d, J = 4.5 Hz, 2H, 2×H-18), 7.18 (t, J = 7.1 Hz, 1H, 
H-13), 7.12 (d, J = 8.2 Hz, 1H, H-12), 6.88 (d, J = 7.0 Hz, 
1H, H-14), 6.74 (s, 1H, H-2), 6.57 (t, J = 5.4 Hz, 1H, NH), 
3.76 (s, 3H, N1-CH3), 3.58-3.46 (m, 2H, 2×H-17), 3.40 
(dd, J = 14.7, 4.4 Hz, 1H, H-4), 3.20-3.16 (m, 1H, H-7), 
3.13-3.06 (m, 1H, H-10), 2.82-2.71 (m, 2H, H-4 and H-9), 
2.54 (s, 3H, N6-CH3 ), 2.41-2.34 (m, 1H, H-8), 2.33-2.27 (m, 1H, H-5), 2.16 (t, J = 11.4 Hz, 
1H, H-7), 1.27 (q, J = 12.3 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): δ 165.8, 150.6 (2C), 
141.5, 134.4, 132.4, 126.3, 122.7 (2C), 120.9 (2C), 112.5, 110.0, 107.0, 67.4, 61.3, 43.8, 43.0, 
40.2, 36.4, 32.7, 32.0 and 26.6; LC-MS (ESI): m/z 375 [M+H]+; purity (HPLC): 98% (tr = 
10.70 min). 
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(5R,8S,10R)-1,6-Dimethyl-8-(picolinoyl)aminomethyl-ergoline (5.12)8 
Pale-yellow solid (0.070 g obtained from 0.100 g of 5.2, 
50%); Rf 0.5 (10% Methanol:DCM); Mp. 168-170 
oC; 1H 
NMR (400 MHz, CDCl3): δ 8.57 (ddd, J = 4.8, 1.7, 0.9 
Hz, 1H, H-21), 8.22 (dt, J = 7.8, 1.1 Hz, 1H, H-18), 8.22 
(br s, 1H, NH), 7.86 (td, J = 7.7, 1.7 Hz, 1H, H-19), 7.43 
(ddd, J = 7.6, 4.8, 1.2 Hz, 1H, H-20), 7.18 (t, J = 7.1 Hz, 
1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.92 (d, J = 
7.4 Hz, 1H, H-14), 6.72 (s, 1H, H-2), 3.75 (s, 3H, N1-
CH3), 3.54-3.50 (m, 2H, 2×H-17), 3.39 (dd, J = 14.7, 4.3 
Hz, 1H, H-4), 3.18-3.13 (m, 1H, H-7), 3.09-3.02 (m, 1H, H-10), 2.79-2.71 (m, 2H, H-4 and 
H-9), 2.51 (s, 3H, N6-CH3), 2.38-2.28 (m, 1H, H-8), 2.26-2.20 (m, 1H, H-5), 2.12 (t, J = 11.3 
Hz, 1H, H-7), 1.28 (q, J = 12.3 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): δ 164.5, 149.9, 
148.1, 137.3, 134.4, 133.0, 126.4, 126.1, 122.7, 122.5, 122.2, 112.6, 110.5, 106.8, 67.4, 61.4, 
43.1 (2C), 40.4, 36.5, 32.7, 32.1 and 26.8; LC-MS (ESI): m/z 375 [M+H]+; purity (HPLC): 
98% (tr = 11.51 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(pyrazinoyl)aminomethyl-ergoline (5.13) 
Off-white solid (0.070 g obtained from 0.100 g of 5.2, 
51%); Rf 0.5 (10% Methanol:DCM); Mp. 202-204 
oC; 1H 
NMR (400 MHz, CDCl3): δ 9.43 (d, J = 1.4 Hz, 1H, H-
18), 8.76 (d, J = 2.4 Hz, 1H, H-20), 8.54 (dd, J = 2.4, 1.4 
Hz, 1H, H-19), 7.96 (t, J = 5.5 Hz, 1H, NH), 7.18 (t, J = 
7.1 Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.90 
(d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 3.75 (s, 3H, 
N1-CH3), 3.55-3.52 (m, 2H, 2×H-17), 3.39 (dd, J = 14.7, 
4.3 Hz, 1H, H-4), 3.16-3.12 (m, 1H, H-7), 3.10-3.03 (m, 
1H, H-10), 2.78-2.72 (m, 2H, H-4 and H-9), 2.51 (s, 3H, N6-CH3), 2.39-2.28 (m, 1H, H-8), 
2.27-2.21 (m, 1H, H-5), 2.13 (t, J = 11.3 Hz, 1H, H-7), 1.28 (q, J = 12.3 Hz, 1H, H-9); 13C 
NMR (100 MHz, CDCl3): δ 163.1, 147.3, 144.5, 144.4, 142.5, 134.4, 132.9, 126.4, 122.7, 
122.6, 112.5, 110.3, 106.9, 67.4, 61.3, 43.1 (2C), 40.3, 36.5, 32.7, 32.0 and 26.8; LC-MS 
(ESI): m/z 376 [M+H]+; purity (HPLC): 97% (tr = 10.67 min). 
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(5R,8S,10R)-1,6-Dimethyl-8-(pyrimidine-4-carbonyl)aminomethyl-ergoline (5.14) 
Pale-yellow solid (0.050 g obtained from 0.100 g of 5.2, 
35%); Rf 0.5 (10% Methanol:DCM); Mp. 168-170 
oC; 1H 
NMR (400 MHz, CDCl3): δ 9.26 (d, J = 1.3 Hz, 1H, H-20), 
8.98 (1H, d, J = 5.0 Hz, 1H, H-18), 8.15 (br s, 1H, NH), 
8.14 (dd, J = 5.0, 1.4 Hz, 1H, H-19), 7.18 (t, J = 7.1 Hz, 
1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.90 (d, J = 7.0 
Hz, 1H, H-14), 6.73 (s, 1H, H-2), 3.75 (s, 3H, N1-CH3), 
3.54-3.51 (m, 2H, 2×H-17), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, 
H-4), 3.15-3.11 (m, 1H, H-7), 3.09-3.03 (m, 1H, H-10), 
2.78-2.71 (m, 2H, H-4 and H-9), 2.51 (s, 3H, N6-CH3), 2.40-2.28 (m, 1H, H-8), 2.27-2.20 (m, 
1H, H-5), 2.12 (t, J = 11.4 Hz, 1H, H-7), 1.28 (q, J = 12.4 Hz, 1H, H-9); 13C NMR (100 MHz, 
CDCl3): δ 162.8, 159.2, 157.8, 156.1, 134.4, 132.9, 126.4, 122.7, 122.6, 118.5, 112.5, 110.4, 
106.9, 67.4, 61.3, 43.3, 43.1, 40.3, 36.4, 32.7, 32.0 and 26.8; LC-MS (ESI): m/z 376 [M+H]+; 
purity (HPLC): 98% (tr = 10.83 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(acetyl)aminomethyl-ergoline (5.15)8 
Off-white solid (0.040 g obtained from 0.080 g of 5.2, 43%); Rf 
0.4 (10% Methanol:DCM); Mp. 191-193 oC; 1H NMR (400 
MHz, CD3OD): δ 7.14-7.10 (m, 2H, H-12 and H-13), 6.87-6.83 
(m, 2H, H-2 and H-14), 3.71 (s, 3H, N1-CH3), 3.43 (dd, J = 
14.5, 4.4 Hz, 1H, H-4), 3.27-3.23 (m, 1H, H-7), 3.22-3.15 (m, 
2H, 2×H-17), 3.05-2.99 (m, 1H, H-10), 2.80-2.73 (m, 1H, H-4), 
2.70-2.65 (m, 1H, H-9), 2.68 (s, 3H, N6-CH3), 2.53-2.46 (m, 
1H, H-5), 2.31 (t, J = 11.8 Hz, 1H, H-7), 2.25-2.16 (m, 1H, H-
8), 2.00 (s, 3H, COCH3), 1.13 (q, J = 12.1 Hz, 1H, H-9); 
13C 
NMR (100 MHz, CD3OD): δ 172.1, 134.6, 131.7, 126.2, 122.6, 122.2, 112.1, 109.0, 106.6, 
67.3, 60.5, 42.6, 41.6, 39.6, 35.5, 31.5, 31.4, 25.7 and 21.1; LC-MS (ESI): m/z 312 [M+H]+; 
purity (HPLC): 96% (tr = 12.98 min). 
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(5R,8S,10R)-1,6-Dimethyl-8-(propanoyl)aminomethyl-ergoline (5.16)8 
Off-white solid (0.129 g obtained from 0.160 g of 5.2, 67%); 
Rf 0.4 (10% Methanol:DCM); Mp. 185-187 
oC; 1H NMR (400 
MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 7.11 (d, J = 
8.2 Hz, 1H, H-12), 6.88 (d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 
1H, H-2), 5.67 (t, J = 5.4 Hz, 1H, NH), 3.75 (s, 3H, N1-CH3), 
3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.35-3.24 (m, 2H, 2×H-
17), 3.12-3.04 (m, 2H, H-7 and H-10), 2.82-2.75 (m, 1H, H-
4), 2.70-2.64 (m, 1H, H-9), 2.53 (s, 3H, N6-CH3), 2.29-2.15 
(m, 4H, H-5, H-8 and 2×H-18), 2.09 (t, J = 11.3 Hz, 1H, H-
7), 1.23-1.14 (m, 4H, H-9 and 3×H-19); 13C NMR (100 MHz, CDCl3): δ 173.9, 134.4, 132.7, 
126.4, 122.7, 122.6, 112.6, 110.1, 106.9, 67.4, 61.3, 43.0 (2C), 40.1, 36.4, 32.7, 31.9, 29.8, 
26.6 and 9.9; LC-MS (ESI): m/z 326 [M+H]+; purity (HPLC): 99% (tr = 10.34 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(butanoyl)aminomethyl-ergoline (5.17) 
Off-white solid (0.090 g obtained from 0.100 g of 5.2, 
71%); Rf  0.5 (10% Methanol:DCM); Mp. 169-171 
oC; 1H 
NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 
7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 (d, J = 7.1 Hz, 1H, H-
14), 6.73 (s, 1H, H-2), 5.58 (t, J = 5.4 Hz, 1H, NH), 3.75 (s, 
3H, N1-CH3), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.35-
3.25 (m, 2H, 2×H-17), 3.11-3.03 (m, 2H, H-7 and H-10), 
2.81-2.74 (m, 1H, H-4), 2.70-2.64 (m, 1H, H-9), 2.53 (s, 
3H, N6-CH3), 2.28-2.14 (m, 4H, H-5, H-8 and 2×H-18), 
2.08 (t, J = 11.3 Hz, 1H, H-7), 1.74-1.65 (m, 2H, 2×H-19), 1.19 (q, J = 12.2 Hz, 1H, H-9), 
0.98 (t, J = 7.4 Hz, 3H, 3×H-20); 13C NMR (100 MHz, CDCl3): 173.1, 134.4, 132.7, 126.4, 
122.7, 122.6, 112.5, 110.2, 106.9, 67.4, 61.3, 43.0 (2C), 40.2, 38.8, 36.5, 32.7, 31.9, 26.6, 
19.2 and 13.8; LC-MS (ESI): m/z 340 [M+H]+; purity (HPLC): 97% (tr = 11.16 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(tert-butanoyl)aminomethyl-ergoline (5.18) 
Yellow solid (0.066 g obtained from 0.100 g of 5.2, 50%); Rf 
0.5 (10% Methanol:DCM); Mp. 102-104 oC; 1H NMR (400 
MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 7.11 (d, J = 8.2 
Hz, 1H, H-12), 6.88 (d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-
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2), 5.77 (t, J = 5.4 Hz, 1H, NH), 3.75 (s, 3H, N1-CH3), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 
3.31-3.27 (m, 2H, 2×H-17), 3.08-3.00 (m, 2H, H-7 and H-10), 2.78-2.71 (m, 1H, H-4), 2.68-
2.62 (m, 1H, H-9), 2.51 (s, 3H, N6-CH3), 2.26-2.12 (m, 2H, H-5 and H-8), 2.04 (t, J = 11.3 
Hz, 1H, H-7), 1.23 (s, 9H, 3×CH3), 1.19 (q, J = 12.2 Hz, 1H, H-9); 
13C NMR (100 MHz, 
CDCl3): δ 178.5, 134.4, 132.9, 126.4, 122.7, 122.5, 112.5, 110.3, 106.9, 67.4, 61.4, 43.1 (2C), 
40.3, 38.8, 36.6, 32.7, 31.9, 27.7 (3C) and 26.7; LC-MS (ESI): m/z 354 [M+H]+; purity 
(HPLC): 98% (tr = 12.19 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(pentanoyl)aminomethyl-ergoline (5.19) 
Off-white solid (0.120 g obtained from 0.100 g of 5.2, 
91%); Rf 0.5 (10% Methanol:DCM); Mp. 166-168 
oC; 1H 
NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 
7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 (d, J = 7.1 Hz, 1H, H-
14), 6.73 (s, 1H, H-2), 5.54 (t, J = 5.2 Hz, 1H, NH), 3.75 
(s, 3H, N1-CH3), 3.38 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 
3.31-3.27 (m, 2H, 2×H-17), 3.06-2.95 (m, 2H, H-7 and H-
10), 2.74-2.64 (m, 2H, H-4 and H-9), 2.48 (s, 3H, N6-
CH3), 2.22 (t, J = 7.4 Hz, 2H, 2×H-18), 2.18-2.07 (m, 2H, 
H-5 and H-8), 2.01 (t, J = 11.3 Hz, 1H, H-7), 1.69-1.61 (m, 2H, 2×H-19), 1.43-1.34 (m, 2H, 
2×H-20), 1.17 (q, J = 12.2 Hz, 1H, H-9), 0.94 (t, J = 7.3 Hz, 3H, 3×H-21); 13C NMR (100 
MHz, CDCl3): δ 173.2, 134.4, 133.1, 126.5, 122.7, 122.5, 112.5, 110.5, 106.8, 67.4, 61.5, 
43.2, 43.1, 40.4, 36.7, 36.6, 32.7, 32.0, 27.9, 26.9, 22.4 and 13.8; LC-MS (ESI): m/z 354 
[M+H]+; purity (HPLC): 97% (tr = 12.05 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(hexanoyl)aminomethyl-ergoline (5.20) 
White solid (0.050 g obtained from 0.070 g of 5.2, 
52%); Rf 0.5 (10% Methanol:DCM); Mp. 133-135 
oC; 
1H NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, 
H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 (d, J = 7.1 
Hz, 1H, H-14), 6.73 (s, 1H, H-2), 5.67 (t, J = 5.4 Hz, 
1H, NH), 3.76 (s, 3H, N1-CH3), 3.39 (dd, J = 14.7, 4.3 
Hz, 1H, H-4), 3.35-3.24 (m, 2H, 2×H-17), 3.14-3.06 
(m, 2H, H-7 and H-10), 2.85-2.78 (m, 1H, H-4), 2.70-
2.64 (m, 1H, H-9), 2.55 (s, 3H, N6-CH3), 2.32-2.18 
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(m, 2H, H-5 and H-8), 2.21 (t, J = 7.4 Hz, 2H, 2×H-18),  2.11 (t, J = 11.4 Hz, 1H, H-7), 1.68-
1.61 (m, 2H, 2×H-19), 1.38-1.26 (m, 4H, 2×H-20 and 2×H-21), 1.19 (q, J = 12.3 Hz, 1H, H-
9), 0.90 (t, J = 6.9 Hz, 3H, 3×H-22); 13C NMR (100 MHz, CDCl3): δ 174.0, 134.4, 130.0, 
125.8, 123.1, 122.9, 112.9, 107.7, 107.4, 67.8, 60.2, 42.1, 41.6, 38.2, 36.6, 34.8, 32.8, 31.5, 
30.9, 25.3, 24.9, 22.4 and 13.9; LC-MS (ESI): m/z 368 [M+H]+; purity (HPLC): 99% (tr = 
13.07 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(heptanoyl)aminomethyl-ergoline (5.21) 
White solid (0.070 g obtained from 0.100 g of 5.2, 
49%); Rf 0.6 (10% Methanol:DCM); Mp. 146-148 
oC; 1H NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 
Hz, 1H, H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 
(d, J = 7.1 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 5.67 (t, J 
= 5.4 Hz, 1H, NH), 3.75 (s, 3H, N1-CH3), 3.39 (dd, J 
= 14.7, 4.3 Hz, 1H, H-4), 3.35-3.24 (m, 2H, 2×H-17), 
3.14-3.06 (m, 2H, H-7 and H-10), 2.85-2.78 (m, 1H, 
H-4), 2.70-2.64 (m, 1H, H-9), 2.55 (s, 3H, N6-CH3), 
2.33-2.19 (m, 2H, H-5 and H-8), 2.21 (t, J = 7.4 Hz, 
2H, 2×H-18),  2.11 (t, J = 11.4 Hz, 1H, H-7), 1.69-1.62 (m, 2H, 2×H-19), 1.38-1.26 (m, 6H, 
2×H-20, 2×H-21 and 2×H-22), 1.19 (q, J = 12.3 Hz, 1H, H-9), 0.89 (t, J = 6.9 Hz, 3H, 3×H-
23); 13C NMR (100 MHz, CDCl3): δ 173.3, 134.4, 132.5, 126.3, 122.7, 122.6, 112.6, 110.0, 
107.0, 67.4, 61.2, 42.9 (2C), 40.0, 36.9, 36.3, 32.7, 31.8, 31.5, 29.0, 26.5, 25.8, 22.5 and 14.0; 
LC-MS (ESI): m/z 382 [M+H]+; purity (HPLC): 99% (tr = 13.74 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(Octanoyl)aminomethyl-ergoline (5.22)   
Off-white solid (0.078 g obtained from 0.100 g of 
5.2, 53%); Rf 0.5 (10% Methanol:DCM); Mp. 
141-143 oC; 1H NMR (400 MHz, CDCl3): δ 7.18 
(t, J = 7.1 Hz, 1H, H-13), 7.10 (d, J = 8.2 Hz, 1H, 
H-12), 6.88 (d, J = 7.1 Hz, 1H, H-14), 6.72 (s, 
1H, H-2), 5.60 (t, J = 5.4 Hz, 1H, NH), 3.74 (s, 
3H, N1-CH3), 3.38 (dd, J = 14.7, 4.3 Hz, 1H, H-
4), 3.30-3.26 (m, 2H, 2×H-17), 3.06-2.95 (m, 2H, 
H-7 and H-10), 2.74-2.63 (m, 2H, H-4 and H-9), 
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2.48 (s, 3H, N6-CH3), 2.21 (t, J = 7.4 Hz, 2H, 2×H-18), 2.19-2.08 (m, 2H, H-5 and H-8), 2.01 
(t, J = 11.3 Hz, 1H, H-7), 1.70-1.62 (m, 2H, 2×H-19), 1.36-1.25 (m, 8H, 2×H-20, 2×H-21, 
2×H-22 and 2×H-23), 1.17 (q, J = 12.3 Hz, 1H, H-9), 0.88 (t, J = 6.9 Hz, 3H, 3×H-24); 13C 
NMR (100 MHz, CDCl3): δ 173.2, 134.4, 133.1, 126.5, 122.7, 122.5, 112.5, 110.5, 106.8, 
67.4, 61.4, 43.2, 43.1, 40.4, 36.9, 36.6, 32.7, 32.0, 31.7, 29.3, 29.0, 26.8, 25.8, 22.6 and 14.0; 
LC-MS (ESI): m/z 396 [M+H]+; purity (HPLC): 99% (tr = 14.56 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(decanoyl)aminomethyl-ergoline (5.23) 
Light-yellow solid (0.050 g obtained from 
0.050 g of 5.2, 64%); Rf 0.5 (10% 
Methanol:DCM); Mp. 138-140 oC; 1H NMR 
(400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, 
H-13), 7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 
(d, J = 7.0 Hz, 1H, H-14), 6.73 (s, 1H, H-2), 
5.56 (br s, 1H, NH), 3.75 (s, 3H, N1-CH3), 
3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.33-
3.26 (m, 2H, 2×H-17), 3.10-3.01 (m, 2H, H-
7 and H-10), 2.80-2.73 (m, 1H, H-4), 2.68-
2.65 (m, 1H, H-9), 2.52 (s, 3H, N6-CH3), 2.27-2.15 (m, 4H, H-5, H-8 and 2×H-18), 2.06 (t, J 
= 11.3 Hz, 1H, H-7), 1.69-1.62 (m, 2H, 2×H-19), 1.38-1.14 (m, 13H, H-9, 2×H-20, 2×H-21, 
2×H-22, 2×H-23, 2×H-24 and 2×H-25), 0.88 (t, J = 6.9 Hz, 3H, 3×H-26); 13C NMR (100 
MHz, CDCl3): δ 173.3, 134.4, 132.8, 126.4, 122.7, 122.6, 112.5, 110.2, 106.9, 67.4, 61.3, 
43.1 (2C), 40.2, 36.9, 36.5, 32.7, 31.9, 31.8, 29.4, 29.3 (2C), 29.2, 26.7, 25.8, 22.6 and 14.0; 
LC-MS (ESI): m/z 424 [M+H]+; purity (HPLC): 99% (tr = 15.80 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(cyclopentanoyl)aminomethyl-ergoline (5.24) 
Light-yellow solid (0.060 g obtained from 0.070 g of 5.2, 
63%); Rf 0.5 (10% Methanol:DCM); Mp. 145-147 
oC; 1H 
NMR (400 MHz, CDCl3): δ 7.18 (t, J = 7.1 Hz, 1H, H-13), 
7.11 (d, J = 8.2 Hz, 1H, H-12), 6.88 (d, J = 7.1 Hz, 1H, H-
14), 6.73 (s, 1H, H-2), 5.57 (t, J = 5.4 Hz, 1H, NH), 3.75 
(s, 3H, N1-CH3), 3.39 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 
3.31-3.27 (m, 2H, 2×H-17), 3.09-3.00 (m, 2H, H-7 and H-
10), 2.78-2.72 (m, 1H, H-4), 2.69-2.63 (m, 1H, H-9), 2.58-
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2.48 (m, 1H, H-18), 2.51 (s, 3H, N6-CH3), 2.25-2.12 (m, 2H, H-5 and H-8), 2.05 (t, J = 11.3 
Hz, 1H, H-7), 1.93-1.71 (m, 6H, 2×H-19 and 4×H-20), 1.65-1.54 (m, 2H, 2×H-19), 1.19 (q, J 
= 12.2 Hz, 1H, H-9); 13C NMR (100 MHz, CDCl3): δ 176.3, 134.4, 132.9, 126.4, 122.7, 
122.5, 112.5, 110.3, 106.9, 67.4, 61.4, 46.0, 43.1(2C), 40.3, 36.6, 32.7, 31.9, 30.5, 30.5, 26.7, 
25.9 (2C); LC-MS (ESI): m/z 366 [M+H]+; purity (HPLC): 97% (tr = 12.28 min). 
(5R,8S,10R)-1,6-Dimethyl-8-(2-piperidinoyl)aminomethyl-ergoline (5.25)  
Yellow solid (0.117 g obtained from 0.200 g of 5.2, 41%); 
Rf 0.8 (20% Methanol:DCM); Mp. 124-126 
oC; 1H NMR 
(400 MHz, CDCl3): 7.18 (t, J = 7.1Hz, 1H, H-13), 7.11 (d, 
J = 8.2 Hz, 1H, H-12), 7.08 (br s, 1H, NH), 6.89 (d, J = 
7.0 Hz, 1H, H-14), 6.72 (s, 1H, H-2), 3.75 (s, 3H, N1-
CH3), 3.38 (dd, J = 14.7, 4.3 Hz, 1H, H-4), 3.34-3.19 (m, 
3H, 2×H-17 and H-18), 3.12-3.05 (m, 2H, H-7 and H-22), 
3.03-2.97 (m, 1H, H-10), 2.76-2.57 (m, 4H, H-4, H-9, H-
19 and H-22), 2.51 (s, 3H, N6-CH3), 2.25-2.11 (m, 2H, H-
5 and H-8), 2.07-2.00 (m, 2H, H-7 and H-19), 1.85-1.78 (m, 1H, H-20), 1.64-1.57 (m, 1H, H-
20), 1.52-1.39 (m, 2H, 2×H-21), 1.18 (q, J = 12.4 Hz, 1H, H-9); 13C NMR (100 MHz, 
CDCl3): δ 173.9, 134.4, 132.9, 126.4, 122.7, 122.5, 112.6, 110.3, 106.9, 67.4, 61.4, 60.3, 
45.8, 43.1, 42.6, 40.4, 36.5, 32.7, 31.9, 30.0, 26.7, 25.8 and 24.9; LC-MS (ESI): m/z 381 
[M+H]+; purity (HPLC): 98% (tr = 8.45 min). 
7.3 The biological assays procedures for target compounds 
7.3.1 Antimycobacterial evaluation protocol 
All the target compounds were evaluated against the H37Rv strain of Mtb using the broth 
microdilution method.9 This method allows a range of compound concentrations to be tested 
on a single 96-well microtitre plate in order to determine the minimum inhibitory 
concentration (MIC). 
A 10 ml culture of Mtb (H37RvMa)10,11 was grown to an OD600 of 0.6 - 0.7. The culture was 
then diluted 1:100 in GAST/Fe medium. In a 96-well microtitre plate, 50 μl of GAST/Fe 
medium was added to all wells from Rows 2-12. The compound to be tested was added to 
Row 1 in duplicate, at a final concentration of 640 µM (stock was made up to a concentration 
of 12.8 mM in DMSO, and diluted to 640 µM in GAST/Fe medium). A two-fold serial 
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dilution was prepared, by transferring 50 μl of the liquid in Row 1 to Row 2 and aspirated to 
mix. 50 μl of the liquid in Row 2 was then transferred to Row 3 and aspirated, and so on. This 
procedure was repeated until Row 12 was reached, from which 50 μl of the liquid was 
discarded so as to bring the final volume in all wells to 50 μl. Finally, 50 μl of the 1:100 
diluted Mtb cultures was added to all wells in Rows 2-12. Cells were not added to Row 1, as 
this serves as a contamination control. Controls include media only, 5% DMSO, rifampicin 
and kanamycin. The microtitre plate was stored in secondary container and incubated at 37 °C 
with humidifier to prevent evaporation of liquid. The lowest concentration of compound that 
inhibits growth of more than 99% of the bacterial population was considered to be the MIC99. 
MIC99 values were scored visually at 7-days and 14-days post inoculation. 
GAST/Fe media: 1L in distilled water contains: 
0.3 g of Bacto Casitone (Difco)  
4.0 g of dibasic potassium phosphate  
2.0 g of citric acid 
1.0 g of L-alanine 
1.2 g of magnesium chloride hexahydrate 
0.6 g of potassium sulfate 
2.0 g of ammonium chloride 
1.80 ml of 10 M sodium hydroxide 
10.0 ml of glycerol 
Tween80 was added to 0.05%. 
0.05 g of ferric ammonium citrate 
Dissolve above components in distilled water. Adjust pH to 6.6 if necessary, then filter 
sterilize (0.2 µM filter) and store at 37 °C. 
7.3.2 Antiplasmodial evaluation protocol 
The in vitro antiplamodial testing of compounds was performed against the NF54 strain of P.  
falciparum using method as described by Desjardins et al.12 Uptake of [3H]-hypoxanthine was 
used as a marker of parasite growth. Chloroquine and artesunate were used as positive 
controls. 
Materials: Screening Medium: RPMI 1640 (10.44 g/l) (no hypoxanthine) supplemented with 
HEPES (5.94 g/l), NaHCO3 (2.1 g/l), Neomycin (100 microg/ml) + Albumax II (5 g/l); 
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Human red blood cells: 50% haematocrit; [3H]-hypoxanthine: dilute stock (5mCi/5ml) ½ with 
50% EtOH. 1ml aliquots were then diluted 1/50 with screening medium ready to use. 
Plates: Falcon 96-well microtiter plates (No. 353072) 
Gas: 37 °C; 93% N2, 4% CO2, 3% O2 
Preparation of stock solution: Compounds were dissolved in DMSO at 10 mg/ml. The 
stocks were kept at 4 °C. For the assays, fresh 4X dilutions of all compounds in screening 
medium were prepared. 
Assay procedure: Blood smears of stock cultures of the NF54 strain were prepared and 
parasitemia was determined (parasitemia < 3% should not be used). Compound stock 
solutions were diluted with screening medium to the right start concentrations. Infected red 
cells solution was prepared as parasitemia (p) of 0.3%, and hematocrit (h) of 2.5%, therefore 
the final concentration of p and h in the assay were 0.3 and 2.5%, respectively.  
Calculation example for one 96-well plate:  
Goal: 10 ml of 0.3% parasitemia / 2.5% hematocrit  
Start solutions:  
- Human erythrocytes (50% hematocrit)  
- Continuous culture with 5% parasitemia (with 5% hematocrit)  
1. 0.3% parasitemia = (x ml * 5% p)/ (10 ml /2); x= 0.3 ml of infected culture  
2. 2.5% hematocrit = [(0.3 ml*5% hematocrit) + (x ml*50% hematocrit)]/10 ml; x = 0.47 ml 
of blood  
3. 10 ml – 0.3 ml – 0.47 ml = 9.23 ml of screening medium  
Mix these three volumes to obtain 10 ml of 0.3% parasitemia / 2.5% hematocrit solution  
1 ml of un-infected red cells solution was prepared (no parasites, 2.5% hematocrit) by mixing 
50 μl of washed human erythrocytes (50% hematocrit) with 950 μl screening medium.  100 μl 
of this were added to each well of the microtiter plate (multipette). 100 μl of screening 
medium, containing 4x the highest compound concentration, were added to wells in row B. 
Serial drug dilutions were prepared with a multichannel pipette. 100 μl were taken from wells 
of row B and transferred, after gentle mixing, to wells of row C. After mixing, 100 μl were 
transferred from wells of row C to wells of row D and so forth to row H. The 100 μl removed 
from wells of row H were discarded. A two-fold serial dilution of compounds was thus 
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obtained. For too active compounds the highest concentration was appropriately lowered. 
Wells of rows A served as controls without drug. 
100 μl of infected blood (parasitemia of 0.3%, 2.5% hematocrit) were added to all wells with 
a multipette. Only the control wells (A9-12) got uninfected blood of 2.5% hematocrit. The 
plates were incubated in an incubation chamber at 37 °C in an atmosphere containing the 
special gas mixture (93% N2, 4% CO2, 3% O2). After 48 hours 50 μl [
3H]-hypoxanthine (= 
0.5 μCi) solution were added to each well of the plate. The plates were incubated for another 
24 hours. The plates then were harvested with a BetaplateTM cell harvester (Wallac, Zurich, 
Switzerland), which transfers the red blood cells onto a glass fiber filter and washes with 
distilled water. The dried filters were inserted into a plastic foil with 10 ml of scintillation 
fluid and counted in a BetaplateTM liquid scintillation counter (Wallac, Zurich, Switzerland). 
The results were recorded as counts per minute (cpm) per well at each compound 
concentration. 
Finally, Data were transferred into a graphic programme and expressed as percentage of the 
untreated controls. The 50% inhibitory concentration (IC50) value is evaluated by Logit 
regression analysis. 
7.3.3 Cytotoxicity evaluation protocol 
Compounds were screened for in vitro cytotoxicity against a mammalian cell-line, Chinese 
Hamster Ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT)-assay. The MTT-assay is used as a colorimetric assay for 
cellular growth and survival, and compares well with other available assays.13,14 The 
tetrazolium salt MTT was used to measure all growth and chemosensitivity. Compounds were 
tested in triplicate on one occasion. 
The test compounds were prepared to a 20 mg/ml stock solution in 100% DMSO and stored 
at -20 ºC until use. Dilutions were prepared on the day of the experiment. Emetine was used 
as the reference drug in all experiments. The initial concentration of emetine was 100 μg/ml, 
which was serially diluted in complete medium with 10-fold dilutions to give 6 
concentrations, the lowest being 0.001 μg/ml. The same dilution technique was applied to the 
all test compounds. The 50% inhibitory concentration (IC50) values were obtained from full 
dose-response curves, using a non-linear dose-response curve fitting analysis via GraphPad 
Prism v.4 software. 
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7.3.4 In vivo pharmacokinetic evaluation protocol 
7.3.4.1 Compound administration and samples collection 
The studied compounds were administered via 2 routes: per oral (p.o) and intravenous (i.v) 
administration. For oral administration, compounds were prepared in 0.5% (hydroxypropyl) 
methyl cellulose in 10% DMSO and administered via oral gavage to three female C57BL/6 
mice to achieve a single dose of 20 mg/kg body weight, while compounds administered 
intravenously were prepared in the mixture [10% DMSO, 30% polyethylene glycol (PEG), 
60% of the mixture (10% Ethanol, 80% Propylene Glycol, 10% Tween20)] and injected 
through the penile vein of three male C57BL/6 mice to achieve  a single dose of 5 mg/kg 
body weight. Mice whole blood was collected at 30 min, 1, 3, 5, 7 and 24 h for oral and 5 
min, 30 min, 1, 3, 5, 7 and 24 h for intravenous administration. Collected blood samples were 
mixed using a vortex and stored at -80 °C until analysis. 
7.3.4.2 Quantification of compounds plasma level  
(a) Calibration standard  
Stock solutions of tested compounds were prepared in DMSO at a concentration of 1 mg/mL. 
The solutions were then diluted in mice blood to obtain standard (S) 1 at a concentration of 
4000 ng/mL. Subsequently, S2 (2000 ng/mL), S3 (1000 ng/mL), S4 (500 ng/mL), S5 (250 
ng/mL), S6 (125 ng/mL), S7 (62.5 ng/mL), S8 (31.25 ng/mL) and S9 (15.625 ng/mL) were 
prepared by serial dilution. The calibration standards were briefly mixed by vortexing and 
stored at −80 °C until analysis. The calibration standards were analysed in duplicate in each 
study sample batch.  
(b) Compounds and standards extraction 
To extract compounds, 20 μL of standards and whole blood samples were thawed on ice. The 
internal standard, prednisolone, was diluted in acetonitrile at the final concentrations of 1200 
ng/ml. One hundred (100) μL of internal standard solution were then added to 20 µL of blood 
samples and mixed by vortexing for 1 min, then centrifuged at 1500g for 5 min at room 
temperature (25 oC). The supernatant (approximately 80 μL) was transferred to a clean tube. 
A “blank” and a “double blank” were equally included in the analysis; these two samples 
consisted of whole blood containing none of the tested compounds. The difference between 
the blank and the double blank is that the first sample is extracted using the solvent 
containing the internal control while the latter is only extracted with the solvent. 
 
Chapter 7: Experimental 
 
231 
 
(c) Chromatography and mass spectrometry 
Compounds were quantified using an Agilent 1100 HPLC (Agilent technologies, USA) 
connected in tandem to an AB Sciex API 2000 mass spectrometer (AB SCIEX, 110 Marsh 
Drive, Foster City, California, USA) equipped with a turbo ion spray (ESI) source. The 
software Analyst 1.5.1 was used to control both, the liquid chromatogram and the mass 
spectrometer. The Gemini 3u C18 110A (50 × 2.0 mm, 5 μm) column (Phenomenex, USA) 
was used for compounds separation. The mobile phases consisted of a gradient of 
acetronitrile and 0.1% formic acid or a gradient of acetonitrile and 5 mM ammonium acetate. 
The system operated at a flow rate of 0.4 ml/min and the volume of injection was 5 μL. The 
ESI interface was used in positive mode and the turbo ion spray source was heated to 300 °C. 
The AB Sciex API 2000 mass spectrometer was operated at unit resolution in the multiple 
reaction monitoring (MRM) mode, monitoring the transition of the protonated molecular ions 
to the product ions. 
(d) Calculation of pharmacokinetic parameters 
The normalized plasma concentrations were plotted as a function of sampling time. The 
pharmacokinetic parameters of each compound were determined using the PK Solutions 2.0, 
non-compartment Data Analysis software (Ashland OH, USA). 
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